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Title: Paracetamol poisoning and its treatment in man 
 
Paracetamol is the most common drug taken in overdose in the UK. Although it 
has been used in overdose for about 50 years, there are many aspects of its 
toxicity and treatment that are not fully understood. In this thesis a series of 
related studies on paracetamol overdose are reported. The nephrotoxic effects of 
paracetamol in overdose have long been recognised. To better understand the 
mechanisms of this effect the effect of acute paracetamol overdose on plasma 
electrolytes were investigated, both retrospectively and, more intensively, 
prospectively. The results of these studies showed paracetamol overdose is 
associated with dose-related hypokalemia, and kaliuresis of short duration 
(<24h), suggesting a specific renal effect of paracetamol in overdose, perhaps via 
cyclo-oxygenase inhibition. This effect seems distinct from any nephrotoxic effect 
of paracetamol. In the third study the possible impact of features at admission, 
including renal impairment, on outcomes in a large cohort of patients who 
developed severe liver injury following paracetamol overdose was evaluated 
retrospectively. The key finding was that plasma creatinine, and gamma glutamyl 
transpeptidase, at first admission appeared to be useful predictors of poor 
outcome. The last three studies focus on antidote treatment of paracetamol 
overdose. Intravenous acetylcysteine (NAC) has been used as treatment of 
choice for over 30 years in patients who are at risk of hepatotoxicity. There are 
reports of liver failure and death in patients who have “non-toxic” plasma 
paracetamol concentrations on the UKL nomogram, and who are therefore not 
treated. To better understand this, the frequency of liver failure in patients who 
had low paracetamol was assessed by examining retrospective data from the 
Scottish Liver Unit over a 12-year period. Similar data was collected in the 
University of Newcastle upon Tyne by colleagues there. Only a small percentage 
of patients developed hepatotoxicity when initial paracetamol was low. It was 
concluded that on a cost-benefit basis the current thresholds for antidote 
treatment should not be lowered. The final 2 studies examine adverse reactions 
(ADRs) to NAC, a common clinical problem. The pattern and mechanisms of 
ADRs in man are not well described or understood. Factors influencing the 
frequency of adverse effects were studied in a prospective manner. Paracetamol 
concentration and male gender were protective and family history of allergy was 
a risk factor for adverse effects in this cohort. In a smaller focussed study the 
roles of histamine and other biomarkers as underlying pathophysiological 
mechanisms in ADR occurrence were studied. The severity of ADRs correlated 
with the extent of histamine release, which was independent of tryptase increase, 
suggesting a non-mast cell source. The mechanisms by which paracetamol might 
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 1-1: Introduction   
 
The name “paracetamol” known as acetaminophen in the US, derives from its 
chemical name para-acetylaminophenol. Paracetamol was first synthesised by 
Morse in Germany in 1878 and it was used clinically as an antipyretic by Von 
Mering in 1887 [1] only for a short period, but was discarded in favour of 
phenacetin because it was assumed that it was less toxic than paracetamol. 
In 1893, paracetamol was discovered in the urine of individuals who had 
taken phenacetin. In 1899, paracetamol was found to be a metabolite of 
acetanilide; however nobody realised the importance of this discovery at the 
time.  
 
In 1948, Brodie and Axelrod’s work led to rediscovery of paracetamol. They 
elegantly demonstrated that the therapeutic effect of phenacetin was due to 
its active hepatic metabolite, paracetamol, and since it did not have the toxic 
effects of phenacetin, they advised use of paracetamol as an analgesic in 
medical treatment [2]. In 1955, for the first time McNeil laboratories in the US 
sold the product under the brand name of Tylenol Children’s Elixir as an 
analgesic and antipyretic in children [3]. 
 
Paracetamol was introduced to the UK market in 1956. Frederick Stearns & 
Co sold 500 mg tablets of paracetamol under the brand name of Panadol as 
a prescribed pain killer and antipyretic. In 1958, Panadol Elixir, a children’s 
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formulation, was introduced. In 1963, paracetamol was added to the British 
National Formulary. Concern about safety postponed its widespread 
acceptance, but, when phenacetin was finally withdrawn from the market 
because of nephrotoxicity in the 1970’s, paracetamol became widely used as an 
analgesic replacement [4]. Due to its few side effects and less interaction with 
other drugs it gained significant worldwide popularity among analgesics and 
it became the most commonly prescribed drug in children [5].   
 
The main topics of study in this thesis are the renal effects of paracetamol, and 
the adverse reactions caused by intravenous infusion of acetylcysteine (NAC), a 
treatment of choice in paracetamol overdose. This introductory chapter includes 
three separate parts. In the first part pharmacology and toxicology of 
paracetamol will be discussed. In the second part renal physiology and the 
pathophysiology of renal dysfunction, in particular toxic effects of paracetamol 
on the kidney are reviewed. Finally in the last part NAC treatment and the 
mechanisms of its adverse reactions in paracetamol overdose are discussed.  
 
1-2: Pharmacology & Toxicology of Paracetamol 
1-2-1: Pharmacodynamics 
 
The main therapeutic effects of paracetamol are analgesia and antipyresis; it 
also has a weak anti-inflammatory effect [6]. Although paracetamol has been in 
clinical use for over half a century, the precise mechanisms of the analgesic and 
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antipyretic effects of paracetamol are still unclear. Like classical non-steroidal 
anti inflammatory drugs (NSAIDs), paracetamol reduces production of 
prostaglandins (PG), a family of pro-inflammatory chemicals, through inhibition 
of cyclo-oxygenase (COX) enzymes. Unlike classical NSAIDs however, 
paracetamol does not have important anti-inflammatory effects [1;7-9].  
However, some studies have suggested that paracetamol may have mild anti-
inflammatory effects. Paracetamol, like selective COX-II inhibitors, decreases 
PG concentrations in vivo, but unlike COX- II inhibitors does not suppress 
severe inflammation [8]. A recent study on healthy volunteers given 1000 mg 
paracetamol orally showed that paracetamol inhibited COX-II by more than 80%, 
i.e. a degree comparable to NSAIDs and selective COX-II inhibitors [10]. This 
study also showed that inhibition of COX-I as measured by thromboxane B2 
(TXB2) synthesis was minor (56%) and not sufficient for suppression of platelet 
function. These data support an anti-inflammatory action of paracetamol, and 
indicate why it has a superior overall gastrointestinal safety profile compared 
with non-steroidal anti-inflammatory drugs (NSAIDs). 
 
In animal studies the antipyretic and analgesic effects of paracetamol have been 
shown to be mediated through COX-III inhibition, a new variant of COX-I, 
[11;12]. However, low level of expression of COX-III  in man  suggests little 
clinical relevance at therapeutic doses [13]. Some studies suggest that the 
central nervous system (CNS) is the site of the anti-nociceptive effect of 
paracetamol [14;15]. Other suggested mechanisms for the analgesic effects of 
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paracetamol are inhibition of nitric oxide generation, and effects on either N-
methyl-D-aspartate (NMDA) or substance P [16]. Recently, an active conjugate 
of paracetamol has been suggested as a mediator of the analgesic effects of 
paracetamol [17]. In this novel metabolic pathway, following deacetylation of 
paracetamol to its primary amine, which occurs mainly in liver, this amine is 
conjugated with arachidonic acid in the CNS to form N-arachidonyol-
phenolamine (AM404). AM404 is postulated to be involved in the analgesic 





The therapeutic dose of paracetamol is 10-15 mg/kg with a therapeutic index of 
approximately 10 [18]. The adult oral dose of paracetamol for 
analgesic and antipyretic effects is 650-1000 mg every 4h, with a maximum daily 
dose of 4g. Following oral ingestion of regular release tablets, paracetamol is 
rapidly absorbed and reaches peak concentration within approximately 45 
minutes. Time to peak for liquid paracetamol is 30 minutes, but food prolongs 
time to peak concentration [19;20].  Peak concentration after recommended 
dose ranges from 8-32 mg/l. Bioavailability of paracetamol is 60-98% with 
protein binding of 10-30% at therapeutic doses [19]. Paracetamol passes 
through the blood brain barrier [21] and placenta [22].  
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The liver is the main organ for metabolism of paracetamol, eliminating 25% of 
the therapeutic dose by first pass metabolism. In adults the majority of 
paracetamol (approximately 90%) is conjugated with glucuronide (40-67%), 
sulphate (20-46%) and cysteine (3%), forming inactive and harmless 
metabolites (Figure 1.1) [1]. In premature infants, newborns, and young infants 
the majority of paracetamol is metabolised by sulphation [23]. Less than 5% is 
excreted unchanged in the urine. 
 
A small, yet significant fraction, ranging from 5-15% is metabolised via the 
hepatic cytochrome P450 enzyme system (cytochrome 2E1: CYP2E1 and 
cytochrome 1A2: CYP1A2 isoenzymes) resulting in the formation of a highly 
toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI). Glutathione is 
immediately conjugated with this intermediate metabolite resulting in 
formation of non-toxic cysteine and mercaptate conjugates, which are 
excreted in urine [24-29] (Figure 1.1). 
 
Some drugs such as carbamazepine, phenobarbital, phenytoin, primidone, 
and rifampicin induce cytochrome P450 enzymes and thus increase 
subsequent production of this  toxic metabolite (NAPQI) [30;31]. The 
interaction between paracetamol metabolism and ethanol ingestion is 
complex and its implication in acute overdose remains controversial. In 
chronic alcoholism the combination of hepatic enzyme induction and 
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glutathione depletion seems to increase paracetamol toxicity. In contrast, 
acute alcohol ingestion reduces toxic metabolic activation due to competitive 
inhibition, and depletion of cytosolic NADPH (nicotinamide adenine 





In general paracetamol, when taken in therapeutic dose, is a safe drug. The 
lowest dose which is generally thought to be capable of causing toxicity is 
considered 7.5 g in adults and 150 mg/kg in children [19]. It is believed that 
toxicity generally occurs above 150 mg/kg [18].  Even after taking a toxic dose, 
the majority of paracetamol absorption occurs within 2h and is thought to reach 
peak plasma levels by 4h [19]. There are case reports of later peaks in 
overdose, particularly in co-ingestion with other drugs that delay gastric 
emptying [38] or following ingestion of an extended release of paracetamol  





Figure 1.1: Metabolism of paracetamol ( From [1] ) 
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1-2-3-1: Epidemiology of toxicity 
 
Paracetamol has been available as an over-the-counter drug (without 
prescription) since 1956, and has a remarkable safety record. 30 million packs 
containing paracetamol are sold in the UK every year [40]. The first report of 
paracetamol toxicity in man was in 1966 [41;42]. It is now the most commonly 
drug used in deliberate self harm in the UK [43-46] and is involved in 48% of 
poisoning admissions to hospital [47]. This trend is not confined to the UK and 
has also been reported in other European countries [48;49], and the US [50]. 
Every year, around 70,000-100,000 cases of paracetamol poisoning occur in 





1-2-3-2-1: Epidemiology of hepatic toxicity 
 
Paracetamol is the commonest cause of fulminant hepatic failure and liver 
transplantation in the UK and in the US [51-56]. The estimated number of deaths 
in the UK following paracetamol poisoning is currently at least 150 per year [57-
59]. The death rate in England and Wales between 1993 and 1997 was higher 
at 500 per year [60]. Mortality in Scotland has been shown to be twice as high 
as England and Wales [61]. Following restricting paracetamol pack sizes in 
September 1998 [62] there have been conflicting reports in regards to effect on 
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hospital admission, admission to  liver units and liver transplantation and 
mortality rate following paracetamol overdose. While the new legislation was 
initially shown to reduce mortality and morbidity following paracetamol overdose 
in England and Wales [63], in Scotland restricting paracetamol pack sizes has 
not had a significant effect on mortality  [64].  Later data for England supports 
the Scottish evidence [65] .  
 
1-2-3-2-2: Pathophysiology of hepatotoxicity 
 
The liver is the main target of acute paracetamol toxicity. The safety of 
therapeutic dose of paracetamol results from the availability of electron donors 
such as glutathione (GSH) and other thiol-containing compounds. When 
paracetamol is taken in appropriate dose glutathione supply far exceeds that 
which is required to detoxify the toxic metabolite, NAPQI, and therefore no 
toxicity occurs. In overdose the rate and quantity of formation of toxic metabolite, 
NAPQI, exceeds glutathione supply. The highly reactive NAPQI rapidly binds to 
cellular macromolecules containing cysteine. This covalent binding causes 
hepatocellular necrosis, predominantly in the centrilobular zone (Zone III), due to 
local formation of NAPQI [19;26;66-68]. In severe toxicity, necrosis may destroy 
the entire liver parenchyma. Severe cases develop fulminant hepatic failure [54]. 
Children with acute febrile illness [66;69] and patients taking P450 enzyme 
inducing drugs and ethanol [70] are at greater risk of hepatotoxicity. Malnutrition, 
when the glutathione supply is inadequate (less than 30% of normal) is also a 
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risk factor. Taking paracetamol even just above daily recommended doses (4g) 
following a period of fasting may cause hepatotoxicity [71]. 
 
The risk of clinically significant hepatotoxicity following paracetamol poisoning 
can be predicted by measurement of plasma concentration of paracetamol at a 
timed interval after poisoning, providing that this time interval is not less than 4 
hours. The concentration is plotted on a paracetamol treatment graph with a 
reference line (‘normal treatment line’) joining plots of 200 mg/l (1.32 mmol/l) at 
4 hours and 6.25 mg/litre (0.04 mmol/litre) at 24 hour [31] (Figure 1.2). Patients 
whose plasma paracetamol concentrations are above the “normal treatment 
line” or “high risk line” in the high risk group are treated with IV NAC. 
 
1-2-3-2-3: Effect of paracetamol on clotting factors 
 
Previous studies have shown that at therapeutic doses paracetamol decreases 
prothrombin index and increases international normalised ratio (INR). The early 
case reports began to appear in the literature in 1968 indicating an interaction 
between coumarin anticoagulants and paracetamol [72],  however, supporting 
scientific evidence was only published in 1998 [73]. The study initially 
investigating risk factors of excessive warfarin anticoagulation in a clinical 
setting reported that paracetamol ingestion was independently in a dose- 
dependent manner associated with high INR greater than 6. 
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Further studies showed that paracetamol increases INR in patients on warfarin 
[74;75] and suppress vitamin K-dependent clotting factors (II, VII, IX, X) , 
supporting the existence of clinically significant interaction between Warfarin and 
daily dose of paracetamol (2-4g) [74-78].The exact mechanism of the interaction 
is not known, but the most plausible hypothesis is that paracetamol or its 
metabolites interfere with enzymes involved in vitamin K-dependent coagulation 
factor synthesis. Although some other studies have not shown significance 
interaction between paracetamol and anticoagulant therapy [79;80], the 
possibility of such an interaction must be considered by clinicians in clinical 
practice. Whether it has any relevance to the measurement of INR as a risk 
assessment in paracetamol overdose is less clear, but in general changes in 




1-3: Paracetamol and Kidney 
 
1-3-1: Epidemiology of Nephrotoxicity 
 
The kidney is the second target organ in paracetamol poisoning. Renal 
insufficiency during the course of paracetamol overdose, with or without 
concomitant hepatic failure, has been reported since the1970s [42;81-90]. The 
incidence of paracetamol-induced renal failure varies in different studies and 
various conditions.  It has been reported that the incidence of acute renal failure 
in paracetamol poisoning is less than 2% overall and 10% in severe poisoning 
 14
[18].  Before usage of NAC as a treatment of choice for paracetamol poisoning, 
renal failure requiring dialysis occurred in approximately 1% of unselected 
patients arriving to hospital following paracetamol overdose [18;91]. In another 
unselected patient series with later presentation (more than 10h), which included 
more severe toxicity, renal failure developed in 21% [90]. This figure increases 
to 50%-70% in patients who have concomitant liver failure [53;92].  
 
In the following section the physiology of kidney function and pathophysiology of 
paracetamol-induced nephrotoxicty are reviewed.  
 
1-3-2: Physiology of Renal function 
 
The kidney maintains the constancy of the extracellular fluid by producing an 
ultrafiltrate of the plasma, free of blood cells and macromolecules, which is 
processed, reclaiming what the body needs, and excreting the rest as urine. 
Every 24 hours, an adult’s kidneys filter 25000 mEq of sodium (total body 
sodium is ~ 1200-2800 mEq), and 180 L of water (total body water is around 
25-60 L). Only 0.5% of the filtered sodium and 1% of filtered water are excreted 
[93]. 
 
Renal function begins with filtration at the glomerulus, which is a highly 
permeable capillary network between afferent and efferent arterioles. The 
relative constriction and dilatation of these arterioles control glomerular 
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filtration rate (GFR). In normal conditions, ~ 20% of the plasma water entering 
in the glomeruli goes through the filter, carrying with it electrolytes and small 
metabolites and leaving behind blood cells and larger proteins. Then, the 
filtrate enters a series of tubules that reabsorb most of it and secrete certain 
molecules such as amino acids and acids/bases into the urinary space. 60-
70% of reabsorption occurs in the proximal tubules. Distal to that is loop of 
Henle, which controls concentration and dilution of the urine. The final part of 
the nephron is distal tubule, which fine-tunes the balance between excretion 
and reabsorption [93]. 
 
 Sodium reabsorption is controlled in the proximal and distal part of the 
tubule. Sodium handling is regulated by hydrostatic and oncotic pressure in 
the peri-tubular capillaries in the proximal tubules; and by hormones such as 
aldosterone in the distal tubules. Water balance is principally regulated by 
the loop of Henle, which makes the medullary interstitium hypertonic; and by 
the level of anti-diuretic hormone (ADH) in the final segment of nephron 
(collecting duct) [93]. Sodium-potassium ATPase (NAKA), also known as 
sodium-potassium pump, in the loop of Henle and collecting duct excretes 
two potassium ions into the lumen in exchange for reabsorption of three 
sodium ions into the blood. The kidneys also regulate potassium and 
hydrogen ions, both of which are affected by aldosterone in the distal tubule 
[94]. The kidney also plays an important role in phosphate homeostasis [95]. 
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1-3-2-1: Renal potassium handling 
 
Potassium is the major intracellular cation in the human body and is 
involved in the regulation of intracellular enzyme function, and 
neuromuscular tissue excitability. The typical Western diet contains 
approximately 70-150 mmol potassium per day. The gastrointestinal (GI) 
tract absorbs potassium efficiently. After absorption from the GI tract, 
potassium is distributed into the intracellular (ICF) and extracellular fluid 
(ECF) compartments. Total ICF potassium body content is 3000-3500 mmol 
in healthy individuals and is primarily located in muscle (70%), with smaller 
amounts present in bone, red blood cells, liver, and skin (Table 1.1). Only 1-
2% of the total body potassium is distributed in ECF [94]. Normally plasma 
potassium has narrow range of 3.5-5.5 mmol/l. The ratio of potassium 
concentration in ICF to ECF is a major determinant of cell membrane 
potential, and intracellular electro-negativity, because of action of 
potassium-selective ion channels. This means that a small change in extra 
cellular potassium concentration can cause a significant effect on 
neuromuscular tissue excitability. Thus, the body has developed complex 






Table 1.1: Distribution of total body potassium distribution in organs and body 




Distribution of total body potassium in organs and body compartments 
Organs and compartment Body compartment concentration  
Muscle  2650 mmol 





Interstitial Fluid 35 mmol 
Red Blood Cells 35 mmol 
Plasma 15 mmol 








With potassium addition to ECF, there is a concomitant shift of potassium from 
the ECF to ICF compartment. Conversely, in the state of potassium depletion 
there is a cellular potassium shift into the ECF, particularly from muscle. This 
process minimises changes in transcellular potassium ratio and membrane 
potential. Accordingly, a small change in ECF potassium concentration is often 
associated with significant change in total body potassium [94;96]. Short-term 
potassium homeostasis occurs via transcellular potassium shifts. There are 
several important factors that affect potassium shift between the ICF and ECF 










Acidosis associated with inorganic anions such as ammonium chloride 
(NH4Cl) and hydrochoric acid (HCL) result in hyperkalemia due to 
movement of potassium out of cells; however, acidosis associated with 
organic acids such as lactic acid have no significant effect on cellular shifts 
of potassium  [97]. 
 
Insulin and ß2-adrenergic receptor activation cause cellular potassium 
uptake by Na+-K+-ATPase stimulation, resulting in lower plasma 
potassium. In contrast, α-adrenergic receptors activation opposes the ß2-
adrenergic receptor effect. Exercise induces α-adrenergic receptors 
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activation and movement of potassium out of skeletal muscle, resulting in 
hyperkalemia [98]. 
 
     The kidney is responsible for long-term potassium homeostasis, primarily 
via urinary potassium excretion, which is regulated extensively by active 
transport in the collecting duct. Potassium is completely ionized and does 
not bind to plasma protein. It is therefore, filtered by the glomerulus (Figure 
1.4). Proximal tubules reabsorb 60-70% of filtered potassium passively, but 
this segment exhibits little regulation in response to changes in dietary 
potassium intake.   
 
    Potassium is then secreted into tubular fluid in the descending limb of loop 
of Henle. The main site of active potassium reabsorption is the thick 
ascending limb of the loop of Henle by the action of “Na+-K+-2Cl- co-
transporter” (Figure 1.5a). Therefore modest net reabsorption of filtered 
potassium usually occurs in the loop of Henle. This reabsorption can be 
altered to secretion by administration of a loop diuretic, or large doses of 
potassium loading. However, the majority of potassium excretion is 
normally modulated by alteration in the rates of active secretion and 
absorption occurring in distal convoluted tubules and collecting duct 
[94;96]. By the end of the distal convoluted tubule, only 10% -15% of 
filtered potassium remains in the tubule lumen. Net potassium transport in 
the collecting duct and outer medullary collecting duct occurs through 
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distinct cell types, named “principal cells” that allow fine regulation of renal 
potassium excretion (Figure 1.5b).  
 
Several factors affect potassium secretion by principal cells. In relative 
order of importance, these factors are: luminal flow rate and distal sodium 
delivery; aldosterone, extracellular potassium and extracellular pH. An 
increase in luminal flow rate induces potassium secretion. In contrast, low 
luminal flow rate status, such as pre-renal uraemia and urinary tract 
obstruction, may result in reduced potassium excretion and hyperkalemia. 
Decreasing apical sodium reabsorption, either from reduced luminal 
sodium delivery or due to sodium channel inhibitors, decreases potassium 
secretion.  Aldosterone increases Na+-K+-ATPase expression and thereby 
stimulates potassium secretion [94].  An increase in ECF potassium 
directly stimulates Na+ -K+ATPase, leading to potassium secretion. 
 
 

















60-70%of filtered potassium is passively reclaimed by the end of the proximal convoluted 
tubules. Potassium is then added to tubular fluid in the descending limb of loop of Henle. The 
main site of active potassium reabsorption is the thick ascending limb of the loop of Henle, so 
that, by the end of the distal convoluted tubule only 10% -15% of filtered potassium remains in 
the tubule lumen. Potassium is secreted mainly by the principal cells of the cortical collecting 
duct and outer medullary collecting duct. Potassium reabsorption occurs via the intercalated 
cells of the medullary collecting duct. Urinary potassium excretion is the result of difference 









Figure 1.5a: Mechanism of potassium reabsorption in the thick ascending loop of 











Finally metabolic acidosis decreases potassium secretion through a direct 
effect on potassium channels, and also through changes in interstitial 
ammonia concentration [101]. Reabsorption of potassium in the medullary 
collecting duct occurs through the action of the intercalated cell (Figure 
1.5c). 
 
      Intercalated cells reabsorb potassium via H+-K+-ATPase which actively 
secretes hydrogen ions [H+] into luminal fluid in exchange for reabsorbed 
potassium. In the status of severe potassium depletion, by this mechanism, 








1-3-2-2: Renal handling of phosphate   
 
The physiological concentration of plasma phosphate in normal adults ranges 
from 0.80–1.44 mmol/l (2.5-4.5 mg/dl), and 80 to 85% of the total body 
phosphate is found in the skeleton. The rest is widely distributed throughout 
the body in the form of organic phosphate compounds. In the extracellular fluid 
phosphate is present mostly in the inorganic form, with over 85% of plasma 
phosphate present as the free ion, the rest being protein-bound. Phosphate 
plays an important role in several aspects of cellular metabolism [95]. Dietary 
intake and GI absorption of phosphate, urinary excretion of phosphate, and 
shifts between the ICF and ECF are major determinants of plasma 
concentration. Abnormalities in any of these steps can cause either hypo- or 
hyperphosphatemia [95;103].  
 
The kidneys play a major role in regulating ECF phosphate homeostasis [104]. 
Under normal conditions, the daily amount of phosphate which is excreted in the 
urine equals that absorbed in the intestine. This comprises 5-20% of filtered 
phosphate. The amount of phosphate which is reabsorbed can be expressed in 
relation to the amount filtered as TRP (total reabsorbed phosphate). TRP is 
calculated from: 
[1- (Cl p / GFR)] * 100 or 1- [(U p * P Cr) / (P p * U Cr)]  
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Phosphate clearance (Cl p), urinary phosphate (U p) and plasma phosphate (P p) 
can all be measured and related to urinary (U Cr) and plasma creatinine. The 
maximal TRP corrected for GFR is called renal threshold phosphate concentration 
(Tm P/GFR) or Bijvoet index [103]. This index represents the concentration above 
which most phosphate is excreted, and below which most reabsorbed. This can be 
estimated from plasma phosphate concentration, and TRP (Figure 1.6).  
 
After passing through the glomerulus, part of the filtered phosphate is reabsorbed 
by the tubules, according to the body’s need.  The majority of phosphate (55-75%) 
is reabsorbed in the proximal convoluted tubules by way of a sodium gradient-
dependent process (Na-Pi co transport) located on the apical brush border 
membrane. Recently two distinct Na-Pi co-transporter proteins have been cloned 
from the kidney (type I and type II Na-Pi co-transporter proteins) [105;106]. Urinary 
excretion of phosphate is modulated by a large number of endocrine and metabolic 
factors, most of which, including alterations in dietary phosphate content and 
parathyroid hormone, have been shown to modulate the proximal tubular apical 








Figure 1.6: Nomogram for the estimation of renal threshold phosphate 






A straight line through the appropriate values of plasma phosphate concentration and 
TRP or Cl p / Cl Cr where Cl is clearance for phosphate (p) and creatinine (Cr) passes 









1-3-2-3: Nephron structure and functional significance of renal 
prostaglandins  
 
Prostaglandins (PGs), prostacyclin and thromboxanes (TX), family of 20-
carbon fatty acids, are synthesised from arachidonic acid in the renal 
tissues (Figure 1.7). PGs have vasodilatory effects and are essential for 
the maintenance of renal perfusion. If there is reduction in actual, or 
effective, circulating volume, they influence water and electrolyte 
homeostasis (Table 1.2). The anatomical sites of production of PGs and 
their metabolites affect their main activity [107;108]. Thus PGI2 is mainly 
found in the glomerulus and is the primary PG that influences glomerular 
hemodynamics [107;109].  
 
Although certain endothelial-derived autacoids such as nitric oxide and 
endothelin-1 balance renal perfusion in both disease and health, PGs have 
minor effects on renal hemodynamics in healthy individuals. However, in 
low renal perfusion states, renal vasodilation is dependent to the presence 
of PGs. Administration of NSAIDs which have inhibitory effects on PG 
synthesis in such circumstances can decrease renal plasma flow and 
glomerular filtration rate (GFR), resulting in an hypoxic insult to the kidney 
[110].   
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Figure 1.7: Metabolic pathway of arachidonic acid cascade (Adapted from [110;111]) 
 
 








                                                                                                                        Arachidonic Acid 
 
                                                                              
  
  Cytochrome P-450                                                                 Cyclo-oxgygenase                (NSAIDs)                                  Lipo-oxygenase                                     
  Mono-oxygenase                                                                         (COX-I, II)                  COX-I and COX-II are irreversibly 
                                                                                                                                         bound by salicylates, reversibly 
                                                                                                                                         bound by other NSAIDs                                                
                                                                                                                                                                                                      Leukotrienes             
    EETs 






                                            Prostacyclin (PG I2)                  Prostaglandins (PGE2, PGD2, PGF2)                  Thromboxanes (TXA2, TXB2) 
                                            antiplatelet aggregation                  erythema, oedema                                                 platelet aggregation                             





EETs: epoxyeicosatrienoic acids; HETEs: hydroxyeicosatetraenoic acids; PG: prostaglandin; TX: thromboxane
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Table 1.2: Effects of renal autacoids in the kidney  ( Adapted from [110]) 
 
    
Location                                                   Autacoid             Response 
 
Glomerular Arterioles       
        
     Afferent                                                       PGI2  *                    Dilation      
                                                                         PGE2                     Dilation 
                                                                                                                                                                 
    Efferent                                                        PGI2                                   Dilation 
 
    Capillary tuft                                                 PGI2                                   Dilation 
 
 
Glomerular Mesangium                                    PGI2                                  Relaxation 
                                                                         PGE2                     Relaxation 
                                                                         TXA2  * *                            Contraction 
 
Proximal tubule (S1 segment)                          5, 6-EET +              Inhibition of Na+-K+-ATPase 
                                                                        12 (R)-HETE ++ 
                                                                         20-HETE 
                                                                    
Loop of Henle 
       Thin segment                                            none                       -                                 
       Thick ascending limb                                5, 6-EET                Inhibition of Na+ -K+ ATPase 
                                                                        12 (R) - HETE 
                                                                        20-HETE 
                                                                         PGE2 
                                                                         PGG2 
                                                                         PGH2 
  
Distal tubule                                                     none-low PGE2        - 
Juxtaglomerular Apparatus                              12 (R) - HETE          Renin releases  
                                                                         PGI2 
   
Collecting tubule, interstitium, and                   PGE2                       Inhibition of ADH or AVP 
Vasa Recta                                                      12-(R)- HETE          Vasodilation 





 PG: prostaglandin * 
TX: thromboxane ** 
EETs: epoxyeicosatrienoic acids + 





The net effect of PGs on renal hemodynamics is the result of interactions 
with a number of other vasoactive compounds in the kidney vasculature. 
While angiotensin II (AII) has minor effects on the afferent arterioles, or 
within the capillaries of the glomerulus, efferent arterioles are extremely 
sensitive to the effect of AII. The vasoconstrictive effects of AII are 
counterbalanced mainly by PGI2 and to a lesser extent by PGE2 [108;109].  
Renin release is also controlled partially by PGI2 [107;108]. Inhibition of PG 
production by administration of NSAIDs can, therefore, affect the renin-
angiotensin-aldosterone system, resulting in hyporeninemic 
hypoaldosteronism, hyperkalaemia and hyponatremia [110;112;113], in 
particular in patients with pre-existing renal impairment. PGE2 is the main 
PG produced in the collecting tubules and interstitium. It is the primary PG 
that influences medullary hemodynamics, and sodium and water handling 
[107;108] (Table 1.2).  
 
PGs have natriuretic effects via two mechanisms: first PGs cause 
vasodilation and increase renal blood flow and subsequently a reduction in 
proximal reabsorption of sodium; secondly, PGs directly inhibit sodium 
reabsorption at the thick ascending limb of the loop of Henle. Thus, 
administration of NSAIDs can cause sodium retention and reduce 




Cytochrome P-450 metabolites of arachidonic acid (HETEs: 
hydroxyeicosatetraenoic acids and EETs: epoxyeicosatrienoic acids) 
(Figure 1.7) are also natriuretic. They are mainly found in the proximal 
tubules and the medullary thick ascending limb of the loop of Henle (Table 
1.2). The primary effect of HETEs is inhibition of “Na+ - K+ - ATPase” at the 
S1 segment of proximal tubules and medullary thick ascending limb, and 
possibly vasodilation of the medullary capillary plexus [110;114].  
 
The enzyme responsible for PG synthesis is cyclo-oxygenase which has 
two isoenzymes known as COX-I and COX-II (Figure 1.7). Both 
isoenzymes are expressed in the kidney. COX-I, which is a constitutive 
enzyme, is expressed in most cells, including platelets. It is involved in 
tissue homeostasis and cell-cell signalling and its inhibition is associated 
with GI bleeding and ulceration. COX-II produces prostanoid mediators in 
inflammatory reactions. The pharmacological effects of some drugs such 
as NSAIDs are due to inhibition of COX-I and COX-II. Most NSAIDs 
currently being used are inhibitors of both isoenzymes and their unwanted 
effects are primarily associated with the inhibition of COX-I. New NSAIDs 
which selectively inhibit COX-II have come on the market, based on the 
hypothesis that by inhibiting only COX-II these agents can be as 
efficacious as nonselective NSAIDs, but with less GI effects. However, 
further studies showed that COX-II inhibitors exhibit the same renal effects 
as non selective NSAIDs. Findings of studies conducted on rofecoxib 
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showed that COX-II is constitutively expressed in the human kidney and 
contributes to production of renal PGs. Thus renal function may be 
adversely affected due to vasoconstriction following NSAID-induced COX-
II inhibition and therefore PG synthesis inhibition, particularly in people with 
underlying renal disease. Rofecoxib and valdecoxib are potent and 
selective COX-II inhibitors [111;115;116] and cases of  acute renal failure  
(ARF) associated with the use of both these agents have been reported 
[115-117].   
 
1-3-3: Pathophysiology of Nephrotoxicity   
 
The kidneys are susceptible to toxic or ischemic injury for five important   
reasons: 
1: while the kidneys make up less than 1% of total body, they receive 20-
25% of cardiac output;  
2: because of high metabolic activity (enzyme systems and transcellular 
transport), they are susceptible to agents that disrupt metabolism;  
3: their ability to remove water from filtrate results in a high concentration 
of toxic substances in the medulla which is harmful to the kidney;  
4: they have the largest endothelial surface by weight;  
5: they alter tubular fluid acidification and this in turn influences plasma 
protein binding.  
All these factors may be affected by toxins [118;119]. 
 33
Injury to any part of the nephron, either glomeruli or tubules, can cause renal 
dysfunction and therefore decrease in GFR and increase in plasma levels of the 
marker substances urea and creatinine. However, the relationship between GFR 
and urea and creatinine is hyperbolic not linear, meaning that a small increase in 
plasma level of these markers denotes a significant renal dysfunction. By the time 
plasma creatinine exceeds the normal range, GFR is already reduced by greater 
than 50% [93]. While nephrotoxins may influence any segment of the nephron 
they usually affect the tubules, the most metabolically active segment of the 
nephron. Glomerular damage may also result from drugs or chemicals. These 
processes are not mutually exclusive, and toxic nephropathy may involve more 
than one part of the nephron (e.g. NSAID-induced ARF and nephrotic syndrome) 













Figure 1.8: Major nephrotoxic processes and the sites of injury induced by 






1-3-4: Acute renal failure (ARF) 
 
ARF is characterized by a sudden decline (hours to days) in renal function 
sufficient to decrease the elimination of urea and creatinine and other 
uraemic toxins [121]. The true incidence of ARF is difficult to determine from 
the literature because of the wide variation in the populations studied, and 
different diagnostic criteria for the definition of ARF. It is generally believed 
that the incidence of ARF in the hospital setting is approximately 5% in all 
patients, and 15-25% in the critically ill patients [122].  ARF can result from 
low renal perfusion without cellular injury; an ischemic, toxic or obstructive 
insult to the tubules; a tubulointerstitial process with inflammation and 
oedema; or a primary reduction in the filtering capacity of the glomerulus.  
 
Traditionally, ARF is classified into three pathophysiological processes: pre-
renal, intrinsic and post-renal failure. If tubular and glomerular function is 
intact, but, renal function is affected by factors compromising renal 
perfusion, the failure is called “pre-renal”.  If the renal dysfunction is caused 
by an obstruction of the urinary outflow tract, it is defined as “post-renal” 
failure; and if the primary source of failure is intra-renal it is termed “intrinsic” 
renal failure. Pre-renal and intrinsic renal failure due to ischemic and 
nephrotoxic insults are the most common causes of ARF [123].  
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1-3-4-1: Pre-renal ARF 
 
Pre-renal ARF is responsible for approximately 70% of community-
acquired [124] and 40% of hospital-acquired ARF cases [125]. Sustained 
hypo-perfusion is the most important predisposing factor for ischemia-
induced tubular necrosis. Pre-renal ARF in the poisoned patient can occur 
from mechanisms leading to hypotension and subsequently renal hypo-
perfusion. These mechanisms include: cardiotoxicity leading to a lower 
cardiac output, vasodilation, vasoconstriction and loss of effective 
circulatory volume due to diuresis, GI fluid loss, bleeding, or third space 
volume such as in a chemical burn. 
 
Nephrotoxins may produce pre-renal failure by affecting the intra-renal 
vasculature, leading to decreased renal blood flow and GFR. Renal blood flow is 
a result of a balance between vasoconstrictors (catecholamines, A II) and 
vasodilator (PG) factors. Some toxins such as NSAIDs inhibit the formation of 
the vasodilatory PGs, causing vasoconstriction. This effect, at therapeutic doses 
of NSAIDs, generally does not compromise renal function, however, in hypo-
perfusion states, such as volume loss, shock or congestive heart failure, it may 
precipitate ARF. Elderly patients are particularly susceptible to pre-renal ARF 
[118;123].
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1-3-5: Risk factors and Mortality of ARF 
 
Risk factors of ARF can be patient related or drug/toxin related (Table 1.3). 
In pre-renal uraemia renal injury is more likely to occur after drugs that 
alter intra-renal haemodynamics, such as NSAIDs [126;127], or reach high 
concentration in the renal tissue, such as aminoglycosides [128]. 
Aminoglycosides are renally excreted and therefore accumulate more 
easily in ARF, and then are concentrated in the kidney and cause injury. 
Patients with a history of renal disease are more susceptible to the 
nephrotoxic drugs [129;130]. Age is also an important risk factor.  Elderly 
patients are more likely to develop ARF and have a poor prognosis 
because of the structural change (reduction in renal size and volume, 
reduction in the number of glomeruls, change in the renal tubules, 
interestitium and renal vessels) and functional changes (reduction in renal 
plasma flow and to lesser extent in GFR) observed in the aging kidney 
[131-133]. Liver disease has been shown to increase the risk of ARF and 
mortality [134]. Patients with non-oliguric renal failure (urinary output  ≥ 400 
ml per day) have a better prognosis [135].  
 
Dialysis requirement in patients with ARF ranges from 20-60%. Less than 
25% of those who survive initial dialysis require long-term dialysis. This 
indicates the potential reversibility of the syndrome [123]. Mortality rate in 
ARF ranges from 7-100% in different population studied. The mortality rate 
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of patients admitted to hospital with pre-renal uraemia has been reported 
as 7% [124]. This increases to 50-100% in patients with post-operative 
ARF [136;137]. In this group of patients ARF will occur largely in the setting 




Table 1.3: Risk factors for Renal Failure (Adapted from [138] 
 
 
Patient-related Risk Factors 
• Age, Sex 
• Previous renal insufficiency 
• Specific disease (diabetes mellitus, multiple myeloma, those associated 
with proteinuria, lupus) 
• Sodium-retaining states (cirrhosis, heart failure) 
• Dehydration and volume depletion 
• Hyperuricemia, hyperuricosuria ) 
• Sepsis, shock 
• Renal transplantation 
 
      Drug-related Risk Factors 
• Inherent nephrotoxic potential  
• Dose 
• Duration, frequency, and form of administration  
• Repeated exposure 
 
 
1-3-6: Laboratory Examinations and Disturbances in ARF 
 
1-3-6-2: Plasma creatinine  
 
Detection of changes in plasma creatinine and urea have long been used as 
conventional surrogate markers for the diagnosis and classification of acute 
renal failure. However, theses markers have some limitations since neither 
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reflect time-course of changes in GFR.  These markers require some time to 
accumulate before being detected in plasma as abnormal, and this potentially 
results in a delay in the diagnosis of the renal dysfunction. Production and 
release of creatinine into plasma can be highly variable. Some factors including 
age, sex, muscle mass (i.e., neuromuscular disease, malnutrition, amputation), 
dietary intake and drugs (e.g., trimethoprim, cimetidine) may affect creatinine 
production and excretion. Moreover, 10-40% of creatinine is excreted by tubular 
secretion and this has the potential to hide a significant initial decline in GFR 
[139]. Nevertheless serum creatinine is still widely used as a surrogate marker 
of renal function by clinicians worldwide, primarily due to simplicity, familiarity 





Hypokalaemia is a common electrolyte abnormality in hospitalised patients. It is 
usually defined as plasma potassium of less than 3.5 mmol/l. Patients with mild 
hypokalaemia (plasma potassium concentration 3.0- 3.5 mmol/l) usually have no 
symptoms. However, patients with more severe hypokalaemia (plasma 
potassium concentration of less than 2.5 mmol/l) may develop generalised 
weakness, muscle necrosis (rhabdomyolysis) and paralysis [140-142]. Both mild 
and severe hypokalaemia increase risk of cardiac arrhythmias [143;144]. 
Hypokalemia also has some other effects including, hormonal, muscular and 
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renal effect [94]. Hypokalemia can be classified in five groups: 
pseudohypokalemia; redistribution or transcellular shift; hormonal imbalance, 
renal potassium loss and other causes.  
 
Pseudohypokalemia: large number of white blood cells in certain disease states, 
such as acute myelogenous leukaemia, when stored for a long period at room 
temperature can take up extracellular potassium resulting in low potassium 
concentration in the laboratory [94]. 
 
Redistribution: more than 98% of total body potassium is located in ICF. 
Therefore, movement of small amount of potassium from ECF to ICF can alter 
plasma potassium concentration markedly. As discussed earlier many hormones 
(insulin, glucagon and aldosterone), ß2-adrenergic agonist, and plasma acid-
base changes stimulate cellular potassium uptake, resulting in hypokalemia 
[94;97;141;145]. 
 
Hormonal imbalance: aldosterone is the most important hormone regulating total 
body potassium homeostasis, resulting in hypokalaemia both by inducing 
potassium uptake into cells, and by increasing potassium excretion [94;141]. 




Renal potassium loss: renal potassium loss is the most common cause of 
hypokalaemia either due to medications, endogenous hormone production, or 
rarely due to intrinsic kidney disease (eg. Bartters’s, Gitelman’s syndrome, 
Liddle’s syndrome). Both thiazide and loop diuretics induce urinary potassium 
excretion in a dose-dependent and treatment duration-related manner 
[94;149;150]. Certain antibiotics such as penicillins [151], aminoglycosides [152], 
and antifungal agents [153] increase renal potassium loss. There have been 
reports of hypokalaemia associated with anticancer drugs such as cisplatin 
[154;155]. Toluene exposure from sniffing certain glues can also cause renal 
tubular acidosis and renal potassium loss [156].  
 
Other causes: magnesium deficiency can cause renal potassium wasting. This 
condition should be considered in any adult patient with hypokalaemia of 
unknown aetiology [157;158]. Any case of increase in distal tubular bicarbonate 
delivery, such as metabolic alkalosis, renal tubular acidosis or treatment of renal 
tubular acidosis can also increase potassium secretion [94]. Hypokalaemia, 
although less frequent, may develop in excessive sweating, chronic diarrhoea, 
vomiting, or prolonged nasogastric suction; however, the main mechanism of 
potassium loss in such circumstances is renal loss due to metabolic alkalosis 




1-3-6-3: Fraction of excretion of filtered electrolytes  
 
The fractional excretion of filtered sodium (Fe Na) can help us to 
differentiate between pre-renal and intrinsic renal failure. Fe Na is 
calculated from: 
Fe Na = (U Na / P Na) ÷   (U Cr / P Cr) × 100 
Fe Na less than 1% is characteristic of pre-renal failure whereas value more 
than 1% indicates with acute intrinsic renal failure [93].  
 
1-3-6-4: Trans-tubular potassium gradient   
 
Trans-tubular potassium gradient (TTKG) is another useful marker of renal 
function. TTKG is a measurement of net K secretion in the distal nephron 
and corrects the urinary potassium for changes in osmolarity that may 
occur with water reabsorption in the collecting duct. TTKG provides an 
indirect measurement of the net potassium secretion of the distal tubules. It 
is calculated from:  
TTKG= (U K/ P K) ÷ (U osm / P osm)  
where U K  and P K  are the concentration of potassium in urine and plasma, 
respectively, and U osm and P osm are the osmolalities of urine and plasma, 
respectively. 
 
TTKG is often used to determine if hyperkalaemia is caused by 
aldosterone deficiency / resistance or secondary to non-renal causes.  A 
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value of less than 5-7 in the setting of hyperkalaemia implies impaired 
distal tubular secretion of potassium due to either aldosterone deficiency or 
resistance. A value of more than 10 indicates increased K intake and 
normal distal nephron handling of potassium [94].   
 
1-3-6-5: Proteinuria and enzymuria 
 
The kidney includes several enzyme systems, found only in specific 
segments of the nephron. Several different tests are being developed 
(enzymuria, renal tubular antigens, to screen for preclinical renal damage. 
The sensitivity and specificity as well as the potential clinical uses of these 
tests remain to be clarified. Additional application of enzymuria tests may 
include a role in localization of site of injury in the nephron. The anatomical 
site of nephrotoxicity may generally be localized by classifying proteinuria 
as either low molecular weight or high molecular weight. Low molecular 
weight proteins such as β2 microglobulin or retinol binding protein, are 
freely filtered at the glomerulus and are taken up by the proximal tubular 
cells, where they are catabolised.  Thus, low molecular weight proteinuria 
is a highly sensitive index of proximal tubular dysfunction. In contrast, high 
molecular weight proteins such as albumin are repelled from glomerular 
filtration because of size and charge restraints. Nephrotoxins that produce 
a loss of glomerular size selectivity or a loss of the glomerular poly-anion 
can cause albuminuria. The Tamm-Horsfall is a specific renal protein 
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located in the thick ascending limb of the loop of Henle. It is a high 
molecular weight protein, and its excretion in the urine increases when this 
segment of the loop of Henle is damaged by toxic agent [93;160].  
 




The mechanism of paracetamol-induced nephrotoxicity is not fully understood. 
Several mechanisms have been suggested. The primary pathological lesion is 
acute tubular necrosis which most often occurs in the context of liver injury 
[83;92]. However, it also occurs rarely in the absence of clinical and biochemical 
evidence of major liver injury [85;90;161]. Evidences of coagulative necrosis of 
the proximal tubular cells, tubular dilation, collection of cellular debris within 
damaged tubules, rupture of tubular membranes, interstitial oedema and 
infiltration with lymphocytes and plasma cells have been shown in the renal 
biopsies and autopsy specimens of patients who developed renal failure 
following paracetamol overdose [162-165]. Interstitial nephritis [166]  and distal 
tubular damage [84] have also been reported. 
 
 Like liver damage, the pathophysiology of renal necrosis after acute 
paracetamol overdose is believed mainly due to formation of NAPQI by P450 
enzymes in the renal parenchyma [18;167;168]. It is likely that the nephrotoxic 
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agent is the quinoneimine metabolite [169]. Further studies indicate that the 
quinoneimine intermediate conjugates with sulphydryl-containing 
macromolecules to cause renal injury [170;171]. While GSH-conjugation is 
primarily considered as a detoxification pathway, experimental studies have 
shown that GSH conjugates of paracetamol metabolism may contribute to 
nephrotoxicity [172].  How the binding of NAPQI-cysteine protein then causes 
renal damage is still not clear. In 1991 Moller-Hartmann and Sieger suggested 
that the mechanism of nephrotoxicity is quite different than that of hepatotoxicity 
in paracetamol overdose, and that paracetamol-S-conjugates might be 
responsible for the nephrotoxic effect of paracetamol [173]. In animal models 
pretreatment with either inhibitors of GGT (gamma glutamyl trans peptidase) or 
the probenecid-sensitive organic anion transporter prevented paracetamol-
induced nephrotoxicity [174;175]. GGT catalyses the initial step in the 
catabolism of GSH conjugates and plays an important roles in the exposure of 
intracellular cells to potentially toxic S-conjugates [176]. One recent 
experimental study suggested a contributory role for paracetamol-GSH-derived 
metabolites in paracetamol-induced renal, as opposed to hepatic injury, that 
involved renal-selective GSH depletion [172].  Acute necrosis in the proximal 
convoluted tubules of the inner renal cortex of the rat was described by Mitchell 
et al. [168] after single non-lethal doses of paracetamol in 1977.  They showed a 
positive correlation between renal injury and degree of covalently bound 
paracetamol in the renal cortex, and also described a negative correlation to 
renal glutathione supply. They suggested that paracetamol is converted to a 
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toxic metabolite by P450 enzyme within the kidney, and that glutathione protects 
against renal damage, in a manner parallel to the liver. 
 
Why the occurrence of renal injury after acute paracetamol overdose is 
uncommon and why some patients are more susceptible to nephrotoxicity is not 
fully understood. This might be due to individual differences in the amount of 
P450 oxidases present in the kidney [164]. An additional factor might be the 
inducibility of oxidative enzyme system. This has been well described in the 
literature [30;177;178]. There are reports of sex differences in susceptibility to 
paracetamol-induced nephrotoxicity in animals [179-181]. Some experimental 
studies have shown that paracetamol-induced nephrotoxicty is more common in 
males [179;180]. The studies suggested that testosterone increases CYP2E1 
activity in the kidney. CYP2E1 is thought to play an important role in the 
metabolic bioactivation of paracetamol resulting in nephrotoxicty. Other 
contributing factors to nephrotoxicity of paracetamol  include volume depletion, 
hepatorenal syndrome, pre-existing renal disease, chronic excessive dosing of 
paracetamol, and co-ingestion with other nephrotoxic drugs [182;183].  
 
Two clinical forms of nephrotoxicity following paracetamol overdose have been 
described. Within 24-48 hours oliguric renal failure develops, accompanied by 
proteinuria and microscopic haematuria. The oliguria usually occurs in the 
context of liver injury and it may last for only few hours or progress to anuria 
requiring haemodialysis [163;184]. The other form of renal failure with a delayed 
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onset is associated with hepatic failure. This form is generally accompanied by a 
multiple organ failure. Endotoxaemia and disseminated intravascular 
coagulation (DIC) have been suggested as aetiological factors in the 
pathogenesis of renal insufficiency [163]. Previous studies have shown that 
plasma renin activity (PRA), atrial natriuretic factor and aldosterone 
concentrations are increased in proportion to the severity of renal failure [185]. 
The increase in PRA is in association with renal vasoconstriction and low renal 
prostaglandin excretion [186].  
 
1-3-7-2: Paracetamol and plasma electrolytes 
 
The adverse effects of aspirin and NSAIDs on the kidney have been previously 
described. NSAIDs interfere with water excretion and natriuresis by PG 
synthesis inhibition,  and, under certain conditions, may reduce renal blood flow 
[187].  The clinical and laboratory features of the renal effects of NSAIDs include 
weight gain, oedema, hyponatraemia, hyperkalaemia and interference with the 
effect of diuretics and antihypertensive drugs [188]. They may also cause acute 
renal dysfunction in patients with underlying kidney disease [189]. Furthermore, 
NSAIDs may cause tubulo-interstitial damage, nephrotic syndrome and renal 
papillary necrosis (analgesic nephropathy) [190].  
 
Paracetamol does not seem to have renal effects similar to NSAIDs, which are 
associated with a more general inhibition of PG synthesis. It does not cause 
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clinically significant fluid and sodium retention, or renal impairment when taken 
in therapeutic doses [187]. Although rare, there have been reports of analgesic 
nephropathy with paracetamol [191].   
 
Haylor and colleagues investigated the renal effects of acute oral administration 
of 1.5 g paracetamol on six healthy female subjects and showed a reduced 
excretion of sodium, water and PGE2 [192]. Berg and colleagues studied the 
acute effect of paracetamol (40 mg/kg/day for 3 days) on renal function and PG 
synthesis. They reported that oral treatment with paracetamol in therapeutic 
doses reversibly reduced thromboxane B2 (TXB2), a potent vasoconstictor, for at 
least 4h after ingestion both in healthy controls and in patients with impaired 
renal function. The study also showed a reduction in PGE2 excretion, a potent 
vasodilator, especially in patients with renal dysfunction, but with no significant 
effect on GFR or plasma electrolytes [193]. Prescott and colleagues, in a study 
on 10 female healthy volunteers given therapeutic dose of paracetamol, (4g 
daily), indometacin (150 mg daily) and placebo for 3 days, showed  paracetamol 
and indometacin had no significant effect of GFR and effective renal plasma flow 
as measured by the renal clearance of inulin, creatinine and PAH (p-
aminohippuric acid) [187]. However, paracetamol, and in particular indometacin, 
did reduce urinary excretion of PGE2. The low urinary excretion of PGE2 induced 
by paracetamol and indometacin was associated with a reduction in urinary 
excretion of sodium and volume retention.  
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Paracetamol acts differently when it is taken in overdose. An animal study [194] 
in which different single toxic doses of paracetamol were given to Wistar rats 
showed  a dose dependent reduction in GFR and renal blood flow (RBF). 
Thereafter distal tubular damage was observed, as detected by alteration in 
renal concentration ability. The time course of this change after a single toxic 
dose of paracetamol (1000 mg/kg) was for an increase in fraction of excretion of 
potassium (FeK) and sodium (FeNa) to reach maximum at 16 hours after 
exposure. FeK and FeNa returned to normal by 24 hours. The authors 
concluded that the early stage of paracetamol nephrotoxicity might be due to 
renal hemodynamic change which may cause tubular dysfunction mainly in the 
distal parts of the medullary tissue. These changes occurred at different doses 
of paracetamol from those usually associated with a reduction in hepatic 
glutathione levels. Renal glutathione reduced only at high doses of paracetamol 
(1000 mg/kg). In this study renal damage occurred in the presence or absence 
of liver damage.   
 
Hypophosphataemia is also a recognised feature of liver failure [195;196] and if 
severe may contribute to the morbidity and mortality by causing mental 
confusion, irritability, coma, blood abnormalities and rhabdomyolysis [197]. It 
has also been described as a general feature of paracetamol poisoning. 
Although the degree of hypophosphataemia is correlated with the severity of 
liver injury, it may also occurs in the absence of clinical or biomedical features of  
liver injury [198]. Several mechanisms, including systemic alkalosis, glucose 
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infusion during NAC therapy, the breakdown of intracellular organic phosphate 
in the presence of intracellular acidosis, and phosphaturia have been suggested 
to contribute in hypophosphataemia. However, the kidney has been suggested 
to play the major role in determining plasma phosphate concentration via the 
degree of tubular phosphate reabsorption and excretion [198-200].  
 
A previous study on patients with paracetamol overdose showed that serum 
phosphate was negatively correlated with markers of liver injury, but, positively 
correlated with plasma potassium concentration [198]. In the same study, the 
renal phosphate threshold concentration (Tm PO4/GFR) was highly significantly 
correlated with degree of hypophosphataemia, and therefore renal loss of 
phosphate rather than intracellular redistribution was considered as the main 
cause of hypophosphataemia [198]. The authors suggested that, although renal 
tubular necrosis in paracetamol overdose is rare, if phosphaturia accounts for 
hypophosphataemia, renal tubular abnormalities appear to be far more common 
than previously recognised and special consideration should be given for 
replacement of phosphate if needed.  
 
A further study [199] in patients with paracetamol overdose confirmed the results 
of the previous study [198] showing a correlation between hypophosphataemia, 
TmPO4/GFR, retinol binding protein (RBP), a biomarker of renal tubular 
damage, and severity of overdose. The authors suggested that both 
phosphaturia and RBP can be used as a marker of nephrotoxicity in 
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paracetamol overdose, however, RBP is a less sensitive marker and increases 
occur only in more severe cases. 
 
1-4: Acetylcysteine (NAC) 
 
1-4-1: NAC, the treatment of choice for paracetamol poisoning 
 
NAC has long been used as an effective antidote in paracetamol poisoning in 
animals [201] and man [202;203]. NAC reduces the extent of glutathione 
depletion following toxic doses of paracetamol [204-206], supports the 
glutathione conjugation of paracetamol, and increases the urinary excretion of 
cysteine and mercapturic acid conjugates of paracetamol following paracetamol 
overdose [18;207].  High doses of paracetamol deplete inorganic sulphate and 
saturate sulphate conjugation. In vitro studies showed that NAC is partly 
metabolised to inorganic sulphates, such as sodium sulphate, and thus supports 
the sulphate conjugation pathway. It also increases the rate of paracetamol 
elimination [208;209].   
 
The optimal route and duration of NAC administration has remained 
controversial. In the US a 72-hour oral regimen has long been used [210] while 
the current protocol for antidote therapy in paracetamol poisoning in the UK, 
Canada and Australia is the Prescott protocol [203], which is a step-down, 20-
hour intravenous (IV) NAC infusion (150 mg / Kg over 15 min in 200 ml 5% 
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dextrose, followed by 50 mg/kg in 500 ml 5% dextrose over 4 hours and 100 
mg/Kg in 1000 ml 5% dextrose over 16 hours). A meta-analysis has shown no 
difference in the outcome between oral and IV NAC regimens, however, a 
shorter hospital stay and the potential reduction in the bioavailability of oral NAC 
due to vomiting and activated charcoal administration make IV NAC regimen 
preferable [210]. For optimal effect it is generally accepted that NAC must be 
given within 10 hours of ingestion. The earlier treatment is given the more likely 
it is to be protective. The protective effect of NAC begins to decline after 8 to 10 
hours and after 12 hours the efficacy rapidly decreases [203;211]. 
 
Patients whose plasma paracetamol concentrations are above the “normal 
treatment line” or “high risk treatment line” in the high risk group are treated with 
IV NAC (Figure 1.2). In remote areas where NAC is not available, methionine, 
which may be prescribed orally, can be given. Providing that the overdose has 
been taken within 10-12 hours and the patient is not vomiting [31].  
 
 When the time of ingestion is not known or when tablets are taken over period 
of several hours (staggered overdose) the plasma paracetamol concentration is 
difficult to interpret. In such circumstances treatment with antidote is 
recommended [31].  
 
Patients who are taking P450 enzyme-inducing drugs including carbamazepine, 
phenobarbital, phenytoin, primidone, rifampicin, alcohol, and St Johns Wort, or 
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who are malnourished (e.g. anorexia, alcoholics, or patients with malabsorption 
or HIV [human immunodeficiency virus] positive) may develop toxicity at a lower 
paracetamol concentration. In this group of patients treatment should be started 
when the paracetamol concentration is above the “high risk treatment line” 
(which is a line plotted at 50% of the normal treatment line [31] (Figure 1.2).  
 
If patients are treated within 10 hours of overdose serious hepatotoxicity is 
uncommon [212]. Without treatment about 60% of patients with a plasma 
paracetamol concentration above the “treatment line” may develop liver injury. 
Of these about 5% will die [213]. The prognostic accuracy of plasma 
paracetamol concentration taken after 15 hours is uncertain, but a concentration 
above the relevant treatment line is considered as carrying a serious risk of liver 
injury [31].  Whether NAC treatment is beneficial in late presentation (>15 h post 
ingestion) and in patients with established liver failure following paracetamol 
overdose is less certain [214]. Studies have suggested that NAC give after 16 
hours, even at the stage of encephalopathy, can improve survival [215;216]. 
Late NAC treatment reduced progression to grade III or IV encephalopathy and 
had a beneficial effect on survival even in patients with poor prognosis [215]. 
The main protective effects of NAC after paracetamol overdose are 
replenishment of reduced intracellular glutathione and detoxification on toxic 
metabolite; however, there are other suggested mechanisms by which NAC 
given in patients with later presentation could be beneficial.  Experimental study 
has shown NAC can restore the capacity of intracellular protelolytic systems to 
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degrade arylated proteins  [217]. Thus in vivo, poisoned cells may remain viable. 
Moreover, neutrophil accumulation within the liver worsens liver damage, and 
the antioxidant properties of NAC may prevent this [215].  
 
1-4-2: Death from low dose paracetamol concentration 
 
There have been reports of death and liver injury in patients with paracetamol 
overdose who had plasma paracetamol concentration under the treatment  
line and therefore, according to protocol, not treated by IV NAC [218]. While 
factors such as inaccurate time of ingestion, unknown number of tablets taken, 
staggered overdose, enhanced susceptibility to liver damage, and co-ingestion 
with other drugs have been suggested to be possible associated factors, 
recently there has been an argument regarding the accuracy of the current 
guideline for the treatment of paracetamol poisoning, in particular when 
identifying high risk patients. It has been suggested that treatment strategy must 
allow a margin of safety that permits some degree of inaccuracy in the patient’s 
history or individual susceptibility to paracetamol [219]. Bridger at al suggested 
changing the current treatment line for use of NAC. They recommended use of a 
lower line passing through 150 mg/l at 4h and 30 mg/l at 12h as the standard 
treatment line and 100 mg/l at 4h for those patients with known risk. This 
standard is widely used in the US [218]. This suggestion has been discussed by 
others [219-226]. While some agreed with this recommendation [219;222], 
others questioned whether there is sufficient evidence for such a change 
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[220;223;225], arguing that only a small fraction of the large group of patients 
who have paracetamol concentration under current treatment line are at risk of 
paracetamol toxicity. Thus, whether using a lower treatment line can justify the 
increase use of in-patient resources that would be needed to treat this 
potentially large population is uncertain, and more information on the occurrence 
of death and liver failure in this group is required [225]. 
 
1-4-3: Effect of NAC on clotting factors 
 
Antidote treatment with NAC reduces the severity of liver injury induced by 
paracetamol overdose [203]. Clotting factors are used as indicators of prognosis 
in fulminant hepatic failure [227], and management decisions in paracetamol 
overdose are partly based on serial measurement of prothrombin time. 
However, NAC itself has been shown to reduce prothrombin index in patients 
with paracetamol overdose [228-230] and also in healthy volunteers [229-231]. 
Prothrombin index measures the relative activity of clotting factor II, VII and X in 
comparison to normal controls. The mechanism behind anticoagulant property of 
NAC is unknown. It is thought that this might be due to destabilization of 
proteins, including clotting factors that contain disulphide bonds [232]. The 
results of previous studies suggest that although the prothrombin index provides 
useful prognostic information, management decisions should not solely rely on 
this value [230].   
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1-4-4: Anaphylaxis and anaphylactoid adverse reactions 
 
The terms anaphylaxis and anaphylactoid reactions were first introduced by 
Charles Robert Richet in 1902 [233].The term anaphylaxis refers to amplified, 
harmful immunologic reactions that occur when the human body is exposed to a 
specific antigen that cross-links antigen-specific IgE molecules. These IgE 
molecules are bound to the surface of mast cells and peripheral basophils. This 
reaction leads to degranulation of mast cell and basophils resulting in immediate 
release of potent mediators such as histamine and tryptase. Furthermore, 
metabolism of arachidonic acid in cell membranes produces other mediators, 
including prostaglandins and leukotrienes (Figure 1.7).  
 
The pre-formed and newly generated mediators of mast cell and basophil 
degranulation are responsible for the sudden and potentially life-threatening 
progression of events involving cardiovascular and respiratory systems, GI 
(gastrointestinal) tract and skin (Figure 1.9 and 1.10). 
 
Initial anaphylactic symptoms include nasal congestion, rhinorrhea, 
conjunctivitis, flushing, pruritus, nausea, vomiting, diarrhoea, urinary urgency 
and uterine cramp. In more severe cases patients may develop hypotensive 
shock and cardiovascular collapse, laryngeal bronchospasm, asphyxia and 
death. Symptoms usually occur within 20 minutes following exposure to the 
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agent; however, the time course can be variable. In general, larger oral doses 




Figure 1.9: Mediators responsible for the signs and symptoms of anaphylactic 





































In anaphylactoid reactions the same chemical mediators that cause clinical 
signs and symptoms of anaphylaxis are also involved, but, the mechanism of 
mediator release and the immediate systemic reactions are not caused by an 
IgE-mediated immune response [236] and in most cases are not fully 
understood. 
 
There are discrepancies in the definition of anaphylaxis and anaphylactoid 
reactions among different physicians. Some define it as skin involvement only, 
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and others define a more severe adverse reaction involving cardiovascular, 
respiratory and gastrointestinal features.  It may be difficult in an individual 
patient to be completely certain of the mechanisms involved, and whether 
immunological or non-immunological processes are causative. 
 
1-4-4-1: Adverse Reactions to NAC 
 
Since the introduction of the NAC treatment regimen for paracetamol overdose 
in 1979, there have been reports of anaphylactoid adverse reactions. The first 
adverse reaction to NAC was reported by Walton et al in 1979 [237]. The 
reported frequency of such reactions, has varied from 3-9% [238-240] to 48.4% 
[241]  in different population of patients with paracetamol overdose who were 
treated with NAC. 
 
The full profile of adverse reactions reported includes rash, pruritus, flushing, 
nausea and vomiting, coughing, dyspnoea, chest pain, bronchospasm, 
wheezing, angioedema, hypotension, hypertension, tachycardia, ECG changes, 
and fever [240;242;243]. Some patients seem to be more susceptible to adverse 
reactions from IV NAC. It has been suggested that asthma is a risk factor for 
NAC ADRs [244;245] and there has been a report of death in an asthmatic 
patient [246]. Some studies report that plasma paracetamol concentration is 
lower in patients with ADRs [239;241;245]. The high incidence of ADRs to IV 
NAC (50%) in healthy volunteers not receiving paracetamol is further evidence 
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that paracetamol itself may have some protective effect against ADRs to NAC 
[231]. 
 
The pathophysiological mechanisms involved in ADRs to NAC are not fully 
understood. In a human study an intra dermal injection of NAC caused a wheal 
and flare reaction. Some authors suggest that a non-allergic release of 
histamine which was a direct, dose-dependent effect of NAC to which individuals 
had variable susceptibility, was the potential mechanism of ADRs [247]. An in 
vitro study has shown histamine release is induced by NAC [248].  Previous 
studies on acute allergic reactions and anaphylactic shock in other situations 
have shown an increase in plasma concentrations of mast cell products 
(histamine and tryptase) [249-252], endothelial injury parameters (von 
Willebrand factor [vWf]) and fibrinolytic parameters (tissue plasminogen activator 
[tPA] [251]. Healthy volunteers given antidotal doses of NAC intravenously who 
developed adverse reactions had elevated factor VIII and vWf within an hour of 
starting IV infusion of the therapeutic dose of NAC (400 mg/kg, over 36h, 
distributed as a 150 mg/kg bolus over 15 min, 50 mg/kg over 4h, and 200 mg/kg 
over 32h). The authors suggested that NAC induces release of vWf from 
endothelial cells in subjects who develop adverse effects [231]. 
 
Interleukin 6 (IL-6) is known to be secreted by mast cells and basophils and has 
also been reported to contribute in allergic reactions [253]. As it has a longer 
half-life (48h) than serum histamine and tryptase, it has been suggested that  
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IL-6 could have a place as a biomarker in the diagnosis of anaphylactoid 
reactions [254]. IL-6 also stimulates C-reactive protein (CRP) production and the 
two correlate with one another in various conditions [255;256] and in acute 
allergic reactions [257]. Whether these response mechanisms apply in patients 
with paracetamol overdose is unknown.  
 
There is a need to better understand the risk factors for these reactions since 
they result in temporary cessation of antidote therapy, cause patient distress, 
and delay treatment and discharge. If the mechanisms were better understood, 

















Paracetamol is the most common analgesic and antipyretic over the counter 
drug and is well tolerated at therapeutic dose by adults and children. It also has 
weak anti-inflammatory effect. The mechanism of action of paracetamol includes 
inhibition of cyclo-oxygenase and prostaglandin synthesis; however, the precise 
mechanism of action is still unclear. In overdose it causes toxicity and this is a 
major public health problem in the UK. Forty percent of all overdose 
presentation to the hospital involve paracetamol, and it is the main cause of 
acute liver failure, resulting in several hundred liver unit admissions and 
substantial deaths each year in the UK.  The liver is the main target organ 
affected in paracetamol overdose.  
 
The kidney controls electrolyte and acid-base homeostasis, and maintains 
the content of extracellular fluid. Nephrotoxicity may be caused by a wide 
variety of drugs and substances which are readily available in routine life, 
and the workplace. Nephrotoxic agents can cause different types of renal 
failure according to the site of action. Acute tubular necrosis is the most 
common type of acure renal failure caused by drugs.  
 
Cyclo-oxygenase I and II are both expressed in the kidney and synthesise 
prostaglandin in the kidney. Prostaglandins are essential for the 
maintenance of renal perfusion. If there is reduction in actual, or effective, 
circulating volume, they influence water and electrolyte homeostasis. 
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Some drugs including NSAIDs have inhibitory effects of cyclo-oxygenase 
resulting in renal failure, in particular in patients with risk factors. Such an 
acute renal impairment is mediated through inhibition of renal 
prostaglandin synthesis, resulting in vasoconstriction and renal 
hypoperfusion. The kidney is also involved in paracetamol toxicity, even in 
the absence of liver injury. The mechanisms of nephrotoxicity are not fully 
understood; however, a specific renal effect of paracetamol possibly due to 
inhibitory effect on cylo-oxygenase and prostaglandin synthesis has been 
suggested. Electrolytes abnormalities, in particular potassium 
abnormalities may occur following renal dysfunction, including drug-
induced acute renal failure.  Early diagnosis, recognition of associated risk 
factors, prevention and follow up of different kidney diseases, in particular 
drug-induced nephropathy, is an important issue in the practice of 
medicine. Whether the toxic effects of paracetamol on the kidney are due 
to similar mechanisms to NSAIDs remains unclear. The relationship 
between renal and hepatic damage in paracetamol overdose is also 
uncertain. 
 
NAC is a treatment of choice in paracetamol poisoning. Some patients develop 
adverse reactions following intravenous infusion of NAC. The mechanisms of 
the reactions are not clear. A possibility of histamine related mechanism for the 
adverse reactions has been suggested.  
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1-6: The focus of the thesis 
 
This thesis composes of studies in which different aspects of paracetamol 
poisoning have been explored.  The main focus of the first three studies is on 
the nephrotoxic aspects of paracetamol overdose. Initially the effect of 
paracetamol overdose on plasma electrolytes was examined, and then the 
mechanisms involved in plasma electrolyte change were identified in a 
prospective intensive study, based on data collected from timed blood and urine 
collections at intervals after overdose. In the third study the frequency of renal 
injury on patients with severe paracetamol overdose admitted to a liver unit was 
assessed retrospectively, and risk factors for renal injury and poor outcome 
assessed. 
 
The last three studies focus on the treatment of paracetamol poisoning. In the 
fourth study the frequency of liver failure in patients who had paracetamol 
concentrations under the current “treatment line” and who, therefore were not 
treated with NAC, was explored. In the fifth study the risk factors for adverse 
reactions to IV NAC in a cohort of patients requiring therapy were examined. 
Finally, a small intensive study investigating the mechanisms of adverse 
reactions to NAC was conducted in patients with paracetamol overdose who 









Chapter II: Effect of Single Paracetamol Overdose on Renal 







































A number of mechanisms have been proposed to explain the analgesic and 
antipyretic effects of paracetamol. Paracetamol can inhibit cyclo-oxygenase 
(COX) but, in contrast to non-sterodial anti-inflammatory drugs (NSAIDs), does 
not have anti-inflammatory effect due to lack of peripheral inhibition of 
prostaglandin (PG) synthesis [258]. Selective inhibition of COX-III by 
paracetamol, a variant of COX-I resulting in central inhibition of PG synthesis 
was proposed by Chandrasekharan [11]. However, there is also some in vivo 
evidence showing that, in addition to its CNS inhibitory effects on COX-III, 
paracetamol can, in fact, inhibit COX-II systemically in a manner similar to the 
selective COX-II inhibitors [8;10]. 
 
Renal PG production is mediated primarily by COX, and plays a major role in 
compensatory renal hemodynamics. NSAIDs have a variety of effects on the 
kidney. Severe adverse renal effects may be in part due to vasoconstriction, 
consequent upon inhibition of renal PG-mediated vasodilatation. This  
decreases renal blood flow, and results  in a reduction in glomerular filtration 
rate [259]. NSAID-induced acute renal failure depends on the drug, dose, 
duration of pharmacologic effect, and the health of patient. Generally, 
individuals who are well hydrated and have normal renal function are unlikely to 
develop acute renal failure [260].  
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Paracetamol in overdose can cause renal failure. The actual mechanism of 
paracetamol-induced nephrotoxicity in man is not fully understood. There is a 
possibility that at high doses paracetamol-induced nephrotoxicity may be due to 
local haemodynamic changes, perhaps through COX inhibitory effects in the 
kidney similar to classical NSAIDs. It has previously been shown, in a study on 
Wistar rats, that single doses of paracetamol caused a significant reduction in 
glomerular filtration rate (GFR) and renal blood flow in a dose dependent 
manner [194]. This altered tubular function, mainly in the distal tubules, 
observed as a change in renal concentrating ability. The maximum changes 
were observed at 16 h post-ingestion, and after 24 h renal function was 
restored. The authors suggest that the early stage of paracetamol-induced 
nephrotoxicity might be due to vasoconstriction. Other work has shown 
phosphaturia after paracetamol overdose, possibly due to tubular effects of 
paracetamol [198;199]. However, studies on therapeutic doses of paracetamol 
have found no effect on plasma electrolytes in man [193;261]. 
 
It has previously been shown that in overdose NSAIDs, such as ibuprofen, 
increase fractional excretion of potassium and cause sodium retention [262] an 
effect that might to be due to renal vasoconstriction and consequent activation 
of the renin-angiotensin-aldosterone system.  
 
It was hypothesized that paracetamol in overdose might cause similar tubular 
effects to NSAIDs via inhibition of PG synthesis, secondary vasoconstriction and 
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activation of renin-angiotensin-aldosterone system which would be identified by 
change in electrolyte handling and urine electrolytes.  
 
In this chapter two separate studies, retrospective and prospective, conducted 
on patients with paracetamol overdose will be discussed. In the retrospective 
study the effect of paracetamol overdose on plasma electrolytes and in the 
prospective study its effect on plasma and urine electrolytes were investigated. 
 




A retrospective cross-sectional study was conducted on patients, male and 
female, age 16-60 year-old, presenting with single acute paracetamol overdose 
within 6 hours (h) post-ingestion and admitted to the toxicology ward of Royal 
Infirmary of Edinburgh from January 2002 to May 2006. Information regarding 
name of tablets taken, time of ingestion, time of presentation to the hospital, 
acetylcysteine (NAC) treatment, other treatment, change in blood pressure and 
past medical history was collected from patient notes. Laboratory test results 
(plasma paracetamol, plasma sodium [Na] and potassium [K] and plasma 
creatinine [Cr]), time and date of sample collection were obtained from the 
hospital laboratory computer system. 
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Case notes of patients presenting within 6 h of a stated ingestion of single 
paracetamol were reviewed. Records of patients who had at least two blood 
tests at 4-6 and 12-24 h post ingestion were extracted and examined to exclude 
later presentations to the hospital (after 4-6 h post-ingestion), mixed overdose, 
staggered overdose (taking tablet over period of longer than 2 h), pregnancy, 
and chronic underlying diseases, including history of kidney disease, liver 
disease, heart disease, hypertension and diabetes. Patients who had  
co-ingested benzodiazepines and/or ethanol with paracetamol were included, as 
these compounds are not thought to be nephrotoxic. Patients who were on 
regular prescribed potentially nephrotoxic drugs according to the British National 
Formulary [31] and cases with missing information, were excluded from the 
study. 
 
The biochemistry results of blood samples on admission (within 4-6 h post-
ingestion) and 12-24 h post-ingestion (plasma paracetamol, Cr, Na, K, and 
bicarbonate [HCO3]) were extracted from the hospital computerised laboratory 
results system. The relationships between plasma paracetamol concentration at 
admission, “4 h”, and subsequent changes in plasma electrolytes seen during 
the period of admission were examined. 
 
Patients were divided into three subgroups according to the plasma 
paracetamol at 4 h post-ingestion for illustrative purposes: group 1: patients with 
plasma paracetamol <100 mg/l (low risk treatment threshold), group 2: patients 
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with plasma paracetamol 100-199 mg/l (high risk treatment threshold), and 
group 3 with plasma paracetamol ≥200 mg/l (normal treatment threshold). In the 
UK NAC is differentially given to patients with specified “risk factors” [31] in 
addition to a high plasma paracetamol.   
 
2-2-2: Statistical analysis  
 
 SPSS version 11.5 was used for statistical analysis. The data was normally 
distributed; and therefore parametric tests were used for statistical analysis.  
Demographic data and two group comparisons were compared using unpaired 
independent student t-test and Mann-Whitney U test as appropriate. Multiple 
comparisons were made by one-way analysis of variance (ANOVA) with post-
hoc Bonferroni test and Kruskal-Wallis H test as appropriate. Correlation 
between variables was made by Pearson correlation test.  Data are reported as 
mean ± standard error of the mean (sem).   
 
2-2-3: Results  
 
 155 patients with paracetamol overdose met the inclusion criteria. 38% were 
male (n=59) and 62% (n=96) female. The patients had mean age of 32.3 ± 2.6 
years. There was a significant correlation (R2=0.10, p<0.0001, n=155, Figure 
2.1) between admission plasma paracetamol (mg/l) and fall in plasma 
potassium (mmol/l) between the admission and second blood sample. The 
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mean time between blood samples was 22.0 ± 0.37 h. The negative dose-
dependent relationship between plasma paracetamol at 4 h and fall in plasma K 
remained when only patients receiving NAC were considered (r= -0.25, p<0.01, 
n=139, reduction in plasma K from 3.86 ± 0.04 to 3.46  ± 0.03 mmol/l, n=139).  
 
 
Figure 2.1: Relationship between plasma potassium change (mmol/l) between 
admission (4 h) and follow-up plasma K and plasma paracetamol (mg/l) at 4 h post 
ingestion in the retrospective study. Mean time difference between two samples was 































When patients were grouped according to admission paracetamol level, the 
mean plasma paracetamol was 69.9 ± 4.4 mg/l in group 1 (<100 mg/l, n=18), 
146.0 ± 3.4 mg/l in group 2 (100-199 mg/l, n=69), and 283.3 ± 9.5 mg/l in group 
3 (≥200 mg/l, n=68). The mean reduction in plasma potassium in the group with 
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highest paracetamol concentration was -0.5 ± 0.05 mmol/l. There was a 
significant difference in change in plasma potassium between groups with low 
 (-0.08 ±  0.10 mmol/l) and high (-0.50 ± 0.05 mmol/l), (p<0.01), and medium 
 (-0.31 ± 0.05 mmol/l) and high paracetamol concentration at admission, 
(p<0.05) (Figure 2.2). 
 
Figure 2.2: Change in plasma potassium (mmol/l) in the groups according to the plasma 
paracetamol concentration at 4h in the retrospective study. 
 
Data shown by risk category (plasma paracetamol <100 mg/l (low, 69.9 ± 4.4, n=18), 100-199 
mg/l (medium, 146.0 ± 3.4, n=69), and ≥ 200 mg/l (high, 283.3 ± 9.5, n=68), in box and whisker 
format (Median, interquartile box). There was a significant difference in the change in plasma 
potassium between groups with low (-0.08 ± 0.10 mmol/l) and high (-0.50 ± 0.05 mmol/l), 
(p<0.01), and medium (-0.31 ± 0.05 mmol/l) and high paracetamol concentration at admission, 
(p<0.05) Circle shows outliers which are cases with values between 1.5 and 3 box lengths from 
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If only patients receiving NAC were considered, the negative dose-dependent 
relationship between plasma paracetamol at 4 h and plasma potassium change 
remained (R2: 0.06, p<0.01, n=139, and plasma potassium fell from 3.86 ± 0.04 
to 3.46 ± 0.03 mmo/l) (see table 2.1 for the number of patients treated with NAC 
and plasma paracetamol concentrations in each group). 
 
Table 2.1: Numbers of subjects in each group according to the plasma paracetamol 
level at 4 h and NAC treatment in the retrospective study. n=155.  
   
n Plasma paracetamol (mg/l)  Groups  
according to plasma 





With NAC Without NAC 
Group 1 10 8 56.29 ± 8.29       78.00 ± 3.29          
Group 2 61 8 145.59 ± 3.54     149.00 ± 11.60      
Group 3 68 0 283.31 ± 9.46   - 
 
 
Blood pressure did not change significantly in either paracetamol or control 
group. Vomiting did not affect change in plasma K significantly (plasma K in the 
group with vomiting: -0.38 ± 0.05 mmol/l, n=94, vs. group without vomiting: -0.34 
± 0.06 mmol/l, n=61). There was neither correlation between plasma 
paracetamol and changes in plasma HCO3 nor between change in plasma K 
and plasma HCO3. There was also no correlation between changes in plasma 








 A prospective cohort study was conducted on patients, presenting with a single 
paracetamol overdose and admitted to the toxicology ward of the Royal 
Infirmary of Edinburgh from July 2004 to April 2006. Subjects who were 
recruited to the prospective study were not included in the retrospective study. 
Inclusion criteria were patients, male and female, aged 16y and over, with single 
paracetamol overdose with or without alcohol co-ingestion, presenting to 
hospital within 6 h post-ingestion. Exclusion criteria included later presentations 
to hospital (>6 h post-ingestion); mixed overdose; staggered overdose; 
pregnancy (relied on patient history and physical exam, not specifically verified 
by pregnancy test); underlying chronic disease, including history of kidney 
disease, liver disease, heart disease, hypertension and diabetes, patients who 
were on regular prescribed potentially nephrotoxic drugs; patients who were not 
conscious at admission, and those who had learning difficulty. Patients who 
withdrew from the study or were not able to give blood and urine samples within 
6 h and/or at least one blood and urine samples at either 12 h or 24 h post-
ingestion were also excluded. As a control group patients with single overdose 
of fluoxetine or paroxetine according to the patient’s history were recruited as an 
example of SSRI ingestion (selective serotonin reuptake inhibitors). Inclusion 




The study was approved by the local Ethics Committee, and informed consent 
was obtained on admission (see appendix 2.1, 2.2, 2.3 and 2.4). Subjects were 
interviewed at admission to hospital, and information regarding name of tablets 
taken, alcohol ingestion, time of ingestion, time of presentation to the hospital, 
vomiting, medical history and drug history was obtained (see appendix 2.5, 2.6 
and 2.7). 
 
At 4 to 6 h after ingestion, a paired blood sample (5ml) for measurement of 
plasma paracetamol and salicylates, plasma Na, K, HCO3, Mg, PO4, Cr, 
osmolality) and a urine sample (10ml, in universal container, for measurement 
of urine Na, K, Mg, PO4, Cr, osmolality) were collected. When subjects were not 
able to give a urine sample at the time of blood collection a urine sample was 
taken within two h of blood collection. Further paired blood and urine samples 
were taken at 12 h and at 24 h post ingestion. Blood and urine samples were 
sent to the Biochemistry laboratory, Royal Infirmary of Edinburgh, within 30 
minutes of collection for analysis.  Not all patients complied fully with urine 
collection protocols, and data reported relates to subjects completing a 
particular study component, however, all subjects included in the analysis had 
paired blood and urine samples  taken within 6 h and at least another paired 
blood and urine samples at either 12 h or 24 h post-ingestion.  
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Fractional excretion (Fe) in percent was calculated for Na, K, PO4 and Mg from 
[urinary/plasma concentration of electrolyte] x [plasma/urinary concentration of 
Cr]*100. Trans tubular potassium gradient (TTKG) was calculated from 
[urinary/plasma K] x [plasma/urine osmolality]. Renal threshold of phosphate 
concentration (TmP/GFR: the ratio of the maximum rate of renal tubular 
phosphate reabsorption to the glomerular filtration rate [GFR]) was calculated 
based on an established nomogram [103].  
 
The relationships between plasma paracetamol at admission “4 h level” with 
changes in plasma and urine electrolytes at 12 h and 24h post-ingestion were 
examined. The predictive value of urinary electrolytes in early detection of 
creatinine rise was also studied. We grouped patients into 3 subgroups 
according to the plasma paracetamol at 4 h post-ingestion for illustrative 
purposes: group 1: patients with plasma paracetamol less <100mg/l, group 2: 
patients with plasma paracetamol 100-199 mg/l, and group 3 with plasma 
paracetamol 200 mg/l and above.  
 
Blood pressure and pulse rate was recorded at admission and at the time of 
blood and urine collection. The observational chart documented routinely by 
nursing staff was also reviewed to exclude haemodynamic compromise as a 
cause of renal dysfunction. Systolic blood pressure less than 90 mmHg or 
diastolic blood pressure less than 50 mmHg was considered as hypotension. 
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2-3-2: Laboratory techniques  
 
Plasma paracetamol was measured by an enzymic method using aryl acyl 
amidase to produce p-aminophenol which reacts with tetrahyroquinoline and 
was measured at 670 nm on a Vitros 250 analyser. Plasma and urine Na and K 
were measured by indirect reading in selective electrolytes on Olympus AU 
2700 analyser. Plasma and urine Mg were measured by complexing to Xylidyl 
blue in a basic solution and measured at 520 nm on an Olympus AU 2700 
analyser.  Plasma and urine inorganic PO4 were measured by complexing to 
molybdate and measured at 340 nm on an Olympus AU 2700 analyser. Plasma 
HCO3 was measured by enzymic method: phosphoenolpyruvate carboxylase 
linked to malate dehydrogenase was measured at 340 nm on an Olympus AU 
2700 analyser. Plasma and urine osmolality were measured using freezing point 
depression.  Plasma and urine Cr were measured using kinetic colour test (Jaffe 
method) on Olympus AU 2700 analyser (all laboratory tests were performed by 
laboratory technicians in the Royal Infirmary of Edinburgh clinical laboratories).  
 
2-3-3: Statistical analysis 
 
 SPSS version 11.5 was used for statistical analysis.  Data was tested for 
normality. As data in each group was not normally distributed, non-parametric 
tests were used for comparison analysis. Mann-Whitney U test was used for 
two-group comparison. Multiple comparisons between groups were made using 
Kruskal-Wallis H test. Correlation between variables was made using Pearson 
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and Spearman correlation test as appropriate. Data are reported as mean ± 




41 cases of paracetamol overdose, 16 male and 25 female, and 18 cases of 
SSRI overdose (16 fluoxetine and 2 paroxetine), 7 male and 11 female, 
completed the study. In both groups 39% were male and 61% female. There 
was no significance difference in either group in respect of age and gender. In 
the paracetamol group mean age was 30.0 ± 1.9 years and in the control SSRI 
group 28.6 ± 2.6 years (Table 2.2). In the paracetamol group, a kaliuresis 
occurred at 12 h. FeK and TTKG at 12 h post-ingestion were significantly 
correlated with plasma paracetamol at admission (r=0.55, n=34, p<0.01 and 
r=0.46, n=34, p<0.01, respectively).  
 
FeK and TTKG at 12 h were significantly different between groups with low and 
medium (p<0.01 and p<0.05, respectively), and between low and high plasma 
paracetamol at admission (p<0.01 in both cases, Figures 2.3 and 2.4). This 






Table 2.2: Demographic characteristics of subjects and study variables in   




Groups number mean± sem          Significance level 





Paracetamol 41 30.04 ± 1.89             Age (Y) 
SSRI 
 
18 28.59 ± 2.63 
NS 
Paracetamol 37 -0.28 ± 0.05              Change in plasma K  




18 -0.07± 0.08   
p<0.01 
Paracetamol 31 -0.23± 0.09               Change in plasma K 




10 -0.05 ± 0.18 
NS 
Paracetamol 41 16.06 ± 1.46              
FeK at 4 h (%) SSRI 
 
18 8.74 ± 1.43 
p<0.01 
Paracetamol 34 16.47 ± 1.70              
FeK at 12 h (%) SSRI 
 
16 11.38 ± 1.80 
p=0.05 
Paracetamol 31 7.35 ± 1.2                  
FeK at 24 h (%) SSRI 
 
9 7.20 ± 1.48 
NS 
Paracetamol 40 300.08 ± 3.55           Plasma osmolality  
at 4 h (mosmol/kg) SSRI 
 
17 302.71± 3.91            
NS 
Paracetamol 37 290.24 ± 2.06           Plasma osmolality  
at 12 h (mosmol/kg) SSRI 
 
18 294.83 ± 2.76 
NS 
Paracetamol 32 287.69 ± 1.29           Plasma osmolality  
at 24 h (mosmol/kg) SSRI 
 
10 288.90 ± 1.62           
NS 
Paracetamol 41 600.12 ± 49.09         Urine osmolality  
at 4 h  (mmol/kg) SSRI 
 
18 581.11 ± 65.81 
NS 
Paracetamol 34 659.94 ± 48.55         Urine osmolality  
at 12 h  (mmol/kg) SSRI 17 777.53 ± 68.99 
NS 
Paracetamol 31 462.26 ± 42.89         Urine osmolality  
at 24 h  (mmol/kg) SSRI 9 905.22 ± 42.80         
P<0.01 
Paracetamol 32 -0.94 ± 1.35            Change in plasma creatinine 
at 12 h (µmol/l) SSRI 
 
9 2.22 ±1.64            
NS 
Paracetamol 37 -1.68 ± 0.83            Change in plasma creatinine 
at 24 h (µmol/l) SSRI 
 







Figure 2.3: Time course of FeK changes according to plasma paracetamol at 4 h in the 
prospective study.  
 
 
Data shown by risk category (plasma paracetamol <100 mg/l (low, 61.3 ± 6.5), 100-199 mg/l 
(medium, 141 ±. 5.4), and >=200 mg/l (high, 286.6 ± 30.0), in box and whisker format (Median, 
interquartile box). FeK at 12 h was significantly different between groups with low and medium 
(p<0.01) and low and high plasma paracetamol (p<0.01). Para: plasma paracetamol (mg/l). 
(Circle shows outliers which are cases with values between 1.5 and 3 box lengths from the 
upper and lower edge of the box. The box length is the interquartile range. Asterisk shows 
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Figure 2.4: Time course of TTKG changes according to plasma paracetamol at 4 h in 
the prospective study.  
 
 
Data shown by risk category (plasma paracetamol <100 mg/l (low, 61.3 ± 6.5), 100-199 mg/l 
(medium, 141 ±. 5.4), and ≥ 200 mg/l (high, 286.6 ± 30.0), in box and whisker format (Median, 
interquartile box). TTKG at 12 h was significantly different between groups with low and medium 
(p<0.05) and low and high plasma paracetamol (p<0.01). Para: plasma paracetamol (mg/l). 
(Circle shows outliers which are cases with values between 1.5 and 3 box length from the upper 
and lower edge of the box. The box length is the interquartile range. Asterisk shows extremes 
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At 24 h, plasma potassium was in a negative dose-dependent relationship with 
plasma paracetamol (r= -0.54, p<0.01, n= 31, Figure 2.5). No relationship was 
seen in the control SSRI group between stated dose of ingested drug and 
plasma K or FeK. The mean plasma K change was significantly different 
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between paracetamol group and control group at 12h (-0.28 ± 0.05 mmol/l vs. -




Figure 2.5: Relationship between plasma potassium (mmol/l) at 24 h post-ingestion and 
plasma paracetamol (mg/l) at 4 h in the prospective study, r= -0.54, n=31, p<0.01.  
 


























No effect on plasma or urinary electrolytes was seen in the SSRI group. There 
was no relationship between stated ingested doses of SSRI and plasma or urine 
electrolytes. Plasma and urine electrolytes did not significantly change at 








Table 2.3: Fraction excretion of electrolytes (Na, Mg, PO4) at different time 
points after ingestion in the control group (SSRI). Nonparametric test (Kruskal- 













Mean±sem n Mean±sem n Mean±sem n  
FeK (%) 8.78±1.43 18 11.38±1.8 16 7.18±1.48 9 NS 
Plasma K (mmol/l) 4.00±0.07 18 3.93±0.06 18 3.94±0.11 10 NS 
FeNa (%) 0.57±0.08 18 0.46±0.06 17 0.41±0.07 9 NS 
Plasma Na (mmol/l) 140.28±0.44 18 140.72±0.39 18 139.5±0.82 10 NS 
FeMg (%) 3.09±0.37 18 1.89±0.24 17 2.7±0.47 9 p<0.05 
Plasma Mg (mmol/l) 0.84±0.02 18 0.83±0.02 18 0.87±0.02 10 NS 
FePO4 (%) 9.38±2.20 18 18.78±2.10 15 14.22±3.23 9 NS 
Plasma PO4 (mmol/l) 1.09±0.05 18 1.17±0.04 16 0.91±0.12 10 NS 
 
 
There was consequently a significant difference between paracetamol and SSRI 
group in FeK at 4 h and plasma K change at 12h (p<0.01). The difference in 
FeK at 12 h between 2 groups was in borderline significance difference 
(p=0.05). The difference in FeK and plasma K change had disappeared by 24 h 
(Table 2.1).  
 
In both groups (paracetamol and SSRI) the ratio of urinary osmolality to plasma 
osmolality (U/P) was high at 4 h (U/P osmolality at 4 h: 2 in paracetamol group 
and 1.9 in SSRI group) and 12 h (U/P osmolality at 12 h: 2.2 in paracetamol 
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group and 2.6 at SSRI group), but, there was no significant difference between 
groups. In the paracetamol group U/P osmolality was restored after 24 h (U/P 
osmolality at 24 h: 2); however, this continued increasing in the SSRI group 
(U/P osmolality at 24 h: 3.1) and that was significantly higher than that of 
paracetamol group (p<0.0001) (Table 2.2). There was no significant difference 
in plasma and urinary excretion of K and PO4 at 4 h, 12 h and 24 h in the 
paracetamol group with (n=31) and without (n=10) co-ingestion of alcohol. 
 
Plasma paracetamol was in a negative dose dependent correlation with plasma 
PO4 (mmol/l) (r=-0.44, n=39, p<0.01) and renal threshold phosphate 
concentration (TmP/GFR, mmol/ll) (r=0-0.33, n=38, p<0.05) at 4 h (Figure 2.6). 
Plasma PO4 decreased at 12 h and 24 h but FePO4 increased at 12 h and 
consequently decreased at 24 h (Table 2.4). In SSRI group plasma PO4 and 
FePO4 did not change significantly at 12 h and 24 h (Table 2.3). 
 
Plasma and urinary Mg did not change in the paracetamol group (Table 2.4), 
however, in the SSRI group there was a reduction in FeMg at 12 h. FeNa 
reduced in paracetamol group without any significant change in plasma Na. No 






Table 2.4: Plasma  concentrations and fractional excretion of electrolytes (K, Na, Mg, 




4 h 12 h 24 h Variables 
Mean ±sem n Mean ±sem n Mean ±sem n 
Sig. 
level 
FeK (%) 16.07±1.47 41 16.47±1.70 34 7.36±1.20 31 P<0.01 
Plasma K (mmol/l) 3.90±0.05 41 3.62±0.06 37 3.65±0.09 31 P<0.01 
FeNa (%) 0.64±0.07 41 0.56±0.05 34 0.40±0.05 31 P<0.05 
Plasma Na (mmol/l) 139.02±0.4 41 138.89±0.48 37 138.81±0.54 31 NS 
FeMg (%) 2.36±0.26 40 2.15±0.24 32 2.52±0.26 9 NS 
Plasma Mg (mmol/l) 0.81±0.02 40 0.74±0.05 35 0.84±0.02 30 NS 
FePO4 (%) 15.28±1.8 38 19.12±1.17 30 12.51±1.51 29 P<0.05 





Figure 2.6: Relationship between renal threshold phosphate concentration (TmP/GFR) 
(mmol/l) and plasma paracetamol at 4 h in the prospective study, n= 38, r= -0.33, 
p<0.05 
 


























Vomiting did not affect plasma potassium significantly. Additionally, there was 
no correlation between changes in plasma HCO3 and in plasma K, or between 
plasma HCO3 and plasma paracetamol. There was no change in plasma Cr. 
Only 3 cases in the paracetamol group developed features of liver injury (rise in 
ALT) at 24 h. Plasma Cr in these three cases was in the normal range. Blood 





Understanding the processes by which paracetamol affects the kidney in 
overdose is key to any prediction of renal toxicity, and evaluation of potential 
antidotal therapy. Identification of patients at risk of renal failure would enable 
them to be targeted for special monitoring and intervention. Most cases of 
paracetamol intoxication seen in the UK are discharged within a 24 h time 
frame, during which hepatic toxicity can be predicted, and appropriate treatment 
continued, or commenced. This is not the case in renal toxicity, which develops 
later. The true extent of renal toxicity is unknown, since only the most severe 
forms re-present as acute renal failure. According to the clinical experience of 
patients presenting to the Toxicology unit of Royal Infirmary of Edinburgh one or 
two out of 1000 cases with paracetamol overdose may develop renal failure 
without significant liver involvement (rise in ALT).  
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The main finding of the retrospective study was the dose-dependent relationship 
between 4 h plasma paracetamol and fall in plasma K. The prospective study 
also demonstrated a relationship between 4 h plasma paracetamol and 24 h 
plasma K and additionally showed an increase in FeK and TTKG at 12 h post-
ingestion, again in dose-dependent relationship with plasma paracetamol that 
had normalised by 24 h. These changes in K were not seen in the SSRI control 
group. Because no patients studied developed a significant rise in Cr, it is not 
possible to state these findings are relevant to the development of 
nephrotoxicity. However, the results of the retrospective and prospective studies 
were consistent with the results of a previous pilot study on ibuprofen overdose, 
a classical NSAID. This also showed a dose-dependent relationship between 
dose of ibuprofen ingested and FeK [262].  
 
The most common causes of hypokalemia from renal K loss are due to either 
medication, endogenous hormone production or in rare cases, intrinsic renal 
defects [94]. The dose-dependent relationship between plasma paracetamol 
and FeK at 12 h post-ingestion implicates renal loss of K to explain the 
hypokalaemia observed in paracetamol overdose. However, there were some 
confounding factors which might affect change in plasma K. 
 
Firstly hydration may have had an effect as the group of patients with high 
paracetamol received NAC in 5% plasma dextrose (total volume of 1700 ml). 
However, there was no significant change in plasma Na relating to NAC 
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treatment in either study, or change in plasma osmolality in the prospective 
study, indicating that it is very unlikely that hypokalemia was a result of dilution.  
 
Secondly, since only cases with a particular risk or high plasma paracetamol 
received NAC infused in 5% dextrose, this may have altered plasma K levels 
through endogenous insulin production induced by the 5% dextrose, resulting in 
movement of K into the intra-cellular compartment. NAC might also have 
affected tubular K handling directly. To determine the effect of NAC and 5% 
dextrose on plasma K and FeK, the ideal would be to compare these 
measurements in two groups with the same plasma paracetamol who did and 
did not receive NAC treatment. However, due to unequal distribution of subjects 
in each group, it was not possible to define such groups for comparison (Table 
2.4). To address this, in the retrospective study the relationship between plasma 
paracetamol at 4 h and plasma K change over 20 h in the NAC treated group 
alone was examined. The significant relationship seen in all subjects persisted 
in this subset. While this does not rule out an effect of NAC, it does suggest that 
plasma paracetamol itself is a factor in plasma K change. Further studies 
investigating the actual effect of NAC in 5% dextrose on renal function and 
electrolyte handling and plasma K in healthy volunteers are required to define 
this further. 
 
Thirdly, vomiting is known to cause hypokalemia as a consequence of metabolic 
alkalosis. However, in neither retrospective nor prospective studies could an 
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effect of vomiting be found. In addition, change in plasma K and FeK did not 
show association with change in plasma HCO3, which would be expected if 
vomiting changed K by causing alkalosis. 
 
As a small number of patients had ingested alcohol before or with drug (n=10) in 
the prospective study, there might be a potential effect of alcohol. An 
experimental study on rats investigating the acute effect of ethanol on renal 
electrolyte transport showed diuresis, an increase in FeNa and no change in 
FeK within an hour after acute ingestion of ethanol [263]. Another animal 
experiment studying the acute effect of ethanol on renal hemodynamics and 
monovalent ion excretion over a longer period showed an increase in excretion 
of sodium at 2 h, 10 h, 18 h and 26 h post-ingestion and a biphasic change in 
potassium excretion [264] while potassium excretion decreased at 2 h and 
started increasing at 10 h, 18 h and 26 h. The maximal change was seen at 18 
h. In the current study, plasma alcohol was not measured, however, changes in 
plasma and urine electrolytes in the groups with and without alcohol ingestion 
was compared. The results of the current study did not show a significant 
difference in plasma Na, K, Mg, PO4, FeNa, FeK, FeMg and FePO4 between 
these groups, suggesting that alcohol is unlikely to be a major contributor to the 
changes in plasma and urine electrolytes observed.  A further study in a larger 
group of subjects with measurement of plasma alcohol could give a better 
understanding of dose and time dependent effect of alcohol on electrolyte 
handling in paracetamol overdose.  
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Finally, paracetamol in aqueous solution has a pH of 6.24 [261]. While the 
buffering capacity of plasma is large, it is possible that a high plasma 
paracetamol is associated with a mild acidosis that resolves as the paracetamol 
falls. This would result in K shifts between the plasma and the intracellular 
compartment. However, there was no correlation between plasma HCO3 and 
paracetamol. Additionally, acidosis would be associated with plasma K egress 
from the intracellular compartment, increasing plasma K, the converse of the 
result observed in this study.   
 
In a study on Wistar rats [194], the effect of different single doses of 
paracetamol on renal function and electrolytes handling was examined. GFR 
and renal plasma flow significantly decreased in a dose-dependent manner. 
Time course of changes in electrolyte excretion in the group given toxic dose of 
paracetamol (1000 mg/kg) showed an increase in FeK and no change in FeNa 
at 1 h, 6 h, and 16 h.  The maximal change in FeK and renal perfusion was at 
16 h post-ingestion and was restored at 24 h. The authors suggested that early 
stages of paracetamol nephrotoxicity are due to renal haemodynamic changes. 
In the current study, renal blood flow was not measured, nor did plasma Cr 
change significantly, though this is a relatively insensitive marker of small 
changes in GFR. The major changes seen in this study were in K with the 
maximum derangement in FeK occurring after 12 h and restored after 24 h 
which was consistent with the results of animal study.  
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Aldosterone is the most important hormone regulating total body K homeostasis, 
causing hypokalemia by stimulating K uptake into cells and increasing renal K 
excretion [94]. Aldosterone secretion is increased by renal hypoperfusion via 
activation of the renin-angiotensin-aldosterone axis. The results of the current 
study could therefore be consistent with the early effects of paracetamol toxicity 
being due to renal haemodynamic change consequent upon activation of the 
renin-angiotensin-aldosterone axis, seen here as increasing K excretion and Na 
retention.  
 
In the SSRI group an increase in urine osmolality at 4 h, 12 h and 24 h supports 
the results of previous studies [265-267], in which hyponatremia secondary to 
SSRI-induced syndrome of inappropriate anti diuretic hormone secretion 
(SIADH) occurred. In this study plasma Na and FeNa did not change 
significantly in SSRI overdose.   
 
The other result of the study was a reduction in plasma PO4 at 12 and 24 h and 
also a negative dose-dependent relationship between plasma paracetamol and 
plasma PO4, and renal threshold phosphate concentration (TmP/GFR) at 4 h 
post-ingestion. This finding was consistent with the results of other studies 
investigating renal loss as a source of hypophosphataemia after paracetamol 
poisoning [198;199]. Hypophosphataemia due to a decrease in renal threshold 
phosphate concentration in the early stage of toxicity has been suggested as an 
early marker in determining the severity of paracetamol toxicity. 
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Because no patients developed significant renal dysfunction the utility of urinary 
excretion of electrolytes in predicting specific renal toxicity could not be 




In conclusion paracetamol overdose is associated with a kaliuresis, and a 
reduction in plasma K which is related to the dose ingested and is of relatively 
short duration, not longer than 24 h post-ingestion in this study. This suggests a 
specific renal effect of paracetamol in overdose. These findings might be 
consistent with increasing aldosterone action on the distal tubules as a fall in 
renal perfusion due to paracetamol-induced renal vasoconstriction consequent 
upon cyclo-oxygenase inhibition, (and hence reduced production of vasodilator 
prostaglandins) activates the renin-angiotensin-aldosterone system. 
Measurement of aldosterone and plasma rennin activity (PRA) in the future 
studies may give us a better understanding of renal effects of paracetamol 
overdose. None of cases developed significant renal impairment. It is therefore 
uncertain whether these effects are directly related to the renal failure seen 




2-6: Limitation of the study 
 
Due to the nature of the retrospective study, it was not possible to obtain precise 
information from patients, and the information recorded in the patient notes was 
used. As the study required having two sets of biochemistry tests in order to 
investigate the changes in plasma electrolytes, only those cases that had at 
least two sets of data were included. This means that the subjects were not 
necessarily representative of the whole population, particularly at lower doses of 
paracetamol.   
 
In the prospective study due to nature of the subjects not all cases were able to 
comply with all blood and urine collections. As routine drug screening for drugs 
of abuse would not have detected non-steroidal presence and since the 
complete screen of this nature would be extremely expensive, a full drug screen 
to rule out co-ingestion of other drugs in the paracetamol group was not 
performed. Cases of mixed overdose were excluded by patient interview, 
however, it would have been more likely that co-ingestion to confound and 
reduce the power of the data and statistical analysis rather than increase it 
giving us the positive result observed. The precise effect of 5% dextrose and 
NAC itself was not clear, but the intention was not primarily to examine this. The 







Chapter III: Frequency of Renal Injury in Significant 
Paracetamol Poisoning and the Impact of Severity of 


































Paracetamol poisoning is responsible for around 200 deaths annually in the 
United Kingdom alone [43;51;268;269]. High doses of paracetamol are capable 
of causing hepatic necrosis and renal tubular necrosis [18;81;85;164]. Renal 
failure is less common than liver failure after paracetamol overdose, and has 
been reported in about 1% of all patients and reaches 8.9-10% in severe 
poisoning [18;91;270]. The occurrence of renal failure is greater in severely 
poisoned patients, and is often observed in those that develop significant liver 
injury [81;271]. Nonetheless, the occurrence of renal failure cannot be attributed 
solely to co-existent hepatic damage, and has been reported as an isolated 
manifestation of paracetamol toxicity [87;89;183]. 
 
Renal injury, as evaluated by plasma creatinine (Cr) concentrations, may be 
used to indicate the severity of paracetamol poisoning, and concentrations 
greater than 300 µmol/l are part of the King’s College  (KCH) Criteria (arterial pH 
< 7.3 or all three of an international normalised ratio [INR] of greater than 6.5, 
plasma Cr > 300 µmol/l and the presence of encephalopathy of grade III or IV 
for liver transplantation) [54;227]. Despite this, comparatively little is known 
about the prognostic value of plasma Cr concentrations in patients referred to 
liver units after severe poisoning. 
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The present study was designed to examine the frequency of renal injury in 
patients with severe paracetamol poisoning. The aim was to identify the possible 
impact of renal impairment on clinical outcomes in this high-risk patient group, 
and risk factors associated with the development of renal failure in this selected 
group. Additionally, the effects of significant paracetamol overdose on plasma 
electrolytes in patients who developed hepatic damage was also investigated. 
 
The specific questions asked were: 
1. What is the frequency of renal insufficiency in severe paracetamol overdose? 
2. Is the timing of onset of renal dysfunction different from liver dysfunction? 
3. What is the effect of delay at first presentation on outcome? 
4. What are the associated risk factors in developing kidney dysfunction in 
paracetamol overdose? 
5. What is the impact of Cr at first admission on outcome? 





3-2-1: Data Collection 
 
The Scottish Liver Transplant Unit (SLTU) is a tertiary referral centre for 
Scotland and part of Northern Ireland, and provides clinical management of 
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patients with severe liver disease and patients that require liver transplantation. 
Patients were identified from a database held within the SLTU that contains 
clinical and laboratory variables and outcome data for patients referred to the 
Unit. Patients referred to the SLTU between 1992 and 2004 inclusive due to 
severe paracetamol-induced liver damage were included. Available data at the 
time of initial referral to SLTU included age, gender, other medication ingested, 
stated dose ingested, associated alcohol, unit of ingested alcohol, interval 
between ingestion and presentation to hospital, plasma paracetamol 
concentration, the presence of hypotension (systolic blood pressure <100 
mmHg), plasma Cr, alanine transaminase (ALT) activity, gamma glutamyl 
transpeptidase (GGT) activity, prothrombin time (PT), plasma sodium (Na), 
potassium (K), bicarbonate (HCO3) and pH at time of admission to referring 
hospital and to SLTU. Additional data were worst recorded PT, and outcome 
data: liver transplant, haemodialysis, intensive care unit (ITU) admission and 
death. Admission to ITU was determined by necessity for ventilation. Patients 
with poor prognosis were identified according to the KCH Criteria. 
 
3-2-2: Data Analyses 
 
Ingestion of paracetamol at a single time-point or within a two-hour period was 
considered as an acute ingestion, whereas ingestion at multiple time-points  
during an interval of more than two hours was considered a staggered overdose.  
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Two time points were recorded in patients with acute ingestion of paracetamol. 
Time from ingestion to first blood taken in referring hospital was considered as 
interval between ingestion and first admission (or delay at first admission) and 
time point from ingestion to first blood taken in SLTU was considered as interval 
between ingestion and admission to SLTU (or delay at admission to SLTU). 
Patients were categorised into four groups according to interval between 
overdose and first presentation to referring hospital: ≤12h, >12h to 24 h, >24h to 
48 h, and >48 h. For some analyses this interval was classified into three 
groups: ≤24h, >24-48h and ≥48h.  
 
 Renal function was classified into four groups according to plasma Cr 
concentration: normal: if Cr<120 µmol/l; mild impairment: if Cr>120≤180 µmol/l; 
moderate impairment: if Cr>180 and <300 µmol/l; and severe impairment: if 
Cr≥300 µmol/l. The effect of different risk factors was examined in these groups. 
 
Liver dysfunction was defined as PT≥25 (s). Worst PT was defined as worst 
recorded PT over hospital stay either in referring hospital or in the SLTU. 
 
In the previous studies reported in this thesis (chapter II) the effect of acute 
paracetamol overdose on electrolytes was investigated. In the current data, the 
effects of acute severe paracetamol overdose on plasma electrolytes, sodium 
(Na) and potassium (K), in the subset of patients with acute paracetamol 
overdose (n=361) presenting at different times after ingestion was examined. In 
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this analysis patients were categorised in three groups according to the time 
between ingestion and first presentation to the hospital (or the time of first blood 
taken in referring hospital): group 1: ≤12h; group 2: >12h to 24h; and group 3: 
≥24h. In this subset, the relationships between plasma K, paracetamol, Cr and 
PT at first admission to hospital were also examined. 
 
3-3: Statistical analyses 
 
Data was tested for normality. The data are presented as mean ± standard error 
of the mean (sem), median and inter quartile range (IQR), and proportions 
where appropriate. Between-group comparisons were made using Student’s t 
test for independent samples for continuous data, and Pearson’s Chi square 
tests for categorical data. Multiple comparisons analysis for continuous data was 
made by one-way analysis of variance (ANOVA) with Post-Hoc Bonferroni for 
parametric data and Kruskal-Wallis test for non-parametric data. Receiver 
operator characteristics (ROC) were used to examine the relationship between 
Cr concentration at the time of admission to referring hospital and end-point of 
prognosis defined by KCH criteria (when mortality was also used as the end-
point, the same result was obtained).  
 
To determine risk factors of renal dysfunction initially univariate analysis was 
performed. In the second step multiple regression analysis was applied, 
however, the model automatically excluded patient with “staggered overdose” 
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because time between ingestion and admission was unknown in this group. As 
this group was found to be an important risk factor in the univariate analysis, use 
of multiple regression was thought likely to be unreliable. The results from the 





3-4-1: Demographic characteristic 
 
Data was available for 522 patients (49.2% men and 50.8% women) with mean 
age of 36 ± 1 y.  In younger patients (<20 y) overdose was more common 
among women, but in older patients (>40 y) overdose was more frequent in men 












Figure 3.1: Distribution of patients with overdose according to sex and age bands. 
 
 
 AGES BANDS sex Total 
  male female   
11-20 YEARS 11 28 39 
  
21-30 YEARS 81 95 176 
  
31-40 YEARS 68 69 137 
  
41-50 YEARS 59 53 112 
  
51-60 YEARS 26 10 36 
 61 AND OLDER 12 10 22 



















































Table 3.1: Demographic characteristic of subjects with paracetamol overdose (n=522) 
with suspected liver damage referred to SLTU at admission to the referring hospital.  
 
 
• Total n (%)                                          522 (100%) 
• Gender  
             Male                                                    257 (49.2%)                                              
            Female                                                 265 (50.8%) 
 
• Age y (mean ±sem)                            35.6 ± 0.6 
             Male                                                    37.2 ± 0.8                         
             Female                                                34.1 ± 0.8 
 
• NAC treatment   
             Yes n (valid %)                                    431 (84.5%) 
              NO n  (valid %)                                   79 (15.5%) 
              Missing data n                                    5 
 
• Staggered overdose 
              Yes n (valid %)                                  128 (26.6%) 
               NO n (valid %)                                  354 (73.4%) 
               Missing data                                     40 
 
• KCH poor prognosis 
             Yes n (%)                                            145 (27.8%) 
              NO n (%)                                            377 (72.2%) 
 
• Dialysis requirement 
             Yes n (valid %)                                   177 (34.2%)                                       
              NO n (valid%)                                    341 65.8%) 
              Missisng data n                                  4 
 
• Mortality 
               Died without transplant n (%)           134 (25.7%)         
               Died with transplant n (%)                 13 (2.5%) 
                         
               Survived without transplant n (%)     347 (66.5%)  















3-4-2: Frequency of renal insufficiency 
 
At first presentation to the referring hospital 463 patients had available data for 
plasma Cr and PT of whom 320 (69.1%) had significant impairment of liver 
function as reflected by PT at first admission ≥25 (s) (Table and Figure 3.2). Of 
patients who had liver injury, 156 (48.8%) had already developed some degree 
of renal dysfunction. Of these, 69 patients had mild, 48 patient moderate, and 39 
patients severe renal injury. At presentation to the referring hospital 143 patients 
did not have significant liver impairment (PT at first admission< 25), but 26 
cases had some degree of renal dysfunction (17 mild, 7 moderate and 2 
severe). All of these 26 patients showed some degree of abnormal liver function, 
although not achieving a PT of ≥25, concomitant with their renal dysfunction 
(see appendix 4-2 for raw data). At the time of first admission to hospital, in the 
total cohort, 18.6% (86/463) had mild, 11.9 % (55/463) moderate and 8.9 % 
(41/463) severe renal impairment (Table 3.2).  
 
 
At the point of admission to the SLTU, 507 subjects had available data for PT 
and Cr. Of these 457 (90.1%) had significant liver damage as defined by plasma 
PT at admission to SLTU ≥25 (s) (Table and Figure 3.2). Of those with liver 
injury more than half of patients (248/457) had renal dysfunction: 17.7% 
(81/457) mild, 21.1% (97/457) moderate, and 15.3% (70/457) severe renal 




Table 3.2: Severity of liver and renal impairment at presentation to referring hospital 
(first admission) and SLTU.  
 
Patients were classified according to the severity of renal dysfunction and presence or absence 
of liver damage.  Liver injury was defined as PT>=25 sec. Renal injury was defined as normal if 
plasma Cr ≤120; mild:  Cr >120, ≤ 180; moderate: Cr >180, <300; severe: Cr≥ 300 µmol/l. PT: 
































    PT≥25 
 (with liver injury) 
 
  PT<25  
(no liver injury) 
       PT≥25  
(with liver injury) 
       PT<25  
(no liver injury) 
 
 
Groups according to 
renal and liver function 
n (%) n (%) n (%) n (%) 
Normal renal function 
 Cr≤120  
164 (35.4%) 
 
117 (25.3%) 209 (41.2%) 26 (5.1%) 
Mild renal dysfunction 
Cr >120, ≤180  
69 (14.9%) 17 (3.7%) 81 (16.0%) 3 (0.6%) 
Moderate renal 
dysfunction 
Cr >180, <300  
48 (10.4%) 7 (1.5%) 97 (19.1%) 9 (1.8%) 
Severe renal 
dysfunction 
Cr ≥300   
39 (8.4%) 2 (0.4%) 70 (13.8%) 12 (2.4%) 
Total 320 (69.1%) 
 
143 (30.9%) 457 (90.1%) 50 (9.9%) 
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 Figure 3.2: Severity of liver and renal impairment at presentation to referring hospital 




























Groups according to the liver and renal function in the 








































3-4-3: Timing of onset of renal and liver dysfunction 
 
Changes in liver function occurred more rapidly than those in renal function. 
Thus PT (s) and ALT (IU/l) were generally abnormal at initial presentation in all 
patients, although higher in those who presented at more than 24 h after 
overdose (PT: 50.8 ± 2.4 (s), ALT: 6227 ± 454 (IU/l)) compared to those 
presented within 24 h (PT: 29.9 ± 1.7 (s), ALT: 1960 ± 264 (IU/l)), p<0.0001 
(Table 3.3).  
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Changes in renal function occurred later after overdose (>48h). Cr 
concentrations (µmol/l) at first admission were significantly higher in patients 
presenting more than 24 h after ingestion (155.8 ± 7.9 µmol/l) whereas patients 
who presenting within 24 h often had a normal Cr (98.3 ± 3.7 µmol/l), p<0.0001 
(Table 3.3). Cr in the group that presented after 48 h (192.6 ± 18.2 µmol/l) was 
significantly higher than that in the group presenting between >24 and 48 h 
(140.6 ± 7.9 µmol/l), p<0.0001. Cr at first admission (µmol/l) in staggered 
overdose was 177.9 ± 12.0 µmol/l). There was no age difference between 
groups presenting within (32.5 ± 0.9 y) or after 24 h (34.6 ± 1.0 y).  
 
 
3-4-4: Effect of delay at first admission on outcome 
 
Mortality rates were highest in patients first presenting to hospital more than 24 
h after ingestion (p<0.01) and after staggered overdose (Table 3.3, Figure 3.3). 
A prolonged interval between paracetamol ingestion and first presentation to 
hospital (>24h) was also associated with an increase in proportion having poor 
prognosis based on KCH and dialysis requirement (Table 3.3, Figure 3.4).  Thus 
in the group who presented after 24 h, 33.6% (49 of 146) had poor prognosis 
criteria as compared to 17.6% (31/176) in patients presenting within 24 h, 
p<0.01 (Table 3.3). Mortality in the group with staggered overdose was 
significantly worse [34.4% (44/128)] than in those with acute overdose [21.5% 




Table 3.3: Laboratory and clinical variables with respect to the interval between acute 
paracetamol ingestion and first blood taken at first admission to hospital in paracetamol 
overdose, presented as mean± sem.  
 
Group comparison was made using ANOVA with post-Hoc Bonferroni for continuous data and 
Pearson Chi-square test for categorical data. n=number of subjects with available data. KCH: 





a  Plasma Cr and PT was  significantly different between groups (p<0.0001). Those presenting 
less than 24h were different to those presenting later (p<0.0001). Cr and PT was also 
significantly higher in the group who presented more than 48h compared to group presenting 
>24-48h (p<0.0001). 
 
b ALT  was higher in patients presenting >24h (p<0.0001) compared to groups presenting within 
24h. ALT was also higher in >48h group compared to >24 to 48h group (p<0.05). 
 
c Dialysis requirement was significantly higher in patients presenting >24h compared to group 
presenting <24h (p<0.0001).  
 
d KCHC poor prognosis and mortality were significantly higher in patients presenting more than 
24h compared to those presenting within 24h (p<0.01 for KCHC poor prognosis, p<0. 05 for 
mortality). 
 
Time between ingestion  
and first blood taken at first 
admission to referring hospital 
≤24h >24 ≤48h >48h Sig level 
Interval (h) 15.2 ± 0.5 (n=176) 37.4 ± 0.8 (n=104)  66.6 ± 2.8 (n=42)  
Cr at first admission (µmol/l) 98.3±3.7(n=161)  140.6±7.9 (n=94)  192.6±18.2 (n=39) p<0.0001  a 
 PT at first admission (s) 29.9±1.7 (n=166) 45.4±2.1 (n=101) 65.0±6.0 (n=39) p<0.0001  a 
ALT at first admission (IU/l) 1960±264 (n=147) 5524±520 (n=75) 7887±875 (n=30) p<0.0001 b 
Worst PT (s) 62.8±2.9 (n=173) 67.3±3.4 (n=104) 77.1± 6.4 (n=42) NS  
Dialysis (%) 19.5 (n=34/174) 44.2 (n=46/104) 34.1 (n=14/41) p<0.0001 c 
KCH poor prognosis (%) 17.6 (n=31/176) 36.5 (n=38/104) 26.2 (n=11/42) p<0.01  d 
Mortality ( %) 15.3 (n=27/176) 28.3 (n=30/104) 23.8 (n=10/42) P<0.05 d 
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Figure 3.3: Survival according to time between ingestion and first admission to the 
hospital.   
 
 
Morality was significantly higher in the group presented after 24 h and in staggered overdose 




Survival Total  Groups according time between ingestion and 
first presentation and staggered overdose survived Died   
<=12 h 54 5 59 
  
>12<=24 h 95 22 117 
  
>24<=48 h 74 30 104 
  
>48 h 32 10 42 
  
Staggered OD 84 44 128 
 









Groups according to time between ingestion and first 
















Figure 3.4: Dialysis requirement according to time between ingestion and first 
admission to the hospital (missing data: 75). 
 
dialysis Total  Groups according to time between ingestion an first 






<=12 h 50 9 59 
  
>12<=24 h 90 25 115 
  
>24<=48 h 58 46 104 
  
>48 h 27 14 41 
  
Staggered overdose 76 52 128 
 




Dialysis required in the group according to time between 



















Overall, 96.6% of patients developed significant liver injury (worst PT ≥25 s). 
Data on the highest Cr during in-patient stay was not available; however, 34.2% 
of patients (177) required dialysis, and 27.8% (145) had poor KCH criteria. 
Overall mortality was 28.2% (147) (Table 3.1). 
 
Stated paracetamol dose in acute ingestions did not correlate with risk of renal 
impairment as judged by Cr at time of admission to SLTU (Cr ≤120 µmol/l: 
paracetamol 34 ± 2 g; Cr>120 and ≤180 µmol/l: paracetamol 28 ± 2g; Cr >180 
and <300 µmol/l: paracetamol 39 ± 3 g; ≥300 µmol/l: paracetamol 27 ± 3 g). 
There was no significant difference in the stated dose of ingested paracetamol in 
the group with acute and staggered overdose (staggered overdose: 30 ± 2.3 g 
vs. acute overdose: 33.5 ± 5 g). 
 
3-4-5: Associated risk factors for developing renal dysfunction 
 
Factors associated with more severe renal impairment at the time of transfer to 
SLTU were age, hypotension at admission to either hospital, and interval 
between ingestion and first presentation to hospital (all p<0.0001). Patients with 
more severe renal injury (defined by Cr at presentation to SLTU) also had a 
higher GGT and PT at first presentation (Table 3.4 and Figure 3.5 and 3.6, 
p<0.0001). There was no statistically significant association between severity of 
renal impairment with weekly alcohol intake or associated alcohol ingestion with 
overdose. Patients with more severe renal dysfunction were more acidotic and 
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hyperkalaemic (Table 3.4). A higher proportion of patients with severe renal 
impairment had taken a staggered overdose, compared to acute overdose 
(Table 3.4). The data showed that males were more likely to develop renal 
dysfunction (p<0.05), however this was confounded by age as men were 




Figure 3.5: Relationship between PT (Sec) at first admission to referring hospital and 
creatinine (µmol/l) at admission to SLTU.  
 
There was significant positive association between PT at first admission and creatinine at 





























R Sq Linear = 0.05
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Table 3.4: Clinical characteristics and outcomes in patients with paracetamol overdose grouped 
by renal function (see text) at the time of admission to SLTU.  
 
Group comparison was made using ANOVA with post-Hoc Bonferroni for continuous variables and Chi-
square test for categorical variables. n=number of subjects with available data.  
 
 
Cr (µmol/l) at 













n (%)  239 (46.8%) 84 (16.4%) 106 (20.7%) 82 (16.0%)  
M / F 102/137 45/39 62/44 42/40  













Alcohol intake  
(Unit per week) 
56.2 ± 7.02 
n=149 
86.5 ± 15.8 
n=58 
90.8 ± 13.3 
n=76 







87/212 38/77 47/90 4/67 P=0.22 











Delay to first 
admission (h)  
25 ± 1 
(n=179) 
28 ± 2 
(n=56) 
36 ± 3 
(n=65) 
43 ± 5 
(n=37) 
p<0.0001 d 
Delay to admission 
to SLTU (h)       
55 ± 2 
(n=158) 
 
55 ± 3 
(n=51) 
59 ± 2 
(n=56) 
68 ± 5 
(n=33) 
p<0.05 e 
PT at first admission 
(s) 
37 ± 9  
(n=211) 
42 ± 2.8 
(n=77) 
51 ± 3.2 
(n=92) 




GGT at first 
admission (u/l)  









 [H+] at first 
admission (mmol/l 
42 ± 1 
 (n=149) 
53 ± 3 
(n=58) 
61 ± 4 
(n=64) 




K at first admission 
(mmol/l) 
3.9 ± 0.05 
(n=222) 
 







Worst PT (sec) 59±2  
(n=235) 
73 ± 5 
(n=84) 
82 ± 5 
(n=106) 




ITU stay (days)  1.4 ± 0.2 
(n=237) 


















Foot notes for Table 3.4 
 
a Patients with mild, moderate and severe renal dysfunction were older (p<0.0001). Those with 
moderate and severe renal dysfunction were older than those with mild renal dysfunction 
(p<0.0001). 
 
b Patients with severe renal dysfunction were more likely to take staggered overdose compared 
to normal renal function (p<0.0001), and mild or moderate renal dysfunction (p<0.01). 
 
c Patients with normal renal dysfunction were less likely to have hypotension at first admission 
compared to other groups (p<0.0001).  
 
d Patients with moderate and severe renal dysfunction presented later than those with normal 
renal function (p<0.0001). Patients with severe renal dysfunction presented later than patients 
with mild renal dysfunction (p<0.01). 
 
eTime from overdose to admission to SLTU was significantly longer in the group with severe 
renal dysfunction compared to group with normal renal function (p<0.05). 
 
f There was significant difference in first admission PT between groups (p<0.0001). PT at first 
admission in those with normal renal function was lower than moderate and severe renal 
dysfunction (p<0.01). Referral PT in mild and severe renal dysfunction was also significantly 
different (p<0.01). 
 
g GGT at first admission was lower in patients with normal renal function (p<0.0001). GGT at first 
admission was higher in severe than mild (p<0.01) or moderate (p<0.05) renal dysfunction. 
 
h [H+] at first admission in the group with normal renal function was significantly different to mild 
(p<0.01), moderate (p<0.0001) and severe (p<0.01) renal dysfunction. 
 
i K+ at first admission in the group with normal renal function was significantly lower than 
moderate and severe renal dysfunction (p<0.0001). K+ at first admission in mild renal 
dysfunction was significantly lower than severe renal dysfunction (p<0.0001). 
 
K Worst PT in normal group was significantly different between group with mild (p<0.05), 
moderate (p<0.0001) and severe renal dysfunction (p<0.05). 
 
 
m Patients with moderate and severe renal dysfunction stayed longer in the intensive care unit 
(ITU) compared to group with normal renal function (p<0.0001, and p<0.01, respectively). 
 
n Mortality in the group with normal renal function was significantly lower compared to the group 
with mild, moderate and severe renal dysfunction (p<0.0001). Group with mild renal dysfunction 




Figure 3.6: Relationship between GGT (U/l) at first admission to referring hospital and 
creatinine (µmol/l) at admission to SLTU.  
 
There was significant positive association between GGT at first admission and creatinine at admission 






























3-4-6: Creatinine at first admission as a prognostic factor 
 
The ROC curve for Cr concentration at first admission as predictor of poor prognosis 
based on KCH criteria gave an area under the curve of 74.3.0% (95% confidence 
interval 70.1 to 78.1%, p <0.0001). This plot indicated that a Cr >123 µmol/l at first 
presentation to the hospital had a sensitivity of 71.3% (95% CI: 62.7-78.9%) and 
specificity of 73.3% (95% CI: 68.3-77.9%) for poor prognosis defined by KCH criteria 
during hospital stay (Figure 3.7).  
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Figure 3.7. Receiver operating characteristic (ROC) for creatinine concentration 
(µmol/l) at first admission to referring hospital and the end point of poor prognosis 
according to “King’s College Criteria” (KCH).  
 
Area under the ROC curve (AUC) = 74.3% (95% Confidence interval 70.1 to 78.1%) 
Significance level p< 0.0001 (versus 0.5 line by z-test). Most ‘accurate’ predictor is referral 
creatinine >123 µmol/L 71.3% sensitivity (95% CI: 62.7-78.9) and 73.3% specificity (95% CI: 






















3-4-7: Effect of acute paracetamol overdose on plasma electrolytes 
 
The number of patients with acute paracetamol overdose and known time of 
ingestion who were entered into this analysis was 316, 49.4% (n=156) male 
and 50.6% (n=160) female, with mean age of 32.2 ± 0.7 y (Table 3.5).  
Median and IQR of time interval between ingestion and first admission in the 
groups presenting within 12 h (group 1, n=59) was 8.0 (6.0-11.0) h; in the 
group with >12 and ≤24 h (group 2, n=115) 18.0 (16.0-22.0) h; and in the 
group with >24 h (group 3, n=142): 44.0 (33.0-52.0) h. As expected plasma 
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paracetamol (mg/l) at first admission was significantly higher in the groups 
presenting earlier (group 1: 166.3 [83.1-266.5], n=53; group 2: 90.7 [42.0-
151.2], n=103; group 3: 37.8 [14.4-93.1 n=117], p<0.0001). There was no 
significant different in plasma K in the groups presenting within 12 or 24 h 
(≤12 h: 3.7 [3.3-4.2] mmol/l, n=53 and >12 and ≤24 h: 3.9 [3.4-4.4] mmol/l, 
n=108), but plasma potassium was significantly higher (4.5 [3.8-5.0] mmol/l, 
n=133) in patients presenting after 24h than those admitted earlier 
(p<0.0001).   
 
 
Plasma K at first admission in the group presenting within 12 h was in a 
borderline significant negative correlation with plasma paracetamol  
(r = - 0.28, p=0.05, n=49, Figure 3.8) and did not correlate to Cr or PT at first 
admission. In patients presenting after 12 h plasma K was significantly 
positively correlated with plasma Cr (r=0.37, n=225, P<0.0001, Figure 3.9), 
PT (r = 0.38, n=237, p<0.0001) and plasma [H+] (r = 0.28, n=163, p<0.0001), 
but not with plasma paracetamol concentration. 
 
There was no significant correlation between plasma sodium and Cr or PT at 
first admission. Plasma [H+] (mmol/l) at first admission was significantly lower 
in the group with normal renal function than groups with renal dysfunction 





Table 3.5: Demographic characteristic of subjects with acute paracetamol overdose 
(n=316) with suspected liver damage at admission to the referring hospital in the 




Group 1:  ≤12 h; group 2:  >12 h and ≤24 h; group 3: >24 h. There was significant difference 
between groups in respect of plasma paracetamol concentration, ALT, PT, Cr and K in the 
groups presented to the hospital in different time after ingestion. Plasma paracetamol 
concentration was significantly higher in the group presented earlier (p<0.0001). Plasma 
ALT, PT, Cr and K was significantly higher in the group presented after 24 h compared to 
those presented before 24 h (p<0.0001). There was no significant difference in plasma PT, 
Cr and K in the group presenting within 12 or 24 h after ingestion. Plasma ALT was slightly 
higher in the group admitted after 12 h compared to the that of group 2, p<0.05. Data was 
presented as median and IQR. Group comparison was made by Kruskal Wallis test. *: 










59 115 142 
Interval (h) 
 
8.0 (6.0-11.0)                    18.0 (16.0-22.0)                  44.0 (33.0-52.0) 
Sex (M/F)**     26/33                                 54/61                                  76/66                               
 
Age (y) **        
 
30.0 (24.0-41.0)                30.0 (23.0-37.0)                  34.0 (24.0-43.0) 
Para (mg/l)*    
 
166.3 (83.1-266.5), n=53  90.7 (42.0-151.2), n=103    37.8 (14.4-93.1), n=117 
ALT (IU/L)*      443 (1770-2100), n=51     878 (409-1785), n=94        5748 (2126-9233), 
n=104 
PT (sec)*        
 
22.5 (16.1-35.8), n=52       22.9 (19.0-31.8), n=112     42.8 (31.5-63.5, n=137 
Cr (µml/l)*       85.0 (75.0-101.0), n=55     90.0 (74.3-110.3), n=104 124.0 (92.0-189.0), 
n=130 
K (mmol/l)*      
 
3.7 (3.3-4.2), n=53            3.9 (3.4-4.4), n=108           4.5 (3.8-5.0), n=133         
H+(mmol/l)**    
 
















 Figure 3.8: Relationship between referring plasma potassium (mmol/l) and 
paracetamol concentration (mg/l) in the group presenting within 12 h post-ingestion. 
  
There was borderline reverse association between plasma potassium and paracetamol 







































R Sq Linear = 0.078
 
 
Figure 3.9: Relationship between plasma potassium (K) and creatinine in the group 
presenting after 12 h post-ingestion.  
 
There was significant positive association between potassium and creatinine in the group 
presenting after 12 h post-ingestion (r=0.37, n=225, p<0.0001). 
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Paracetamol poisoning is a common presentation and early identification of 
patients with more severe poisoning is key to improving outcomes. Present 
approaches are based on risk stratification using paracetamol concentrations 
timed after ingestion, but this is dependent on accurate history and assumes 
an acute ingestion time point. This is also less accurate beyond 15 h after 
ingestion. Thus, work that is aimed to improve outcome prediction based on 
paracetamol concentrations [272] may not be applicable to many in this 
cohort.  Previous work has identified acidosis and hypophosphataemia as 
potential early markers of more severe toxicity  [198]. Patients in this cohort 
often did not have phosphate measured and this has not been a focus of this 
study. 
 
Although renal failure is a recognised complication of paracetamol toxicity, 
the underlying mechanisms are poorly understood. Toxic metabolites of 
paracetamol are generated by local metabolism in the kidney and may cause 
acute tubular necrosis, particularly in conditions associated with glutathione 
depletion [168]. Even in the absence of acute renal failure, paracetamol 
ingestion is associated with dose-dependent changes in electrolyte transport, 
suggesting a direct pharmacological action of paracetamol on renal tubular 
function [194;273]. Risk factors such as glutathione depletion in the kidney, 
concomitant ingestion of nephrotoxic substances, dehydration at 
presentation, chronic excessive overdose of paracetamol, and pre-existing 
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liver and renal insufficiency have been suggested to promote the risk of renal 
injury after paracetamol overdose [183]. 
 
As expected, most patients in the current series of tertiary referrals after 
paracetamol overdose had evidence of acute liver dysfunction defined by PT 
≥ 25 sec (96.6%). Within this patient population there was a high prevalence 
of serious renal impairment (34.2% of patients required dialysis). In 
comparison the incidence of paracetamol-induced nephrotoxicity (blood urea 
nitrogen>6.4 mmol/l, or Cr>97.2 µmol/l) in adolescents (12-18y) who were 
admitted to a tertiary hospital was reported to be 8.9% [270]. In the current 
study 15.4% (6/39) of patients aged 11-20y had Cr≥120 µmol/l and 13% 
(n=5) required dialysis. The overall incidence of paracetamol-induced 
nephrotoxicity in unselected patients has previously been reported to be 
around 1-2 %  rising to 10% in more severely  poisoned patients [18;91;274]. 
The high incidence of renal impairment in the current study is likely to be due 
to the highly selected patient population, who were characterised by liver 
dysfunction secondary to paracetamol overdose sufficient to warrant referral 
to a tertiary centre. Severe liver failure itself was found to be an important 
associated factor in developing renal failure.  
 
As shown in Table 3.3 the onset of renal dysfunction seems to be later than 
liver dysfunction. Other studies also report liver dysfunction starts within 24 h 
after overdosage while renal dysfunction occurs one to three days later, and 
often is in association with severe liver damage [18;42;83;91]. In some 
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cases, although rare, renal failure due to paracetamol overdose occurs in the 
absence of liver injury [84;87;90;161;183]. In the current data set all patients 
with renal impairment also had some degree of concomitant liver dysfunction. 
 
Importantly the data indicate that Cr at the time of first admission was an 
important predictor of developing poor prognosis (as defined by KCH criteria) 
and thus the need for liver transplantation (Figure 3.7). Groups with more 
severe renal injury at presentation had worse outcome, as indicated by 
higher PT, longer stay in ITU, greater need for dialysis, and higher mortality 
(Table 3.4).  
 
Renal dysfunction was more severe with later presentations, in patients with 
hypotension at admission, those who were older and those who had a high 
GGT. However, in this data set there was no significant association between 
weekly intake of alcohol or history of alcohol abuse and renal dysfunction. 
Renal dysfunction was also worse in those who had taken the overdose in a 
staggered manner. The findings of the current study are similar to those in 
children, in whom prolonged interval between ingestion and presentation to 
hospital, and renal impairment were both associated with poorer prognosis 
[275].  
 
Mortality in the current study (28.2%) is lower than that reported in a previous 
study from another UK tertiary care date set (62% in 1987 and 40% in 1993). 
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This may suggest an improvement in the quality of care given for this patient 
group in the UK in the recent years, or be due to changes in referral practice.  
 
The current data comes from a large acute UK centre but may not be 
representative of other liver units. Other factors not tested in this study 
include social deprivation, which has also been found to be associated with 
poor outcome from paracetamol overdose in Scotland [276]. The use of 
plasma creatinine needs to be tested independently by others. The present 
data underpin the importance of prompt administration of acetylcysteine, 
which has been shown to be most effective when given within the first 8-12 h 
after paracetamol ingestion [277]. Another study on similar patients admitted 
to an acute liver unit in the UK showed that patients  who were  not treated 
with NAC, or in whom NAC was started after 24h, had significantly higher 
mortality rate [53].  It is increasingly recognised that patients presenting to 
hospital after staggered overdose are at substantially increased risk 
compared to those after acute ingestion. This is reflected in the present data, 
where staggered overdoses comprise a high proportion of patients referred to 
the SLTU. Thus close attention to Cr concentration, presence of hypotension 
and GGT activity should allow earlier identification of patients that are at 
greater risk of poor outcome.  
 
In the subset of patients with acute (non-staggered) overdose, in the 
group who presented early (within 12h) plasma K was in a borderline 
dose-dependent negative relationship with plasma paracetamol. This 
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finding is similar to the results of previous human and experimental 
studies [194;198;273] (chapter II of the thesis) in which the effect of 
paracetamol overdose on plasma electrolytes were investigated. There 
was no association between plasma paracetamol and plasma K in the 
group presenting later than 12h. In these patients plasma K was in 
significant positive relationship with plasma Cr and PT. This suggests 
relationships between plasma K and plasma paracetamol vary with time 
after exposure. In the early stages of toxicity fall in plasma K might be 
associated with higher plasma paracetamol concentrations, and hence 
ingested dose. Later changes reflect renal injury, either secondary to 




While renal impairment is relatively uncommon after mild to moderate 
paracetamol overdose [271], it is a common complication in patients referred 
to a tertiary centre with severe paracetamol toxicity. The timing of onset of 
renal dysfunction is later than liver injury. Important clinical factors predicting 
poor outcome were: presentation to hospital after 24 h after ingestion, high 
Cr concentration at the time of first presentation, hypotension, staggered 
overdose, raised GGT and concomitant liver dysfunction. Renal dysfunction 
at first presentation appears an important predictor of subsequent liver 
toxicity and death.  Further work is required to explore whether more subtle 
markers of renal impairment might allow better risk stratification in patients 
that present to hospital after paracetamol overdose. The effect of 
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paracetamol on plasma potassium varies with time after ingestion, 
suggesting different mechanisms for plasma K change in early and later 
stage of toxicity. Fall in plasma potassium in the early stage may be due to 
cyclo-oxygenase inhibitory effects of paracetamol, which alter renal 
haemodynamics and tubular handling of electrolytes in the kidney. Later 
changes in plasma K are likely to be due to direct nephrotoxic effects of 
paracetamol.  Measurement of renal effects of paracetamol overdose may 









































Chapter IV: Liver Admission Following Paracetamol 




















Paracetamol overdose is a major public health problem in the UK and the 
cause of 40% of all overdose presentations to hospital. Paracetamol 
overdose is the commonest cause of acute liver failure in the UK [51],  
resulting in several hundred liver unit admissions and about 200 deaths each 
year [278;279]. Patients at sufficient risk of hepatotoxicity are treated with the 
intravenous antidote acetylcysteine (NAC), which has been used as the 
treatment of choice for paracetamol overdose since 1979 [203]. For patients 
presenting within 15 hours (h) after ingestion, the need to antidote therapy is 
determined on the basis of a nomogram which relates plasma paracetamol 
concentration to the time since ingestion. Patients are stratified depending on 
their “risk factors” including: chronic alcohol misuse [280], chronic enzyme 
induction [281], and malnutrition [282]. Those with no risk factors are treated 
if they have a paracetamol concentration above a line starting at 200 mg/l at 
4 h and subject to first-order decline with 4 h half-life (the “200 line”). Those 
with risk factors of enhanced hepatotoxicity are treated at half these 
concentrations (“100 line”). If patients are not treated with antidote, more than 
60% of patients with plasma paracetamol concentration above the treatment 
line may develop serious liver damage, and of those about 5% may die [213]. 
 
In 1998, 4 cases of fatal hepatotoxicity were reported following paracetamol 
overdose with plasma concentration below the “200 line”. All 4 patients 
presented within 4-6 h pots-ingestion. None of the cases received antidote 
therapy initially and in three of four this action was consistent with current UK 
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guidelines [218]. The authors suggested lowering treatment threshold by 
25% to a “150 line” (in the absence of risk factors) to bring them in the line 
with nomograms used in some other countries, including the US. The report 
generated much controversy with both support [219] and criticism 
[220;221;223;224;283]. However, the absolute risk of hepatotoxicity in 
patients with paracetamol concentration between the 150 and 200 lines has 
not determined accurately, and it remains unclear whether the benefits of 
treatment outweigh the risks, or if additional treatment is cost-effective in this 
group. Consequently, UK treatment guidelines have not been changed. 
 
The current study is a systemic retrospective survey performed in defined 
geographic areas over specific time periods, to establish the numbers of 
patients admitted to two liver units with paracetamol-induced hepatic 
dysfunction who had initial paracetamol concentration below the current 




The records of all patients admitted to the Scottish Liver Transplant Unit 
(SLTU) in Royal Infirmary of Edinburgh and regional liver service in 
Newcastle with paracetamol overdose and liver dysfunction were reviewed. 
The period of study was from January 1992 to June 2004 for SLTU data and 
from September 1996 to March 2003 for Newcastle data set. These two 
services cover a population of 9.0 million people, and therefore the period of 
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study encompassed about 95 million person-years. Data in Edinburgh and 
Newcastle were separately extracted, and amalgamated.  
 
Details of all patients were recorded at the time of admission and were 
available in Edinburgh from the SLTU database. The clinical details, including 
patient’s history and biochemistry results were sought from the clinical notes 
in the referring hospital and SLTU. Data collected included plasma 
paracetamol concentration at initial presentation and the timing of this 
following overdose, the presence of risk factors for enhanced hepatotoxicity, 
use and timing of NAC treatment and liver function tests. Patients with a 
plasma paracetamol concentration below threshold were identified and 
reviewed. Information on the overall pattern of paracetamol poisoning was 
obtained from a survey of hospitals in North East England performed in 1994 
[278] , and from review of patients with paracetamol poisoning presenting to 
the Newcastle Hospital NHS Trust during 2004. Data from the SLTU in 
Edinburgh was collected by myself. The data collection for Newcastle, risk 
analysis and cost-benefit calculations were performed by colleagues in 
Newcastle. The results presented in this chapter are a summary of the 




During the period of study, 696 patients (522 SLTU and 174 Newcastle) with 
possible paracetamol hepatotoxicity were admitted to the two liver units. Of 
these, 553 (79%) presented more than 15 h post-ingestion and in 19 (2.7%) 
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there was no adequate information available. Of the remaining 124 
presenting within 15 h, 105 (81%) had a plasma paracetamol above the 
appropriate treatment line, and 19 below it. Of these 19, 5 cases were 
excluded; in two cases because plasma paracetamol had been taken less 
than 4 h after ingestion and results were therefore uninterpretable, and in 
three cases liver function tests or clotting factor was already deranged at 
presentation, indicating the paracetamol overdose may have been taken 
earlier than stated (Figure 4.1).  
 
Thus 14 patients (6 from SLTU), 10 female and 4 male, with mean age (SD) 
of 30.4 ± 10.8 y were admitted to a liver unit after presenting within 15 h of 
overdose, with no evidence of abnormal liver function, and with a plasma 
paracetamol concentration below the appropriate treatment line (Figure 4.1) 
at presentation (for raw data for cases from SLTU see appendix 4.1). 
 
Eight of these patients had normal venous bicarbonate concentrations at 
initial presentation; results were not available in the other six. Ten had no 
recorded features to indicate high risk; of these, four were below the “100 
line”, four between “100 and150 lines” and two between the “150 and 200 
lines”.  Four patients were at high risk, all as a result of excess alcohol 
consumption, and all had paracetamol concentration below the “100 line”. 
 
Two patients were treated with NAC soon after presentation, but the 
remaining 12 were not treated until abnormal liver function or clotting 
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developed. Two patients died; one after undergoing liver transplantation, and 
other from sepsis. The remainder recovered. 
 
Figure 4.1: Patient inclusion and exclusion diagram                                    
 
                                                                 
 
 > 15 h (n=553), Excluded                                                          
                                                                                            
Not sufficient information (n=19), Excluded                                                                                      
Paracetamol above treatment line (n=105), Excluded 
 
                                                                                           
 
Paracetamol was taken < 2 h post-ingestion (n=2), Excluded 
Deranged liver function test at admission (n=3), Excluded 
 
                                            
                                                            Inclusion criteria                   
 Presenting within 15 h     
 Plasma paracetamol below treatment line          





     Total: 696 
< 15 h (n=143) 
Paracetamol below treatment 
line (n=19) 
Total included patients 
(n=14) 
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Table 4.1 : Demographic and characteristic of patients with paracetamol overdose presenting within 15 h post-ingestion with normal liver function and plasma 
paracetamol concentration below current UK guideline (n=14) to two liver centres (SLTU and Newcastle liver centre).  
SLTU: Scottish Liver Transplant Unit, P’mol: paracetamol; OD: overdose; M: male; F: female; Max: maximum; TP: transplantation; HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: 


















































(314, MM080409) 40/F 25 45.6 6.0 Below 100  Alcohol 
Hysterectomy 
for cancer 10 














excess High 30 
INR 
11.3 56 9740 48 No R 
 
3 (SLTU) 
(432, CR070556) 40/F 29 62.5 6.0 Below 100 
Codeine, 
fluoxetine, 
diazepam - Normal 16 INR 9.1 20 10183 84 No R 
 
4 (SLTU) 
(11, DA030015) 26/F 10 95.2 6.0 100-150 
Alcohol, 
salicylates - Normal Not treated INR 3.2 80 11000 57 No R 
5 (SLTU)  







failure NK 18 INR 4.8 55 9945 63 No R 
 
6 (SLTU) 
(169, NG040228) 29/F 10 93 5.0 Below 100 - 
Cardiac 
failure Normal 48 
INR 
11.8 51 7430 65 No R 
7 (Newcastle) 
 NK/F NK 24.5 4.2 Below 100 Alcohol 
Chronic 
alcohol 
excess High 8 
INR 
10.9 53 13173 40 No R 





p’mol OD one 
day earlier Normal 26 PT 87 s 61 - - No R 
9 (Newcastle) 30/F 13 71 8.3 150-200 - - Normal 32 PT 82 s 81 9380 48 No R 






excess High 47 Pt 64 s NK 4780 50 No R 
11 (Newcastle) 17/F 25 136 4.0 100-150 - - Normal 24 PT 76 s 58 4610 96 No R 




alcohol High NK PT 35 s 90 - - No D 
13 (Newcastle) 15/F 7.5 170 4.0 150-200 Alcohol - Normal 33 PT 160 52 11396 46 Yes D 
14 (Newcastle) 29/M 24 107 4.0 100-150 Alcohol - Normal 24 PT 79 s 42 114900 52 No R 
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In data collected from patients presenting with paracetamol overdose 
(n=352) to the Newcastle Clinical Toxicology Service in 2004, 71% (250) had 
plasma paracetamol under the “100 line”, 15% (53) between “100 and 150 
lines” and 3.8% (13) between “150 and 200 lines”. This figure was similar to 
data collected from six A&E departments in the north-east of England in 1994 
(n=287).  The proportions of all patients presenting with plasma paracetamol 
concentrations at presentation below “100 line", between “100 and 150 lines 
“and between “150 and 200 lines” was 64% (184), 13% (37) and 6.4% (18), 




These data confirm the previous observation [218] that some patients with 
relatively low plasma paracetamol concentrations and normal liver function 
tests and clotting factors at admission when apparently presenting within 15 
h of overdose develop severe, and occasionally fatal, hepatic necrosis. In the 
current systematic retrospective analysis, about 2% (14/696) of patients 
admitted to liver units following paracetamol overdose fell into this category.  
From the catchment populations of the liver units concerned and the time 
periods studied, (95 million person-years population) this equates to a 
presentation rate of 0.15 episodes per million populations per annum 




 In the context of the frequency of paracetamol overdose, these cases 
therefore occur very infrequently. The possibility that, in some of these cases, 
unexpected hepatotoxicity developed because the interval between overdose 
and presentation was not given or recorded accurately cannot be excluded. 
In addition some patients with liver failure may not have been referred for 
assessment. 
 
The previous study [278;279] reported an annual presentation rate for 
paracetamol overdose of 750 cases/million population/year. Assuming the 
same presentation rate, the total number of patient presenting with 
paracetamol overdose during the study population is 71250 (750*95). If the 
number of patients presenting in each concentration range was assumed as 
midway between the figures obtained in 1994 [278] and 2004 (67.5% below 
“100 line”, 14% between “100-150 lines” and 5.1% between “150-200 lines), 
the numbers of patients presenting in each paracetamol concentration range 
each year can be derived (48093 below “100 line”, 9975 between “100-150 
lines” and 3634 between “150-200 lines”). Using data provided by this study 
on the numbers of patients requiring liver unit admission in each of these 
concentration ranges (8 below “100 line”, 4 between “100-150 lines” and 2 
between “150-200 lines”), it is possible to estimate the risk for each group. 
For patients with concentrations between the 150 and 200 lines, the 100 and 
150 lines and below the 100 line, respectively, these risks would be 
approximately 1:1250, 1:1850 and 1:4400. However, these estimates should 
be interpreted with caution: proportions are based on limited patient 
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numbers, and the data collection periods and geographic areas are not 
identical with the liver unit data presented here. Furthermore, factors for 
enhanced hepatotoxicity are ignored, as there was inadequate information 
about presentation patterns in relation to them. The frequency of severe 
poisoning may have been reduced by legislation affecting pack sizes [284]. 
Not all patients with severe hepatotoxicity will be referred to a liver unit. 
Finally, an unknown number of patients in each category will have been 
treated with NAC in spite of their low initial paracetamol concentration, 
especially following the Bridger [218] publication. This may reduce the 
numbers of these patients needing liver unit admission, and thus result in an 
underestimation of risk. The proportion of patients treated with NAC 
increased from 25% to 76% for patients between the 150 and 200 lines, and 
from 2% to 15% for those between the 100 and 150 lines comparing the 
1994 [278] and 2004 North-East England data sets. On the basis of these 
data, use of the 150 line for determining need for treatment would prevent 
only a few liver unit admissions; use of lower thresholds still would require 
treatment of very large patient numbers and would avoid only a few further 
episodes. These marginal benefits need to be offset against the 
inconvenience and costs of therapy and the risk of adverse reactions. 
Although usually not severe, anaphylactoid reactions to acetylcysteine 
appear more common in patients with lower plasma paracetamol 
concentrations [245]. In a randomized controlled trial, drug-related adverse 
effects occurred in 45% and anaphylactoid reactions in 18% of recipients of 
the standard acetylcysteine infusion schedule [285]. It is possible that lower 
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doses of acetylcysteine may be effective and safer for patients with 
paracetamol concentrations below current UK thresholds. Clinical trials of 
these would be helpful, but are difficult to perform because of the very large 
numbers of participants that would be required to achieve adequate study 
power to demonstrate efficacy in this group. Larger observational studies, 
which include the simultaneous collection of data on presentation patterns 
and risk factors, would be helpful in order to obtain more accurate estimates 
of risks without antidotal treatment in these patient groups. Abnormal liver 
function tests were present at presentation in some of the patients who went 
on to develop severe hepatic dysfunction, suggesting a longer interval 
between overdose and presentation than that suggested by the history. It 
may therefore be appropriate that liver function tests should be performed on 
all patients at their original presentation; those with abnormal values should 
receive acetylcysteine irrespective of the plasma paracetamol concentration 




Only a very small percentage of patients with plasma concentrations below 
UK treatment threshold may develop features of liver toxicity. In the view of 
the rarity of this event, the costs of therapy and risk of adverse reactions the 
results of this study does not suggest a need to lower current UK thresholds 
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The current protocol for antidote therapy in paracetamol poisoning in the UK is 
the Prescott protocol [203],  which is a step-down, 20-hour intravenous NAC 
infusion (150 mg /kg over 15 min in 200 ml 5% dextrose, followed by 50 mg/kg 
in 500 ml 5% dextrose over 4 hours and 100 mg/Kg in 1000 ml 5% dextrose 
over 16 hours). IV infusion of NAC causes adverse reactions in some patients 
[237]. The frequency of such reactions, varies from 3-9% [238-240] to 48.4% 
[241] in different studies. Some factors including asthma [244;245] and low 
paracetamol concentration [239;241;245;286] have been reported to associated 
with ADRs. Death has been report in an asthmatic patient due to adverse effects 
of a therapeutic dose of IV NAC [246].  In 1984, two deaths were reported due to 
ADRs to overdose of IV NAC [238]. In both these cases the dose of NAC given 
was 10 times higher than therapeutic. The high incidence of ADRs to IV NAC 
(50%) in healthy individuals not receiving paracetamol is further evidence that 
paracetamol itself may have some protective effect against ADRs to NAC [231]. 
 
The mechanisms of ADRs to NAC remain unclear. A non-allergic release of 
histamine has been suggested as a potential mechanism of ADRs [247]. An in 
vitro study has shown histamine release induced by NAC [248].  Previous 
studies on acute allergic reactions, and anaphylactic shock, in other situations 
have shown an increase in plasma concentrations of mast cell products 
(histamine and tryptase) [249-252], endothelial injury parameters (von 
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Willebrand factor [vWf]) and fibrinolytic parameters (tissue plasminogen activator 
[tPA]) [251]. Healthy volunteers given therapeutic doses of NAC intravenously 
who developed ADRs had elevated factor VIII and vWf within an hour of starting 
NAC. The authors suggested that NAC induces release of vWf from endothelial 
cells in subjects who develop adverse effects [231]. 
 
Interleukin 6 (IL6), released from mast cells and basophils, has also been 
reported to contribute in allergic reactions [253]. IL6 also stimulates C-reactive 
protein (CRP) production and the two correlate with one another in acute allergic 
reactions [257]. 
 
The aim of this study was to examine the profile of ADRs to NAC and potential 
risk factors in a patient cohort with paracetamol overdose. In addition the 




This was a prospective study on patients admitted to the Royal Infirmary of 
Edinburgh from July 2006 to May 2007 with paracetamol overdose who required 
NAC treatment. The study was approved by the Local Ethics Committee and 
informed consent form (see appendix 5.1, 5.2 and 5.3) was obtained from all 
patients who took part. All patients who received antidotal therapy were carefully 
monitored for adverse effects. Patients were seen during their hospital stay, with 
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case note review and telephone follow up of patients discharged from hospital 
over night, at weekends or public holidays. Data collected included age and 
gender; type and number of paracetamol tablets taken; time(s) and date of 
ingestion; plasma paracetamol concentration at admission; UK risk 
categorisation for treatment [31]; alcohol history; history of allergy, including 
atopy, asthma or drug; family history of allergy; previous NAC treatment; history 
of ADRs to NAC; nature of any reaction to NAC in the current admission, 
together with treatments given, including necessity to interrupt the NAC infusion 
(see appendix 5.4, 5.5 and 5.6). 
 
In a subset “convenience” sample, a more intense study was conducted in 
patients who gave additional consent. This more detailed study involved blood 
sample collection immediately before and during antidote treatment. 
Measurements included (see also appendix 5.7): 
-Paracetamol:  baseline and 4h after NAC 
 -Histamine: baseline, 15min, 30min, 1h, 2h 
- NAC: baseline, 30min, 2h, 4h, 20h 
- Tryptase: baseline, 30min, 1h, 2h 
-IL6: baseline, 30 min, 1h, 2h, 4h, 20h 
-C-reactive protein (CRP): baseline, 1h, 2h, 4h 
-Clotting factors (II, V, VII, VIII, IX, X, XI, XII): baseline, 30min, 1h, 2h, 4h, 20h 
-vWf: baseline, 30min, 1h, 2h, 4h, 20h 
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The blood was collected from the contra-lateral arm to that in which the NAC 
infusion was given. In addition, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), temperature (T), O2 saturation (O2 Sat) and peak expiratory 
flow rate (PEFR) were measured at baseline, 30 min, 1h, 2h, 4h and 20h after 
NAC infusion initiation. The precise details of any reactions, including time of 
initiation, any treatment and termination, were recorded. Hypotension was 
defined as a SBP <90 mmHg. Tachycardia was defined as pulse rate>100 and 
fever as temperature ≥ 38 ºC.   
 
In view of the sampling protocol, this study was carried out in daylight hours. 
In both parts of the study, overall severity of reaction was graded clinically as 
minimal if patients had no reaction or only gastrointestinal (GI) signs and 
symptoms with or without anti-emetic treatment;  moderate if patients had GI 
signs and symptoms requiring temporary NAC infusion cessation and/or mild 
flushing, pruritus and/or breathlessness (in the intensive study reduction in 
PEFR ≥ 25 and <50 % from baseline), and/or mild chest pain; and                      
severe If NAC was stopped for adverse effects such as severe flushing and/or 
respiratory distress (in the intensive study: ≥ 50% reduction in PEFR from 
baseline) and/or severe chest pain. 
 
To examine the stability of histamine in plasma if processed at different time 
points after blood collection an experiment was conducted on 8 healthy 
volunteers. 4 male and 4 female subjects, older than 16 year-old and non-
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pregnant, took part in the study. In this group plasma histamine of samples 
collected at once but spun at different time points after collection were 
compared. 
 
5-2-1: Blood collection, sample processing and laboratory analysis 
 
Two cannulas were inserted, one in each arm: one for NAC infusion and one, in 
the contra lateral arm for blood collection. After inserting the sampling cannula 5 
ml normal saline was flushed into the vein. Before blood sampling at each time 
point 5 ml blood was collected and discarded. After blood sampling at each time 
point 5 ml normal saline was flushed. More details of blood collection, sampling 
process and laboratory analysis for each marker is as shown below. Plasma 
histamine analysis was measured by myself and a laboratory technician in 
Clinical Pharmacology Unit in the University of Edinburgh. Measurement of 
plasma NAC was performed by the Free radical Research Facility, UHI 
Millennium Institute, Inverness (Prof Megson). The rest of tests were performed 
by biochemistry and haematology technicians in the Royal Infirmary of 
Edinburgh clinical laboratories. 
 
5-2-1-1: Plasma histamine 
 
3 ml of blood was collected by venepuncture with 5 ml syringe and immediately 
transferred to two aliquots (1.5 ml each, containing EDTA) and after shaking on 
a roller (5 min), it was cooled in crushed ice and spun by a micro centrifuge 
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(15000 rpm, 3 minutes, 4ºC) within 30 minutes. The supernatant was transferred 
into two plane aliquots and stored in -80ºC for later analysis.  
 
In the histamine experiment study, 15 ml blood was collected (using 10 ml and a 
5 ml syringe) at once. The blood was immediately distributed in 4 paired 
aliquots, 1.5 ml each. Samples were shaken on the roller for 5 minutes and 
cooled in crushed ice immediately. Each paired sample was spun at 5min, at 
20min, 35min and 65min after collection. The supernatant was transferred into 
two plain tubes and stored at -80 ºC and analysed within 2 months. Plasma 
histamine was measured using an EIA (Enzyme Immunoassay) kit 
manufactured by Bio Source Europe S.A.  The sensitivity of the technique was 
0.1ng/ml for plasma histamine.   
 
5-2-1-2: Plasma NAC 
 
The blood collection and sampling process was the same as histamine. NAC 
was measured by high performance liquid chromatography (HPLC; Agilent 1200 
series with fluorescence detector, Agilent Technologies, South Queensferry, UK) 
using a published method for thiol analysis [287-289] with minor modifications.  
 
5-2-1-3: Plasma tryptase 
 
10 ml blood was collected by venepunture by a plain white top tube, allowed for 
10-15 min to clot in room temperature. The sample was spun (3000 rpm, 4 ºC, 
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15 min) within 30min and the supernatant was stored in two aliquots in -80ºC for 
later analysis. Plasma tryptase was measured by a fluoroenzyme immunoassay 
(ImmunoCAP Tryptase; Phadia AB, Uppsala, Sweden), which detects both α- 
and β-tryptase (mean: 3.8 µg/l, 95% upper limit: 11.4 µg/l, detection limit <0.1 
µg/l). 
 
5-2-1-4: Plasma tPA activity and antigen 
 
5 ml blood was taken by 5ml syringe and transferred immediately to Stabilyte 
tube. The sample was shaken on roller for 5min and cooled in crushed ice and 
spun (3000 rpm, 15 minutes, 4ºC) within 30 min. The supernatant was stored in 
-80ºC in two plain aliquots. The plasma tPA activity and antigen were assayed 
by ELISA (tPA Combi Actibind, Technoclone, Vienna, Austria).  
 
5-2-1-5: Clotting factors, vWf and IL6 
 
9 ml blood was collected by venepunture (using three 3ml green top tubes). The 
samples were shaken for 5 min on a roller, cooled in crushed ice and spun 
(15000 rpm, 15 minutes, 4ºC) within 30 min and stored in two plain aliquots in -
80ºC. The plasma clotting factor activity assays were all performed by ELIZA 
using the CA 600 instrument manufactured by Sysmex. Plasma vWf antigen 
was performed by an ELISA (Enzyme-Linked Immuno Sorbent Assay) technique 
using antibodies supplied by Dacko, Denmark. Plasma IL6 was measured by 
ELISA (Quantikin Human IL-6, R&D Systems, USA). 
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5-2-1-6: Plasma paracetamol and salicylate 
 
 5 ml venous blood was collected by venepunture using (5 ml orange top tube) 
and shaken on a roller for 5 min. The sample was cooled in crushed ice and 
spun (15000 rpm, 15 min, 4ºC) within 30 min. The supernatant was stored in two 
aliquots in -80ºC for later analysis. Plasma paracetamol was measured by an 





5 ml blood was taken by venepunture using (orange top tube). After shaking on 
a roller for 5 minutes it was cooled in crushed ice and spun within 30 minutes 
(3000 rpm, 4 ºC, 15 min). Supernatant was extracted and stored into two plain 
aliquots in -80ºC for later analysis. Plasma CRP was measured by an 
immunoturbidometric technique.  
 
5-2-2: Measurement of PEFR  
 
PEFR (peak expiratory flow rate) is the patient’s maximum ability to expel air 
from the respiratory system. It is measured by a small hand-held device called a 
peak flow meter. Peak flow is a measure of the degree of restriction in the 
airways by measuring airflow rate. Peak flow reading is high when patients are 
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well and is lower when there is bronchoconstriction. The peak flow meter is 
normally used to monitor severity and treatment options in asthmatic patients 
[290]. The main weakness of peak flow meter is that it is patient dependent, and 
if patients do not co-operate may not be an accurate reflection of airway 
function. Its advantages are its simplicity in use, and general reproducibility in 
co-operative patients. 
 
5-2-2-1: Method of measurement of PEFR  
 
Step 1: make sure that marker or arrow on the Peak Flow Meter was at the 
bottom of the numbered scale (zero or the lowest number on the scale).  
Step 2: patients were asked to remove gum or any food from their mouth, to 
take a deep breath (as deep as they could) and to put the mouthpiece of the 
peak flow meter into their mouth. They were told to close their lips tightly around 
the mouthpiece, made sure to keep their tongue away from the mouthpiece and 
in one breath blow out as hard and as quickly as possible until they emptied out 
nearly all of the air from their lungs.  
Step 3: the force of the air coming out of the respiratory system caused the 
marker to move along the numbered scale. The number was recorded as peak 
flow. 
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Step 4: the same steps were repeated twice and the highest number was 
recorded [290]. 
5-2-2-2: Severity of bronchospasm according to PEFR 
Less than 25% reduction in PEFR from baseline was considered as no or mild,  
≥25% and <50% reduction in baseline PEFR: moderate, and ≥50% reduction 
was considered as severe bronchospasm [290]. 
5-3: Statistical analysis 
 
Analysis in the total cohort focused on the pattern of adverse effects and 
potential risk factors. In the more intensive study the relationship between 
severity of ADRs and the changes in the various biological markers were 
examined. Data are presented as mean and 95% confidence intervals or median 
and interquartile range. For two-group comparisons, the Mann-Whitney U test 
was used and for multiple group comparisons of continuous data, a Kruskal-
Wallis H test was performed. AUC (area under the curve) analyses of the 
change from baseline histamine concentration was undertaken between 0 and 
120 min, and a simple linear imputation method was used to minimize the 
potential effects of missing data on AUC analyses. A Chi-square tests was 
performed to compare categorical data. Univariate analyses were performed 
using Spearman’s rank correlation, and possible risk factors were examined 





5-4-1: Result of total cohort 
 
5-4-1-1: Demographic data 
 
Over the period of the study, 193 patients were admitted to the Toxicology unit 
of Royal Infirmary of Edinburgh who required IV NAC infusion following 
paracetamol overdose. Data were not available in 24 cases because the 
patients had absconded from the ward or took their own discharge against 
medical advice and could not be interviewed. Therefore, the study population 
consisted of 169 patients (71 men, 42.0%) with mean (95% confidence interval) 
age 37 y (35 to 39 y).  
 
5-4-1-2: Clinical features of ADRs 
 
Reported adverse effects were nausea (70.4%), vomiting (60.4%), flushing 
(24.9%), pruritus (20.1%), dyspnoea (13.6%), chest pain (7.1%), dizziness 
(7.7%), fever (4.7%), wheezing and bronchospasm (7.1%), and rash and 
urticaria (3.6%) (Table5.1).  
 
None of the patients developed hypotension. Severity was graded minimal in 
101 (39: no ADRs, 62 mild ADRs), moderate in 51, and severe in 17 patients 
(Figure 5.1 and Table 5.2). NAC infusion was stopped temporarily due to 
adverse effects in 18 patients. 
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Table 5.1: Occurrence of ADRs to intravenous NAC in patients with paracetamol 
overdose (n=169). 
 
Signs & Symptoms n (%) 
Nausea 119 (70.4%) 
Vomiting 102 (60.4%) 
Gastrointestinal 
Abdominal discomfort 8 (4.7%) 
Flushing 42 (24.9%) 
Pruritus 34 (20.1%) 
Skin 
Rash and urticaria 6 (3.6%) 
Dyspnoea 23 (13.6%) 
Wheeze & bronchospasm 12 (7.1 %) 
Respiratory 
Coughing 4 (2.4%) 
Dizziness 13 (7.7%) 
Chest Pain 12 (7.1%) 
Fever (temperature ≥38 ºC) 8 (4.7%) 
Other 




Table 5.2: History of asthma, drug allergy, family history of allergy and previous ADRs 
to NAC in the group with minimal and moderate or severe ADRs to NAC.  
M: male, F: female. 
                 
 
Severity of ADRs 
Minimal  
(no:39, mild: 62) 
Moderate and severe  
(moderate: 51, severe: 17) 
Total number (n=169)  101  68  
Gender (M/F) 39/62 32/36 
Age (mean 95% CI) (y) 38.1 (35.0-41.2) 34.8 (31.6-38.0) 
Paracetamol level at admission (mg/l)  
(mean 95% CI )  
130.0 (114.6-145.3)  104.4 (81.2-127.7) 
  
Asthma, n (Yes/No) 13/88 10/58 
Drug allergy, n (Yes/No) 17/84 17/51 
Family allergy, (Yes/No) 
 Total=151, unknown=18  
32/59 32/28 
Previous allergy to NAC, (Yes/No) 
Total: 52, Unknown: 19, No previous 




Figure 5.1: Diagrammatic representation of adverse effect profiles in patients treated 
with acetylcysteine for paracetamol poisoning, categorised by adverse effect severity: 

























































Plasma paracetamol concentration was lower in patients with severe adverse 
effects [median (IQR) in severe: 46 mg/l (0 to 101 mg/l), moderate: 108 mg/l (54 
to 178 mg/l) and minimal: 119 mg/l (77 to 174 mg/l)], p=0.002 by 3-way 
comparison. Concentrations were undetectable in 4 patients; two had taken a 




5-4-1-4: Associated factors of ADRs 
 
Logistic regression (stepwise backward) analyses of possible risk factors of 
ADRs showed that moderate to severe adverse effects were correlated inversely 
with plasma paracetamol concentration [odds ratio (95% CI): 0.99 (0.99 -1.00)] 
and male gender [odds ratio (95% CI): 0.45 (0.22 - 0.92)], and correlated 
positively with a family history of allergy [odds ratio (95% CI): 2.89 (1.39-5.99)]. 
No significant correlations were found with age, history of asthma, or previous 









Table 5.3: Stepwise backward binary logistic regression for possible variables 
associated with moderate to severe adverse effects of NAC. 
 
 * Change in risk related to each year of life and each mg/l increase in paracetamol 
concentration, other variables treated as categorical data. Analyses were made between two 
groups: minima ADRs group (n=101) and moderate or severe ADRs (n=68).  
 
 Odds ratio (95% CI) p-value 
Univariate analyses   
Male gender 0.40 (0.19 to 0.84) 0.016 
Age (y) * 0.98 (0.95 to 1.00) 0.102 
[paracetamol] (mg/l) * 1.00 (0.99 to 1.00) 0.062 
Asthma 1.09 (0.42 to 2.83) 0.867 
Drug allergy 1.82 (0.73 to 4.52) 0.200 
Family history of allergy 2.36 (1.09 to 5.08) 0.029 
Constant 6.02 0.032 
 
Logistic Stepwise backward regression analyses 
  
Male gender 0.45 (0.22 to 0.92) 0.028 
[paracetamol] (mg/l) * 0.99 (0.99 to 1.00) 0.043 
Family history of allergy 2.89 (1.39 to 5.99) 0.004 
Constant 2.452 0.147 
 
 
5-4-2: Result of the intensive study 
5-4-2-1: Demographic data 
 
 22 patients (11 male and 11 female) with mean age (95% CI) of 34.6 (21-45) y 
were recruited into the more intensive study. These patients were almost all 
studied in daylight hours and therefore are not representative of the total cohort 
with respect to nature of paracetamol overdose, often being later presentations. 
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Some patients did not complete the whole course of the study because they did 
not require a full course of NAC treatment, self-discharged or withdrew from the 
study. All patients completed the first 2 hours of the study, 18 the first 4h and 16 
completed the full study (20h).  
 
5-4-2-2: Severity of ADRs 
 
 10 subjects (45%) had minimal, 5 (23%) moderate and 7 (32%) severe ADRs 
(Table 5.4 and 5.5).There was no significant difference between groups with 
respect to systolic blood pressure at baseline or during antidote infusion (Table 
5.6). The onset of ADRs in most subjects occurred within the first hour and 15 
min after commencement of treatment (see appendix 5.8). There was no 
significant difference between these groups in terms of age and gender.  
 
 
5-4-2-3: Plasma Paracetamol 
 
As in the total study paracetamol at baseline (median and IQR) was significantly 
lower in patients with severe ADRs (severe: 0.0 mg/l [0.0-41.0] vs. minimal: 





5-4-2-4: Plasma NAC 
 
As expected, plasma NAC concentration was maximal at the 30min time point 
after infusion. There was no difference in plasma NAC in the groups with 
different ADRs severity at any time point (Table 5.7) (see appendix 5.9 for raw 
data).
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Table 5.4: Clinical features of ADRs to NAC in patients with severe ADRs, n=7 (intensive study) 
 
* Vomiting: mild: no treatment required; moderate: treatment required; severe: required temporary IV NAC infusion stop 
** Bronchospasm: moderate: if reduction in baseline PEFR ≥25% and ≤50%; severe: if reduction in baseline PEFR≥50% 
*** Chest Pain: moderate: feeling tight chest with no sharp pain; severe: with a sharp pain in the chest requiring temporary stop in NAC 
infusion               
 
Features of ADRs 
 Case 1 Case  2  Case 3 Case 4  Case 5  Case 6 Case 7 
Rash (Yes, No)  No  No  No  No  No    No 
Pruritus (Yes, No)  No  No Yes  No  No Yes  No 
Urticaria (Yes, No)  No  No  No  No  No  No  No 
Angioedema (Yes, No)  No  No  No  No  No  No  No 
Nausea(Yes, No) Yes  No Yes Yes Yes Yes  No 
Vomiting (Yes *, No) Yes (Moderate)  No Yes (Moderate) Yes (Moderate) Yes (Severe) Yes (Moderate)  No 
Chest Pain (Yes, No)  No  No  No  No  No  No  No 
Abdominal cramp (Yes, No)  No  No  No  No  No  No  No 
Diarrhoea (Yes, No)  No  No  No  No  No  No  No 
Flushing (Yes, No) Yes  Yes  Yes  Yes  Yes  Yes  Yes  
Fever (Yes, No)  No  Yes  No  No  No  No  No 
Coughing (Yes, No)  No Yes Yes  No Yes  No Yes 
Wheezing (Yes, No)  No Yes  No  No  No  No  No 
Dyspnoea (Yes, No) Yes Yes Yes  No Yes  No Yes 
Bronchospasm (Yes **, No) Yes (Moderate) Yes (Severe)  No  No Yes (Severe)  No Yes (Moderate) 
Chest Pain (Yes***, No)  No  No Yes (Moderate)  No Yes (Severe)  No Yes (Moderate) 
Tachycardia (Yes, No)  No Yes  No  No Yes  No  No 
Hypertension (Yes, No)  No Yes  No  No Yes  No  No 
Hypotension (Yes, No)  No  No  No  No  No  No  No 
Faint/dizziness (Yes, No)  No Yes  No  No  No  No  No 
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Table 5.5: Peak flow rate (L/per min) at base line and time points (30min, 1h, 2h, 4h and 20h) after IV NAC commencement. 
ND: No data available. 
Pt No Severity 
PEFR BASE 
L/pm T1 h PEFR 1 T2  PEFR 2 T3  PEFR 3 T4 PEFR 4 T5 PEFR 5 
5 1 ND  ND  ND  ND  ND  ND 
6 1 400.00  ND 0.90 470.00 2.10 470.00 4.00 420.00 20.00 520.00 
7 1 340.00 0.50 250.00 1.30 380.00 2.30 220.00 4.50 250.00 20.50 340.00 
9 1 ND  ND  ND  ND  ND  ND 
13 1 ND  ND  ND  ND  ND  ND 
17 1 600.00 0.50 550.00 1.00 575.00 2.10 430.00 4.10 440.00 22.00 520.00 
18 1 360.00 0.50 300.00 1.00 300.00 2.00 340.00 5.00 340.00 21.00 370.00 
19 1 575.00 0.60 420.00 1.10 390.00 2.10 430.00 4.10 420.00 20.50 440.00 
20 1 180.00 0.50 150.00  ND 2.00 150.00 4.00 150.00 20.00 200.00 
22 1 280.00 0.50 230.00 1.00 210.00 2.30 230.00 4.00 200.00  ND 
1 2 500.00 0.50 480.00 1.00 450.00 2.00 490.00 4.50 500.00  ND 
2 2 490.00 0.50 450.00 1.10 450.00 2.20 440.00 4.50 ND 20.00 450.00 
12 2 210.00  ND 1.10 200.00 2.10 220.00 4.60 180.00 20.20 240.00 
15 2 ND  ND  ND  ND  ND  ND 
21 2 350.00 0.50 410.00 1.00 400.00 2.10 400.00 4.20 400.00 20.00 350.00 
3 3 480.00 0.50 300.00  ND 3.00 440.00 4.00 370.00 20.30 410.00 
4 3 340.00 0.50 120.00 1.00 290.00 2.00 340.00  ND  ND 
8 3 260.00 0.40 390.00 1.50 250.00 2.50 300.00 4.10 320.00 20.50 340.00 
10 3 520.00  ND  ND    ND  ND 
11 3 600.00 0.60 250.00 1.30 440.00 2.10 500.00 4.00 600.00 20.30 570.00 
14 3 380.00 0.50 330.00 1.00 300.00 2.40 350.00  ND  ND 
16 3 300.00   1.00 200.00 2.00 270.00 4.20 300.00  ND 
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Table 5.6: Systolic blood pressure (SBP) at baseline and time points after IV NAC 
infusion commencement in the groups according to the severity of ADRs.  
 
There was no significant difference in SBP between groups at baseline and any time points after 
IV NAC infusion commencement. n: number of subjects (intensive study). 
 
SBP in the groups 
according to ADRs 
Minimal 
Median and IQR,  n 
Moderate 
Median and IQR,  n 
Severe 
Median and IQR,  n 
baseline  127.0 (107.3-146.3), 10 112.0 (109.0-115.5),  5 123.0 (112.0-147.0), 7 
30min 128.5 (105.5-154.5), 8 122.0 (117.0-127.0), 4 131.0 (125.0-171.5), 5 
1h  128.0 (112.3-133.5), 10 116.0 (109.0-131.0), 5 146.0 (121.0-172.0), 6 
2h  124.5 (106.8-155.5),10 117.0 (115.5-124.5), 5 125.0 (109.5-157.5), 6 
4h  151.0 (113.0-168.8),10 128.0 (112.5-146.5), 5 133.0 (114.8-173.8), 4 
20h  126.0 (114.0-140.5), 9 112.0 (109.50-127.3), 4 137.0 (97.0,- ), 3 
 
 
5-4-2-5: Plasma Histamine 
 
There was no significant difference in plasma histamine concentrations between 
groups at baseline. After commencement of NAC, plasma histamine increased 
in the groups with moderate and severe ADRs and it reached maximum (2.5 fold 
increase) between 30 to 70 min.  There was significant difference in change in 
plasma histamine between groups at 1h (p=0.02) (Figure 5.2) (see appendix 
5.10, 5.11 and 5.12 for raw data). 
 
 The AUC of histamine-time expressed as change from baseline (median and 
IQR) was significantly different between groups (p=0.01):minimal: -6.4 ng/ml.min 
[-60.3-10.8];  moderate 25.6 ng/ml.min [2.9-128.7];  severe 49.0 ng/ml.min [21.0-
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68.0].The significance level was between minimal and severe ADRS groups 
(p=0.005). The difference between AUC change of minimal and moderate group 
just failed to pass conventional significance level (p=0.06), perhaps due to small 
number of subjects in each group. 
 
In the experimental study on 8 healthy volunteers there was no significant 
difference in plasma histamine concentration when centrifuged and separated 
either at 5min, 15min, 30min or 1h after blood collection (Table 5.8) (see 
appendix 5.13 for raw data). 
 
5-4-2-6: Plasma tryptase 
 
 There was no significant difference in change in plasma tryptase concentration 
between groups at 30 min and 1h following IV NAC infusion. Plasma tryptase 
change at 2h was significantly different between groups, but not related to the 
severity of adverse reactions (Table 5.9) (see appendix 5.14 for raw data). 
Change in AUC tryptase (0-2h) was not significantly different between groups 
(p=0.22).  
 
Median and IQR of AUC change of tryptase (0-2h) was -85.0 [-182.50- (-32.5)] 
µg/l.min in the minimal ADRs group; 59.50 [-254.35-207.50] in the moderate 
group and -67.0 [-106.0-81.0)] in the severe group.  
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Table 5.7: Median plasma NAC concentration (IQR) (mg/l) after intravenous infusion 
according to the severity of adverse effects: minimal, moderate, and severe.  
 
NAC reached maximum concentration at 30min time point. After 30min NAC decreased steadily. 
There was no significant difference in plasma NAC concentration between groups with different 
ADR severities at any time point. n=number of subjects. 
 
plasma NAC (mg/l) and 
time Median (IQR) 
 
Minimal ADRs  
 
Moderate ADRs  
 
Severe  ADRs  
































Figure 5.2: Median change in plasma histamine concentrations (ng/ml) at 15 min, 30 
min, 1h and 2h after commencing intravenous NAC infusion from baseline according to 
the severity of ADRs: minimal ( ), moderate ( ), and severe (▲). 
 
Data in the table shows median and IQR and data in the graph represent median. 3 -group 
comparison showed a significant difference between groups at 1h time point (p=0.02). The 
difference was between groups with minimal and severe ADRs (p=0.01).  n: number of subjects. 
 
 
Change in plasma 




Minimal ADRs  
 
 
Moderate ADRs ) 
 
 
Severe  ADRs  
 
15min: 15.0 [15.0-18.0]  -0.25 [-0.64-(-0.03)] -0.11[ -0.16-1.13 ] -0.05 [-0.21- 0.11] 
30min: 33.0 [30.0-35.0] -0.09 [-0.59-0.08] 0.33 [-0.11-1.23] 0.67 [-0.11-1.16] 
60min: 65.0 [60.0-70.0] -0.04 [-0.61-0.18] 0.50 [0.16-1.43] 0.63 [0.23-1.40] 
120min: 124.0 [120.0-
130.0] 
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Table 5.8:  Effect of delay in sample processing on plasma histamine assay (ng/ml) in 8 
healthy volunteers (4 male and 4 female). 
 
 Samples were collected and cooled at once, but processed at different time points after blood 
collection (5min, 15min, 30min and 60min). Data are reported as median and IQR. There was no 
significant difference in plasma histamine when processed either at 5min, 15min, 30min or 1h 





Table 5.9: median change in plasma tryptase concentrations (µg/l) at 30 min, 1h and 2h 
after commencing IV NAC infusion from baseline according to the severity of ADRs 
(minimal, moderate and severe). 
 
Change in plasma tryptase at 2h was significantly different between groups according to the 
severity (p=0.02) and the difference was between minimal and moderate ADRs (p=0.03) and 
minimal and severe ADRs (p=0.016). n=number of subjects 
 
Change in plasma tryptase 




Minimal ADRs  
 
 
Moderate ADRs  
 
 
Severe  ADRs  
 
30min: 33.0 [30.0-35.0] -1.16 [-1.37-(-0.18)] 
n=8 

















Time from collection to sample processing 
 
Median and IQR (ng/ml) 
 
  n 
5min 0.53 (0.48-0.82) 8 
15min 0.62 (0.51-0.73) 8 
30min 0.64 (0.35-0.78) 8 
60min 0.55 (0.43-0.81) 8 
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5-4-2-7: Plasma CRP and IL6 
There was no significant difference in plasma CRP or plasma IL-6 between 
groups with different severity at baseline, or subsequently (see appendix 6.15 
and 6.16 for raw data).  
 
5-4-2-8: tPA antigen and activity 
 
There was no significant change in plasma tPA antigen between groups with 
different severity at baseline or time points after NAC infusion. Change in 
plasma tPA activity at 1h and 2h were significantly higher in the severe group 
compared to minimal group (p=0.007 and p=0.02, respectively) (Table 5.10), 
however, AUC change of tPA (0-4h) was not significantly different between 
groups. Median and IQR of AUC change of tPA (0-4h) was -2.3 [-36.1-5.1] 
(u/ml.min) in the minimal group; 0.0 [-26.4-34.5] in the moderate and -10.9 
 [-49.8-76.6] in the severe group (see appendix 6.17 and 6.18 for raw data).  
 
Table 5.10: Change from baseline in plasma tPA activity concentration (u/ml) at time 
points after start of IV NAC infusion commencement in the groups according to the 
severity of ADRs.  
 
Data are reported as median and inter-quartile range (IQR).   
 
Change in plasma tPA 











1h: 1.08 [1.00-1.16] 0.00 (-0.13-0.13) 0.00 (-0.20-0.80) 1.00 (0.23-1.15) 
2h: 2.06 [2.00-2.18] 0.00 (-0.26-0.00) 0.00 (-0.05-0.15) 0.10 (0.00-0.30) 
4h: 4.1 [4.0-4.3] 0.00 (-0.18-0.13) 0.00 (0.00-1.35) -0.25 (-0.58-0.23) 
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5-4-2-9: Clotting factors and vWf factor 
 
There was no association between plasma vWf and plasma clotting factor 
activity and severity of ADRs (see appendix 5.19 to 5.26 for raw data). Activity 
for the clotting factors II, VII, IX and X were, however, significantly decreased 
within 4h of NAC infusion commencement. Maximum derangement in factor II, 
IX and X occurred within an hour and for factor VII at 4h (Figure 5.3 and Table 
5.11). There was significant correlation between plasma factor VIII and its carrier 
(plasma vWf) at baseline (r=0.4, p=0.05, n=22), at 1h (r=0.6, p=0.01, n=18) and 
at 2h (r=0.6, p=0.006, n=21).  
 
Figure 5.3: Clotting factor activity (mean, iu/l) at baseline and time points (30min, 1h, 
2h, 4h and 20h) after IV NAC infusion in patients with paracetamol overdose.  
 
Activity of factor II (◊), factor VII ( ), factor IX (●), and factor X (▲). Factors: II, VII, IX and X 
were significantly decreased compared to baseline within 4h of NAC infusion initiation (see also 
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Table 5.11: Clotting factor activity (II, VII, IX, X, V, VIII, XI) (Median and IQR) at baseline and time points after IV NAC infusion 
commencement in patients with paracetamol overdose (n=22).  
 
Time points: baseline and 30min, 1h 2h 4h and 20h after NAC infusion commencement. Activity of clotting factors in each time point were 
compared with factors at baseline. Clotting factor in each time point was compared with baseline using Mann Whitney U test. p is significance for 
paired comparison. Factors: II, VII, IX and X were significantly decreased compared to baseline within 4h after NAC infusion initiation. Factor VIII 
and XI did not change significantly. a n=22;  b n=21;  c n=20 ;  d n=18;   e n=19;   f  n=16,   
 
Clotting factor activity 
(iu/l), time point 











         4h 
 
20h 
Factor II activity 0.84 (0.76-0.93) a  
 
0.69 (0.60-0.77) b  
p=0.008 
0.70 (0.60-0.80) d 
p=0.01 
0.75 (0.67-0.84) b 
p=0.1 
0.77 (0.67-0.86) e 
p=0.2 
0.81 (0.68-0.94) f 
n=0.8 
Factor VII activity 0.79 (0.45-0.70) a 
 
0.56 (0.45-0.70) d 
p=0.05 
0.54 (0.40-0.68) d 
p=0.02 
0.57 (0.44-0.70) b 
 p=0.04 
0.51 (0.40-0.63) d 
p=0.006 
0.59 (0.45-0.74) f 
p=0.09 
Factor IX activity 0.99 (0.87-1.12) a 
 
   0.79 (0.68-0.90) c 
p=0.02 
0.80 (0.67-0.93) d 
p=0.04 
0.88 (0.71-1.06) b 
 p=0.07 
0.85 (0.72-0.97) d 
p=0.1 
0.99 (0.81-1.16) f 
p=0.9 
Factor X activity 0.88 (0.78-0.97) a 
 
0.69 (0.61-0.76) c 
p=0.009 
0.68 (0.59-0.78) d 
p=0.01 
0.74 (0.62-0.85) b 
 p=0.03 
0.69 (0.61-0.78) d 
p=0.01 
0.71 (0.60-0.81) f 
p=0.05 
Factor XI activity 0.73 (0.64-0.81)) a  0.67 (0.60-0.75) c 
p=0.4 
0.68 (0.58-0.77) d 
p=0.5 
0.73 (0.61-0.84) b 
p=0.09 
0.65 (0.57-0.73) d 
p=0.3 
  0.66 (0.57-0.75) f 
p=0.4 
Factor V activity 0.69 (0.57-0.82) a 
 
0.67 (0.56-0.79) c 
p=0.9 
0.71 (0.56-0.86) d 
p=0.9 
0.80 (0.65-0.94) b 
p=0.3 
0.79 (0.64-0.93) d 
p=0.3 
0.89 (0.71-1.07) f 
p=0.02 
Factor VIII activity 1.31 (1.04-1.58) a 
 
1.28 (0.91-1.05) c 
p=0.5 
1.36 (0.95-1.77) d 
p=0.8 
1.43 (1.05-1.81) b 
p=0.9 
1.39 (1.11-1.68) d 
p=0.5 
1.40 (1.22-1.57) f 
p=0.2 
5-5:Discussion  
NAC has been a treatment of choice in paracetamol overdose since its 
introduction in the 1970s [202;203]. Anaphylactoid reactions following IV NAC 
infusion were reported soon after its introduction [237;291], however the 
mechanism of the ADRs is not fully understood. The reported incidence of ADRs 
varies from 3% to 50% [231;239-241;243;292]. In the current study the 
incidence of anaphylactoid reactions was found to be 40.2% (10.1%: severe and 
30.1% moderate). The discrepancy in ADRs incidence among different studies 
is likely due to variability in definition of ADRs, in mode of administration of NAC 
infusion (drip or pump), and possibly different study populations. The present 
study suggests that paracetamol concentration at the time of antidote use might 
be an important confounder. 
 
Factors reported to increase the risk of anaphylactoid reactions to NAC, include 
history of asthma [237;244;245;293;294], atopy [295], drug allergy [245] and low 
plasma paracetamol concentration [239;241;245]. Female gender, family history 
of allergy and low paracetamol concentration were the only independent risk 
factors that were identified in the current study. It is unclear why asthma should 
be identified as a risk factor by Schmidt & Dalhoff, but not in this study. Whether 




During an anaphylactic reaction, mediators are released and can be detected in 
the blood soon afterwards. Histamine is detectable in plasma 10 minutes to 1h 
after reaction initiation [296;297]. Following bee sting histamine and tryptase 
have been shown to be in a significant association with clinical severity of 
anaphylactic reactions [250].  
 
In man, a dose-dependent wheal and flare response to intradermal injection of 
Parvolex (the pharmaceutical branded preparation containing 200 mg/ml NAC 
together with EDTA [ethylene diamine tetra acetic acid] as a stabilizer and 
sodium hydroxide to correct pH) has been reported [247]. Pre-treatment with a 
specific H1 antagonist (terfenadine) suppressed the weal and flare response.  
NAC also caused dose-dependent histamine release from cultured mouse mast 
cell (PT18 cell line) and human basophils [248]. The authors suggested that 
ADRs to NAC might be attributed to a direct effect on mast cell and basophils.  
An in vitro study [298] showed that NAC induced spontaneous histamine release 
from human peripheral leukocytes. The main finding of the current study was a 
higher histamine concentration in the group with severe ADRs. Adding this 
finding to the previous studies findings, it seems clear that histamine is involved 
in mediating ADRs following IV NAC infusion; however this is not primarily due 
to variability in NAC concentration as there was no difference in NAC 
concentration between groups (Table 5.7). 
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The measurement of plasma tryptase along with plasma histamine has been 
suggested for the diagnosis of anaphylaxis and change can be detected 1 to 2 
hours after initiation of anaphylactic responses [297]. In this study no 
relationship was found between ADRs severity and change in plasma tryptase 
(Table 5.9). These findings suggest either very low levels of release from mast 
cells, or more likely, that the source of histamine was basophils which have far 
lower tryptase levels [299]. 
 
Endothelial injury and activation of the coagulation system occurs in anaphylaxis 
[300-302]. An elevation in vWf factor, a marker of endothelial injury, has been 
reported in anaphylactic shock [251]. A study on healthy volunteers receiving 
therapeutic doses of NAC showed a rapid increase in factor VIII and its carrier, 
vWf factor, in the group with anaphylactoid reactions but not in the group without 
ADRs [231]. In the present study there was no association between changes in 
the activity of clotting factors and vWf and severity of reaction. Furthermore, vWf 
did not correlate with histamine. It is possible that the presence of paracetamol 
or recent paracetamol overdose may accounts for this difference, but further 
studies are required to understand the reason for the difference in adverse 
effects profile.  
 
As reported by others there was a significant fall in vitamin K dependent clotting 
factor activity (II, VII, IX and X) in all subjects within 1 to 4h of NAC infusion 
commencement  (Figure 5.3 and Table 5.11) [302]. While this may be relevant 
 167
to the diagnosis of hepatotoxicity following paracetamol overdose there was no 
relationship to ADR occurrence. There was a significant correlation between 
factor VIII activity and its carrier, vWf factor, confirming previous findings [231].  
 
Anaphylaxis also activates the fibrinolytic system, an effect thought to be due to 
release of mast cell products, resulting in endothelial cell stimulation [302-306] . 
In a study on subjects with anaphylactic shock after insect sting challenge both 
tPA, a marker and fibrinolytic injury, and vWf, a marker on endothelial injury, 
increased within a few minutes of onset of clinical symptoms [251]. In this study 
the effects on tPA were not significant when AUC of response was examined, 
suggesting this mediator is not a primary factor in this adverse reaction. In vitro 
studies have shown that toxic, but not therapeutic, doses of paracetamol inhibit 
the function of lymphocytes, [307]  neutrophils, [308] and platelets [309]. The 
suggested mechanism is thought to be paracetamol-induced reversible cyclo-
oxygenase inhibition, resulting in reduction in PG and thromboxane synthesis, 
indicating that paracetamol may perhaps have some specific mast cell effects. 
Since PG is a key mediator in anaphylactic reactions [309], its inhibition by 
paracetamol might play a role in preventing ADRs to NAC . The present data 
showed an inverse relationship between plasma paracetamol and severity of 
ADRs, which also confirms the results of other studies, suggesting that higher 
concentrations of paracetamol are protective against anaphylactoid reactions to 
NAC. More studies are required to elucidate the effect of paracetamol on PG 
synthesis, mediator release and inhibiting anaphylactoid reactions. 
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It thus appears that NAC-induced histamine release in paracetamol overdose 
occurs in the absence of release of other traditional markers of mast cell 
degranulation or endothelial dysfunction. The source of histamine therefore 
seems most likely to be from basophils, which have lower tryptase content. The 
protective role of paracetamol implies a pharmacological effect on the 
mechanisms involved in the ADR process. The most likely target would seem to 
be cyclo-oxygenase. In a previous study discussed in this thesis it was 
hypothesized that paracetamol effects on renal potassium loss in overdose are 
due to inhibitory effects of paracetamol on cyclo-oxygenase [273]. In vitro data 
suggests that NAC may modulate PG synthetic pathways, promoting  
bronchoconstriction by increasing synthesis of PGF2 alpha and reducing 
synthesis of bronchodilator PGE [298]. Although asthma was not a predominant 
feature a significant minority of patients had bronchoconstriction, which is in 
keeping with this hypothesis.  
 
In the intensive study one patient (subject number one, see appendix 5.11) who 
had severe vomiting with no obvious features of anaphylactoid reaction in whom 
NAC infusion was stopped also had an increase in plasma histamine 
concentration within 30min after infusion, which was 5 times higher (2.44 ng/ml) 
than baseline (0.48 ng/ml) level. Other subjects with ADRs showed 
combinations of vomiting and feature of anaphylactoid reactions and it is 
therefore unclear whether the release of histamine contributes to the nausea 
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caused by this antidote. The rates of nausea and vomiting observed in this study 
were high and this raises the issue of whether routine anti-emetic prophylaxis 
with an antihistamine would be effective and if histamine release is involved in 
their causation. The ADR profiles illustrate the inter- individual susceptibility to 
different ADR features. The reasons for this variability also require to be 
understood if the incidence of ADRs to NAC is to be reduced. There appear to 
be other individual factors that underlying the risk of having an ADR to NAC, and 
family history of allergy and gender effect suggest that genetic factors may be 
relevant here. Whether reducing the initial bolus dose of NAC or prolongation of 
loading dose infusion would reduce the incidence of adverse effects without 




Anaphylactoid reactions to acetylcysteine are relatively common in patients with 
paracetamol overdose. Low paracetamol concentration is a risk factor in 
developing ADRs. Histamine release is associated with the reaction severity. 
Future study is required to elucidate the specific effects of paracetamol that 
protects against ADRs to its antidote and these seem likely to involve inhibition 
of PG synthesis. The involvement of histamine in the reaction raises the 















































6-1: Summary of the thesis 
 
Paracetamol has been available as an over-the-counter drug (without 
prescription) since 1956, with a remarkable safety record at normal therapeutic 
doses. Although it has been used for more than 50 years, there are still many 
unknown aspects in regards to its toxicity and treatment in overdose. The first 
toxicity of paracetamol in overdose in man was reported in 1966 [41;42]. It is the 
most commonly used drug in deliberate self harm [43-46] being involved as a 
component in 48% of poisoning admissions to hospital in the UK [47]. 
Paracetamol is the commonest cause of fulminant hepatic failure and liver 
transplantation in the UK and the US [40;51-57]. Renal insufficiency during the 
course of paracetamol overdose, with or without concomitant hepatic failure, has 
also long been recognised [42;81-90]. However, the mechanism of the 
nephrotoxicity in man is not fully understood.  
 
The main pharmacological effect of paracetamol is inhibition of cyclo-oxygenase 
(COX) and thus prostaglandin (PG) synthesis [6]. In overdose non-steroidal anti-
inflammatory drugs such as ibuprofen, cause dose-dependent increase in 
urinary potassium excretion (FeK) and sodium retention [262], probably due to 
vasoconstriction. It was therefore hypothesised that paracetamol in overdose 
may affect renal function due to similar mechanisms.  
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To examine this hypothesis the effect of acute paracetamol overdose on plasma 
and urinary electrolytes was investigated retrospectively, and more intensively 
prospectively (Chapter II). The results of these studies showed paracetamol 
overdose is associated with dose-related hypokalaemia, and kaliuresis of short 
duration (less than 24 h post-ingestion). A previous study also showed 
hypophosphatemia and dose-dependent phosphaturia following paracetamol 
overdose [198], but this effect of paracetamol overdose on potassium handling 
has not been previously reported. The findings of the current and previous 
studies suggest a specific renal effect of paracetamol in overdose. This is likely 
to be due to inhibitory effect on COX and PG synthesis.  
 
Liver failure is a well-known toxic effect of serious paracetamol overdose. Renal 
failure is less common than liver failure and occurs in only 1% of all patients with 
paracetamol overdose. This has been reported to reach 10% in severe 
paracetamol poisoning [18;91;270]. In most cases kidney failure occurs 
concomitantly with liver failure, although isolated kidney damage following 
paracetamol overdose has been reported [87;89;90].  
 
In the third chapter of this thesis the frequency of renal failure, the associated 
risk factors of renal injury and impact of kidney damage on outcomes in a large 
cohort of patients who developed liver failure following paracetamol overdose 
were examined. The results of the study showed that whereas renal impairment 
is known to be relatively uncommon after mild to moderate paracetamol 
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overdose, it was a common complication in patients referred to a tertiary centre 
following severe paracetamol poisoning. Important associated factors in 
predicting poor outcome were hypotension, higher plasma creatinine 
concentration, raised GGT and concomitant liver dysfunction at first presentation 
to hospital. Presentations to hospital more than 24 h post-ingestion and 
staggered overdose are also poor prognostic factors. However, the population 
studied was from a single large UK centre and may therefore not be an accurate 
reflection of patients in other liver units around the world.  
 
In these patients with severe paracetamol overdose the relationship between 
time of presentation and plasma electrolytes at presentation was examined. This 
analysis showed that paracetamol overdose had time-dependent effects on 
potassium. In the earlier stages (within 24 h), plasma potassium fall is in a dose-
related association with plasma paracetamol concentration, probably due to 
pharmacological effect of paracetamol in the kidney described in chapter three. 
In the later stage of toxicity, rise in plasma potassium is associated with rise in 
plasma creatinine concentration secondary to the nephrotoxic effect of 
paracetamol. Thus different mechanisms for changes in plasma potassium exist 
at different time after poisoning. The finding of the prospective study in the 
chapter 3 of the thesis showed kaliuresis. This suggests that fall in plasma 
potassium in the earlier stage is due to renal loss, possibly due to inhibitory 
effect of paracetamol on cyclo-oxygenase which alters renal hemodynamics and 
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tubular handling of electrolytes. Later changes in plasma potassium are likely 
due to direct nephrotoxic effects of paracetamol.  
 
In the fourth and fifth chapters the focus of the thesis was on antidote treatment 
of paracetamol poisoning.  Acetylcysteine (NAC) has long been used as a 
treatment of choice for the treatment of paracetamol overdose in patients who 
are at risk of hepatotoxicity. There have been reports of liver failure and death in 
patients who had plasma paracetamol concentration below the current UK 
treatment threshold nomogram, and who are therefore not treated [218].These 
authors suggested lowering the current UK treatment threshold line. The report 
generated controversy with both support [219] and criticism of the suggested 
policy change [220;221;223;283]. To establish the numbers of patients 
presenting with severe liver dysfunction when initial paracetamol concentrations 
are below the current nomogram level, a systemic retrospective study survey on 
patients presenting to two tertiary liver centres due to suspected liver failure 
following paracetamol poisoning was performed in defined geographic area over 
a specific time. The findings of the study showed that this event occurs only in a 
very small proportion of patients. In the view of the rarity of the event, the costs 
of therapy and risk of adverse reactions (ADRs) the study concluded that it is 
unnecessary to lower the current UK threshold for antidote therapy in 
paracetamol overdose.  
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One other important problem in the management of paracetamol overdose is 
ADRs to intra venous infusions of NAC. The current protocol for antidote therapy 
in paracetamol poisoning in the UK is the Prescott protocol [203]. Intravenous 
infusion of NAC causes adverse reactions in some patients [237].The frequency 
of such reactions, varies from 3-9% [238-240] to 48.4% [241] in different studies. 
Some factors including asthma [244;245] and low paracetamol concentration 
[239;241;245] have been reported to associated with ADRs. The patterns and 
mechanisms of ADRs in man are not well described or understood. A non-
allergic release of histamine has been suggested as a potential mechanism of 
ADRs [247]. In the last two studies described in the thesis (chapter VI) the 
frequency, risk factors and mechanisms of ADRs to NAC were examined. In a 
prospective study the factors that influence frequency of ADRs were studied. In 
a smaller intensive study the role of histamine and other biomarkers as 
underlying pathophysiological mechanisms in the ADRs were explored. The 
results of these studies showed that nausea and vomiting (mild ADRs) occurred 
in 60% of the patients, and anaphylactoid reactions (moderate and severe 
ADRs) in 40%. Plasma paracetamol concentration at the time of admission and 
male gender were protective, and having family history of allergy was a risk 
factor in developing ADRs to NAC. The results of the intensive study showed the 
severity of ADRs was associated with higher plasma histamine, and lower 
plasma paracetamol concentrations. In this study plasma tryptase and other 
markers of anaphylaxis and anaphylactoid reactions did not change significantly. 
This may suggest a non-mast cell source for the release of histamine, possibly 
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from circulating basophils, which have low levels of tryptase. A relationship 
between paracetamol concentration and severity of ADRs has already been 
reported in the literature [231;239], but this is the first time histamine rise in 
plasma has been shown to be an underlying mechanism of ADRs to NAC in 
man, and related to degree of severity. It is possible that inhibitory effect of 
paracetamol on cyclo-oxygenase and PG synthesis, which are important 
mediators in anaphylactoid reactions, may contribute to the protective effect of 
paracetamol against ADRs to NAC.  
 
  6-2: Conclusion  
 
From the work presented in this thesis it is possible to draw the following 
conclusions:  
 
           1. Paracetamol overdose is associated with dose-related hypokalaemia, and 
kaliuresis of short duration (<24 h), suggesting a specific renal effect of 
paracetamol in overdose perhaps via cyclo-oxygenase and prostaglandin 
synthesis inhibition. This effect seems distinct from any nephrotoxic effect of 
paracetamol. 
 
2. Creatinine at first admission appears to be a predictor of poor outcome in 
paracetamol overdose. A better understanding of mechanisms involved in 
causing renal dysfunction may offer potential therapeutic targets for improving 
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outcomes in this common poisoning. Additionally, staggered overdose, liver 
dysfunction, raised GGT and hypotension at first admission are also risk factors 
of both renal injury and poor prognosis. 
  
3. Liver dysfunction following overdose causing plasma paracetamol 
concentrations below the current UK treatment threshold occurs in very small 
percentage of patients with paracetamol overdose. Thus in view of the rarity of 
this event, the work reported here does not suggest that lowering the current 
thresholds for antidotal treatment is likely to be cost-efficient.  
 
4. ADRs to IV NAC predominantly involve the gastrointestinal (GI) and 
respiratory system and skin. Chest pain was also a feature observed. GI 
involvement is more common and the reaction is often mild. More severe ADRs 
are associated with rash, bronchospasm and chest pain. The severity of ADRs 
correlates with the extent of histamine release as measured in plasma. 
Histamine release in the patients studied appeared independent of tryptase 
release, suggesting a non-mast cell source. Paracetamol is protective against 






6-3: Weaknesses of the thesis 
 
The studies presented in this thesis had the following weakness:  
 
1. The thesis presents studies on the theme of paracetamol overdose. 
Studies in this area are challenging due to the nature of the population involved. 
The recruitment rate was often slow and the study groups often thus smaller 
than originally conceived. 
 
2. Some of the studies were retrospective and therefore there was a limited 
control on collection of required information. Clinical assays vary from time to 
time and place to place which could affect the conclusions in the retrospective 
cohorts studied. However, the large numbers involved will tend to reduce the 
impact of this. 
 
3. In the prospective studies the number of subjects who eventually completed 
the whole study or in part was small. This was due to difficult population 
involved, and complexity and time dependent nature of the design of the studies. 
 
4. The studies have been conducted on a Scottish population, and therefore the 
results might not be generally reproducible to other population due to difference 




5. In the NAC intensive study, due to the nature of study most patient were 
recruited during the daylight when patients who present later after ingestion tend 
to be admitted and therefore have lower plasma concentrations.  As this was 
found to be a risk factor in developing adverse reactions to NAC this may be a 
confounder. Thus the frequency of ADRs to NAC in this group was not an 
accurate reflection of all paracetamol admissions to hospital who received NAC 
following overdose, as is shown from the larger cohort studied. Sample 
collection and handling in a clinical environment also present challenges that 
might have affected sample stability, although careful steps were taken to 
minimise this risk. 
 
6-4: Further studies 
 
The findings of this thesis suggest following futures studies: 
1. Further studies are required to measure the effect of paracetamol overdose 
on renal function and hemodynamics using more sensitive surrogate markers of 
renal injury. Measurement of renal PG, aldosterone and plasma renin activity 
would also give us a better understanding of renal effects of paracetamol in 
overdose.  
 
2. Further studies on healthy volunteers are required to examine the effect of 
NAC on kidney function.  
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3. Further studies are required to examine whether more subtle biomarkers of 
renal dysfunction such as urinary enzymes biomarkers can be used as 
predicting factors of renal injury at early stage of renal impairment following 
paracetamol overdose, and whether these biomarkers are useful in predicting 
liver injury. 
 
4. Further studies are required for greater understanding of mechanisms of 
paracetamol nephrotoxicity in severe paracetamol poisoning and whether the 
renal injury is an independent phenomenon or as consequence of liver damage. 
 
5. Further studies at the molecular level are required to elucidate the specific 
effects of paracetamol on PG synthesis and its relationship with histamine 
release in anaphylactoid reactions to IV NAC. 
 
6. Further study is required to investigate the frequency of ADRs on patients 
with paracetamol overdose who are pre-treated with antihistamine and 
antiemetics before receiving antidote treatment.  
 
7. Further studies are required to investigate the underlying mechanisms of 
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Renal Function Study-Patient invitation letter 




You are being asked to take part in a study in which we are examining how 
certain drugs affect kidney function. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please 
take time to read the information will be given you carefully and ask if there is 
anything that is not clear or you would like more inform. If you wish not to 





Dr Nasrin Pakravan MD 
 














Renal Function Study-Patient Information Sheet 




You are being asked to take part in a study in which we are examining how certain 
drugs affect kidney function, and would be grateful of your help. 
 
  It is thought that overdose of some drugs such as paracetamol (Panadol), 
ibuprofen (Brufen) and some antidepressants can adversely affect the way kidneys 
work, and by measuring marker substances in blood and urine we may be able to 
predict this, and therefore protect the kidney. A greater understanding of this 
process may be a useful step in improving care of overdosed patients in general.  
 
You are being asked to take part in study as you have taken an overdose of one of 
these drugs. The actual risk of you suffering kidney damage is small, but your 
results will assist us in determining the best markers to use for predicting kidney 
problems. 
 
 If you agree to take part in this study, you will be asked to allow us to use the 
routine urine and blood samples taken when you were admitted for this research, 
and to provide an extra blood and urine sample at 12 hours and 24 hours after 
ingestion for more investigations to guide your care.  We are also asking your 
permission to use these clinical samples for research. To evaluate your kidney’s 
function accurately we need to check your blood pressure and pulse rate regularly. 
 
Blood samples will be taken either by one of the nursing staff or myself. All the 
results will be kept anonymous, and your personal details will not be disclosed to a 
third party.  
We also inform your general practitioner (GP) of this study, unless you object to this. 
 























Renal function: study-GP Information Letter 
Researcher: Dr. Nasrin Pakravan 
 
 
Dear Dr.  ………………………… 
I am a Ph-D medical student doing a research study on patients with certain kinds of 
drug overdose, including paracetamol, ibuprofen and SSRIs to evaluate their effect 
on kidney function. 
 
I am writing to inform you that Mr/ Mrs…………… 
who was admitted to the toxicology ward of Royal Infirmary of Edinburgh with an 
overdose of one of these drugs, with his/her permission provided samples of urine 





Dr Nasrin Pakravan MD 







Appendix 2.4: Patient’s Consent Form 
 
Version 1 




Renal function: Patient’s Consent Form 






Patient’s Name:  …………………………………………………………………. 
 
I have read and understood the patient information regarding the above study, and 
agree to take part. I understand that this will involve me providing up to three blood 
and urine samples in addition to routine samples being taken during my time in 
hospital. In addition my blood pressure and pulse rate will be recorded regularly at 
hourly intervals, which is more frequently than would otherwise be the case. I 
realized that I can withdraw my consent at any time, without giving any reason, and 






Signed: ……………………………………                 Date  
 
 











Appendix 2.5: Data Collection Sheet 
 
Patient Data Collection Sheet  
Renal Function Study In Drug Overdose 
 
Study Ref Number: 04/S1101/20 
Clinical Research Fellow: Dr Nasrin Pakravan 
1: Patient’s ID 
2: Patient’s height 
3: patient’s weight: 
4: Date of admission 
5: time of admission of Ingestion 
6: Date of ingestion 
7: time of ingestion 
8: Admission to                   A&E                                     CAB6 
9: Name of tablet taken      Paracetamol and other preparations 
                                           SSRI (Fluoxetine, Paroxetine)              
                                           Others 
10: Number of tablet taken 
11: Vomit after taking the tablet 
12: Co-ingestion of alcohol with drug before or after drug ingestion    No          YES 
13: Underlying disease      Diabetes      Chronic renal disease       Chronic heart 
disease               
                                           Chronic liver disease                  Other   
14: Drug history 
15: Initial Vital sign    Blood Pressure                                    Pulse rate   
                                  Respiratory Rate                                 Temperature     
16: Samples to be taken at 4h post-ingestion          
   
   Biochemistry:  Blood sample (5cc in orange top tube) at 4h post-ingestion   date 
&time 
                          Urine sample (10 cc in universal container)     
                
17: Samples to be taken at 12h post-ingestion 
 
  Biochemistry:  Blood sample (5cc in orange top tube) at 4h post-ingestion   date & 
time: 
                          Urine sample (10 cc in universal container)                            date & 
time 
 
18: Samples to be taken at 24h post-ingestion 
 
Biochemistry:  Blood sample (5cc in orange top tube) at 4h post-ingestion   date & 
time: Urine sample (10 cc in universal container)                            date & time   
 
19: NAC treatments                                                YES               NO 
 20: Vomit after over hospital stay  
 21: Blood pressure and PR                 at 4h          12h                 24h             date 
&time 
 22: Hypotension over hospital stay                       YES                NO 
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Appendix 2.6: Study Guideline  
 
Study Guideline  
Study Ref No: 04/s1101/20 
 
Project Title 
Effect of single paracetamol overdose on renal function and plasma and urine 
electrolytes 
Clinical Research Fellow 
Dr Nasrin Pakravan 
Subjects 
Inclusion Criteria  
 -Single overdose with paracetamol, ibuprofen, fluoxetine, and benzodiazepines. 
 -Mixed overdose of each of this drug with benzodiazepines or alcohol 
 -Patients admitted 4 or less than 4 hours after ingestion 
 -Age 16 years and older 
 -Non-pregnant patients  
Exclusion Criteria 
-Patients under 16 and over 60 years old 
-Pregnant women 
-Patients with inability to read and understand the information sheet and consent 
forms   
-Patients with underlying disease: Diabetes mellitus, chronic renal   failure,     
   Chronic heart failure, hypertension, hypovolaemic shock 
-Mixed overdose with other drugs except with benzodiazepines or alcohol 





Appendix 2.7: Study Flow chart 
 
 










                         Invitation   
                                                                 Information sheet              
                                                                                                                     
                                                                                                                     
                                                                                                                    
 
 









                                                      4-hr post-ingestion samples 
 
 
  For Biochemistry                                     - 5 cc blood sample in orange top tube 
   (use labels provided for biochemistry)      -10 cc urine sample in universal container 
 
 
                    
 
 
   12 hr- post-ingestion samples     
 
 
    For Biochemistry                                    -5 cc blood sample in orange top tube 





 take 24 hr- post-ingestion samples 
 
    For Biochemistry                                   -5 cc blood sample in orange top tube 
   (use labels provided for biochemistry)     -10 cc urine sample in universal container 
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Appendix 2.8: Original data of patients with single paracetamol overdose 
(Retrospective study), n=155. 
 




para Sali Cr1 Na1 
1 24.03.1970 24.09.2005 M  35.53 single od 259 0 97 140 
2 28.12.1950 07.09.2002 F 51.73 single od 524 . 92 133 
3 24.02.1962 29.08.2003 F 41.54 single od 382 . 64 138 
4 24.07.1984 26.10.2005 F 21.27 single od 288 0 60 137 
5 06.11.1956 09.04.2006 M  49.45 single od 238 0 76 134 
6 19.07.1983 18.12.2004 F 21.43 single od 105 0 60 141 
7 24.05.1985 03.04.2006 F 20.87 single od 207 0 77 140 
8 20.05.1982 16.03.2002 F 19.84 single od 106 . 88 135 
9 23.08.1977 11.01.2002 F 24.4 single od 405 0 99 136 
10 13.09.1980 27.04.2004 F 23.64 single od 260 0 66 138 
11 13.09.1980 16.01.2005 F 24.36 single od 179 0 75 141 
12 28.03.1960 05.01.2002 M  41.8 single od 178 . 75 136 
13 19.01.1962 19.02.2004 M  42.11 single od 180 . 88 137 
14 19.01.1962 16.05.2004 M  42.35 single od 138 0 106 141 
15 24.02.1985 02.02.2004 F 18.95 single od 125 . 76 138 
16 07.12.1973 11.09.2005 F 31.78 single od 179 0 75 142 
17 10.03.1955 09.02.2003 F 47.95 single od 226 . 72 137 
18 11.06.1974 10.10.2004 F 30.35 single od 504 0 75 134 
19 23.03.1968 31.10.2005 M  37.63 single od 148 0 76 137 
20 23.03.1968 02.11.2005 M  37.64 single od 155 0 79 139 
21 23.03.1968 06.11.2005 M  37.65 single od 123 0 72 140 
22 23.03.1968 09.11.2005 M  37.66 single od 136 0 70 142 
23 23.03.1968 04.12.2005 M  37.73 single od 117 0 82 142 
24 25.05.1984 04.07.2002 F 18.12 single od 222 . 70 139 
25 14.12.1962 06.03.2006 F 43.25 single od 446 0 77 140 
26 30.11.1957 07.12.2003 M  46.05 single od 346 0 114 137 
27 07.02.1979 15.08.2002 M  23.53 single od 151 0 102 141 
28 27.09.1977 12.07.2004 M  26.81 single od 207 0 101 143 
29 30.07.1973 06.07.2003 M  29.95 single od 76 0 99 138 
30 01.11.1974 27.05.2003 M  28.59 single od 194 0 90 138 
31 22.10.1995 19.09.2003 M  7.92 single od 95 0 91 139 
32 22.07.1988 25.01.2005 F 16.52 single od 368 0 86 142 
33 22.07.1988 15.03.2005 F 16.66 single od 463 . 84 144 
34 19.11.1962 28.10.2005 F 42.97 single od 72 . 78 145 
35 26.11.1942 11.04.2002 F 59.41 single od 208 . 84 133 
36 26.02.1958 15.01.2005 F 46.92 single od 133 0 59 141 
37 10.08.1968 10.04.2004 M  35.69 single od 92 0 76 138 
38 01.08.1958 14.12.2002 M  44.4 single od 288 0 96 138 
39 13.05.1961 20.12.2003 F 42.63 single od 138 0 73 140 
40 11.07.1949 02.03.2002 M  52.68 single od 89 . 84 137 
41 21.05.1946 25.10.2002 F 56.47 single od 135 0 75 135 
42 29.04.1987 07.11.2005 F 18.54 single od 255 0 69 141 
43 06.02.1960 15.11.2003 M  43.8 single od 176 0 87 138 
44 05.05.1963 16.04.2003 F 39.98 single od 92 0 93 136 
45 08.08.1941 20.10.2004 F 63.24 single od 261 0 80 129 
46 22.01.1946 14.08.2002 F 56.6 single od 156 . 85 134 
47 16.02.1981 04.10.2003 M  22.64 single od 100 0 99 141 
48 24.07.1972 08.04.2006 M  33.73 single od 233 0 93 140 
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para Sali Cr1 Na1 
49 05.09.1972 13.08.2003 F 30.96 single od 206  75 140 
50 22.11.1984 02.10.2003 F 18.87 single od 237  77 139 
51 10.11.1982 14.01.2006 F 23.19 single od 372 0 79 137 
52 22.03.1955 15.11.2004 M  49.69 single od 74 0 102 142 
53 15.05.1984 09.04.2006 F 21.92 single od 63 0 85 143 
54 18.07.1976 31.08.2004 F 28.14 single od 239  78 140 
55 02.12.1963 20.03.2002 F 38.32 single od 132  78 139 
56 02.12.1963 21.02.2004 F 40.25 single od 137 0 67 143 
57 28.08.1980 14.02.2003 M  22.48 single od 115  91 141 
58 24.06.1968 24.04.2002 F 33.85 single od 468  97 140 
59 27.08.1980 07.09.2004 M  24.05 single od 108 0 96 142 
60 23.08.1965 09.02.2005 F 39.49 single od 388 0 81 145 
61 10.06.1981 01.03.2002 M  20.74 single od 247  95 142 
62 17.09.1961 28.12.2004 M  43.31 single od 163 0 126 143 
63 09.06.1971 15.03.2003 M  31.79 single od 149 0 95 133 
64 07.12.1987 31.01.2005 M  17.16 single od 173 0 102 142 
65 07.03.1973 10.09.2002 M  29.53 single od 201 0 79 139 
66 16.01.1969 06.10.2002 M  33.74 single od 125  88 137 
67 07.09.1972 25.12.2003 F 31.32 single od 122 0 108 139 
68 08.10.1986 18.04.2004 F 17.54 single od 260  73 141 
69 08.10.1986 21.04.2004 F 17.55 single od 242  71 138 
70 08.10.1986 15.05.2004 F 17.61 single od 265 0 79 142 
71 08.10.1986 20.05.2004 F 17.63 single od 258  83 140 
72 08.10.1986 27.07.2004 F 17.81 single od 148  78 140 
73 04.10.1965 13.05.2002 F 36.63 single od 222 0 82 139 
74 26.06.1983 29.07.2003 M  20.1 single od 110  86 136 
75 20.05.1967 19.09.2002 F 35.36 single od 340  81 139 
76 29.08.1966 18.05.2003 M  36.74 single od 395  91 135 
77 21.03.1987 01.06.2004 F 17.21 single od 34  79 139 
78 01.08.1963 21.11.2003 M  40.33 single od 55 0 90 140 
79 13.06.1973 29.06.2003 F 30.06 single od 141  77 137 
80 22.03.1984 11.03.2006 F 21.98 single od 224 0 5.5 140 
81 11.08.1983 19.04.2005 M  21.7 single od 242 0 88 143 
82 09.12.1985 01.12.2003 F 17.99 single od 74  78 136 
83 27.01.1986 03.11.2003 F 17.78 single od 176  86 141 
84 07.10.1958 12.01.2006 F 47.3 single od 157 0 80 139 
85 27.10.1961 24.04.2002 F 40.52 single od 300  78 139 
86 27.10.1961 02.08.2002 F 40.79 single od 353  72 138 
87 27.10.1961 29.04.2003 F 41.53 single od 202 0 56 139 
88 27.10.1961 17.09.2003 F 41.92 single od 125 0 77 143 
89 02.06.1968 03.04.2006 F 37.86 single od 208 0 67 142 
90 11.01.1980 20.10.2003 M  23.79 single od 277  75 141 
91 07.07.1976 03.09.2003 M  27.18 single od 147 0 91 145 
92 02.03.1976 14.12.2005 F 29.81 single od 84 0 89 141 
93 05.11.1950 05.12.2002 M  52.12 single od 72 0 84 138 
94 28.04.1959 05.09.2004 F 45.39 single od 190 0 78 134 
95 28.04.1986 19.11.2002 F 16.57 single od 70  69 137 
96 25.03.1980 01.07.2004 F 24.28 single od 233  93 140 
97 03.03.1985 16.07.2005 F 20.38 single od 175 0 89 143 
98 28.09.1966 30.08.2002 M  35.95 single od 113 0 83 140 
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para Sali Cr1 Na1 
99 05.06.1987 01.05.2005 F 17.92 single od 111 0 72 140 
100 11.11.1980 27.03.2003 M  22.39 single od 316 0 92 145 
101 02.08.1963 16.03.2003 F 39.65 single od 121 0 84 142 
102 02.08.1963 08.12.2005 F 42.38 single od 147  85 145 
103 02.08.1963 09.08.2005 F 42.05 single od 107  80 143 
104 23.05.1967 30.05.2003 F 36.04 single od 249  64 137 
105 04.08.1988 01.05.2003 F 14.75 single od 101 0 86 139 
106 28.03.1957 19.01.2003 F 45.84 single od 254  79 141 
107 12.03.1956 10.02.2003 M  46.95 single od 127  90 135 
108 19.09.1976 29.08.2004 M  27.96 single od 230 0 81 131 
109 19.09.1969 21.09.2004 F 35.03 single od 266 0 82 139 
110 19.09.1969 12.10.2004 F 35.09 single od 198 0 80 137 
111 12.07.1988 15.10.2004 F 16.27 single od 117 0 76 142 
112 12.07.1968 18.10.2004 F 36.29 single od 120 0 73 140 
113 03.02.1965 23.03.2005 M  40.16 single od 180 . 85 135 
114 25.02.1982 06.08.2003 F 21.46 single od 205 . 81 138 
115 13.06.1975 08.09.2002 M  27.26 single od 119 0 88 140 
116 13.06.1975 09.10.2003 M  28.34 single od 222 0 84 144 
117 04.06.1983 20.11.2005 M  22.48 single od 192 0 91 145 
118 03.09.1979 05.04.2003 F 23.6 single od 279 0 76 137 
119 05.12.1970 02.03.2006 F 35.26 single od 420  72 138 
120 24.07.1984 12.04.2005 F 20.73 single od 285 0 68 141 
121 01.09.1958 01.11.2002 F 44.2 single od 233  83 138 
122 27.12.1982 26.01.2005 M  22.1 single od 67 0 97 141 
123 25.02.1972 18.09.2002 M  30.58 single od 148  77 140 
124 13.10.1984 17.11.2002 F 18.11 single od 190  82 141 
125 06.07.1967 27.03.2003 M  35.75 single od 35 0 111 139 
126 23.08.1966 23.04.2006 F 39.69 single od 224 0 69 136 
127 02.11.1971 10.12.2003 F 32.13 single od 199 0 85 138 
128 24.03.1970 21.01.2005 M  34.85 single od 153 0 101 139 
129 24.03.1970 22.11.2005 M  35.69 single od 119 0 88 138 
130 25.09.1967 09.04.2006 F 38.56 single od 180 0 76 138 
131 26.06.1984 18.11.2005 F 21.41 single od 172 0 81 141 
132 24.04.1958 18.05.2003 F 45.1 single od 160  84 146 
133 23.11.1968 14.07.2005 M  36.66 single od 75 0 103 139 
134 16.04.1950 20.03.2005 F 54.96 single od 39 0 63 141 
135 05.07.1976 26.07.2002 M  26.07 single od 176  101 138 
136 06.08.1985 14.11.2004 F 19.29 single od 282 0 75 144 
137 20.05.1977 21.10.2002 F 25.44 single od 150  95 141 
138 06.06.1973 26.06.2005 F 32.08 single od 139 0 73 133 
139 16.10.1971 16.05.2005 M  33.61 single od 127 0 90 140 
140 05.10.1956 02.08.2003 F 46.85 single od 176  80 134 
141 05.10.1956 03.04.2005 F 48.53 single od 238 0 74 139 
142 05.10.1956 21.05.2005 F 48.66 single od 156 0 81 135 
143 05.10.1956 26.08.2005 F 48.92 single od 118 0 66 142 
144 09.10.1966 08.05.2002 M  35.6 single od 185 0 106 135 
145 12.05.1976 16.08.2002 F 26.28 single od 247  86 141 
146 12.05.1976 06.09.2002 F 26.34 single od 226  82 143 
147 30.09.1971 16.01.2004 M  32.32 single od 326 0 77 142 
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para Sali Cr1 Na1 
148 16.09.1963 22.08.2004 M  40.96 single od 231 0 79 134 
149 17.10.1981 26.04.2004 F 22.54 single od 127 0 77 139 
150 08.10.1986 19.05.2004 F 17.62 single od 258  83 140 
151 08.10.1986 18.04.2005 F 18.54 single od 260  73 141 
152 08.10.1986 15.05.2006 F 19.61 single od 265 0 79 142 
153 18.04.1973 26.04.2005 F 32.04 single od 244 0 87 141 
154 16.09.1967 20.03.2004 M  36.53 single od 292 0 86 139 




Code K1 TCO21 Cr2 Na2 K2 TCO22 DT NAC Vomit 
1 3.8 22 91 . 3.2 24 19 YES YES 
2 4.1 25 105 126 3.6 20 19 YES YES 
3 3.2 20 60 138 2.8 26 33 YES YES 
4 3 19 71 135 3.5 20 26 YES YES 
5 3.5 22 88 135 3.2 20 19 YES YES 
6 3.8 24 58 140 3.6 25 22 YES NO 
7 3.5 18 77 140 3.4 25 22 YES YES 
8 3.7 19 82 142 3.3 30 23 YES YES 
9 3.4 17 96 138 3.1 21 21 YES YES 
10 3.6 22 66 139 2.9 26 20.5 YES YES 
11 3.4 24 60 141 3.1 26 23 YES YES 
12 3.7 23 75 139 3.6 28 12.5 NO YES 
13 3.6 25 81 140 3.8 28 23 YES NO 
14 3.4 21 103 141 3.4 27 13.5 YES YES 
15 4.1 19 73 136 3.8 25 22 YES YES 
16 4 26 75 139 3.5 25 13 NO NO 
17 4.1 24 73 137 3.2 26 24 YES YES 
18 4.4 20 68 136 4.4 17 24 YES NO 
19 3.9 24 80 140 3.9 23 22 YES YES 
20 3.9 24 72 138 3.3 25 23 YES YES 
21 4.4 21 74 139 3.8 23 22 YES YES 
22 3.5 22 75 138 3.8 28 18 NO YES 
23 4.7 26 71 139 3.7 27 24 YES YES 
24 3.6 24 88 142 3.4 26 23 YES YES 
25 4.6 24 78 138 3 21 31 YES YES 
26 4 24 76 137 3.6 26 26 YES YES 
27 4.4 22 83 136 3.5 27 23.5 YES NO 
28 4.1 21 94 139 4.2 30 24 YES YES 
29 4.1 25 94 138 3.5 31 21 YES YES 
30 4.1 25 90 137 3.8 26 19 YES NO 
31 3.4 21 98 138 4.1 23 11 YES YES 
32 3.5 21 81 137 2.9 26 20 YES YES 
33 4.2 26 73 140 3 25 24 YES NO 
34 4.2 23 65 140 3.9 24 25 YES NO 
35 2.8 21 73 136 3.5 27 24 YES YES 
36 3.4 28 60 138 2.9 31 24 YES NO 
37 4 19 77 138 3.4 24 19 YES YES 
38 3.9 21 87 138 3.6 25 21 YES YES 
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Code K1 TCO21 Cr2 Na2 K2 TCO22 DT NAC Vomit 
39 3.4 18 71 136 3 22 19 YES YES 
40 4.7 23 71 134 4.6 27 22 YES YES 
41 3.3 24 71 138 3.3 23 22.5 YES NO 
42 3.5 25 62 137 2.6 27 21 YES YES 
43 3.9 22 81 140 3.7 23 22 YES NO 
44 3.6 22 80 138 3.4 24 26 NO NO 
45 2.5 20 78 130 2.4 26 21.5 YES YES 
46 3.6 27 73 141 3.5 30 12 YES YES 
47 3.8 24 88 137 3.8 29 29 YES NO 
48 4.1 26 88 139 3.5 27 19.5 YES YES 
49 4 22 69 139 3.5 27 21 YES YES 
50 4.2 18 64 138 3.3 21 23.5 YES YES 
51 4.4 25 80 137 3 28 20 YES YES 
52 3.8 24 88 137 3.5 23 14 YES NO 
53 3.2 23 69 141 3.6 23 21.5 YES YES 
54 4.1 24 79 139 3.4 26 22.5 YES YES 
55 3.5 26 78 137 3.6 26 23 YES YES 
56 3.4 24 71 137 3.2 25 21 YES NO 
57 3.4 25 106 141 3.3 23 14 NO YES 
58 3.8 23 105 136 3.8 21 21 YES YES 
59 3.8 24 85 140 3.6 26 8 YES NO 
60 3.7 19 72 141 3.3 20 21 YES YES 
61 4.1 22 95 141 4 30 21 YES YES 
62 5.2 28 112 143 3.9 28 22 YES NO 
63 3.7 20 100 138 4.1 23 24 YES NO 
64 3.7 25 96 141 3.8 24 24 YES YES 
65 4 29 75 140 4 29 28 YES NO 
66 3.7 22 85 137 3.4 28 22.5 YES NO 
67 3.8 21 64 141 3.5 23 23.5 YES YES 
68 3.9 23 70 139 3.3 23 27 YES YES 
69 4.3 20 68 139 3.5 21 22 YES NO 
70 3.7 23 73 141 3.3 25 21 YES YES 
71 4.5 20 78 136 3.4 21 22 YES NO 
72 3.9 22 77 138 3.8 23 24 YES NO 
73 3.3 23 72 137 3.4 27 28 YES NO 
74 3.3 23 79 138 3.3 27 22 YES YES 
75 3.3 18 68 137 3 27 23.5 YES YES 
76 3.6 24 80 135 3.3 24 30 YES YES 
77 3.6 23 78 141 3.9 26 5.5 NO NO 
78 3.7 23 102 141 3.9 26 20 NO YES 
79 3.9 19 77 140 3.2 26 19 YES YES 
80 4.4 27 76 140 3.7 26 24 YES YES 
81 4 21 106 138 3.9 25 22 YES NO 
82 3.8 27 84 134 3.2 26 23 YES YES 
83 4.2 23 82 140 3.2 26 22 YES YES 
84 3.8 28 80 135 3.1 29 20 YES NO 
85 4.8 27 76 138 3.8 26 23 YES NO 
86 3.9 28 69 138 3.4 27 23 YES YES 
87 4.1 22 64 136 3.5 23 22 YES YES 
88 3.8 23 72 138 4.4 22 21.5 YES YES 
89 3.5 22 69 139 3.7 24 21.5 YES YES 
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Code K1 TCO21 Cr2 Na2 K2 TCO22 DT NAC Vomit 
89 3.5 22 69 139 3.7 24 21.5 YES YES 
90 4 21 85 138 3.5 25 28.5 YES NO 
91 3.8 19 85 137 3.6 25 21 YES NO 
92 3.9 25 93 141 3.8 26 . NO NO 
93 4.1 27 89 141 3.6 22 14 NO NO 
94 3.9 18 76 138 3.1 23 23.5 YES NO 
95 4.1 24 63 137 3.6 22 22 YES NO 
96 4 23 82 138 3.4 22 21.5 YES YES 
97 3.6 20 77 140 3 21 24 YES YES 
98 3.4 27 82 138 3.2 27 29 YES YES 
99 3.9 23 72 138 3.9 24 22.5 YES NO 
100 4 19 84 138 3.1 24 21.5 YES YES 
101 3.5 22 76 139 3.2 24 22.5 YES YES 
102 4.2 25 72 138 3.2 25 24 YES YES 
103 3.7 24 81 140 3.5 26 27 YES YES 
104 2.9 22 66 135 3 27 25 YES YES 
105 4.1 26 81 139 4.1 25 7.5 NO NO 
106 3.9 24 72 141 3.2 29 22 YES YES 
107 4 21 94 139 4.2 28 21 YES NO 
108 4 27 63 141 3.4 25 22 YES NO 
109 4.1 25 71 138 3.3 23 22.5 YES NO 
110 4.1 24 75 138 3.7 24 24 YES NO 
111 3.8 23 69 139 3.8 23 24 YES NO 
112 3.8 25 72 139 3.7 25 20 YES NO 
113 3.8 22 97 136 3.8 24 18 NO NO 
114 3.7 20 82 137 3.7 25 24 YES YES 
115 3.9 22 93 140 3.3 25 21 YES NO 
116 3.9 25 77 140 3.1 25 23 YES YES 
117 4.3 25 93 140 3.6 28 21 YES NO 
118 3.3 13 79 135 3.1 17 19 YES YES 
119 3.6 22 68 136 3.2 23 24.5 YES YES 
120 4 20 76 142 3.3 24 26 YES YES 
121 3.3 22 77 134 3 26 12 YES YES 
122 3.9 22 95 139 4 22 28 NO NO 
123 4 19 73 139 3 28 21 YES YES 
124 3.3 24 81 137 3.2 26 23.5 YES YES 
125 3.4 24 104 139 4.3 26 19 NO NO 
126 4.3 21 68 138 3.4 23 25 YES NO 
127 4.4 21 65 138 3.4 23 24 YES YES 
128 4.1 24 101 142 4 24 22 YES YES 
129 4 26 84 138 3.4 26 22 YES NO 
130 3.6 23 76 137 3.5 21 21 YES YES 
131 4.6 24 80 141 3.2 25 30 YES YES 
132 3.6 30 61 136 3.3 26 22 YES YES 
133 3.6 24 93 141 3.6 . 32 YES NO 
134 4.1 22 62 138 3.9 25 24 NO NO 
135 3.4 23 103 136 3.1 28 33 YES YES 
136 3.8 22 76 140 3 24 20 YES YES 
137 3.8 21 96 138 4.2 24 21.5 YES YES 
138 3.9 24 62 135 3.3 26 23.5 YES YES 
139 4.2 20 84 140 3.5 26 21 YES NO 
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Code K1 TCO21 Cr2 Na2 K2 TCO22 DT NAC Vomit 
140 3.7 21 69 133 3.5 23 24 NO NO 
141 4.7 19 65 136 3.3 23 26 YES NO 
142 4.3 25 80 135 4.4 24 7 YES NO 
143 4.4 21 62 138 3.7 23 24 YES NO 
144 3.1 25 103 139 3.2 27 20 YES YES 
145 4 29 78 140 3.1 29 23 YES YES 
146 4 29 78 141 3.9 29 38 YES NO 
147 3.7 28 84 140 3.4 29 28 YES NO 
148 3.7 16 75 137 3.2 24 22.5 YES NO 
149 3.8 23 62 140 3.5 27 14 NO NO 
150 4.5 20 78 136 3.4 21 22 YES NO 
151 3.9 23 70 139 3.3 23 22 YES YES 
152 3.7 23 73 141 3.3 25 23 YES YES 
153 4.4 25 79 142 3.7 26 29 YES YES 
154 4.1 21 88 138 3.4 22 21.5 YES YES 




Code: patient code 
DOB: date of birth 
F: female; M: Male 
DOA: date of admission 
1: frist sample taken at admission;  
2: second sample taken 
Cr: plasma Creatinine (µmol/l);  
Na: plasma sodium (mmol/l); 
K: plasma potassium (mmol/l);  
TCO2: plasma bicarbonate (mmol/l), 
DT: time between two first and second sample (h),  
4h para: plasma paracetamol at 4h post-ingestion (mg/l) 





























Code age y Sex tab gr Risk 
 
Vom_p_inges NAC Vom_p_NAC ST4h ST12h 
1 21.5 F 17 No Yes Yes Yes 4.3 15 
2 18.9 F 11.5 No Yes Yes Yes 4 12 
3 37.5 F 17 Yes No No  5.5 12 
4 55 M 10 No No No  4 12 
5 18.5 M 40 No No Yes Yes 4 12 
6 20.5 M 24 No Yes No  4 12 
7 17.5 F 27.5  Yes Yes  4 12 
8 42.4 F 13.5 No No Yes Yes 4 12 
9 37.5 M 13 Yes No No  4.5 12 
10 22 F 40 No Yes Yes Yes 3.5 11 
11 37.6 M 24 Yes No Yes Yes 4.5 13 
12 16 F 14 No Yes No  4 12 
13 34.8 M 26.5 Yes Yes Yes Yes 5 12 
14 22 M 18 No No No  4 12 
15 37.6 F 16 Yes No Yes No 4 12 
16 35.9 M 30 Yes No Yes No 4 12 
17 21.3 F 15 No No Yes Yes 4 12 
18 16.6 F 10 No No No No 4.5 12 
19 30.2 M 8 No No No No 4 12 
20 22.1 F 20 No Yes Yes Yes 4 12 
21 26.3 F 20 Yes No Yes Yes 4 12 
22 37.8 M 8 No No Yes No 4.5 12 
23 37.7 M 24 Yes No Yes No 4 12 
24 43.6 F 16 No No Yes No 4 12 
25 19.8 M 12 No Yes No  3.5 13 
26 57.8 F 7.5 No Yes Yes No 5 12 
27 19.5 M 10 No No No  4 12 
28 18.8 F 25 No No Yes Yes 4 13 
29 18.7 M 12 No Yes No  4.5 12 
30 46.2 M 32 No No Yes Yes 6 12 
31 47.4 F 20 No No Yes Yes 4.5 12 
32 27.7 F 16 No Yes Yes Yes 4 12 
33 37.3 M 24 No No No  4 12 
34 43.4 F 20 Yes No Yes Yes 4.2 12 
35 17.9 F 22 No No Yes No 4 13 
36 19.4 F 14.5 No No No  4.4 12 
37 48.7 F 10 Yes Yes No  6.6 14 
38 16.4 F 5 No No No  4 12 
39 19.8 F 4 No No No  4 12 
40 43.9 F 12 No No No  4 12 
41 18.2 F 15 No Yes Yes Yes 4.5 15 
 20
Code ST24h 4hpara K4h K12h K24h FeK4h FeK12h FeK24h 
1 24 93 3 2.9 3.5 9.1 7.4 6.6 
2 26 157 3.9 3.3 3.5 18.4 15.3 4 
3 24 75 3.7 3.5  14.7 4.4  
4 24 74 4.2 3.7 3.7 6.4 7.2 7 
5 24 285 3.2 3.2 3 24 30.7 6 
6 24 50 4 3.9 3.9 10.5  3.7 
7 24 89 3.9 3.5 3.4 15.3 13.7 6.7 
8 28 137 4.2 4 3.3 8.1 39.5 0.7 
9 24 34 4 4.2  13 9.7  
10 24 112 4.1 3.8 3.4 19 15.8 7.8 
11 24 129 4.5 4 4.1 18.5  9.4 
12 24 44 4.4 4.1  8 7.8  
13 24 115 4.1 3.6 3.4 10.3 22.1 4.9 
14 24 80 4.2 3.6  18.6 3.7  
15 26 139 4.1  4.3 16.4  5.2 
16 24 159 3.7 4 3.5 40.9 27.5 31 
17 24 190 4.2 4.3 3.3 8.8 26 4.6 
18 24 61 3.9 3.5 3.7 15 5.8 2.5 
19 24 83 3.9 3.9  15.3 14  
20 24 200 4 3.8 3 32 26.6 5 
21 24 108 3.9 3.3 4.7 14.7 7.7 4.8 
22 24 129 3.5 3 3.9 7.4 24 6.6 
23 24 151 3.9 3.3  11.3 40.1  
24 24 177 3.5 3.3 3.7 14.8 11.7 7.9 
25 22 99 4.7 4.1 3.9 4.3 11.2 4.3 
26 24 140 3.5 . 2.8 48.6  17.1 
27 23 127 4.1 3.4 3.4 5.1 15.7 5.5 
28 24 216 4 3.2  25.8 31.6  
29 27 116 3.7 3.4 3.8 16.2 16.9 1.9 
30 28 270 4  3.5 27.8  7.4 
31 23 167 3.5 3.2 3.1 21  7.8 
32 24 398 4.3 4.1  9.7 26.6  
33 19 148 4.2 3.7 4.2 17.5 8.5 3.6 
34 28 391 3.1 2.9 2.9 4.6 19.5 6.4 
35 24 246 3.9 3.6  19.8 19.2  
36 23 137 4 3.9 3.9 9.8 7.8 4.7 
37 20 24 3.9 3.5 3.7 23.4 12.6 4.8 
38 22 36 3.9 4.2 3.9 8.6 5.3 6.4 
39 24 24 3.7  4.8 5.3  4.8 
40 25 32 4 3.6 3.8 21.5 9.6 29 











Code TTKG4h TTKG12h TTKG24h PO44h PO412h PO424h FePO4h FePO12h
1 3.20 4.59 3.74 0.76 0.88 0.63 10.6 26.6
2     0.8 1.04   
3 7.55 3.71  1.62 1.46  10.7 22.7
4 5.04 5.47 6.07 0.93 1.22 0.66 5.5 12.6
5 10.49 17.52 6.37 0.87 1.21 1   
6 9.56  2.85 1.52 1.46 0.87 5.3  
7 9.39 10.63 7.23 1.09 1.07 0.74 13.6 25.9
8 4.06 21.24 10.09 1.09 0.96 0.85 10.9 24
9 10.23 5.31   1.4    
10 9.12 8.09 7.44 0.96 0.96 0.92 21.4 12.4
11 10.90  6.96 1.42 1.16 1.08 5  
12 9.02 7.33  1.66 1.6  5.2 18.4
13 8.00 13.09 3.47 1.15 1.26 1.23 13.8 8.8
14 8.16 2.49  1.41 1.41  18 15.1
15 8.59  3.87 1.41  1.12 5.7  
16 11.71 10.93 12 1.17 0.69 0.76 29.3 27.9
17 4.85 12.42 5.98 1.67 1.78 0.91 2.7 17
18 10.10 3.1 3.08 0.93 1.02 0.85 11.8 31
19 10.23 9.12 . 1.57 1.28  31.3 26.2
20 12.84 9.51 4.46 0.96 0.8 0.85 30.8 11.8
21 5.25 4.01 2.92 1.4  1.19 14.1  
22 3.50 14.48 5.84 1.32 0.95 0.74 12.8 18
23 5.91 20.97 . 1.21 1.05  28.3 26.3
24 9.57 5.88 6.96 1.24 1.24 1.22 9 17
25 6.56 10.25 5.4 1.38 1.61 1.17 5.5 16
26 12.67  9.12 1.06  0.42 37.5  
27 5.17 12.75 5.15 0.89 1.23 1.01 5.2 14.3
28 14.82 18.06 . 1.13 1 0.98 18.8 15.3
29 11.47 13.34 2.36 1.07 1.05 0.58 17.5 22.2
30 8.27  4.53 0.8  0.65 43.2  
31 15.14  5.38 0.95 0.72 0.68 16.4  
32 3.92 12.98  0.88 0.91  1.5 26.2
33 10.53 6.17 2.62 1.2 1 0.82 8.6 17.8
34 3.18 10.77 5.44 0.55 1.03 1.35 13.8 25.2
35 13.19 13.85  1.48 1.56  11.8 9.7
36 7.48 6.36 3.86 1.14 1.35 0.72 5.8 20.3
37 20.62 11.05 5.01 1.05 1.11 0.68 45.5 27.6
38 5.98 3.07 3.44 1.48 1.49 1.28 15 12.7
39 3.43  3.37 0.93  0.95 6.9  
40 17.87 7.27 23.57 1.46 1.21 0.97 10.4 15.4











Code FePO424h CNa12h CNa24h FeNa4h FeNa12h FeNa24h CMg12h CMg24h
1 14.1 0 0 1.66 0.84 1.16 0.05 0.09
2  -2 0 0.60 0.82 0.22   
3  2  0.62 0.34  -0.03  
4 13.8 -2 0 0.37 0.4 0.48 0.04 -0.01
5  0 0 1.17 0.65 0.25 0.18 0.29
6 4.5 1 0 0.17 . 0.33 0.08 0.07
7 24.6 -1 0 0.56 0.38 0.25 0.15 0.06
8 0.7 -1 0 0.16 0.13 0.04 -0.12 -0.1
9  -1  0.22 0.63  -0.01  
10 18.1 2 0 0.57 0.66 0.45 0.04 0.03
11 7.5 -4 0 0.44  0.55 0.03 -0.02
12  2  0.29 0.25  0.05  
13 22.1 0 0 0.50 0.59 0.62 0.02 0.06
14  -1  0.91 0.63  -0.01  
15 6.4  0 0.72  0.58  0
16 25.1 -2 0 2.00 1.57 0.67 -0.04 0
17 4.5 -3 0 0.60 0.54 0.12 0.09 0.04
18 8.6 -1 0 0.49 0.95 0.16 0.1 0.05
19  -3  0.36 0.27  0  
20 14.2 3 0 0.74 1.05 0.17 -0.04 0.12
21 3 1 0 1.68 0.91 0.69 0.01 -0.02
22 14.2 1 0 0.51 0.46 0.36 -0.09 -0.03
23  1  0.85 0.49  0.12  
24 15.9 2 0 0.35 1.03 0.63 0.03 0.05
25 13.7 3 0 0.11 0.13 0.03 0.05 -0.02
26 0.8  0 1.78 . 0.67  0.11
27 6.1 1 0 0.26 0.37 0.22 0.07 0.18
28  -1  0.52 0.56  0.08  
29 1.9 1 0 0.33 0.14 0.01 0.1 0.16
30 28.8  0 1.11  0.23  0.19
31 20.9 -3 0 0.44  0.82 0.04 0.02
32  -2  0.78 0.67  0.03  
33 11.5 1 0 0.32 0.3 0.3 0.02 -0.01
34 14.4 4 0 0.54 0.32 0.06 0.13 0.18
35  -2  0.42 0.36  0.19  
36 19.1 1 0 0.54 0.44 0.38 0.13 0.07
37 19.8 0 0 0.24 0.23 0.1 -0.02 -0.03
38 6.9 -2 0 0.39 0.72 1.03 -0.02 -0.04
39 1.1  0 1.16  0.57  0
40 20.5 -1 0 0.32 0.61 0.27 0 -0.06











Code FeMg4h FeMg12h FeMg24h Cr4h Cr12h Cr24h Ucr4h UCr12h 
1 6.5 1.5 3.1 68 67 82 8 5.3
2    63 64 64 10.2 10.9
3 1.3 4.1  83 78  3.5 10.5
4 1.1 1.6 1.7 97 90 95 4.7 7.8
5 2.8 0.6 2.4 83 83 86 12 19.1
6 2.7  5 101 90 93 38.5  
7 1   66 61 68 13.8 9
8 4.3 0.6 0 62 66 67 1.1 9.2
9 1.5 3.2  82 76  11.8 5.4
10 2.1 3.9 1.5 78 81 70 1.9 5.8
11 0.7  2.4 77 78 74 15.8  
12 2.1 2.2  78 80  22.2 16.1
13 2.7 0.4 1 87 78 73 21.5 17.8
14 1.8 3  87 85  4.9 17
15 0.8  1.8 78  85 4.4  
16 1.7 1.2 1.1 102 92 91 5.8 11.4
17 3 2.1 1.5 83 85 73 7.6 11.6
18 2.2 3.2 2.9 84 77 90 20.2 1.9
19 1.8 1.2  72 72  9.9 9.9
20 0.8 2.8 2.5 74 75 71 1.1 7.5
21 2.9 4.1 3.4 83 79 84 2.6 6.2
22 4.2 1.3 1.2 78 75 77 1.8 4.9
23 1.5 1  78 84  10.3 11
24 0.6 2.4 2.6 92 86 81 9.4 5.1
25 1.6 0.9 1.5 110 101 97 50.6 34.3
26 9.4 . 2.8 86  102 4.5  
27 1.5 0.9 3.8 85 89 93 6.1 23.2
28 3.3 2.8  79 80 77 1.3 11.4
29 0.6 0.6 2.1 83 93 91 22 26.7
30 1.5  2.5 106  98 10  
31 2.1  3.3 69 64 68 10.6  
32 5 2  79 83 . 5.5 12.5
33 2.3 3.6 6.9 88 89 95 14.4 24
34 2 0.5 2 80 80 81 11.2 4.1
35 1.5 1.1  75 70 . 13.5 13.9
36 1.7 2.6 3.3 82 82 74 6.7 13.7
37 1.6 0.8 2.9 64 63 61 11.7 9.7
38 3.5 5.5 4.4 69 70 69 8.2 6.2
39 2.4  3 74  78 11.8  
40 2 2.6 0.5 83 72 74 10.7 11.8













Code UCr24h CTOC2-12h CTCO2-24h U/Posom12h U/Posom4h U/Posmo24h 
1 5.7 2 1 1.28 3.33 1.22 
2 5.1 -3 1 2.81  0.92 
3  -2  1.62 0.82  
4 7.3 -2 -2 1.14 0.61 0.89 
5 25.4 -1 1 4.03 3.31 2.77 
6 14.2 2 0  4.19 1.98 
7 15.1 3 3 1.91 3.41 2.08 
8 67 1 3 2.59 0.35 0.6 
9  3  1.3 1.83 0 
10 4.2 0 0 1.4 0.51 0.63 
11 8.4 -2 1  3.49 1.54 
12 0 1  2.13 2.52  
13 17.5 -2 -1 3.84 3.17 3.39 
14  1  3.01 1.28 0 
15 9  3  1.08 1.44 
16 5.9  -4 3.11 1.99 1.04 
17 9.6 0 2 2.87 1.67 1.01 
18 8.8 -2 -3 0.46 3.58 0.79 
19  2  2.11 2.05  
20 7.2 0 0 2.79 0.37 1.12 
21 3.3 -1 1 1.51 0.88 0.65 
22 10.8 5 3 1.08 0.49 1.58 
23  3  2.5 2.52  
24 13 2 2 1.18 1.58 1.83 
25 32.6 8 9 3.71 3.05 2.71 
26 3.2  -1  2.01 0.59 
27 18 -3 1 3.21 0.71 2.06 
28  2  2.49 0.29 0 
29 25.9 -4 3 3.64 3.75 2.34 
30 12.5  1  3.17 2.08 
31 3.1 0 1 0 2.13 0.66 
32 . 0  3.08 1.72  
33 23.9 -1 0 3.68 2.71 3.45 
34 8.7 0 2 0.93 2.03 1.27 
35  -1  2.75 2.7  
36 5.7 3 2 2.06 1.07 0.93 
37 16.2 -1 2 1.76 2.08 2.54 
38 6.3 -1 1 1.55 1.71 1.72 
39 7.8  2  2.44 1.42 
40 14.2 1 5 2.18 1.55 2.37 









Risk: high risk; Vom_P_inges: vomiting post ingestion; Vom_P_NAc: vomiting post NAC 
infusion; ST4h: time of 4h sample taken (h); ST12h: time of 12h sample taken (h); ST24h: 
time of 24h sample taken (h); 4hpara: paracetamol level at 4h (mg/l); K4h: plasma potassium 
at 4h (mmol/l); K12h: plasma potassium at 12h; K24h: plasma potassium at 24h; FeK4h: 
FeK at 4h (%); Fe12h: FeK at 12h; Fe24h: FeK at 24h; TTKG4h: TKG at 4h; TTKG12h: 
TTKG at 12h; TKG24h: TTKG at 24h; PO44h: plasma phosphate at 4h (mmol/l); PO412h: 
plasma phosphate at 12h; PO424h: plasma phosphate at 24h; FePO4h: FePO4 at 4h (%); 
FePO12h: FePO4 at 12h; FePO24h; FePO4 at 24h; CNa12h:cange in plasma sodium at 12h 
(mmol/l); CNa24h: change in plasma sodium at 24h; FeNa4h: FeNa at 4h (%); FeNa12h: 
FeNa at 12h; FeNa24h: FeNa at 24h; CMag12h: Change in plasma magnesium at 12h 
(mmol/l); CMg24h: Change in plasma magnesium at 24h; FeMg4h: FeMg at 4h (%); 
FeMg12h: FeMg at 12h; FeMg24h: FeMg at 24h; Cr4h: plasma Creatinne (Cr) at 4h (µmol/l); 
Cr12h: plasma Cr at 12h; Cr24h: plasma Cr at 24h; UCr4h: urine Cr at 4h (mmol/l), UCr12h: 
urine Cr at 12h; UCr24h: urine Cr at 24h; CTCO2-12h: change in plasma bicarbonate at 12h 
(mmol/l); CTCO2-24h: change in plasma bicarbonate at 24h; U/Posmo12h: urinary 





































Appendix 2.10: Original data of patients with single SSTI (Fluoxetine) overdose 
(Prospective study), n=18. 
 
 
Code age y Sex tablet gr Vom_Pingestion T4h T12h T24h 4hpara
1 28 M 0.48 No 4 12 . 0 
2 27 M 0.46 No 3.5 12 24 0 
3 21 F 0.6 No 4 12 20 0 
4 43.8 F 0.4 No 5 12 . 0 
5 25.7 M 0.4 No 5 12 24 0 
6 54.5 F 2 Yes 6 12 0 0 
7 19.6 F 0.4 Yes 4 12 . 0 
8 37.1 M 0.44 Yes 6 12 . 0 
9 22.9 F 0.84 Yes 4 12 24 0 
10 24.3 F 0.42 No 4 12 21 0 
11 17 F 1.2 Yes 6 12 24 0 
12 45.8 F 0.9 Yes 4 12 20 0 
13 16.2 M 0.6 No 7 10 . 0 
14 19.2 M 0.52 No 4 13 20 0 
15 20.4 F 0.18 Yes 7 12 22 0 
16 27.2 F 3.6 No 2.5 12 . 0 
17 41.6 M 6 No 7 16 . 17 




Code cK12h cK24h FeK4h cFeK12h cFeK24h TTKG4h cTTKG12h cTTKG24h 
1 -0.2  8.2 0.03  4.96 4.98  
2 -0.1 0.6 31 -0.07 -0.14 0.00 13.14  
3 -1 -1.2 7.1 0.00 -0.04 5.34 0.00 -1.39 
4 -0.4  8.9 -0.04  5.27 -0.86  
5 -0.1 -0.4 5.7 0.06 -0.01 4.34 2.72 -1.18 
6 0  9.6 0.11  7.59 8.14  
7 0.1  4 -0.01  2.40 0.48  
8 0  14.2 0.12  11.26 5.29  
9 -0.5 0 6.6 -0.01  8.20 -2.17  
10 0 0 7.7  0.02 3.04  2.33 
11 0.1 -0.1 3.7 0.02 -0.01 3.80 2.29 0.59 
12 0.5 0.6 8.6 0.02 -0.01 13.26 -4.17 -6.06 
13 0.5  7.7 0.06  4.64 3.83  
14 0.3 0.5 6.8 -0.03 0.01 3.57 0.16 1.96 
15 -0.1 -0.5 6.6 -0.01 -0.03 3.85 -0.01 -0.50 
16 -0.1  7.8 0.03  7.34 1.86  
17 -0.2  9.6 0.08  7.46 4.25  











Code PO44h cPO412h cPO424h FePO44h 4hPO4 cFePO12h cFePO424h 
1 1.03 -0.12  3.3 1.03 0.09  
2 1.11 0.23 0.14 14.2 1.11 0.10 0.22
3 0.83  -0.21 8.4 0.83  -0.05
4 0.88 0.31  14 0.88 0.06  
5 1.65 -0.31 -0.3 13.4 1.65 0.06 0.09
6 1.02 -0.17  30.3 1.02 -0.03  
7 1.14 -1.14  12.3 1.14   
8 1.08 0.05  18.6 1.08 0.18  
9 1.25 0.15 -1.25 5.8 1.25 0.03  
10 1.11 0.01 -0.02 21 1.11  -0.05
11 0.95 0.23 0.09 0.7 0.95 0.04 0.00
12 0.88 0.51 0.33 10.1 0.88 0.10 0.07
13 1.46 -0.15  12.9 1.46 -0.01  
14 1.19 -0.05 -0.37 7.4 1.19 0.18 0.05
15 0.92 0.12 -0.08 34.6 0.92 -0.10 -0.09
16 1.08 -0.03  10.4 1.08 0.04  
17 1.22 -0.11  27 1.22 -0.09  
18 0.86 0.39 0.02 4  0.10 0.14
 
 
Code CNa12h CNa24h FeNa4h cFeNa12h cFeNa24h CMg12h CMg24h FeMg4h
1 -1  0.60 -0.005  -0.03 . 1.8
2 -2 -6 0.80 0.000 -0.003 -0.07 -0.05 3.7
3 2 -1 0.40 0.004 -0.001 0.09 0.1 1.4
4 2  0.70 -0.004  0.01 . 3.7
5 1 -5 0.60 0.002 -0.002 -0.07 0.03 3.1
6 0  0.40 0.001  -0.01 . 2.7
7 -2  1.00 -0.005  -0.02 . 3.8
8 -2  0.60 0.000  -0.02 . 3.4
9 -2 -3 0.20 0.000  -0.07 0.01 1
10 0 -1 1.60  -0.007 -0.01 0.03 3.2
11 0 -1 0.30 0.002 0.000 -0.01 0.02 2.9
12 2 5 0.00 0.003 0.002 0.07 0.07 2.1
13 5  0.70 0.001  0.03 . 2.6
14 2 0 0.40 -0.003 0.001 -0.02 0.02 5.4
15 0 2 0.60 -0.003 -0.004 0.06 0 2.2
16 3  0.50 0.000  -0.03 . 1.9
17 -4  0.40 0.000  -0.06 . 3













Code cFeMg12h cFeMg24h cCr12h cCr24h CTOC2-12h CTCO2-24h 
1 -0.005  1  -1 . 
2 -0.019 -0.026 -6 -4 2 1 
3 0.007 0.016 0 5 3 1 
4 0.007  -1  0 . 
5 -0.014 -0.012 15 2 0 . 
6 -0.017  3  3 . 
7 -0.004  2  -3 . 
8 -0.029  -2  1 . 
9 0.010  -6  1 2 
10  -0.013 3 6 0 -1 
11 -0.014 -0.004 -7 -1 -1 -1 
12 -0.012 -0.010 -9 -6 2 -1 
13 0.000  7  -4 . 
14 -0.029 -0.037 7 3 2 2 
15 -0.005 0.012 2 7 3 5 
16 -0.007  3  6 . 
17 -0.004  7  -1 . 




Code U/Posom12h U/Posom4h U/Posmo24h 
1 3.81 2.47 . 
2 2.36 . 2.89 
3 1.4 1.87 3.31 
4 2.84 2.42 . 
5 2.58 1.96 3.08 
6 2.57 0.94 . 
7 4.01 3.4 . 
8 2.85 2.1 . 
9 3.55 3.29 . 
10 . 1.29 2.82 
11 0.95 0.29 3.42 
12 2.96 2.44 3.26 
13 1.82 0.74 . 
14 3.96 2.65 3.83 
15 3.33 3.3 3.32 
16 2.26 1.9 . 
17 2.97 1.25 . 
18 0.74 0.36 2.29 
 
cK12: change in plasma potassium at 12h (mmol/l); cK24h: change in plasma potassium at 
24h; cFeK12h: change in FeK at 12h (%); cFeK24h: change in FeK at 24h; cTTKG12h: 
change in TTKG at 12h; cTTKG24h: change in TTKG at 24h; cPO412h: change in plasma 
phosphate at 12h (mmol/l); cPO424h: change in plasma phosphate at 24h; cFePO412h: 
change in FePO4 at 12h (%); cFePO424h: change in FePO4 at 24h; cNa12h: change in 
plasma sodoium at 12h (mmol/l); cNa24h: change in plasma sodium at 24h; cFeNa12h: 
change in FeNa at 12h (%); cFena24h: change in FeNa at 24h; cMg12h: change in plasma 
magnesium at12h (mmol/l); cMg24h: change in plasma magnesium at 24h; cFeMag12h: 
change in FeMg at 12h (%); cFeMg24h: change in FeMag at 24h; cCr12h: change in plasma 




Appendix 3.1: Collected data from 522 patients admitted to Scottish Liver Transplant 
Unit from referring hospital in Scotland. 
Number Code DOB Sex Age Age band No Tablet Stag OD 
1 TA040001 24-Jun-79 female 16 11-20 YEARS 50 NO 
2 DA090002 23-Jun-52 male 47 41-50 YEARS 12 YES 
3 IA020004 15-Jan-56 female 36 31-40 YEARS  NO 
4 DA070006 24-Apr-62 male 36 51-60 YEARS 32 NO 
5 PA030007 15-Oct-65 male 28 21-30 YEARS 40 NO 
6 JA080009 30-Dec-75 female 23 21-30 YEARS 40 NO 
7 SA080010 30-Mar-65 female 33 31-40 YEARS  YES 
8 CA050012 13-Jul-60 female 35 31-40 YEARS 50 NO 
9 RA060014 25-Nov-45 male 51 51-60 YEARS 100 NO 
10 DA120687 12-Dec-61 female 43 41-50 YEARS  NO 
11 DA030015 31-Dec-67 female 26 21-30 YEARS 20 NO 
12 AA050016 01-Sep-68 male 28 21-30 YEARS 72 NO 
13 CA070017 06-Jun-76 female 22 21-30 YEARS 15 NO 
14 EA060019 30-Mar-35 female 61 61 AND OLDER 40 NO 
15 AA030021 14-Mar-69 male 25 21-30 YEARS 220 NO 
16 JA060023 12-Sep-30 male 66 61 AND OLDER  NO 
17 DB020024 05-Nov-55 female 39 31-40 YEARS 18 NO 
18 JB060026 16-Jun-48 male 50 41-50 YEARS 100 YES 
19 JB120685 21-May-76 female 27 21-30 YEARS 60 YES 
20 SB100028 29-Feb-60 female 41 41-50 YEARS 80 NO 
21 KB110029 14-Sep-53 female 48 41-50 YEARS  YES 
22 MB070030 14-Dec-58 male 39 31-40 YEARS 125 NO 
23 MB050032 13-Dec-56 female 39 31-40 YEARS 50 NO 
24 VB120681 12-Jul-62 female 42 41-50 YEARS 35 YES 
25 DB060034 17-Dec-61 male 35 31-40 YEARS 44  
26 SB040037 27-Nov-65 male 29 21-30 YEARS 60 NO 
27 WB060038 02-Jul-60 male 36 31-40 YEARS 48 NO 
28 LB110039 21-Sep-82 female 19 11-20 YEARS 64 NO 
29 AB120682 23-Dec-50 male 53 51-60 YEARS 112 YES 
30 MB050040 21-Jan-51 female 46 41-50 YEARS 100 NO 
31 JB070041 14-Mar-55 male 43 41-50 YEARS 75 NO 
32 EB060042 09-Feb-74 female 23 21-30 YEARS 50 NO 
33 IB060043 10-Feb-57 male 40 31-40 YEARS 150 NO 
34 RB040045 11-Feb-43 male 52 51-60 YEARS  YES 
35 SB090046 25-Apr-76 female 24 21-30 YEARS 14 YES 
36 AB050047 19-Feb-71 female 25 21-30 YEARS 48 YES 
37 NB100048 07-Jun-64 male 37 31-40 YEARS 46 NO 
38 AB070050 05-Mar-77 male 20 11-20 YEARS 42 NO 
39 AB010051 12-Apr-42 male 50 41-50 YEARS 80 NO 
40 GB120662 16-Aug-48 female 43 41-50 YEARS 95 NO 
41 CB040053 03-Mar-58 female 36 31-40 YEARS 37  
42 AB060055 04-Feb-43 male 54 51-60 YEARS   
43 LB060056 12-Sep-67 female 29 21-30 YEARS 60 NO 
44 KB050057 08-Jan-50 male 46 41-50 YEARS 50 NO 
45 HB070058 11-Nov-77 female 22 21-30 YEARS 40 NO 
46 JB120680 24-Jun-86 female 17 11-20 YEARS 35 NO 
47 FB020059 12-Feb-51 female 41 41-50 YEARS 30 NO 
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Number Code DOB Sex Age Age band No Tablet Stag OD 
48 NB080060 24-Jun-48 female 50 41-50 YEARS  YES 
49 JB090062 13-Feb-77 male 23 21-30 YEARS 104 YES 
50 JB050063 20-Jun-74 male 22 21-30 YEARS  YES 
51 LB060064 25-Feb-68 female 29 21-30 YEARS 72 NO 
52 GB110066 01-Feb-40 male 52 51-60 YEARS 50 NO 
53 MB060067 01-Oct-75 male 21 21-30 YEARS 50 NO 
54 SB100068 17-Jul-66 female 34 31-40 YEARS 64 NO 
55 VB080069 11-Jul-63 male 35 31-40 YEARS   
56 MB100070 02-May-77 male 24 21-30 YEARS  NO 
57 AB020071 16-Jun-42 male 50 41-50 YEARS 50 YES 
58 MB130705 27-Dec-78 male 25 21-30 YEARS 70 NO 
59 SB090073 16-Sep-77 female 22 21-30 YEARS 60 NO 
60 MB030075 03-Jan-71 female 23 21-30 YEARS 50 NO 
61 MB030076 03-Jan-71 female 23 21-30 YEARS 80 NO 
62 RB070079 11-Sep-65 female 33 31-40 YEARS 40 NO 
63 JB050080 02-Jul-57 male 39 31-40 YEARS 128  
64 RB090081 19-Apr-74 male 26 21-30 YEARS 116 NO 
65 PB040082 02-Jul-61 male 34 31-40 YEARS 150 NO 
66 MB050083 04-Nov-53 female 40 31-40 YEARS 60 NO 
67 SB080085 19-Oct-71 male 27 21-30 YEARS 50 NO 
68 GB110086 16-Sep-67 male 34 31-40 YEARS  YES 
69 IB050088 24-Oct-45 male 50 41-50 YEARS 40 NO 
70 CC060089 24-Jun-62 male 34 31-40 YEARS 50 NO 
71 JC040092 30-Oct-74 male 22 21-30 YEARS 50 YES 
72 LC050094 22-May-68 female 28 21-30 YEARS 77 NO 
73 PC090095 09-Feb-65 male 35 31-40 YEARS 32 NO 
74 PC100096 09-Jul-63 female 38 31-40 YEARS 189 NO 
75 SC070098 01-Jun-69 female 29 21-30 YEARS 48 NO 
76 SC060100 26-Apr-67 male 30 21-30 YEARS 74 NO 
77 EC110102 01-Sep-72 female 29 21-30 YEARS 30 NO 
78 MC060103 25-Jun-60 male 37 31-40 YEARS 8 NO 
79 JC100105 22-May-82 male 18 11-20 YEARS 40 NO 
80 MC020108 30-Nov-59 female 34 31-40 YEARS 60 NO 
81 HC070109 18-Sep-62 female 35 31-40 YEARS 85 NO 
82 VC120683 03-Jun-80 female 23 21-30 YEARS 32 NO 
83 JC100113 24-Oct-75 female 25 21-30 YEARS 100 NO 
84 AC110114 09-May-76 female 52 21-30 YEARS 64 NO 
85 AC080115 13-Jun-65 female 34 31-40 YEARS 55 NO 
86 DC110116 03-Nov-75 female 26 21-30 YEARS 23 YES 
87 JC120674 28-Oct-55 male 48 41-50 YEARS 50 NO 
88 LC070117 29-Jul-68 female 30 21-30 YEARS 30 NO 
89 MC040118 03-Jul-61 female 34 31-40 YEARS 50 NO 
90 JC110119 08-Nov-65 male 36 31-40 YEARS 40 NO 
91 DC070120 14-Sep-41 male 56 51-60 YEARS 45 NO 
92 AC17711 07-Aug-71 male 33 31-40 YEARS 100 YES 
93 JC040121 18-Sep-58 male 37 31-40 YEARS 25 NO 
94 AC070122 17-Mar-66 male 32 31-40 YEARS 25 NO 
95 DC070123 11-Oct-60 male 38 31-40 YEARS 60 NO 
96 WC110124 19-Aug-39 female 63 61 AND OLDER  UNKNOWN 
97 JC110125 03-Dec-50 male 21 51-60 YEARS  YES 
98 GC100126 10-Sep-66 male 34 31-40 YEARS 35 NO 
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Number Code DOB Sex Age Age band No Tablet Stag OD 
99 HC060127 15-Nov-63 male 33 31-40 YEARS 48 NO 
100 GC070129 12-Aug-57 male 40 31-40 YEARS 34 YES 
101 CC050131 15-Aug-47 female 49 41-50 YEARS 40  
102 WC080132 29-Oct-72 male 26 21-30 YEARS 130 NO 
103 AC120135 27-Aug-38 female 65 61 AND OLDER 90 NO 
104 LC040136 06-Nov-71 female 23 21-30 YEARS  NO 
105 AC090137 24-Apr-78 female 21 21-30 YEARS  YES 
106 JC120138 05-Mar-49 male 54 51-60 YEARS 100 NO 
107 RC100140 23-Sep-47 male 53 51-60 YEARS 50 NO 
108 CC110141 13-Sep-46 male 55 51-60 YEARS  YES 
109 PC040142 30-Jul-74 male 20 11-20 YEARS  YES 
110 PC130708 18-Jan-72 male 32 31-40 YEARS  YES 
111 SC100144 29-Jan-60 female 40 31-40 YEARS 70 NO 
112 FC100145 23-Apr-68 female 33 11-20 YEARS  UNKNOWN 
113 JC130689 31-Dec-58 male 42 41-50 YEARS 24 NO 
114 MC020146 10-Aug-30 female 63 61 AND OLDER   
115 MD120147 27-Feb-73 male 30 21-30 YEARS 22 NO 
116 JD020150 29-Aug-51 male 35 31-40 YEARS 50 NO 
117 PD030151 17-May-62 female 31 31-40 YEARS 30 NO 
118 MD020153 17-Mar-39 female 54 51-60 YEARS 100 NO 
119 FD110154 30-Nov-58 male 41 41-50 YEARS 128 NO 
120 GD050157 30-Aug-72 male 25 21-30 YEARS 120 NO 
121 HD070158 24-Mar-74 female 24 21-30 YEARS 38 NO 
122 DD100159 11-Jun-68 male 33 31-40 YEARS 16 YES 
123 LD080160 11-Dec-57 female 41 41-50 YEARS 50 NO 
124 MD050161 07-Feb-50 female 45 41-50 YEARS  YES 
125 RD080162 03-Mar-73 male 26 21-30 YEARS  YES 
126 AD050163 08-Jun-52 female 44 41-50 YEARS 100 NO 
127 JD080164 30-Jun-56 male 43 41-50 YEARS 50 YES 
128 PD120168 11-Sep-59 male 43 41-50 YEARS 40 NO 
129 SD040169 15-Jul-73 female 22 21-30 YEARS 50 NO 
130 RD050170 30-May-41 female 54 51-60 YEARS  NO 
131 VD080171 17-Mar-38 female 61 61 AND OLDER 14 YES 
132 SD040174 03-Jul-76 male 19 11-20 YEARS 50 NO 
133 SD050175 18-Dec-56 female 39 31-40 YEARS 58 NO 
134 MD040176 16-Jun-30 female 64 61 AND OLDER 140 NO 
135 AD090177 09-Mar-58 male 42 41-50 YEARS 90 YES 
136 PD060178 05-Dec-52 female 44 41-50 YEARS  YES 
137 AD060179 09-Aug-46 female 50 41-50 YEARS   
138 DD120180 21-Nov-50 male 52 51-60 YEARS 160 NO 
139 PD120181 27-Aug-79 male 22 21-30 YEARS  YES 
140 JE130709 17-Apr-68 male 36 31-40 YEARS  NO 
141 IE050185 20-Jul-53 male 44 41-50 YEARS 200 NO 
142 BE120187 31-Mar-75 female 28 21-30 YEARS 20 YES 
143 RE060188 25-Apr-37 male 59 51-60 YEARS 40 NO 
144 FF060189 15-Dec-71 female 25 21-30 YEARS 50 NO 
145 TF040190 29-Oct-70 female 24 21-30 YEARS 48 NO 
146 HF120191 16-May-53 female 50 41-50 YEARS  UNKNOWN 
147 CF020192 11-Apr-37 male 56 51-60 YEARS  YES 
148 GF100193 14-Jan-47 female 54 51-60 YEARS 92 NO
149 GF050194 14-Jul-68 male 28 21-30 YEARS 36 YES 
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Number Code DOB Sex Age Age band No Tablet Stag OD 
149 GF050194 14-Jul-68 male 28 21-30 YEARS 36 
 
YES 
150 NF060197 01-May-59 male 38 31-40 YEARS 120 NO 
151 RF030198 16-Sep-66 male 28 21-30 YEARS  YES 
152 SF030202 24-Sep-73 female 20 11-20 YEARS 30 NO 
153 AF090203 23-Mar-62 female 38 31-40 YEARS 50 NO 
154 MF130704 27-Nov-38 female 65 61 AND OLDER  UNKNOWN 
155 EF080205 12-Nov-57 female 41 41-50 YEARS 42 NO 
156 YF09207 29-Aug-63 female 37 31-40 YEARS  UNKNOWN 
157 JF09208 25-Mar-51 male 47 41-50 YEARS 170 NO 
158 JF070210 12-Nov-47 male 50 41-50 YEARS 150 NO 
159 AF060211 03-Feb-70 female 27 21-30 YEARS 50 NO 
160 AF050213 13-Jul-29 female 66 61 AND OLDER   
161 EF060218 21-May-56 male 41 41-50 YEARS 75 NO 
162 KF050219 21-Jun-66 male 30 21-30 YEARS 90 NO 
163 AF100220 26-Mar-56 male 45 41-50 YEARS 80 YES 
164 DF090222 16-Feb-71 female 29 21-30 YEARS  YES 
165 RG050224 22-Dec-76 male 19 11-20 YEARS 300 NO 
166 SG050225 16-Sep-66 male 30 21-30 YEARS 54 NO 
167 CG100226 22-Feb-32 male 69 61 AND OLDER 89 NO 
168 LG110227 11-Jul-80 female 21 21-30 YEARS 48 NO 
169 NG040228 04-Aug-74 female 20 11-20 YEARS 20 NO 
170 SG020230 14-Jul-71 male 22 21-30 YEARS 17 NO 
171 CG130707 26-May-71 male 33 31-40 YEARS 130 YES 
172 JG020231 05-Jun-55 male 38 31-40 YEARS 100 NO 
173 LG100232 13-Mar-72 male 29 21-30 YEARS 60 YES 
174 AG110234 30-Jun-55 male 46 41-50 YEARS  YES 
175 MG030236 15-Apr-58 female 36 31-40 YEARS 50 NO 
176 SG100237 04-Feb-82 male 29 21-30 YEARS 50 NO 
177 MG030239 17-Sep-76 female 17 11-20 YEARS 40 NO 
178 AG100242 17-Oct-59 male 41 41-50 YEARS 40 YES 
179 AG030243 25-Sep-71 female 22 21-30 YEARS 24 NO 
180 DG090244 11-Dec-76 male 23 21-30 YEARS 100 NO 
181 SG080245 29-Oct-68 female 30 21-30 YEARS  NO 
182 SG080248 03-Feb-75 female 23 21-30 YEARS 50 NO 
183 SG060249 27-Sep-81 female 16 11-20 YEARS 38 NO 
184 CG120251 20-Oct-65 female 37 31-40 YEARS  UNKNOWN 
185 DG120252 26-Aug-72 female 30 21-30 YEARS 20 NO 
186 FG100253 24-May-74 female 27 21-30 YEARS 40 NO 
187 SG040254 13-Dec-69 female 26 21-30 YEARS 50 NO 
188 LG080255 15-Oct-68 female 31 31-40 YEARS 32 YES 
189 PG040256 24-Jul-71 male 23 21-30 YEARS 70 NO 
190 SG090260 21-Mar-69 female 31 31-40 YEARS 90 YES 
191 JH050263 06-Feb-47 female 49 41-50 YEARS 72 NO 
192 RH120264 15-Feb-44 male 59 51-60 YEARS  YES 
193 IH020265 11-Mar-74 female 19 11-20 YEARS  NO 
194 AH010268 16-Sep-70 male 22 21-30 YEARS  YES 
195 MH060269 12-Feb-80 female 17 11-20 YEARS 70 NO 
196 WH020271 10-Sep-44 male 48 41-50 YEARS 50 NO 
197 JF030273 21-Oct-64 female 29 21-30 YEARS 30 NO 
198 JH080274 30-Sep-37 male 62 61 AND OLDER  YES 
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Number Code DOB Sex Age Age band No Tablet Stag OD 
199 KH030275 19-Mar-45 male 48 41-50 YEARS 250 NO 
200 RH060276 09-Jan-55 male 42 41-50 YEARS 60 NO 
201 PH110277 19-Sep-62 female 39 31-40 YEARS  YES 
202 BH090279 29-Jun-71 female 29 21-30 YEARS 100 NO 
203 JH070280 10-Apr-72 male 26 21-30 YEARS 60 NO 
204 PH060281 10-Dec-44 male 53 51-60 YEARS 40 NO 
205 LH120282 20-Oct-60 female 42 41-50 YEARS 32 NO 
206 KH060283 02-Apr-80 female 17 11-20 YEARS 40 NO 
207 AH040284 22-Jun-74 female 21 21-30 YEARS 48 NO 
208 VH060286 08-Sep-79 female 18 11-20 YEARS 14 NO 
209 KH090287 08-Dec-67 male 32 31-40 YEARS 50 NO 
210 AH050288 20-Jan-72 female 24 21-30 YEARS 60 NO 
211 LH070289 22-Jan-77 female 21 21-30 YEARS 48 NO 
212 BH080290 05-Jan-82 male 17 11-20 YEARS  UNKNOWN 
213 CH090291 07-Oct-55 female 45 41-50 YEARS 48 YES 
214 SH130692 24-Aug-60 male 43 41-50 YEARS 100 NO 
215 LH030293 18-Sep-62 female 31 31-40 YEARS 35  
216 TH070294 10-Feb-40 male 58 41-50 YEARS 72 YES 
217 TI060296 25-Dec-68 female 28 21-30 YEARS 70 NO 
218 JI040297 09-Jun-79 female 16 11-20 YEARS 40 NO 
219 LI120355 14-Mar-74 female 28 21-30 YEARS 100 NO 
220 RI120298 24-Mar-54 female 47 41-50 YEARS 60 NO 
221 FI050300 10-Mar-63 male 32 31-40 YEARS 100 NO 
222 JJ080302 27-May-43 male 56 41-50 YEARS 40 YES 
223 MJ100303 10-Apr-44 female 57 51-60 YEARS 56 NO 
224 BJ090304 03-Apr-55 male 45 31-40 YEARS 80 YES 
225 AJ090305 20-Dec-67 male 32 31-40 YEARS 10 YES 
226 WJ030306 27-Jun-49 male 44 41-50 YEARS 100 YES 
227 AJ050307 09-Aug-75 female 20 11-20 YEARS 60 NO 
228 BJ040308 08-Nov-76 female 18 11-20 YEARS 16 NO 
229 AJ100309 09-Nov-62 female 38 31-40 YEARS 196 NO 
230 EJ080310 05-Apr-43 female 56 51-60 YEARS 70 UNKNOWN 
231 SJ010311 28-Feb-63 female 29 21-30 YEARS  UNKNOWN 
232 PJ110312 06-Jun-69 male 33 31-40 YEARS  YES 
233 TK120313 17-Mar-76 male 23 21-30 YEARS 50 NO 
234 BK050314 16-Jul-65 male 30 21-30 YEARS 100 NO 
235 JK100316 16-Jul-61 male 40 31-40 YEARS 32 NO 
236 KK060317 28-Jan-81 female 16 11-20 YEARS 32 NO 
237 MK090318 24-Nov-76 female 24 21-30 YEARS 38 YES 
238 RK090320 08-Mar-47 male 52 51-60 YEARS 50 NO 
239 WK060321 24-Apr-52 male 44 41-50 YEARS 100 NO 
240 LK040323 22-Mar-61 female 34 31-40 YEARS 10 NO 
241 WK130700 29-Aug-29 male 74 61 AND OLDER 96 NO 
242 GK120327 18-Dec-45 male 57 51-60 YEARS 60 NO 
243 JK020330 27-Oct-59 female 34 31-40 YEARS 20 NO 
244 TK050331 14-Dec-71 male 24 21-30 YEARS 200 NO 
245 SK100333 16-Aug-76 male 25 21-30 YEARS 72 YES 
246 JK120334 08-Dec-73 male 29 21-30 YEARS 100 NO 
247 LL060335 26-Mar-60 female 36 31-40 YEARS  UNKNOWN 






Number Code DOB Sex Age Age band No Tablet Stag OD 
249 FL090338 06-Oct-66 female 34 31-40 YEARS  UNKNOWN 
250 KL050339 08-Jul-74 female 22 21-30 YEARS 18 NO 
251 SL050340 21-Apr-81 female 14 11-20 YEARS 35 NO 
252 DL070341 27-Feb-74 male 24 21-30 YEARS 93 NO 
253 JL120676 29-Aug-24 female 79 61 AND OLDER  UNKNOWN 
254 LS050343 15-Oct-44 male 50 41-50 YEARS 70 NO 
255 JL090344 03-Oct-50 male 49 41-50 YEARS  NO 
256 AL030345 08-Mar-65 female 29 21-30 YEARS 35 NO 
257 JL030347 18-Dec-67 female 26 21-30 YEARS 30 NO 
258 WL040348 21-Sep-60 male 34 31-40 YEARS 100 NO 
259 DL070349 20-Mar-22 female 76 61 AND OLDER   
260 SL050351 27-Mar-75 female 21 21-30 YEARS 20 NO 
261 KL120352 07-Jul-73 female 30 21-30 YEARS 60 NO 
262 LL040353 17-May-79 female 16 11-20 YEARS 80 NO 
263 EL030354 13-Jan-33 male 61 61 AND OLDER  NO 
264 CL030356 08-Jul-57 female 37 31-40 YEARS 50 NO 
265 RL050367 17-Aug-74 male 22 21-30 YEARS  UNKNOWN 
266 SM120594 04-Nov-76 male 26 21-30 YEARS 70 NO 
267 DM080358 27-May-99 male 55 41-50 YEARS 12 YES 
268 CM080359 23-Jul-55 female 44 41-50 YEARS   
269 KM030360 21-Jun-69 female 25 21-30 YEARS 50 NO 
270 FM030361 19-Jul-60 female 33 31-40 YEARS 42 YES 
271 RM070362 28-Apr-53 female 44 41-50 YEARS  YES 
272 SM120363 07-Aug-74 female 27 21-30 YEARS 32 NO 
273 LM100364 25-Oct-79 female 22 21-30 YEARS 170 NO 
274 JM030367 14-May-57 female 38 31-40 YEARS  YES 
275 VM080368 18-Sep-71 female 27 21-30 YEARS 96 NO 
276 WM080369 28-Jul-38 male 60 51-60 YEARS 100 NO 
277 WM040370 12-Jul-54 male 40 31-40 YEARS  NO 
278 KM100371 31-Oct-77 female 23 21-30 YEARS  YES 
279 CM090372 02-Apr-75 female 23 11-20 YEARS 96 YES 
280 BM100374 01-Nov-73 male 28 21-30 YEARS 16 YES 
281 SM030375 24-Aug-82 female 11 11-20 YEARS 20 NO 
282 CM060377 02-Apr-76 male 21 21-30 YEARS 27 NO 
283 SM060378 06-Oct-64 male 32 31-40 YEARS  NO 
284 SM040379 21-Jul-64 female 30 21-30 YEARS 130 NO 
285 UM040380 17-May-53 female 41 41-50 YEARS  YES 
286 WM040382 09-Jul-50 male 45 41-50 YEARS 200 NO 
287 AM100383 01-Feb-29 male 71 61 AND OLDER  UNKNOWN 
288 JM110384 15-Oct-62 male 39 21-30 YEARS  UNKNOWN 
289 AM070385 19-Aug-75 female 22 21-30 YEARS  NO 
290 CM110386 23-Dec-63 female 38 31-40 YEARS 60 NO 
291 JM110387 23-Oct-35 male 66 61 AND OLDER 85 NO 
292 SM130693 27-Dec-65 male 38 31-40 YEARS 130 YES 
293 KM050389 15-Dec-56 female 39 31-40 YEARS  YES 
294 TM120678 11-Oct-28 male 75 61 AND OLDER  YES 
295 EM060390 29-Jun-50 female 47 41-50 YEARS   
296 KM130694 14-Jan-83 male 21 21-30 YEARS 20 YES 
297 SM070391 08-Mar-68 male 30 21-30 YEARS 55 NO 
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298 SM030392 19-Sep-69 female 24 21-30 YEARS 42 NO 
299 GM060393 25-Jul-77 male 19 21-30 YEARS 40 NO 
300 AM060394 09-Jun-73 female 24 21-30 YEARS 50 NO 
301 SM080395 03-Aug-73 male 26 21-30 YEARS 50 NO 
302 RM060396 28-Aug-75 female 21 21-30 YEARS 20 NO 
303 JM070397 03-Mar-70 male 28 21-30 YEARS 150 NO 
304 DM100399 23-Jul-60 male 40 31-40 YEARS 16 NO 
305 EM030400 03-Nov-68 female 25 21-30 YEARS   
306 CM100402 27-Sep-60 female 40 31-40 YEARS 150 NO 
307 DM040403 13-Apr-69 female 26 21-30 YEARS 21 NO 
308 DM060404 05-May-77 male 20 11-20 YEARS 100 NO 
309 DM090405 21-Nov-57 male 43 41-50 YEARS  NO 
310 JM120673 16-Oct-58 male 45 41-50 YEARS  YES 
311 LM060406 04-Jul-70 female 26 21-30 YEARS 100 NO 
312 FM020407 12-Nov-61 female 31 31-40 YEARS 50 NO 
313 JM080408 23-Jun-74 female 24 21-30 YEARS 50 NO 
314 MM080409 06-Jan-59 female 40 31-40 YEARS 50 NO 
315 HM020411 29-Sep-68 female 24 21-30 YEARS 100 NO 
316 JM090412 08-Mar-61 male 39 31-40 YEARS 100 NO 
317 JM100413 15-Feb-70 male 31 31-40 YEARS 80 NO 
318 CM080414 30-Jun-62 female 36 31-40 YEARS 40 NO 
319 TM050416 16-Dec-74 female 21 21-30 YEARS 40 NO 
320 GM070417 18-Apr-46 female 52 51-60 YEARS   
321 PM050418 26-Sep-51 female 45 41-50 YEARS 50 NO 
322 SM040419 11-Sep-46 female 48 41-50 YEARS  YES 
323 DM020420 26-Feb-64 male 29 21-30 YEARS  YES 
324 DM100421 19-Feb-34 male 66 61 AND OLDER 50 NO 
325 LM060422 11-Mar-67 female 30 21-30 YEARS 100 NO 
326 MM040423 30-Mar-45 female 50 41-50 YEARS  YES 
327 AM090424 18-Dec-48 male 52 51-60 YEARS   
328 NM050427 05-Sep-72 male 24 21-30 YEARS 196 NO 
329 HM090430 01-Nov-56 female 44 31-40 YEARS  UNKNOWN 
330 JM010431 09-Sep-52 female 40 31-40 YEARS  UNKNOWN 
331 TM050433 17-Mar-72 female 23 21-30 YEARS 40 NO 
332 JM040435 13-Mar-57 male 37 31-40 YEARS 69 NO 
333 JM110436 31-May-74 male 28 31-40 YEARS 40 NO 
334 SM030437 27-May-63 female 31 31-40 YEARS 70 NO 
335 AM100428 29-May-85 female 16 11-20 YEARS 50 NO 
336 NM090439 06-Jan-79 female 21 21-30 YEARS 70 NO 
337 VM030440 01-Oct-45 male 49 41-50 YEARS 50 NO 
338 AM070441 17-Apr-34 male 64 61 AND OLDER 50 NO 
339 JM020443 27-May-69 female 23 21-30 YEARS 30 NO 
340 MM050444 14-Apr-38 female 58 51-60 YEARS 102 NO 
341 FM070445 24-Aug-71 female 27 21-30 YEARS 15 NO 
342 MM030446 11-Jun-63 female 30 21-30 YEARS 50 NO 
343 EM110448 30-Sep-67 female 34 31-40 YEARS 32 NO 
344 IM100449 05-Jul-57 female 43 41-50 YEARS  YES 
345 DM100450 22-Jul-58 female 41 41-50 YEARS 32 NO 
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346 DM130688 29-Jun-69 male 34 31-40 YEARS 100 NO 
347 TM020451 25-Dec-68 female 24 21-30 YEARS 100 NO 
348 HM050452 15-Oct-41 male 55 41-50 YEARS 100 NO 
349 AM120679 17-Jan-67 female 36 31-40 YEARS  NO 
350 GM120453 15-Nov-29 male 73 61 AND OLDER  YES 
351 SM100454 19-Jan-73 male 28 21-30 YEARS 50 NO 
352 AM040455 19-Sep-69 female 25 21-30 YEARS 100 NO 
353 EM110456 26-Sep-65 male 37 31-40 YEARS 40 YES 
354 MM030457 09-Sep-53 female 40 31-40 YEARS 100 NO 
355 TM060461 28-Aug-61 male 35 31-40 YEARS 20 NO 
356 PM090462 15-Oct-65 male 34 31-40 YEARS 100 NO 
357 AM120465 22-Jun-47 male 55 51-60 YEARS 60 NO 
358 GM020466 02-Jul-70 male 23 21-30 YEARS 30 YES 
359 AM050467 24-Apr-74 female 22 21-30 YEARS 100 NO 
360 MM130696 24-Jan-82 female 22 21-30 YEARS 20 NO 
361 BM110468 31-May-58 male 43 41-50 YEARS 40 YES 
362 FM060469 30-Jul-75 male 21 21-30 YEARS 50 NO 
363 JM040470 24-Aug-53 male 41 41-50 YEARS 50 NO 
364 JM080471 25-Feb-68 female 31 31-40 YEARS 95 NO 
365 DM070473 21-Jan-60 male 38 31-40 YEARS  YES 
366 JM060474 16-Nov-54 male 43 41-50 YEARS 30 NO 
367 BM090475 07-Sep-54 female 46 41-50 YEARS 30 NO 
368 SM120476 12-Aug-61 female 42 41-50 YEARS 16 YES 
369 AM120477 09-Feb-43 male 60 51-60 YEARS 64 NO 
370 HM080478 09-Jun-61 female 37 31-40 YEARS  YES 
371 AM110479 22-Jan-52 female 50 41-50 YEARS  YES 
372 BM030480 05-May-40 male 54 51-60 YEARS 40 YES 
373 JM070481 20-Dec-72 male 25 21-30 YEARS 30 YES 
374 JM030482 18-Jun-76 female 28 21-30 YEARS 90 YES 
375 TM060483 20-May-68 female 28 21-30 YEARS 55 NO 
376 KM100485 17-Jul-87 male 13 11-20 YEARS 36 NO 
377 EM080487 16-Jul-76 female 23 21-30 YEARS  YES 
378 CM050488 09-Apr-79 female 16 11-20 YEARS 35 NO 
379 GM030489 20-Oct-62 male 31 31-40 YEARS 100 NO 
380 AN100490 14-May-72 male 28 21-30 YEARS  YES 
381 DN060491 06-Dec-56 male 40 31-40 YEARS 50 NO 
382 EN030493 14-Sep-51 female 42 41-50 YEARS  YES 
383 JN040494 09-Mar-65 male 30 21-30 YEARS 100 NO 
384 WN130697 22-Jul-72 male 32 31-40 YEARS  YES 
385 RN090495 04-Dec-67 male 23 21-30 YEARS 100 NO 
386 SN110496 27-Jan-71 female 31 31-40 YEARS 60 NO 
387 LO090498 12-Nov-70 female 30 21-30 YEARS 80 NO 
388 DP110503 21-Jan-75 male 27 21-30 YEARS 90 NO 
389 JP070504 05-Jun-66 male 31 31-40 YEARS 50 NO 
390 RP110505 21-Jun-81 male 20 11-20 YEARS 30 NO 
391 EP090507 28-May-56 female 44 31-40 YEARS 70  
392 CP040509 24-Feb-53 male 42 41-50 YEARS 100 NO 
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393 MP120510 27-Jun-61 male 42 41-50 YEARS 64 NO 
394 SP020511 09-Aug-75 female 18 11-20 YEARS 55 NO 
395 HP050512 10-Apr-66 female 29 21-30 YEARS 120 NO 
396 JP100513 11-Feb-54 female 47 41-50 YEARS  NO 
397 CP100514 27-Dec-54 female 46 41-50 YEARS 6 NO 
398 JP120516 21-Mar-66 male 37 31-40 YEARS 70 YES 
399 MP070517 06-Jun-69 female 28 21-30 YEARS 55 YES 
400 YP070518 09-Oct-71 female 27 21-30 YEARS 50 YES 
401 DP040519 07-Nov-26 male 68 61 AND OLDER 36 NO 
402 PP040520 13-Sep-57 male 37 31-40 YEARS  UNKNOWN 
403 JP120521 26-Oct-55 female 47 41-50 YEARS 70 NO 
404 LP120670 18-Oct-66 female 37 31-40 YEARS  YES 
405 LP060522 16-Oct-51 female 45 41-50 YEARS   
406 WP020523 04-Jul-69 female 23 21-30 YEARS 55 NO 
407 AQ030524 24-Dec-75 female 18 11-20 YEARS 50 NO 
408 MQ110525 29-Jun-65 female 37 31-40 YEARS 20 NO 
409 PQ050526 09-Apr-42 male 54 51-60 YEARS 100 YES 
410 HR050527 08-Nov-78 female 18 11-20 YEARS 14 NO 
411 MR100528 05-Apr-51 female 49 41-50 YEARS 96 NO 
412 GR040529 16-Jun-73 male 21 21-30 YEARS 60 NO 
413 LR050531 06-Mar-62 female 34 31-40 YEARS 60 NO 
414 AR080532 25-Oct-67 male 31 31-40 YEARS  YES 
415 MR040533 24-Aug-47 female 47 41-50 YEARS  YES 
416 NR090534 14-Jan-79 female 21 21-30 YEARS 70 NO 
417 MR050535 01-Sep-69 male 26 21-30 YEARS 56 NO 
418 MR030537 18-Jul-64 male 29 21-30 YEARS 30 YES 
419 SR050536 30-May-69 male 27 21-30 YEARS 48 YES 
420 WR120538 08-Aug-51 male 51 41-50 YEARS 50 NO 
421 AR090539 20-Sep-73 male 26 21-30 YEARS 112 NO 
422 PR110542 27-Oct-73 male 28 21-30 YEARS 100 YES 
423 JR040543 20-Nov-78 male 16 11-20 YEARS 70 NO 
424 CR120545 01-Mar-59 female 44 41-50 YEARS  YES 
425 CR040546 17-Oct-63 male 31 31-40 YEARS 40 NO 
526 DR120547 16-Sep-60 male 42 41-50 YEARS 130 YES 
427 DR090548 24-Nov-78 female 21 21-30 YEARS 40 NO 
428 JR040550 25-Mar-63 female 31 31-40 YEARS 30 NO 
429 JR070552 25-Jun-58 female 40 31-40 YEARS 60 NO 
430 PR120554 04-Sep-52 female 50 41-50 YEARS  YES 
431 WR070555 18-Jan-69 male 29 21-30 YEARS 20 NO 
432 CR070556 24-Nov-58 female 39 31-40 YEARS 48 NO 
433 JR030557 07-Nov-68 male 25 21-30 YEARS 100 NO 
434 JR120686 07-Jun-56 female 47 41-50 YEARS  NO 
435 NR050558 15-Nov-79 male 16 11-20 YEARS 22 YES 
436 MR120684 20-May-61 female 42 41-50 YEARS 60 NO 
437 GR040559 11-Jan-66 male 29 21-30 YEARS 150 YES 
438 WR080560 27-Sep-53 male 45 41-50 YEARS 16 NO 
439 IR100562 15-Dec-55 female 45 41-50 YEARS 30 NO 
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440 JR090563 17-Dec-65 male 34 31-40 YEARS 98 NO 
441 ER090564 16-May-71 male 29 21-30 YEARS 100 NO 
442 MR040565 30-Jan-64 male 31 31-40 YEARS 60 YES 
443 KS080569 23-Nov-65 female 33 31-40 YEARS 24 YES 
444 WS030570 29-Oct-55 male 38 31-40 YEARS 90 NO 
445 SW030571 26-Jan-50 male 43 41-50 YEARS 80 NO 
446 KS130695 19-May-69 female 34 31-40 YEARS 10 NO 
447 JS090574 23-Feb-51 female 49 41-50 YEARS  YES 
448 BS020575 04-Mar-72 male 21 21-30 YEARS 140 NO 
449 SS060576 17-Apr-45 female 46 41-50 YEARS 150 YES 
450 KS110578 31-Oct-57 male 44 41-50 YEARS  YES 
451 NS110579 20-Jul-60 female 42 41-50 YEARS  YES 
452 PS080580 31-May-58 female 40 31-40 YEARS 9 YES 
453 WS020582 11-Apr-68 male 25 21-30 YEARS 50 NO 
454 AS090583 16-Jan-64 male 35 31-40 YEARS 50 NO 
455 IS100584 13-Mar-75 male 26 21-30 YEARS 100 NO 
456 JS030585 20-Dec-52 male 41 41-50 YEARS 100 NO 
457 MS050587 12-Apr-59 male 36 31-40 YEARS 80 NO 
458 LS130710 10-Sep-64 male 39 31-40 YEARS 60 NO 
459 SS060589 05-May-71 female 25 21-30 YEARS 46 NO 
460 TS080590 20-Feb-42 female 57 51-60 YEARS  YES 
461 JS020591 27-May-58 female 35 31-40 YEARS 60 NO 
462 DS040592 07-Sep-70 male 24 21-30 YEARS 200 NO 
463 ES100594 25-May-67 male 34 31-40 YEARS  NO 
464 PS030595 07-Nov-49 female 45 41-50 YEARS  UNKNOWN 
465 GS110597 08-Feb-02 male 22 21-30 YEARS 32 NO 
466 JS040598 09-Mar-64 male 31 31-40 YEARS 80 NO 
467 MS110600 02-May-48 male 53 41-50 YEARS 100 NO 
468 PS030601 16-Jun-67 male 26 21-30 YEARS 60 NO 
469 AS080602 30-Mar-68 female 31 31-40 YEARS 90 YES 
470 JS030603 25-Feb-41 female 53 51-60 YEARS 60 NO 
471 WS090605 04-May-58 male 41 41-50 YEARS 70 NO 
472 AS060606 01-Nov-59 female 37 31-40 YEARS 45 YES 
473 RT060608 17-Jan-54 male 43 41-50 YEARS 72 NO 
474 BT060610 06-Mar-65 female 32 31-40 YEARS 48 NO 
475 CT120677 30-Apr-60 female 43 41-50 YEARS  YES 
476 DT010612 25-Feb-70 male 23 21-30 YEARS 200 NO 
477 ET050613 27-May-70 male 26 21-30 YEARS 50 NO 
478 RT040614 19-Jun-66 male 28 21-30 YEARS 30 NO 
479 AT060615 07-Jan-76 female 20 11-20 YEARS 25 NO 
480 CT030616 09-Dec-51 male 42 41-50 YEARS   
481 DT090617 22-Feb-57 male 43 41-50 YEARS 120 YES 
482 ET040618 20-Apr-74 female 21 21-30 YEARS 24 NO 
483 JT060620 17-Dec-24 male 54 51-60 YEARS 100 NO 
484 VT110621 28-Nov-65 female 36 31-40 YEARS 96 NO 
485 DT040622 06-Jan-64 male 30 21-30 YEARS 55 NO 
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486 CT080623 24-Jan-65 female 34 31-40 YEARS  NO 
487 JT050624 11-Dec-51 male 45 41-50 YEARS 30 NO 
488 KT100625 24-Apr-46 female 55 41-50 YEARS  YES 
489 GT110626 06-Jun-80 male 21 21-30 YEARS 30 NO 
490 GT010627 09-May-58 male 34 31-40 YEARS 100 NO 
491 ST070628 10-Dec-62 male 35 31-40 YEARS 48 NO 
492 ST110629 26-Sep-86 female 15 11-20 YEARS 100 NO 
493 DW050632 26-Nov-70 male 25 21-30 YEARS 150 NO 
494 EW050633 02-Dec-46 female 49 41-50 YEARS 60 NO 
495 JW030634 20-Jun-47 male 46 41-50 YEARS 110 NO 
496 PW070635 18-Apr-53 male 44 41-50 YEARS 30 NO 
497 PW100636 25-Jan-44 male 45 41-50 YEARS 60 YES 
498 MW060637 26-Jun-55 female 42 41-50 YEARS 120 YES 
499 SW040638 23-Jul-54 female 40 31-40 YEARS 19 YES 
500 DW120639 07-Sep-70 female 22 21-30 YEARS 32 NO 
501 IW060640 10-Jul-80 female 16 11-20 YEARS 70 NO 
502 PW070642 18-Apr-53 male 44 41-50 YEARS 30 NO 
503 PW090643 27-Dec-71 male 28 21-30 YEARS 60 YES 
504 WW080644 28-Oct-48 male 50 41-50 YEARS 18 YES 
505 CW100645 17-Jul-62 female 38 31-40 YEARS  UNKNOWN 
506 DW120647 21-Nov-77 male 31 31-40 YEARS 12 YES 
507 EW120648 05-Mar-57 female 46 41-50 YEARS  YES 
508 MW040649 19-Jun-61 female 34 31-40 YEARS  UNKNOWN 
509 JW070650 18-Feb-45 male 53 51-60 YEARS 82 NO 
510 MW010651 17-Oct-66 female 26 21-30 YEARS 42 NO 
511 BW080652 23-Mar-65 male 34 31-40 YEARS 100 YES 
512 LW050653 02-Aug-73 male 23 21-30 YEARS 75 NO 
513 SW130703 30-Mar-60 female 44 31-40 YEARS 140 YES 
514 JW070655 25-Dec-46 male 52 41-50 YEARS 40 NO 
515 JW040656 14-May-68 male 26 21-30 YEARS 40 NO 
516 KW060657 12-Oct-68 female 28 21-30 YEARS 150 NO 
517 RW090658 16-Oct-65 male 34 31-40 YEARS 60 NO 
518 EW090659 16-Aug-78 female 21 21-30 YEARS 64 NO 
519 KW060660 17-Apr-71 male 26 21-30 YEARS  YES 
520 HW110662 19-Aug-42 female 60 51-60 YEARS 20 NO 
521 TW100666 08-Nov-77 female 23 21-30 YEARS 40 NO 
522 MZ030667 15-Jan-64 female 30 21-30 YEARS 80 NO 
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Ref BP gr RIE BP 
mmHg 
RIE BP gr 
1 NO  106/52 normotensive 137/55 normotensive 
2 NO 10 150/64 normotensive 137/75 normotensive 
3  7 130/70 normotensive 115/60 normotensive 
4 YES 56 190/80 normotensive 123/69 hypotensive 
5 YES 30 140/60 normotensive 104/49 normotensive 
6 YES 10 125/65 normotensive 125/59 normotensive 
7 YES 100 124/65 normotensive 98/50 hypotensive 
8   50/35 hypotensive 120/60 normotensive 
9 YES 10 115/54 normotensive 130/58 normotensive 
10 YES 34 84/49 hypotensive 100/60 hypotensive 
11 YES 180   90/40 hypotensive 
12 YES 140 130/70 normotensive 116/46 normotensive 
13 NO 12 150/80 normotensive 160/80 normotensive 
14 NO  180/95 normotensive 135/75 normotensive 
15 NO  130/69 normotensive 140/85 normotensive 
16 YES 60 170/83 normotensive 90/40 hypotensive 
17 YES 12 95/40 hypotensive 90/60 hypotensive 
18 YES 20 135/60 normotensive 143/93 normotensive 
19 NO 14 140/70 normotensive 140/60 normotensive 
20     80/50 hypotensive 
21 YES  91/41 hypotensive   
22 NO 20   140/70 normotensive 
23 NO 10 95/49 hypotensive 122/72 normotensive 
24 YES 350 147/88 normotensive 108/40 normotensive 
25 YES 28 170/92 normotensive 159/73 normotensive 
26 NO 10 157/110 normotensive 110/70 normotensive 
27 YES 50 106/78 normotensive 142/70 normotensive 
28 NO 10 118/76 normotensive 110/70 normotensive 
29 YES 350 139/96 normotensive 91/52 hypotensive 
30 NO 12 121/82 normotensive 128/73 normotensive 
31 YES 30 140/60 normotensive 130/50 normotensive 
32  5 109/59 normotensive 117/63 normotensive 
33 YES 84 156/77 hypotensive 137/75 normotensive 
34 YES 210 140/70 normotensive 80/40 hypotensive 
35 YES 280 122/76 normotensive 104/44 normotensive 
36 NO 5 99/50 hypotensive 128/79 normotensive 
37 NO 6 153/64 normotensive 131/74 normotensive 
38 NO 30 120/70 normotensive 123/76 normotensive 
39 YES 540 90/52 hypotensive 95/0 hypotensive 
40 NO 28 162/83 normotensive 160/60 normotensive 
41 YES 21 80/40 hypotensive 80/0 hypotensive 
42  32 105/50 hypotensive 86/50 hypotensive 
43 YES 10 105/59 normotensive 102/47 normotensive 
44 NO    120/64 normotensive 
45 YES 5 138/62 normotensive 118/62 normotensive 
46 NO  120/65 normotensive 117/76 normotensive 
47 NO 10 120/70 normotensive 120/70 normotensive 
48 YES 140 110/40 normotensive 106/60 normotensive 
49 YES  110/70 normotensive 126/58 normotensive 
50 YES 20 115/70 normotensive 180/60 normotensive 
51 NO  120/80 normotensive 100/59 hypotensive 
52 NO 20 151/81 normotensive 94/43 hypotensive 
 41




Ref BP gr RIE BP 
mmHg 
RIE BP gr 
53 NO 36   135/70 normotensive 
54 YES  120/70 normotensive 125/70 normotensive 
55 NO  120/75 normotensive 115/69 normotensive 
56 NO  125/71 normotensive 136/67 normotensive 
57 NO 4   130/50 normotensive 
58 YES 28 152/81 normotensive 155/85 normotensive 
59   114/56 normotensive 100/60 normotensive 
60 NO 180 125/80 normotensive   
61 NO 180 130/85 normotensive 100/60 hypotensive 
62 NO  120/60 normotensive 108/50 normotensive 
63 NO  179/102 normotensive 155/85 normotensive 
64 YES 20 147/92 normotensive 158/99 normotensive 
65 NO 4 140/74 normotensive 130/70 normotensive 
66 NO 20 181/105 normotensive 170/80 normotensive 
67 NO  125/68 normotensive 123/64 normotensive 
68 YES      
69 YES 21 120/70 normotensive 125/80 normotensive 
70 YES 20 140/80 normotensive 110/610 normotensive 
71 YES 90 150/80 normotensive 116/58 normotensive 
72 NO 5 130/80 normotensive 120/70 normotensive 
73 NO 168 103/50 hypotensive 131/64 normotensive 
74 NO  140/70 normotensive 117/60 normotensive 
75 NO  103/55 hypotensive 130/55 normotensive 
76 NO    120/60 normotensive 
77  21 118/91 normotensive 120/50 normotensive 
78 YES 25 95/70 hypotensive 157/109 normotensive 
79 NO 40 140/76 normotensive 120/80 normotensive 
80 NO 10 81/44 hypotensive 110/70 normotensive 
81 YES  107/70 normotensive 117/42 normotensive 
82 YES 140   140/80 normotensive 
83 NO  140/85 normotensive 140/66 normotensive 
84 NO  136/94 hypertensive 113/61 normotensive 
85 NO 5 102/62 normotensive 123/62 normotensive 
86 YES 80 137/62 normotensive 136/52 normotensive 
87 NO 350 122/80 normotensive 122/80 normotensive 
88 NO  100/85 normotensive 128/82 normotensive 
89 NO  130/80 normotensive 115/60 normotensive 
90 YES    76/40 hypotensive 
91 YES 200 141/76 normotensive 80/55 hypotensive 
92 YES 140 135/62 normotensive 130/72 normotensive 
93 YES 102 90/60 hypotensive   
94 YES 90 128/79 normotensive 118/64 normotensive 
95 YES 40   130/84 normotensive 
96 NO  67/49 hypotensive 77/55 hypotensive 
97 YES 200 99/71 hypotensive 86/45 hypotensive 
98 YES 126 150/92 normotensive 180/80 normotensive 
99 NO 60 125/65 normotensive 130/78 normotensive 
100 YES 100 121/64 normotensive 132/60 normotensive 
101   80/67 hypotensive 75/20 hypotensive 
102 YES 56 190/98 hypertensive 144/70 normotensive 
103 NO  140/86 normotensive 122/65 normotensive 
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Ref BP gr RIE BP 
mmHg 
RIE BP gr 
104   104/60 normotensive 94/60 hypotensive 
105 YES 16 130/70 normotensive 144/96 normotensive 
106 YES 200 90/42 hypotensive 108/45 hypotensive 
107 YES 50   140/30 hypotensive 
108 YES 280   113/65 normotensive 
109 YES 20 118/64 normotensive   
110 YES 50 112/67 normotensive 106/52 normotensive 
111 NO  92/60 hypotensive 110/80 normotensive 
112  210 140/75 normotensive 85/50 hypotensive 
113 YES 240 141/88 hypotensive 139/76 normotensive 
114  80 95/60 hypotensive   
115 NO 64 107/58 normotensive 149/84 normotensive 
116 YES 35   110/70 normotensive 
117 NO 8 120/72 normotensive 118/50 normotensive 
118 NO 10 110/60 normotensive 120/60 normotensive 
119 NO 140 114/76 normotensive 158/88 normotensive 
120 YES  155/75 normotensive 120/75 normotensive 
121 NO  105/60 normotensive 124/74 normotensive 
122 YES 315 94/42 hypotensive 101/44 normotensive 
123 YES  95/50 hypotensive 112/60 normotensive 
124 NO  60/20 hypotensive 87/21 hypotensive 
125 YES 45   136/60 normotensive 
126 NO  113/47 normotensive 120/40 normotensive 
127 NO  69/45 hypotensive 90/40 hypotensive 
128 NO 12 134/87 normotensive 134/88 normotensive 
129 NO  71/61 hypotensive 101/43 normotensive 
130 NO  120/70 normotensive 121/57 normotensive 
131 NO 8 145/49 normotensive 127/31 hypotensive 
132 YES 28 146/82 normotensive 140/80 normotensive 
133 YES  152/97 normotensive 154/74 normotensive 
134 YES 14 128/76 normotensive 120/50 normotensive 
135 YES  169/111 hypertensive 88/58 hypotensive 
136  60 138/78 normotensive 115/50 normotensive 
137 NO  178/60 normotensive 162/56 normotensive 
138   94/42 hypotensive 124/65 normotensive 
139 NO 60 148/92 hypertensive 120/80 normotensive 
140 NO 14 143/84 normotensive 144/90 HYPERTENSIVE 
141 NO    109/43 normotensive 
142 NO  132/64 normotensive 110/55 normotensive 
143 NO 60 99/46 hypotensive 99/51 hypotensive 
144 YES  130/80 normotensive 141/78 normotensive 
145 NO      
146  140 124/68 normotensive 120/60 normotensive 
147 NO 25 110/80 normotensive   
148 NO  160/120 hypertensive 110/65 normotensive 
149 NO 210   140/65 normotensive 
150 NO 84   114/70 normotensive 
151 YES 90 130/70 normotensive 100/80 hypotensive 
152 NO  129/79 normotensive 120/80 normotensive 
153 YES 70 109/61 normotensive 110/70 normotensive 
154 YES 280 78/38 hypotensive 98/68 normotensive 
155 NO  132/63 normotensive 97/43 hypotensive 
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Ref BP gr RIE BP 
mmHg 
RIE BP gr 
156  14 120/60 normotensive 120/60 normotensive 
157 YES  113/58 normotensive   
158 YES 30 130/70 normotensive 143/75 normotensive 
159   90/40 hypotensive 140/83 normotensive 
160 NO  100/64 normotensive 113/67 normotensive 
161 YES 100 133/72 normotensive 126/68 normotensive 
162 YES 70 140/80 normotensive 170/83 normotensive 
163 NO  125/72 normotensive 150/62 normotensive 
164 YES 100 74/35 hypotensive 93/45 hypotensive 
165 YES  130/74 normotensive 145/55 normotensive 
166 NO 14 160/72 normotensive 120/82 normotensive 
167   149/82 normotensive 138/72 normotensive 
168 YES 14 118/65 normotensive 125/38 normotensive 
169 NO  110/80 normotensive   
170 NO 40 120/80 normotensive 136/90 normotensive 
171 YES 8 149/69 normotensive 132/80 normotensive 
172 NO 40   130/70 normotensive 
173 NO 140 127/88 normotensive 152/89 normotensive 
174 NO  140/90 normotensive 140/70 normotensive 
175 YES 20 130/70 normotensive 105/50 normotensive 
176 YES 6 109/54 normotensive 95/60  
177 YES  132/80 normotensive 116/63 normotensive 
178 YES 10 164/86 normotensive 136/63 normotensive 
179 YES 50 135/82 normotensive 110/70 normotensive 
180 NO  122/60 normotensive 133/61 normotensive 
181  560 88/60 hypotensive 110/55 normotensive 
182 NO 10 130/80 normotensive 105/44 normotensive 
183  8 138/80 normotensive 127/65 normotensive 
184   88/72 hypotensive 140/70 normotensive 
185  24 111/59 normotensive 132/65 normotensive 
186 NO  113/47 normotensive 115/65 normotensive 
187 NO  100/60 normotensive 120/50 normotensive 
188 YES  112/89 normotensive 114/36 hypotensive 
189 NO 20 135/82 normotensive 140/80 normotensive 
190 YES 50 110/60 normotensive 120/60 normotensive 
191 NO  121/49 normotensive 100/50 normotensive 
192 YES 100 92/51 hypotensive 138/70 normotensive 
193 NO  150/90 normotensive 120/70 normotensive 
194  10 97/50 hypotensive 90/30 hypotensive 
195  21 112/63 normotensive 117/72 normotensive 
196 YES 50     
197 YES 10 114/70 normotensive 120/60 normotensive 
198 NO 8   126/80 normotensive 
199 YES 14   85/50 hypotensive 
200 NO 80 170/80 normotensive 131/63 normotensive 
201 YES 300 158/122 hypertensive 90/70 hypotensive 
202 NO 14 105/64 normotensive 120/70 normotensive 
203 NO  130/70 normotensive 114/36 normotensive 
204 NO 14   142/56 normotensive 
205 YES    128/62 normotensive 
206 NO  117/65 normotensive 140/80 normotensive 
207 YES  110/60 normotensive 89 normotensive 
 44
 




Ref BP gr RIE BP 
mmHg 
RIE BP gr 
208 YES  113/63 normotensive   
209 YES 60 128/70 normotensive 110/60 normotensive 
210 NO  115/65 hypotensive 133/64 normotensive 
211 NO  110/60 normotensive 105/43 normotensive 
212 YES  140/80 normotensive 160/75 normotensive 
213 YES    107/51 normotensive 
214 YES 40 97/43 hypotensive 114/96 normotensive 
215 NO 10 120/60 normotensive 110/80 normotensive 
216 YES 28   170/100 HYPERTENSIVE 
217 YES 30 128/64 normotensive 124/62 normotensive 
218 NO  100/80 normotensive 115/50 normotensive 
219 YES 50 144/91 hypertensive 125/60 normotensive 
220 YES 20 119/86 normotensive 97/47 hypotensive 
221 NO 14 116/73 normotensive 130/65 normotensive 
222 YES 100 138/90 normotensive 130/40 normotensive 
223 NO  116/58 normotensive 140/68 normotensive 
224 NO 100 123/78 normotensive 186/103 HYPERTENSIVE 
225 YES 100 110/60 normotensive 110/70 normotensive 
226   86/50 hypotensive   
227 YES 7 115/96 normotensive 106/43 normotensive 
228 NO  105/45 normotensive 90/45 hypotensive 
229 NO 27 140/80 normotensive 119/52 normotensive 
230     121/57 normotensive 
231   0/0 hypotensive 0 normotensive 
232 YES 60 94/34 hypotensive 121/45 normotensive 
233 NO 40 124/74 normotensive 125/85 normotensive 
234 NO 125   150/70 normotensive 
235 YES 140 120/80 normotensive 140/61 normotensive 
236 YES 5 110/60 normotensive 114/60 normotensive 
237 NO  135/68 normotensive 119/42 hypotensive 
238 YES 16 140/90 normotensive 155/78 normotensive 
239 YES 28 120/70 normotensive 138/74 normotensive 
240 NO 20 120/70 normotensive 169/90 normotensive 
241 NO 98 130/50 normotensive 118/50 normotensive 
242 YES    180/120 hypertensive 
243 NO 8 108/74 normotensive 110/60 normotensive 
244 YES 20 142/66 normotensive 127/72 normotensive 
245 YES 54 148/94 normotensive 124/67 normotensive 
246       
247 NO  140/60 normotensive 132 normotensive 
248 NO  102/62 normotensive 100/60 normotensive 
249  14 130/70 normotensive 139/72 normotensive 
250 NO 10 122/37 normotensive 108/46 normotensive 
251 NO  149/67 normotensive 115/55 normotensive 
252 NO 20 140/90 normotensive 122/42 normotensive 
253   75/40 hypotensive 84/38 hypotensive 
254 YES 14 138/87 normotensive 141/90 normotensive 
255 NO  90/70 hypotensive 90/50 hypotensive 
256 NO 18   130/75 normotensive 
257 YES 10 115/70 normotensive 130/70 normotensive 
258   105/60 normotensive 120/60 normotensive 
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Ref BP gr RIE BP 
mmHg 
RIE BP gr 
259   90/56 hypotensive 130/80 normotensive 
260 YES 20 130/62 normotensive 119/55 normotensive 
261 YES 21 123/72 normotensive 127/82 normotensive 
262   125/55 normotensive 134/74 normotensive 
263 NO 7 130/50 normotensive 120/60 normotensive 
264 NO    105/52 normotensive 
265  10 150/70 normotensive 144/84 normotensive 
266  50 130/80 normotensive 150/80 normotensive 
267 YES 50 122/68 normotensive 117/47 hypotensive 
268  210 151/120 normotensive 103/67 hypotensive 
269 NO  100/60 normotensive 107/50 normotensive 
270 NO 10 110/60 normotensive 118/75 normotensive 
271 NO 28 122/67 normotensive   
272   121/63 normotensive 105/64 hypotensive 
273 NO 20 152/84 normotensive 140/72 normotensive 
274 YES 70 84/50 hypotensive 80/0 hypotensive 
275 YES 10   115/60 normotensive 
276 YES 100 60/30 hypotensive 78/42 hypotensive 
277 NO 20   90/0 hypotensive 
278 NO  98/41 hypotensive  hypotensive 
279 NO  120/80 normotensive 75/45 hypotensive 
280 NO 28 120/92 normotensive 99/33 hypotensive 
281 NO    135/63 normotensive 
282 NO 10   104/60 normotensive 
283   145/70 normotensive 182/95 normotensive 
284 YES 4 130/70 normotensive 114/50 normotensive 
285  200 90/60 hypotensive 110/50 normotensive 
286 YES  140/60 normotensive 120/70 normotensive 
287 YES 150 138/76 normotensive 115/62 normotensive 
288 YES 70 125/75 normotensive 122/88 normotensive 
289   98/50 hypotensive 115/64 normotensive 
290 NO 18 100/40 normotensive 120/60 normotensive 
291 NO 30 122/74 normotensive 167/90 hypertensive 
292 YES 120 102/70 normotensive 139/79 normotensive 
293 YES 56 107/54 normotensive 120/55 normotensive 
294 YES 40 115/80 hypotensive 100/48 hypotensive 
295 YES 60 150/70 normotensive 120/50 normotensive 
296  36 80/50 hypotensive 108/62 normotensive 
297 YES 56 146/95 normotensive 146/95 normotensive 
298 NO 10 100/40 normotensive 79/38 normotensive 
299  20 150/60 normotensive 115/45 normotensive 
300 NO 14 120/70 normotensive 100/70 normotensive 
301       
302 NO 14 121/71 normotensive 126/71 normotensive 
303 YES  148/78 normotensive 120/70 normotensive 
304 YES 420 82 hypertensive 121/89 normotensive 
305       
306  6 93/53 hypotensive   
307 YES 14 80/40 hypotensive 115/60 normotensive 
308 YES 21 127/74 normotensive 135/65 normotensive 
309 YES 25 136/96 normotensive 130/70 normotensive 
310 NO 40 130/80 normotensive 135/70 normotensive 
 46




Ref BP gr RIE BP 
mmHg 
RIE BP gr 
311 NO 28 99/53 normotensive 105/50 normotensive 
312 NO 7   133/84 normotensive 
313 NO  125/76 normotensive 132/62 normotensive 
314 NO    114/59 normotensive 
315 NO 10 128/78 normotensive 120/70 normotensive 
316 YES 450 109/60 normotensive 148/91 normotensive 
317 NO 20 88/40 hypotensive 160/70 normotensive 
318 NO  110/59 normotensive 130/70 normotensive 
319 NO 10 138/74 normotensive 134/50 normotensive 
320  28 92/56 hypotensive 143/81 normotensive 
321 NO  80/50 hypotensive 94/26 hypotensive 
322 YES 35   88/0 hypotensive 
323 YES 140 140/80 normotensive 150/85 normotensive 
324 NO 210 170/90 hypertensive 151/61 normotensive 
325   125/80 normotensive 9./35 hypotensive 
326 YES 180   158/78 normotensive 
327       
328 NO  150/100 normotensive 150/85 normotensive 
329 YES      
330      hypotensive 
331 YES 14 122/60 normotensive 127/54 normotensive 
332   154/83 normotensive   
333 YES 30 132/68 normotensive 140/70 normotensive 
334 NO 8   105/70 normotensive 
335 NO  133/61 normotensive 102/63 normotensive 
336 YES 4 130/76 normotensive 110/60 normotensive 
337 YES 210   134/70 normotensive 
338 NO    138/78 normotensive 
339 NO 10   116/58 normotensive 
340   145/50 normotensive 85/45 hypotensive 
341 YES 4 124/60 normotensive 118/55 normotensive 
342 NO    141/80 normotensive 
343 YES 200 118/66 normotensive 147/96 HYPERTENSIVE 
344 YES 50 112/60 normotensive 80/20 normotensive 
345 NO  97/79 hypotensive 121/64 normotensive 
346 YES 112 144/96 hypertensive 105/45 hypotensive 
347 NO 10     
348 YES 60 140/90 normotensive 114/48 normotensive 
349 YES  100/60 hypotensive 100/60 hypotensive 
350 YES 40 132/86 normotensive 118/45 hypotensive 
351 YES 21 143/85 normotensive 131/61 normotensive 
352 NO 10   130/90 normotensive 
353 YES 75 119/55 normotensive 118/54 normotensive 
354 YES 70   73/38 hypotensive 
355 YES 80 154/112 normotensive 139/95 normotensive 
356 NO 10 113/74 normotensive 120/65 normotensive 
357 YES 210 107/65 normotensive 130/70 normotensive 
358 NO 10 120/80 normotensive 160/85 normotensive 
359   120/60 normotensive 95/36 hypotensive 
360 YES  118/61 normotensive 117/70 normotensive 
361 YES 140   110/55 normotensive 
362 NO 30 130/56 normotensive 137/65 normotensive 
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Ref BP gr RIE BP 
mmHg 
RIE BP gr 
363 NO 6 180/100 normotensive 100/0 hypotensive 
364 NO 6 137/68 normotensive 116/70 normotensive 
365 YES 40 116/60 normotensive 112/60 normotensive 
366 YES 40 140/86 normotensive 130/70 normotensive 
367 NO 63 184/92 hypertensive 128/60 normotensive 
368 NO 26 105/70 hypotensive 105/70 normotensive 
369 YES 98 105/65 normotensive 124/70 normotensive 
370 YES 14 95/54 hypotensive 120/70 normotensive 
371 NO 14 111/55 normotensive 139/90 normotensive 
372 NO 720 100/60 normotensive 140/70 normotensive 
373 YES 180 127/75 normotensive 151/84 normotensive 
374 NO    126/64 normotensive 
375 NO  118/48 normotensive 112/50 normotensive 
376 NO  118/87 normotensive 118/70 normotensive 
377 YES 10 68/40 hypotensive 110/30 hypotensive 
378 NO  147/95 normotensive 138/79 normotensive 
379 YES 40   130/70 normotensive 
380 NO  170/100 hypertensive 95/44 hypotensive 
381 NO 40 170/94 normotensive 135/80 normotensive 
382 NO 720   120/70 normotensive 
383 NO 20   135/80 normotensive 
384 YES 280 176/108 hypertensive 100/30 hypotensive 
385 NO  122/68 normotensive 82/50 hypotensive 
386 NO 14 123/52 normotensive 120/70 normotensive 
387 NO  116/66 normotensive 115/70 normotensive 
388   144/69 normotensive 70/40 hypotensive 
389 YES 120 130/70 normotensive 112/39 normotensive 
390 YES  110/50 normotensive 138/74 normotensive 
391 NO    101/40 hypotensive 
392 NO  132/70 normotensive 105/80 normotensive 
393 NO 14 150/70 normotensive 120/60 normotensive 
394 NO 10   120/70 normotensive 
395 NO  146/67 normotensive 110/54 normotensive 
396 NO  116/79 normotensive 101/52 normotensive 
397 NO 14 126/90 normotensive 82/40 hypotensive 
398 NO 6   130/72 normotensive 
399  14 131/67 normotensive 119/62 normotensive 
400 NO  140/80 normotensive 96/60 hypotensive 
401 YES 126 90/60 hypotensive 129/65 normotensive 
402   150/70 normotensive 130/70 normotensive 
403 NO  130/79 normotensive 138/68 HYPERTENSIVE 
404  63  hypotensive 120/60 normotensive 
405  14 60/40 hypotensive 99/47 hypotensive 
406 NO    110/70 normotensive 
407 NO 10 108/70 normotensive 120/60 normotensive 
408 YES 78 127/60 normotensive 117/82 normotensive 
409 NO 30 150/100 normotensive 105/55 normotensive 
410 YES 10 110/50 normotensive 114/52 normotensive 
411 YES 20     
412 NO 20   100/55 normotensive 
413 NO    123/73 normotensive 
414 NO 10 102/68 normotensive 115/68 normotensive 
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Ref BP gr RIE BP 
mmHg 
RIE BP gr 
415 YES    78/40 hypotensive 
416 YES 14 141/81 normotensive 110/45 normotensive 
417 YES 80 113/43 normotensive 116/66 normotensive 
418 NO 50 150/75 normotensive 110/70 normotensive 
419 NO 50 123/72 normotensive 150/70 normotensive 
420 YES 300 177/115 hypertensive 128/72 normotensive 
421 NO  140/50 normotensive 120/60 normotensive 
422 YES 26 192/103 hypertensive 197/96 HYPERTENSIVE 
423 NO  160/80 normotensive 145/57 normotensive 
424 NO    178/86 HYPERTENSIVE 
425 YES 40   148/68 normotensive 
526 YES 200 134/79 normotensive 145/75 normotensive 
427 NO 14 139/88 normotensive 130/90 normotensive 
428 NO    126/63 normotensive 
429 NO  129/83 normotensive 152/101 HYPERTENSIVE 
430     80/40 hypotensive 
431 NO 20 91/52 hypotensive 127/85 normotensive 
432 NO 30   125/72 normotensive 
433     127/87 normotensive 
434   126/86 normotensive 120/70 normotensive 
435 NO  160/90 normotensive 120/60 normotensive 
436 NO  136/76 normotensive 115/70 normotensive 
437 NO 50 95/45 hypotensive 110/80 normotensive 
438 YES 315 110/59 normotensive 80/40 hypotensive 
439 YES  113/78 normotensive 120/60 normotensive 
440 NO 8 144/78 normotensive 98/47 hypotensive 
441 YES    110/70 normotensive 
442  28 170/90 normotensive 170/90 normotensive 
443 NO  108/50 hypotensive 110/60 normotensive 
444 NO 360   170/80 normotensive 
445 YES 4   142/89 normotensive 
446 NO  53/41 hypotensive 86/44 hypotensive 
447 NO  64/49 hypotensive 114/62 normotensive 
448 NO 10   90/35 hypotensive 
449 YES 14 90/68 normotensive 106/67 normotensive 
450 YES 210 122/77 normotensive 127/77 normotensive 
451 NO 400 114/65 normotensive 100/60 normotensive 
452 NO  110/68 normotensive 115/42 normotensive 
453 NO 10   122/68 normotensive 
454 YES 118 133/87 normotensive 138/63 normotensive 
455 NO 24 150/75 normotensive 110/70 normotensive 
456     128/66 normotensive 
457 NO 18 140/80 normotensive 138/63 normotensive 
458 YES  125/94 hypertensive 125/94 HYPERTENSIVE 
459 NO  113/69 normotensive 114/55 normotensive 
460 NO 63 115/69 normotensive 140/75 normotensive 
461 NO 10   105/50 normotensive 
462 NO 70   100/20 hypotensive 
463  14 141/88 normotensive 180/102 HYPERTENSIVE 
464 YES 180   154/67 normotensive 
465 NO 10 130/77 normotensive 140/70 normotensive 
466 NO 154   133/52 normotensive 
 49




Ref BP gr RIE BP 
mmHg 
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467 YES    105/60 normotensive 
468 NO 10   130/75 normotensive 
469  20 108/50 hypotensive 114/67 normotensive 
470 YES 50   132/83 normotensive 
471 NO 10 113/72 normotensive 120/60 normotensive 
472 YES 50 140/50 normotensive 134/60 normotensive 
473 YES 40 146/81 normotensive 107/66 normotensive 
474 NO  110/70 normotensive 126/78 normotensive 
475 YES 200 100/60 normotensive 98/50 hypotensive 
476 NO 10   150/70 normotensive 
477 YES 14 139/88 normotensive 123/76 normotensive 
478 NO    110/55 normotensive 
479 NO 24 120/70 normotensive 133/47 normotensive 
480  8   108/50 normotensive 
481  160 160/80 normotensive 114/87 normotensive 
482 NO  120/88 normotensive 125/55 normotensive 
483   142/80 normotensive 101/35 normotensive 
484 YES 20 103/72 normotensive 119/46 normotensive 
485 NO 20 125/86 normotensive 103/60 normotensive 
486 NO    116/61 normotensive 
487 YES  135/79 normotensive 127/75 normotensive 
488 NO 50 80/60 hypotensive 140/50 normotensive 
489 YES 70 139/55 normotensive 146/56 normotensive 
490 YES 140 130/70 normotensive 145/65 normotensive 
491 YES 40 147/85 hypotensive 85/38 hypotensive 
492 YES 9 123/92 normotensive 115/64 normotensive 
493 NO  154/88 normotensive 151/76 normotensive 
494 NO  110/60 normotensive 105/56 normotensive 
495 NO 10   75/54 hypotensive 
496 YES 260 240/170 hypertensive 120/60 normotensive 
497 YES 420 74/40 hypotensive 117/72 normotensive 
498 YES 45 118/62 normotensive 100/72 normotensive 
499     115/80 normotensive 
500 NO 21 62/32 hypotensive 90/40 hypotensive 
501 YES 30 136/60 normotensive 125/55 normotensive 
502  60 120/60 normotensive 90/48 hypotensive 
503 NO    100/20 hypotensive 
504 NO 70 150/90 normotensive 110/60 normotensive 
505 NO 14 138/80 normotensive 136/68 normotensive 
506 NO 25 144/74 normotensive 160/80 normotensive 
507 YES 140 130/79 normotensive 130/79 normotensive 
508  540   135/71 normotensive 
509 YES 35 160/110 hypertensive 183/98 normotensive 
510 NO 10   124/57 normotensive 
511 YES 7 138/75 normotensive 140/71 normotensive 
512 YES  120/60 normotensive 125/66 normotensive 
513 YES 280 140/82 normotensive 110/76 normotensive 
514 NO 24 170/100 hypertensive 147/73 normotensive 
515  14 125/75 normotensive 130/57 normotensive 
516 NO  105/38 normotensive 119/63 normotensive 
517 YES 20  normotensive 120/70 normotensive 
518 YES 60 107/82 normotensive 114/64 normotensive 
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Ref BP gr RIE BP 
mmHg 
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519 NO 30 137/63 normotensive 122/57 normotensive 
520 YES 90   150/90 normotensive 
521 YES 18 130/90 normotensive 110/70 normotensive 




Number Ref Na Ref K Ref Bic Ref Bil Ref ALP Ref GGT Ref H+ Ref Cr Ref ALT Ref PT 
1 138 3.4 19    44 98 50 71.3 
2 144 4.3  77 71 61  99 81 40.6 
3 135 6.1 7 22 449 68 37.8 130 90 142 
4 135 3.3 17 186 87   129 99 40 
5 137 4.9 11    60.4  167 71 
6 144 3.6 23     89 53  
7 135 3.9 4 77 394 129 72.5 138 124  
8 136 5.1 8 99 70  58 305 387 81.8 
9 135 3  58 45 22  52 62 13.8 
10 136 4.5 13 80 378 59  275 264 51.3 
11 141 3.8 26 12 140   70 186 16 
12 142 3 23 34 209 161  74 266 50 
13 138 3.9  9 182 19 32 101 70  
14 141 3.3 20 976    83 336 36 
15 145 4.6  76 102 26  174 93 54 
16 128 3.2 21 3297 157   123 175 14 
17 134 5.2  79 94 45 49 369 369 172 
18 136 4.3 24 75 171    182  
19 136 4.7  65 72 46 53.7 179 216 35 
20           
21 129 4.1 19 87 185 388 34 175 193 31 
22 145 4.7 10 121 395 63 74 141 216 33 
23 137 5 24     210 348 43 
24 138 3.5  165 178   67 62 25 
25 131 4.4 19 36 242 51 36 426 660 68 
26 142 3.9  29 113  38 63 259 14 
27 131 3.9 23.5 6880 114 194 32.8 92 83 35 
28 141 3.2 18 47 193 11 37 110 91 35 
29 136 3.7 23 116 92   116 286 14 
30 135 4.9  103 253 33 37.8 340 304 50 
31 144 4.9  123 237   161 120 58 
32 136 4 17.3 76 219  36.5 80 52 25 
33 142 4 22 54 92 44 31 50 56 15.3 
34 129 4.5 20.9  188 219 40 394 544  
35 135 3.8 26 211 221 81  79 270 15 
36 140 4.7 21 34 90 42 37 99 81 42 
37 136 3.8  165 286 59   225 87 
38 136 3.7 24 69 64 24 38 78 68 21 
39 137 5  178 312 157 42 462 460 38 
40 136 5.2 15 74 154  63 111 419 52 
41 123 5.7     36 297 253 143 
42 119 7.3 7 240 1910 850 81 339 362 101 
43 141 4.1 21 6  38  84 400 13.8 
44 14 4.9 16 45   37  116 20 
 51
Number Ref Na Ref K Ref Bic Ref Bil Ref ALP Ref GGT Ref H+ Ref Cr Ref ALT Ref PT 
45 139 4.6 24 39 284 44 41 57 93 27.2 
46 140 4.1 21 75 599 64  79 73  
47 134 4.3 20 62 72 30 39 86 61 22.5 
48 132 5.8 13    40.5 457 529 77 
49 139 3.4  24 84 21  107 108 12 
50 128 4.1  97 286 192  450 488 51 
51 140 3.5 17 39 220  43 65 176 16 
52 130 4.5 10 81 168 132 83 221 317 37.4 
53 134 4 25 52 298 95  66 42 30 
54 137 4.9  62 92 70  112 85 27 
55 140 4 26.2 118 69 46 33.5 80 72 18.3 
56 136 5.8  31 127 98 35 150 80 53 
57 134 4.4  124 122 174  141 277 65 
58 134 3.8 34 129 256 53 32 107 75 32 
59 128 4.9 19 55 326   129 107 63 
60 132 3.2 23 35 179 79 35 92 54 16 
61 141 4.4 13    56.7 130 115 19 
62 138 4.2 23    33.2 90 80 21 
63 139 3.4 16 33 80 215 38 70 250 43 
64 144 4.3 6.9 85 156  67 126 112 21.5 
65 138 3.7 20 101 126 14 46.6 111 75 22 
66 140 4.3  60 193 38  93 184 63 
67 142 3.3 26 29 96  36 94 134  
68           
69 134 4.2 26 83 129 102  95 137 42 
70 138 3.6 28 96 74 167 39  74 14 
71 134 3.5 18 23 251 120 42 99 70 18.1 
72 141 3.3 13.4    63.8 98 56 27.8 
73 130 3.4  145 353 276  195 305 76.6 
74 137 4 22 42 286 20 24.9 79 65 29.5 
75 137 4.4 17 81 149 31 35.2 59 38 14 
76         208 18 
77 142 2.9 17 44 212 43  84 65 18 
78 133 7.2 26 176 269 421  122 219 28 
79 134 3.9 29 130 271  44.1 80 99 30 
80 139 5 17 82 260 55 46 108 118 39 
81 142 3.7 9  117  60 133 132 67 
82    119 146  31 96 95 30 
83 141 4 25 66 624 36  90 97 40 
84 138 4.2  54 193 19  80 83 32 
85 145 3.8 13.8     70 45 25 
86 137 5.3 9 100 428 317 42 104 78 85 
87 144 4.5  69 129 267 33 119 124 23.8 
88 136 3.5 30 48 140 23 34 67 64 39 
89 138 3.1 22.7 15 126 12 32 73 145 21 
90 135 3.6  166 293 347  79 224 51 
91 141 4 20.5 45 182 69  96 119 23 
92 132 4.4  132 293 260 36.1 75 75 69 
93 129 5.6  63 532 376 87.2  301 180 
94 140 3.6  57 113 53  83 85 19.3 
95 142   47 109 103  99 140 14.8 
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96  137 4.3 15 39  531 64.2 170 136 18 
97 136 3.7 19 118 372 424 44 95 354 22 
98 140  26 109 104   87 147 13 
99 131 6.7 21.4  161  35 167 158 63 
100 138 3 19.1 109 112 170 48.6 97 85 42.9 
101 143 5  65 139 85 94.4 260 340 54.9 
102 140 4.3 22 139 63 52 35.2 122 121 13 
103 138 3.2  4 80 24 47.9 101 123 10 
104 136 4.8 8 65 103 28 60 200 281 120 
105 140 2.8 22 36 53   93 67  
106 134 5.1  139 631 315 58 573 507 50 
107         298  
108         81  
109 141 3.8 20 47 80 61 50 99 71 27.8 
110 129 6 18 154 354 192 37.9  547  
97 136 3.7 19 118 372 424 44 95 354 22 
98 140  26 109 104   87 147 13 
99 131 6.7 21.4  161  35 167 158 63 
100 138 3 19.1 109 112 170 48.6 97 85 42.9 
101 143 5  65 139 85 94.4 260 340 54.9 
102 140 4.3 22 139 63 52 35.2 122 121 13 
103 138 3.2  4 80 24 47.9 101 123 10 
104 136 4.8 8 65 103 28 60 200 281 120 
105 140 2.8 22 36 53   93 67  
106 134 5.1  139 631 315 58 573 507 50 
107         298  
108         81  
109 141 3.8 20 47 80 61 50 99 71 27.8 
110 129 6 18 154 354 192 37.9  547  
111 136 4.3 5 12 59  124  90 23 
112 120 3.4 17 79 199   246 239 66 
113 135 4.8  118 89 117  113 114 26 
114 133 4.1 24 82 199 151 58 317  59.3 
115 141 4.8  150 313 140 69.6  256 25 
116 136 3.1  124 170  35.4 102 70 22 
117 137 3.5 21 72 91 44 44 74 97 16.5 
118 134 4.8 18 112 236  46 205 255 86.4 
119 136 3.7 15    41.3 132 132 21 
120 142 4.6 15 13 217  35.7 111 102 20 
121 130 4.1 27 57 79 40  76 148 34 
122 127 4.9  137 736 393  423 398 67 
123 136 4.5 9 77   40 102 67 41 
124 125 4.2 8 109 387 345 125 490 598 180 
125 129 6.8 16 106 331   389 415 53 
126 135 3.3  41 205 26  76 74 25.2 
127 146  4 46 302 31 91 210 172 39 
128 132 4.7  152 201 442  123 123 33 
129 138 4.5 6 50 119 103 104 130 126 50 
130 139 3.2  38 317 45  94 114 17 
131 134 5 19 123  137  156 296  
132 133 2.8 25 17 334 113 38 80 148 30 
133 145 3 18 91 49 79  68 103 30 
134 144 3.8 25 70 94 180 36 120 274 30 
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135 146 5.5 3    134  416 103 
136 134 3 16 61 21 220 42 55 159 25 
137 140 2.9 14 80 134 235 40.6 116 112 28 
138 135 3.4 21 14 158 21  95 22 14.8 
139 136 3.9  189 172 139 41 207 125  
140 148 2.9 13 101 352  38.5 114 84 51 
141  6.6 12.9    52.1 238 250 69 
142 138 3 20 33 35 7 32 46 61 21 
143 139 4.8 15.9 73 160 182 45 246 481 54 
144 142 3.4 12.3 43 543  63 74 41 19 
145 140 3.7  59 65  34 97 62 20 
146 135  7 63 278 211 106.2 204 260 79.6 
147 133 5.4 16 74 682 397 38 189 419 79 
148 136  20 52 348  34 65 81 35 
149 134 4.3 18 123 154 153  137 162 86.8 
150 140 4.4 20  357  40.4 89 108 44 
151 140 5  72 140  40 128 183 62 
152 141 3.3 17  174 59 36 79 95 30 
153 140 3.4  79 80   83 96 12.2 
154 133 3.7  106 220 554 49.9 93 147 48 
155 147 3.2 7     130 147 106 
15 131 5.6  106 459  36.2 485 453 58 
157 130 3.1  6 182 36  85  10 
158 136 3.9 21  63 114 35 78 82 18.3 
159 140 4.5 14 80 101 51 47 85 52 39 
160 140 3.4 21 68 119 20 33.8 75 336 44 
161 141 5.1 16 73  94 36 94 292 28 
162 134 3.3       56 33.6 
163 136 3.9 24    39.7 83 108  
164 130 4.6 23 130  264 47.2 459 381 56.8 
165 131 4.5  116 145  43 130 107 39 
166 135 3.4 24.9 26 136 113 35.8 282  43.9 
167 141 4.7 28 96 309 115 35 105 106  
168         156 72 
169 145 3.5 17 87 196 34 41 116 68 155 
170 132 5.6  96 76 161 32 273 291 99 
171 140 3.6 19    38.9 109 97 23 
172 144 3.8     48  102 39 
173 137 3.2  47 100 28  84 88 15 
174 139 3.1 27 19 225 107 30 80 140 67 
175 142 3.2 17 19 80   103 341 33.6 
176 136 4.9 3.7 35 127 66 73.3 217 139 22 
177 135 3.7  73 88 36  64 56 38 
178 141 3.9  86 313  41 97 88 24.4 
179 140 3.5  62 210 30  93 125 32 
180 140 4.6  44 89 26  68 70 14 
181 138 4.5 12  340  54 185 263 84 
182 137 5.2 19 68 399 148 43.1 316 417 37.9 
183 133 3.6 26 71 112 50 40.5 63 47 37 
184 134 5.1  84 264 43 75.4 204 237 60 
185 143 4.8 18 130 211 188 40.3 341 341 64.7 
186 138      35.8 179 134 51 
187 141 2.8 14 75 227  40.2 65 250 20 
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188 141 3.6 9 137 828 530  134 147 79 
189 132 3.6     40 75 57 60 
190 142 5 32 63 104  37 77 73 25 
191 140 4.3 30 41 170  34.4 189 263 71 
192 125 5.4  64 716   380 346 46.5 
193 145 4.1 13 26 270   90 119 30 
194 138  6 42 159   101 203 84 
195 142 4.6 8 35 124  41 131 109 18 
196 139 4 28 76 160 26  111  15 
197 143 2.4  25 42 96 47 53 46 18.6 
198 133 4.2  42 338   79 47 36 
199 144 4.6 9 78 85 124 114 98 234 54.9 
200 146 4.6 6    89 95 421 21 
201 140 4.2  163 460 707 62.3 218 216  
202 141 3.4 18 61 233 69  80 17 30 
203 140 3.9 19 86    75 285 63 
204 135 4.7 18 58 107 290 63 359 367 41.7 
205         117  
206 141 3.9 24 67 85 45 36 92 76 52 
207 137 5.5 20 110 174  39 267 255 50 
208 144 2.3 11 38 79 25 35 100 54 19.6 
209 139 3.3 5.7 135 153 192 7.07 116 208 38.3 
210 136 3.7 18.2 33 202  41.8 75 291 17 
211 135 3.9 20  63 23 35 76 81 23.5 
212 143 4.1  43 278   85 212 19 
213 139 3.7 23 8 236 25  75 171 15 
214 141 3.9  46 82 45 38 155 141 15 
215 142 4     40 143 186 44 
216 132 3.7 26 140 250   85 164 60 
217 140 3.4  30 163  39.8 94 285 19 
218 145 5.4 7  378 19 115 175 136 58 
219 132 3.7  46 72 33 33.1 82 82 29 
220 136 5.2 11 65 144 30 58.3 151 166 55 
221    2086 137 137 44 169 95 90 
222 137 5.4 8    159 181 216 50 
223 144 4.6  53 146 45 43.9 124 208 48.4 
224 134 4.5  180 136 180  105   
225 139 3.9 14    53 157 211 123 
226 130 8.5 6     254 212 120 
227 134 3.2 26 12 233  36.4 100 92 12.8 
228 146 4.6 5.2 85 298  90 140 177 66 
229 147 4.4 23 42 127 20 120 47 106 14 
230 136 4.2 9 93 166   315 323 67 
231 138 5.4     86  376 100 
232    109   40 32 327 50.5 
233 136 4.4 13 187 173   125 99 88 
234 139 4.3 23 870 57 38 38 120 95 18 
235 144 4 14 162 120   133 140 40 
236 143 4.8 25 43 110 52  96 84 54 
237 138 4.5  197 149   107 136  
238 134 5.2   333 420  142 271 25 
239 137 3.9 18  262 97 36.2 102 73 24.9 
240 136 3.3 14.7  241 284 50.9 504 1359 32.9 
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241 141 4.5  112 112 148 49 176 173 37 
242         119  
243    48   40 360 340 64 
244 138 4 28 112 1011 142  100 82 83.3 
245 143 3.1 25  95   105 89 14 
246 132 3.4  111 88   96 110 28 
247 149 5.3 9    70.4 290 243 127 
248 135 6.8  29 154 69 46 137 313 50 
249 137 5.2  80 269 108 45 108 133  
250 141 5.1 14 119 70 24 75 189 250 87 
251 141 3.4 21 58 2877 64  92 66 30.9 
252 142 4.5 11 97 236 48 51 125 106 40.9 
253 140 5.1  102 119 304 77.6 249 249 42 
254 134 4.3 19 31 162 60  92 122 16.8 
255 139 5.5 4 61 320 237 112 159 188 50 
256 143 3.4  23 57 24  92 169 20 
257 140 3.8 26.5 50 92   98 341 28.3 
258 140 3.5 6  159  52 312 346 10 
259 142 4.1 14 26 60 20  73 126 20.5 
260 139 3.9 28 64 76 26  65 67 53.7 
261 132 3.2 21 49 56 89 37 67 227 18.8 
262 131 4.2 19    35 115 91 111 
263 136 3.8 29 32 107  31 193 226 18 
264         82 35 
265 138 4.8 17 87 133 41 36 124 141 31.9 
266 132 3.2  86 94 233 33.7 71 95 24.8 
267 132 6.6 4.1 80 0 102  156 253  
268 139 3.8 18.7 127 115 314 41.7 209 281 70.3 
269 137 4.9  120 438 70  71 76 136 
270 137 3.3 21.4 48 119 26  84 66 165 
271 132 4.2  104 152 0 40 293 347 63 
272 123 4.4  170 210 202 38  361 45 
273 137 5.5 14.8 60 267 29 44 85 90 44 
274 126 3.7 29 89 180 303 31 571 548 73 
275         78 26 
276 136 4.7 8.1     292 214  
277 140 4.1 24 57 281  43 99 298 22.8 
278 135  6 48   90 195 331 138 
279 138 2.3 11 120 147  51  66  
280 139 4.7  96 273   225 329 79 
281 144 4.1  30 460 47  77 41 21 
282 140 4.3 18.4 100 93 56 39.92 10 67 35 
283 137 4.1 30.9 210   29.2 730 644 77 
284 137 3.5  108 124  36 87 86 26 
285 144 4.1 8    95 220 245 120 
286 142 4 28 29 116  44 95 105 21 
287 130 4.6  173 130 307  238 229 112 
288 137 2.2 28 155 196   107 109 20 
289 132 5.1   157 35 42 104 73 85 
290 138 4.7 26 115  110 40 76 90 56 
291 136 3.1 21 19 75 118 37 108 95  
292 140 3.2  27 156  40 89 180 17 
293 139 3.3 23  285 85 44 475 355 42 
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294 134 3.9 17 72 284 273 67 121 259 71 
295 142 4.2 13 54  56 65 102 174 70 
296 144 6.1  16 43  58 155 366 14 
297 131 5.2 21 116 117 308 38 183 216 74.1 
298 146 4.7  74 125 46 69 177 166 84 
299 133 5 27    39 87 73 60 
300 138 3.1 14 19 84 21 49 89 118 16.8 
301 140 4.3  18    78 65 200 
302 137 3.7 17  312 38 37 95 44 42 
303 137 4.6 17.2 30 263 59 44.9 136 241 23.5 
304 136 4.2 25 108 383 186  149 155 66 
305 145 3.4 19     71  16.1 
306 132 4.5 25 75 320 115  178 191  
307 133 4.5 19.4 23 86 15 45 79 75 42 
308 136 6  129 141 89  99 96 71 
309 139 3.8  90 91   84 194 16.1 
310 133 4.2 34 69 122 168 34.6 160 128 22 
311 140 3.7 22 58 97 50  62 69 32 
312 138 3.6 24 60 56 52 38  172 25 
313 141 4.1     39.6 70 57 31 
314  2.7 23     80 50 23 
315 137 3.8     36  86 60 
316 136 5.1  81 117  47 177 232 64.4 
317 135 4.6 12    80.8 113 128 16 
318 140 3.4  57 182 13  74 48 21.9 
319 134 5.6 18 111   42 95 123 100 
320 139 4.4 29  210 396  558 594 40.8 
321 139 4.4      179 231 65 
322 126 4.6  62 1080 491 38 446 498 42.9 
323 136 3.7 21 250 204   100 78 30 
324 142 3.6  67   34.4 127 201  
325 134 5 19 127 158 45 36 121 84 88 
326         136  
327           
328 137 4.7 11    59 121 92 108 
329         182  
330           
331 138 3.8 20 75 54 68 39 84 74 22.9 
332 135 3.9  44 193 61  78 90 17 
333 138 4.5 23 66 317 113 40.9 137 390 34 
334         56  
335 135 5.1 16 104 461 44 43 107 103 86.9 
336 137 3.9 18 6 192 12 44 71 71 15 
337        284 420 23 
338 135 2.8   185 32  82 89 42 
339 140 4.2  33 293 49  83 87 21.6 
340 134 4.6 14 61 178  69 160 173 35 
341 139 3.7 22 61 98  39 78 59 20 
342         96  
343 135 5.3  84 136   151 278 50.8 
344 128 3.8 21 98 690 153 45.9 75 73 78.8 
345 139 3.9 17 54 334 76 66 99 109  
346 147 3.6 16 70 260 201 69 129 223 28.2 
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347 142 3.6 17 98 93 42 35 68 113 20.7 
348 137 4.6 20 24000   58 203 281 79.2 
349 145 3.6  76 136 56 120 207 246 36 
350 128 6.6  129 406 424 38 448 359 60.7 
351 140 3.8     39.3 97 236 61.6 
352 142 3.7 17    45 43 70 20 
353 132 5.4  103 119 137 34.7 111 86 30 
354 142 4.2 13 46 207 455  138  28 
355 137 4.5 19 89 275 341 49 154 176 36 
356 141 3.2 16 97 351  42.7 75 91 20 
357 132 6.2  93 102 245  192 215 37.3 
358 140 4.1 18.6 239 239 210  110 137  
359 135 3.5 18.5 94 151 56 50 80 98 46.8 
360 133 3.3  75 76 22 36.5 70 104 20.3 
361         106  
362 139 4.6 19 78 178 71 36 108 74 77 
363 137 6.7 20  425 182 34 401 439 34.3 
364 141 3.8 13 31 255 9  37 36 20 
365 137 4.6  192 135   494 535 104 
366 136 6.9  120 482  36 249 248 34 
367 135 4.1  53 76   63 81 18 
368 127 6.1  65 259 146 70 138 138 112 
369 137 5.5 12 127 311 632 45 258 315 34 
370 133 3.7 17 26 545  59 140 165 52 
371 129 6.3  41 605 171  477 419 52.2 
372 131 5.1 14 134 309 231 39 190 157 46 
373 133 4.3 31 79 128 175  118 555 19.8 
374    9    120 149 30 
375 139 4.4 28 21 92 12 29 66 92 13 
376 147 3.7  15   48  87 18 
377 138 4.4  92 278 155 43 403 454 38.4 
378 140 3.5 20    48 81 58 15 
379 141 3.4   171   82 207 17 
380 130 4.1  140 163 332 47.6 444 452 40 
381 140 3.4 25.5 47 52  35 77 65 21 
382 133 4.1  104 195 314  226 303 14.5 
383 141 4.4 21 129 192 290 41 104 197 35.5 
384 139 5.7 7 64 543 239 144 126 219 34.6 
385 140 4.6 12 23 314 26 43 129 284 21 
386 139 5.1 19 142 224  38 128 196 28 
387 138 3.1  93 283 51 41 47 79 35 
388 140 5.9 4  262 54 98.1 111 260 78 
389 143 4 21 54 240 67 35 83 129 28 
390 143 4.6  5 98 50 33 101 107 48.4 
391         394  
392 139 4.6 20 108 82 39 40 180 356 92.4 
393 140 2.9  30 94 128 39 85 60  
394 136 3.8 17 12 45   79 61 23 
395 141 3.8      75 186 86 
396 127 4.9 8 29 246 155 78 74 130 24.8 
397 144 5.3  82 118 82 100 255 270  
398         108 91.2 
399 139 3.3 13 31 124 24 49 88 59 36.9 
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400 144 4.1 18 36   37 62 43  
401 138 4 19.3  100  47 178 161 32 
402 138 4.3 22 105 125  38 105 70 56 
403 137 3.5  33 101 18  107 118 19 
404 138 3.6  133    250 203 36 
405 134 5.8  79 472 671 79 453 470 89 
406 138 4.4 19 19 3.5   100 421 51 
407 143 3.5       61 26 
408 145 4.8 12 40  26 37.6 100 105 32.6 
409 131 4.3 17 177 350   79 163 39 
410 137 3.5 24 97 423 206 37 63 56 19.8 
411         340  
412 139 4.7   424   92 73 56 
413 138 3.1 12 68    70 52 16.9 
414 141 6.2 20 206 260 131  379 496 49 
415         711  
416 133 3.3 19  248 24 52 77 76 24 
417 136 4.3 19 172 512 91 33 193 170 57.9 
418 134 3.5  69 84 163 37 91 461 45.2 
419 139 3.8  52 189 334  99 233 27.1 
420 143 4.4 13 122 428 198 69.2 124 118 29.4 
421 144 6.3 4 63 102 51 67 240 215 24.6 
422 134 4.3  30 174 232 38.1 254 318 23.5 
423 133 4.9 25 99 593 47 38.8 84 80 44.1 
424 133 3.6  44 181 292 46 90 83 12 
425   22.3 64  404 38 116 174 19.3 
526 132 4.5 23 104 139 98  86 95 44 
427 137 3.8 16 67 84  38 90 89 25 
428 136 4.8  125 162   85 71 56 
429 136 4.8 20.3 79 151 343 41.8 80 146 35.3 
430         234  
431 143 5.4  177 698 194 36 274 588 87 
432 131 4.8 19 21 180 15 37.3 60 100 108 
433 136 3.6 20.2 33 166 20 44 93 68 27.5 
434 136 4.2  165 548 166 36 137 132 55 
435 136 4.7 27 74 255 103  62 79 12 
436 133 4.8 23 83 192 67 34 102 82 46.8 
437 137 3.6 21 87 113 53 41 113 148 26 
438 143 4.9 6     250 196 39 
439 137 3.8 22 75  30   74 15.4 
440 139 4.7 18 49 170  45 90 130 33 
441   21 35 110  40  88 31 
442 135 3.8  175 166 137  88 319 62 
443 145 3.8 20 41 245 27 36 69 63 19 
444 137 3.4 24 24 288 36 39 81 60 15 
445 143 4.8       67 20 
446 134 6.2   501 116 95.8 160 155 85 
447 123 6 13    67 422 389 95 
448 142 3.7 8.1 33 304 29 81 132 222 15.6 
449 134 3.4 21.1  62 51 38.7 95 74 42 
450 135 3.1  19 116 199 31.6 80 111 11 
451 135 2.6 29 113 130 766  66 63 23 
452 136 3.7  120 270 392  290 327  
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453 139 2.9 19 15 96 17 33 99 87 24.8 
454 143 3.3 23 30 202   98 208  
455 134 4.3 17.3 42 190 20  189 251 27.9 
456 147  4    110 386 352 68 
457 139 4.8 25.6 73 496 79 36 113 116 68 
458 4   85 154 227  85 85 17 
459 141 3.7 19 31 250 47 34 119 69 25 
460 132 5.6  71 156 168  220 265  
461 140 3.7 20.4 86 90   91 85 25 
462 138 4.1 19 55 115  37 134 93 18 
463 134 3.6  11 276   95 100 100 
464 134 5.8 12 277 733 126 41 1196 1212 18 
465 136 4.8 22 59 326 22 35 111 116 40 
466 137 4.6 18 48 131  41 95 67 26.4 
467 136 5  182   70 130 163 45 
468 135 4.1 25.6 146 313 181 37 72 80 110 
469 145 2.3 14     122 74 21.7 
470 141 4.5 9 92 139 83 76 179 179 55.2 
471 139 6.9  104 121 226  109 164 21.9 
472 134 3.3 24 42 82 78 34 98 75 17.4 
473 145 4.3 10    76 122 109 25 
474 136 3.6 21 36 78 26 37 164 181 41 
475 128 4.2  125 501  54.6 118 78 58 
476 143 4.2 30 56 201 26 32 106 240 22.7 
477 129 3.6  125 174 124  416 432 49 
478 140 3.7     34 88 68 21.5 
479 133 3.3  111 120 139  75 82 16.2 
480 135 5.6     166  197 60 
481 139 3.3  102 106 327 37 149 31 38 
482 141 3.3 15  56 26  101 83 28.8 
483 142 4.8 14 29 60  76 223 256  
484 139 5.3  61 118   99 75 17 
485 146 4.2 16     166 489 50 
486 143 4.8 21 43 92  33 124 72 22 
487 135 3.2 17 47 76 66 32 100 98 15 
488 137 3.6 24 79 123  37 118 113 49 
489 144 4  130 191 156 37.7 95 85 18 
490 138 3.3  62 98 90  94 180 41 
491 139 3.7 25 53 260 62 34 72 155 16 
492 141 4 21 57 342 28  77 78 20 
493 135 5.3  113 187 109  72 73 59 
494 143 4.8 29 80 386  37 126 89 34 
495 138 4.2 10.1 72 125 110 62 122 243 50 
496 130 3.5 20 171 438 318 47.9 252 175 71 
497 138 5.8 12 208 273 179  294 295 41 
498 142 2.9 42 145 172   262 281 74 
499 138 5 20 98 236 40 40 100 77 88 
500 147 5.3 6 49 253 71 122 208 250 88 
501 140 4.2  82 350 30  143 175 58 
502 130 3.5 20  438 318 47.9 252 175 24 
503         463  
504 138 4.6 20 96 445 165 36.6 99 213 38.3 
505 140 3.8 25 95 126 337 33 118 98 28 
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506 140 3.3  92    84 218 23 
496 130 3.5 20 171 438 318 47.9 252 175 71 
497 138 5.8 12 208 273 179  294 295 41 
498 142 2.9 42 145 172   262 281 74 
499 138 5 20 98 236 40 40 100 77 88 
500 147 5.3 6 49 253 71 122 208 250 88 
501 140 4.2  82 350 30  143 175 58 
502 130 3.5 20  438 318 47.9 252 175 24 
503         463  
504 138 4.6 20 96 445 165 36.6 99 213 38.3 
505 140 3.8 25 95 126 337 33 118 98 28 
506 140 3.3  92    84 218 23 
507 134 3.9  129 208 487 34.7 339 164 45 
508 136 4.2  210 161 344  160 100 48.8 
509 133 4.1 26 69 269 214  214 269 38 
510 137 6.1  58   76.1 103 94 30.4 
511 142 4.5 26 92 233 51  95 92  
512   17.8 105 127 132 43 132 177 42.8 
513    165 135 391  55 52 60 
514 141 3.7 17 48 267 58  110 83 23 
515    173 99 46   83 33 
516 140 3.3 24 57 97 101 37 68 221 39.5 
517 142 2.2  28 177  66 123 84 18 
518 143   48   44 90 76 24 
519 139 2.9 17.7 32   46.7 84 145 77 
520 134 4  57 343 130  120 72 45 
521 142 2.9 19 42   60.8  113 22.2 




Number RIE APTT RIE Na RIE K RIE Bil RIE GGT RIE ALP RIE H+ RIE Bic RIE Cr 
1 46.9 137 2.6 134 76 188   50 
2  144 3.6 79 62 98 30.1 25.5 81 
3 68 149 2.9 78   38.5 23.8 90 
4 48 134 3.2 205 214 87 39.3 20 99 
5 85.5 133 5.8 107 42 46 57 13 167 
6 51 137 4.2 114 39 178   53 
7 63 127 3 62 100 62   124 
8 164 136 4.4 94 78 130 97 6.3 387 
9 48.6 129 3.6 97 56 83   62 
10 57 126 4 101 59 192   264 
11  127 4 112 156 115 30.3 25.8 186 
12 70.9 133 4.2 146 139 185 41 22 266 
13 50.7 126 6.9 64 107 50 7.07 5 70 
14 47 134 3.9 50 148 111   336 
15  143 5.2 46 17 57 39.6 26.7 93 
16 34.3 130 3 78 336 182   175 
17 80 134 5.2 79 45 94 49 15 369 
18 54.1 128 3.6 69 101 82   182 
19 77 138 3.9 64 50 69 37 16 216 
20          
21 73 136 3.5 49 152 75   193 
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22 84.3 140 4.1 39 44 72 41.3 19 216 
23 78.4 138 2.9 68 90 188 40.2  348 
24 93 135 3.6 212 208 156 31.7 27.5 62 
25 50.7 131 4.7 111 92 134 38.7 21.6 660 
26 76.8 133 3.9 100 261 157 37.4 27.8 259 
27 33.8 133 3.3 83 131 104   83 
28 35 138 3 29 11 79   91 
29 53 136 4.4 181 565 137 36.5 20.2 286 
30 36.3 136 4 82 24 90 27.1 27.6 304 
31 47.5 138 4.3 122 172 81 38 19 120 
32 41 136 3 39 35 89 33 24 52 
33 59.8 138 3.8 143 143 126 31 25.5 56 
34 56.7 127 3.5 216 288 155 40.9 23.2 544 
35 75 113 4.2 202 76 91 30.8 24 270 
36  139 3.8 19 22 97   81 
37 50 137 5.6 197 97 222   225 
38 45 135 3.5 75 46 84 36 26 68 
39 62 134 4.5 133 109 87   460 
40 1 132 4.2 135 149 142 52.9 17.9 419 
41 93 127 3.7 112 124 143 36.4 28.3 253 
42 70.3 124 6.8 268 152 1018 103 9 362 
43 46.3 133 3.9 74 493 158   400 
44 60.3 140 3.9 106 68 119   116 
45 4404 140 3.4 22 56 124 36 23 93 
46 46 139 3.6 55 60 183   73 
47 41 138 3.9 207 67 89 37 19 61 
48 120 125 5.4 182 52 106 7.42 20 529 
49 60 138 3.5 82 38 123 36.8 19 108 
50 48 131 3.9 125 149 192 24.6 38.5 488 
51 96.9 146 3.7 71 26 106 76 10.5 176 
52 100 132 4.9 43 80 39 79.5 12.2 317 
53 59.7 136 3.1 78 73 148   42 
54 73 132 3.7 104 77 103 37.9 20.4 85 
55 43.1 139 3.4 68 26 70   72 
56 58 135 4.2 36 93 103 32 25.2 80 
57  125 3.3 127 187 110   277 
58 38 137 3.4 81 78 83   75 
59 49 134 4.2 86 28 144 35.4 22.3 107 
60 56.3 140 3.5 63 106 99 33 25 54 
61  138 2.9 92 79 140 29 25 115 
62 443 140 3.8 96 39 110 32 22 80 
63 34.3 138 3 68 230 119 37 19.5 250 
64  130 3.2 192 84 157 36 19 112 
65 34.9 140 3.3 101 25 61 38 21 75 
66 66 127 3.8 57 28 63 41 16 184 
67 48 133 4 37 28 118 7.47 27 134 
68          
69 56.2 137 3.2 112 106 189   137 
70 42.4 134 4.1 58 145 94   74 
71  136 4 141 98 188 36 23 70 
72  134 4.2 57 27 91   56 
73 59 129 3.7 136 104 78 32 27.5 305 
74  137 3 39 25 108 33.3 26.3 65 
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Number RIE APTT RIE Na RIE K RIE Bil RIE GGT RIE ALP RIE H+ RIE Bic RIE Cr 
75 74.5 139 3.2 90 50 94   38 
76 47 130 3.8 108 39 144  21 208 
77 60 132 3.9 103  141   65 
78 50 131 4.1 94 174 47 36 24 219 
79 46 131 3.2 149 79 146 35 27 99 
80 41 137 3.7 56 54 103   118 
81 43.5 141 3.8 117 24 26 41 . 132 
82 57 137 3.1 129 224 195 32.3 24.7 95 
83 37 134 3.4 58 35 240   97 
84 42 141 3.4 39 32 92   83 
85 46 135 3.9 76 47 67   45 
86 44 133 3.5 99 290 132   78 
87 72 128 3 90 296 132 30 27.8 124 
88 45.3 143 4.1 83 38 145 31.2  64 
89  140 2.9 67 27 81 32  145 
90 60 138 3.3 145 190 77 41.2 23.7 224 
91 72.4 137 3.8 58 104 99 39.2 17.9 119 
92 53 127 4.2 107 222 101   75 
93 170 125 5.4 79 169 87 51 13 301 
94 41.5 136 3.5 68 59 146 34 29 85 
95 43.1 132 3.1 117 199 124   140 
96 120 132 3 31 47 92 57.1  136 
97 79 124 2.9 137 400 139 43  354 
98 60 146 3.5 93 93 65 27.5 30.3 147 
99 46 129 5.9 87 90 120   158 
100 57.6 131 4 118 110 100 34.3 22.4 85 
101 114 134 4.4 42 56 107 49.2 15.7 340 
102 55.1 136 3.7 182 58 90   121 
103  132 4.7 144 85 137 33.4 23.8 123 
104  129 5.3 66 14 79 53 15.8 281 
105 43 138 4 94 20 96   67 
106 76 139 4.9 85 159 129 135.1 5.8 507 
107  135 4.8 94 293 150 141.7 6.9 298 
108 55 135 3.5 7 297 190   81 
109  139 3.8 114 59 130   71 
110 62 130 4.1 134 123 88 51  547 
111 63 145 3.7 19 25 34 38.6 18.1 90 
112 70 124 4.1 49 308 162 70.3  239 
113 64 135 5.2 147 168 103 41.3 7.97 114 
114          
115 41 133 4.2 176 119 94 38.9 18.9 256 
116 50 138 4 177 237 107 37 23 70 
117 48 138 4.1 98 39 127   97 
118 58 127 3.2 109 165 194 38.3 23 255 
119 34 139 3.7 88 63 128 38.1 20 132 
120 45.1 137 3.2 32 39 137 38 24.5 102 
121  125 2.8 30 38 71 37 23 148 
122 59 132 4.8 168 391 302   398 
123 622 131 3.9 77 48 52  20 67 
124 84 130 5.1 94 115 162 129.7 6.9 598 
125 58 132 5.5 106 72 107  19.8 415 
126  142 3.9 28 33 137 36 26.7 74 
127 62 139 5.2 88 19  48.3 16.3 172 
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Number RIE APTT RIE Na RIE K RIE Bil RIE GGT RIE ALP RIE H+ RIE Bic RIE Cr 
128 43 132 4.7 152 443 201 38.9 22.4 123 
129 54 132 5.4 83 98 140 37.9 21.3 126 
130 48 134 4.9 80 73 314 36 20 114 
131 66 139 5.9 76 58 49 95 8 296 
132  136 4.2 94 228 167   148 
133 31.3 134 3.6 91 96 70   103 
134 56 137 2.7 84 166 121 36.9 25.2 274 
135 74 138 5.7 81 232 229 85.6  416 
136 40.3 134 4.8 81 213 110 41 17 159 
137 46.8 135 3.3 122 186 112 39 11 112 
138 59   12126 86 37   22 
139 51 134 4 170 114 121 38.5 21.7 125 
140 2.5 135 4.2 113 107 172 36.7 23.5 84 
141 46.7 134 6.4 78 54 109   250 
142 54 134 3.1 68 14 74   61 
143 105 135 4.2 122 64 76   481 
144 28.6 134 3.9 36 48 55 48 19.5 41 
145 38.9 140 3.3 47 49 128 37 21 62 
146 51 135 4.7 58 119 152 56.1 15.8 260 
147 102 140 4.2 104 229 147 45.3 19.5 419 
148 46 137 3 38 32 129   81 
149 66.4 129 2.5 124 172 141 31 32 162 
150 63.8 135 4.1 124 55 135 37.7 19.2 108 
151 57.1 136 4.9 63 43 141 40 23.5 183 
152  134 3.7 79 61 74 33 20 95 
153 55 134 3.3 90 96 80 28.1 24.4 96 
154 58 131 4 69 390 92 85.9 10.7 147 
155 43 134 3.2 18 41 56 7.27 5 147 
15 55 133 4.4 76 342 109 60.3 14.4 453 
157          
158 38.5 133 3 92 212 82 33 23 82 
159 54.8 138 3.5 100 26 96 37 26 52 
160 46 139 4.2 78 37 74 36 23.8 336 
161 57.3 134 3.4 116 101 170 32 31.4 292 
162 49 132 3.1 46 383 124   56 
163 69 139 3.9 42 67 74 34.5 26.1 108 
164 54 124 3.5 111 240 132 35.8 24.3 381 
165 51 133 3.5 93 39 112 29 21 107 
166 45.6 132 3.1 65 96 112    
167 43 141 4.3 105 111 107   106 
168 4.8 139 4.5 79 56 113 41.6 17.1 156 
169 43.7 142 3.6 105 39 125 32 25.5 68 
170 89 129 4.7 105 72 162 44 17 291 
171 42 142 3.6 55 47 74 34.7 26.5 97 
172 47 138 3.3 99 75 93 34 28.6 102 
173 210 141 3 200 62 143 35 27.1 88 
174 40 142 3.7 98 202 106 32 29 140 
175 108 137 3.9 55 28 86 62 18 341 
176 63 134 4.1 92 81 131 35.7 20.1 139 
177  131 3.7 47 86 140 32 18 56 
178 50 139 3.9 132 196 110   88 
179 55.6 141 3.4 117 38 134 37 20.5 125 
180  140 4.1 92 54 126   70 
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Number RIE APTT RIE Na RIE K RIE Bil RIE GGT RIE ALP RIE H+ RIE Bic RIE Cr 
181 65.2 138 4.5 60 35 127 87.3 16.5 263 
182 43 137 5.1 55 159 169   417 
183  140 3.7 100 36 108   47 
184 90 133 5 62 32 107 77.1 13.3 237 
185 50 140 4.1 87 97 128 33.7 30.3 341 
186 63 141 3 82 35 109 25 21 134 
187 210 138 3.3 98 51 69 52.4 17.9 250 
188 59 138 3.5 145 252 138  . 147 
189 47.8 137 3.3 84 79 145   57 
190 41 135 3.5 51 270 110   73 
191 51.8 139 3.9 44 11 41 32.1 32.1 263 
192 74 119 4.8 73 493 234 69.8 12.3 346 
193 63 138 6.2 61 27 138 41  119 
194 200 128 5.1 69 210 159 58.8 16 203 
195 50.7 136 4 55 104 120 45 22 109 
196  130 3.6 104 87 204    
197  141 3.8 61 42 96 31 13 46 
198 49 132 4.4 53 60 149   47 
199 145 136 3.2    37 15.8 234 
200 154 142 6.1 99 182 60 54.7 10 421 
201 112 130 4 60 239 195 139.3 4.5 216 
202 38 136 4.1 77 79 89   17 
203 86.8 128 4 75 48 184 38.5 25 285 
204 52.8 131 4.5 83 325 125 45 19 367 
205 56 129 4.1 103 499 237   117 
206 45.5 142 3.9 48 40 73  34 76 
207 41.3 134 5.5 85 103 153 36 27 255 
208 58 140 4.4 71 37 211 31.4 18.4 54 
209 68 138 4.9 96 82 66 26.1  208 
210 240 129 3.7 73 31 114 49.3 21.3 291 
211 47.4 139 3.7 84 30 104   81 
212 34 139 4.7 140 169 210 35.6 24.1 212 
213 39 135 3.6 25 77 125 34 23 171 
214 60 137 5.2 35 36 48 38 22.7 141 
215 66.4 134 3 96 35 89 38  186 
216  130 4 162 39 118   164 
217 57 134 3.3 63 194 117   285 
218 55.6 137 4.8 39 13 83 54.5 15.9 136 
219 41 133 3.7 41 35 61 33.1 21.6 82 
220 73 134 5.1 44 17 92 66.1 12.9 166 
221  135 2.9 107 119 94 30 30.5 95 
222 138.3 137 5.1 101 35 33 7.37 16.1 216 
223 50 136 3.4 59 95 161 33 3.2 208 
224  133 4.5 183 195 119    
225 98 129 4.4 84 128 171 32.8 23.2 211 
226 200 135 7.3 79 46 79 106 4.7 212 
227 41.5 127 3.2 119 21 118   92 
228 74 134 5.9 85 20 194 67.4 10 177 
229 43 141 4.3 105 111 107   106 
230 78 137 3.9 45 85 32   323 
231 47 138 5.4 79 53 178 40.8 12.7 376 
232 47 129 2.8 117 348 126   327 
233 62 136 5.5 166 27 48 33.2 12.7 99 
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RIE APTT RIE Na RIE K RIE Bil RIE GGT RIE ALP RIE H+ RIE Bic RIE Cr  
234 50.6 138 3.5 190 50 143 35  95 
235 47 135 4.1 198  172 4.1 20 140 
236       27.7 19 84 
237 66 129 4.6 161 49 126 63.2 11.3 136 
238 53 134 4.5 149 216 129 34 26 271 
239 40.3 141 3.3 22 97 112   73 
240 37.3 126 3.8 371 378 336 47 18 1359 
241 61 136 4.1 110 139 98 42.8 16.1 173 
242 41 137 4.2 115 102 146 47.4 15.2 119 
243 92.6 128 3.3 42 42 77 40 21 340 
244 70.3 138 4 106 107 271 33 28 82 
245 56 136 3.7 160 74 94 36 25 89 
246 69 129 4 129 231 112 42.8  110 
247 72.8 146 3.8 36 8 63 66 12.3 243 
248 71 133 5.2 36 76 165   313 
249 60 136 4 75 74 81 36.8 21.7 133 
250 74 133 4.3 106 27 94 44.6 16.4 250 
251 40.9 138 3 35 73 159   66 
252 51.7 141 4.2 69 45 65 44 15 106 
253 49 140 5.1 102 304 119   249 
254 45 133 3.9 121 135 98 35 25 122 
255 63 125 5.8 63 194 115 94  188 
256 42 136 3.8 47 83 123 34 20 169 
257 44.8 129 3.8 84 108 165   341 
258 81 131 3.2 81 69 96 38 20 346 
259 63.8 132 3.7 26 24 65 38 17 126 
260 36 137 4.5 121 57 103 24 26.3 67 
261  132 3.8 66 109 98   227 
262 59.8 136 3.8 87 29 127 32 27 91 
263  132 3 44 143 122 33 27 226 
264 81 132 4.2 68 32 113   82 
265 53.1 139 3.3 118 33 187 26.2 30.8 141 
266 66 135 3.6 136 183 91 30.7 28.4 95 
267 109 123 6.2 77 37 80 7.38 16 253 
268 67 135 3.4 85 96 54 . . 281 
269  132 3.7 104 47 14   76 
270 44.2 140 3.2 24 69 61 35 24.5 66 
271 75.1 132 4.2 198 104 62 33.4 14.4 347 
272 90 132 3.6 151 149 172 35.3  361 
273 40 134 4.3 61 28 91 39.8 19.6 90 
274 52.7 120 3    53 18.5 548 
275 56.3 139 3.3 82 149 296 32.9 22.6 78 
276 240 131 4.1 34 61 60 96.2 12.6 214 
277 81.2 140 5.1 119 46 113   298 
278 74 137 4.4 47 68 106 . . 331 
279 50.6 138 3.3 171 84 167   66 
280 110 136 4.9 53 33 68 43.7 19.5 329 
281 46 136 4.1 32 38 364   41 
282 33.3 137 3.7 60 29 91   67 
283 200 134 3.1 139 107 96 24 34 644 
284 49.8 132 3 61 27 69   86 
285 55.4 134 4.1 52 247 75 81 11 245 
286 200 138 3.8 89 92 106 34.4 15.4 105 
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Number RIE APTT RIE Na RIE K RIE Bil RIE GGT RIE ALP RIE H+ RIE Bic RIE Cr 
287 69 128 4.1 169 300 118 35 19.7 229 
288 56 136 3.2 229 723 79   109 
289 86.8 137 3.7 78 35 121 45.3 14.2 73 
290 54 137 4.4 116 132 118 35.5 24.3 90 
291 31 136 3.4 116 192 90   95 
292 75 137 3.5 139 109 99 40 15 180 
293 46.1 140 3 58 57 93 36  355 
294 94 138 4.6 38 140 85 119 7.5 259 
295 50.7 130 6.3 57 84 50 44.1 20.1 174 
296 73 143 5.3 13 33 55 50.4 17.9 366 
297 75.1 126 3.9 94 232 11   216 
298 83.9 138 4.1 51 46 21   166 
299 55.6 134 3.9 121 48 202 35 28 73 
300 41.8 134 3 19 36 114   118 
301 30 137 4 16 20 56 . . 65 
302 44 134 3.5 31 31 30 35 22.5 44 
303 37 137 3.4 43 59 148 37 24 241 
304 56 135 4.1 113 205 163   155 
305          
306  132 3.6 70 83 114 34.9 23.3 191 
307 62 137 3.7 37 47 101   75 
308  137 5.3 116 51 131   96 
309 55 137 3.8 81 100 111   194 
310 50 134 3.4 64 140 90 30.3 34.4 128 
311 60 137 3.9 42 65 99 36 21 69 
312  136 2.7 76 167 73   172 
313 44.5 139 4 34 19 74 7.54 22 57 
314 36 134 2.2 43 65 130   50 
315 39 137 2.5 80 49 113 33 18.5 86 
316 62 130 4.8 100 150 147 35 25 232 
317 42 135 4.3 157 109 202   128 
318 47 139 3.6 56 28 108   48 
319 62 126 6.3 86 33 84 42 17 123 
320 40.5 157 4.5 161 262 142 32 28 594 
321 45 141 5.1 57 67 199 65.7 18 231 
322 60.8 121 4.5 69 308 132 57 20 498 
323 44 135 2.7 341 544 87   78 
324 54 137 3.6 128 322 132   201 
325 70.5 135 3.7 117 38 149 34 24 84 
326  127 3 161 228 174  36 136 
327          
328 42.1 137 3.7 106 65 97 34 21 92 
329 54 125  170 209 188 34 22 182 
330          
331 44.8 137 3.2 100 109 107   74 
332 57.2 137 4.2 113 191 122   90 
333 68 138 4.2 74 145 124 40.4 21.2 390 
334 48.8 135 3.9 86 34 554 39 22.5 56 
335 9 127 4.1 72 31 134 32 26.9 103 
336  136 3.9 24 40 90   71 
337 50 132 3.9 118 138 95 35 26 420 
338  135 3.1 72 23 89 37 23 89 
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Number RIE APTT RIE Na RIE K RIE Bil RIE GGT RIE ALP RIE H+ RIE Bic RIE Cr 
339 38 141 3.8 29 52 140   87 
340 67 139 4.2 96 79 124 62.4 14.2 173 
341 44.3 138 3.4 61 31 140   59 
342 56 142 4.1 98 73 206   96 
343 53 134 3.4 79 200 114   278 
344 85 129 4 132 166 235 42.2 19.5 73 
345 74 138 4 58 69 149 56 3.6 109 
346 67 137 4.7 108 218 115 51.6 9.8 223 
347 63 132 3 135 30 155 35 25 113 
348 62.6 126 5.9 79 73 94 29.6 25 281 
349  162 4.1 46 30 73 151 4.2 246 
350 48 127 4.4 118 259 120 48 23.5 359 
351 2.2 4  11746 171 43   236 
352 63.8 141 3.3 65 46 93 38 18 70 
353 57 86 3.1 101 130 97 34.3 27 86 
354 92 138 4.4    120 6.4  
355 44.8 129 3.5 95 265 96 38 21 176 
356 49 133 4.1 179 89 159   91 
357 61 126 4.3 100 207 82   215 
358 49 144 3 392 104 162   137 
359 72 139 4.1 92 47 181 31.6 19.5 98 
360 45 135 3 70 26 81   104 
361 57 139 3.8 86 99 99   106 
362 47 136 3.3 56 65 110 36 19 74 
363 120 138 4 167 96 97   439 
364 40 130 3.1 53 26 114   36 
365 91 124 4.7 208 232 73 58.2 5.8 535 
366 43.2 133 4.5 100 317 131   248 
367  133 3.4 69 87 114   81 
368 155 127 6.1 65 146 259 70 8.4 138 
369 39 137 4.8 131 501 125 48.8 17.7 315 
370 71.4 132 3.7 42 125 307 7.4 22 165 
371 46 128 5.4 43 176 221   419 
372 51 132 3.6 107 203 107 39 18.7 157 
373 37.8 127 3.2 58 139 108   555 
374 46.3 134 3.6 35 16 107   149 
375 52.2 130 3.3 88 27 164 24 25 92 
376 30 138 3.5 31 25 204 39.6 21.3 87 
377 45 137 4.4 78 96 83   454 
378 33 133 4.3 63 23 119 39 18.5 58 
379 55.6 136 3.1 131 718 106 40 24.5 207 
380 50 125 4.5 137 306 149 57.3 16.8 452 
381 30.6 137 3.2 44 207 91   65 
382 64.6 125 5 125 212 97 41 20 303 
383 49.3 138 3.7 137 303 102   197 
384 115 136 6.4 59 126 159 105.2 8.2 219 
385 115 139 5.2 55 21 123 45.7 13 284 
386 44 130 4.4 130 95 186   196 
387 43 138 4 93 106 171   79 
388 103 127  87 46 67 67.5 13.9 260 
389 45.9 136 4.3 74 97 102   129 
390 57 133 3.7 91 95 162   107 
391 42 136 4.8 111 60 111 39.5 24.3 394 
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392 43 136 3.8 97 40 91 21 26 356 
393  135 3 76 127 158   60 
394 61.1 136 3 77 16 103 34  61 
395 52 137 4 133 26 143 41 21 186 
396 45 134 4.1 42 162 104 40.4  130 
397 120 139 5.2 53 119 97 118 4 270 
398 48 132  62 248 91   108 
399 40.6 137 3.2 31 23 52   59 
400 43.4 135 3.5 72 85 136   43 
401  140 3.9 68 45 93   161 
402 70.7 136 3.7 75 49 93 25.7  70 
403 58 136 2.9 74 59 114   118 
404 104 135 3.5 85 63 83   203 
405 78.9 136 4.2 68 196 126 76.4 11.7 470 
406 33 136 3.1 21 73 116   421 
407 44 136 3.4 52 48 127 33 18 61 
408  132 4.1 56 35 106 38.3 23.2 105 
409 60 130 4.4 176 255 135 35.1  163 
410 53 137 3.7 128 176 217 34.6 26.8 56 
411 51 128 4 99 89 75   340 
412  137 3.5 30 31 92   73 
413 54 137 3 84 165 240   52 
414 44 136 4.6 169 75 181  2.56 496 
415  128 3.1 38 66 84 44.8 18 711 
416 56 136 3.3 81 47 124 22 18.5 76 
417  135 3.8 197 65 211   170 
418 57.6 132 3.6 98 208 114   461 
419 56 135 3.6 112 268 227 34.7  233 
420 53 138 4.8 107 182 127 45.1 14.1 118 
421 74 138 3.5 57 40 72 37 16.5 215 
422 43 127 4.1 27 198 164   318 
423 67.9 130 4.2 93 44 210 44.6 27.1 80 
424 34 132 3.7 56 232 170 46 . 83 
425 56 137 3.5 133 320 134 36 23.6 174 
526 6 131 3.9 108 112 156 38.8 22.3 95 
427 37 134 3.2 86 36 84 38.8 21.4 89 
428 48.4 137 4.4 126 68 139   71 
429 48.3 133 3.2 45 187 85   146 
430 122 149 3.8 54 192 69   234 
431 101 126 5.2 158 162 100   588 
432 51 135 3.5 68 66 120   100 
433  136 4.1 95 48 95   68 
434 77 132 3.4 122 116 205 33 28.5 132 
435 45 136 3.8 68 103 249 31 27 79 
436 37 137 3 47 94 92 30.7 25.8 82 
437  138 4.3 81 54 68 38 24 148 
438 70 137 5.5 77 51 20  7.4 196 
439 52 137 3 82 28 108 35.9  74 
440 39 140 5 93 41 86 47 13.8 130 
441 53 137 3.8 42 44 133   88 
442 67 135 4.3 175 193 180 36.1 22.8 319 
443 74.1 138 3.6 59 17 122 7.43 24 63 
444  142 3.3 118 114 178   60 
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445  135 3.6 77 43 122 32 34 67 
446 94 141 5.1 28 45 91 112.4  155 
447 105 126 5.1 53 39 62 104.4 10.7 389 
448 200 142 4.4 33 20 89 122  222 
449 48.9 127 3.1 20 60 53   74 
450 53 133 3.4 190 571 274   111 
451 47 134 2.9 102 778 117   63 
452 42.5 131 3.2 124 582 239   327 
453  142 3.9 31 22 60   87 
454 45 135 3.7 97 160 113   208 
455 53 135 5 85 34 115 34.9  251 
456 256 128 5.3 59 50 111 66.1 16.7 352 
457  140 4.4 69 51 225   116 
458 42 1  85 154 227   85 
459 44.3 137 2.6 48 29 114   69 
460 82 131 4.2 73 90 99   265 
461 43 138 2.8 55 29 81 35 25 85 
462 46.4 147 3.9 126 10 38   93 
463 56 140 4.1 125 215 144 33 23 100 
464 38.2 132 5.1 245 200 323 47.2 21.3 1212 
465 34 137 3.2 45 37 167   116 
466  138 3.3 70 163 138   67 
467 76 134 5.5 98 92 69 70.3 13.7 163 
468 81.3 134 3.4 161 163 130   80 
469  138 4.1 53 32 96   74 
470 49.1 141 4.5 92 83 139 76 5 179 
471 240 128 4.7 66 88 26 51.6 14.9 164 
472 57.6 134 3 109 125 132 35 18.5 75 
473 50.3 136 5.4 110 56 48 49 6 109 
474 30.4 140 2.9 28 41 93   181 
475 62 124 4.1 108 404 176 49.8 15.4 78 
476 56 128 2.8 112 34 102 25  240 
477 76.6 129 2.8 101 86 109 25.1 26.4 432 
478  141 3.5 39 32 115 34 29 68 
479 61 132 4.2 105 82 118 33.3 23.3 82 
480 110 135 5.6 68 41 100 139  197 
481 40 139 3 261 346 102 30 27 31 
482  139 4.2 117 25 92 31 25 83 
483 108 143 3.8 24 24 72 77.6 16 256 
484 53 135 3.4 94 72 156   75 
485 110 129 4.6 81 29 90 41 22.1 489 
486 44.5 139 3.6 29 61 131   72 
487 51.4 134 3.9 96 145 114   98 
488  137 3.4 71 146 91 31.7 25.6 113 
489 46 134 3.7 113 167 94   85 
490 62 135 3.3 93 185 121 32 26 180 
491 61.2 136 3.9 105 99 162   155 
492 42 140 3.6 52 29 129   78 
493 61.9 135 4 145 125 189 32 27 73 
494 43.2 131 3.4 83 49 167   89 
495 73.7 131 6.3 72 22 89   243 
496 46.5 132 2.9 230 297 162 28.8 25.6 175 
497 64 131 3.9 195 194 98   295 
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Number RIE APTT RIE Na RIE K RIE Bil RIE GGT RIE ALP RIE H+ RIE Bic RIE Cr 
498  133 2.8 120 135 98  44 281 
499 67.5 137 3.2 60 29 69 28  77 
500 135 140 6.1 26 27 75 71  250 
501 38.8 141 5.2 70 26 175 46 13 175 
502 56.7 132 2.9 230 297 162 28.8 25.6 175 
503  128 6.3 192 180 133 70 10.5 463 
504 38.3 130 4.5 76 235 256   213 
505 41 142 5 90 309 113 44.7 23.9 98 
506 53 134 3.3 67 119 101 36.7 24 218 
507 38 133 2.8 129 441 149 33.6 21.1 164 
508 35.3 135 3.1 244 348 169   100 
509 52.3 118 2.9 89 180 122 31 24 269 
510 40 140 4.7 99 85 125   94 
511 53 138 3.3 73 28 83  30.7 92 
512 56.1 137 5.3 97 76 92 43 17.8 177 
513 38 131 3.6 182 672 150 35 25 52 
514 44 133 2.7 57 49 137 35 22 83 
515  136 2.7 187 50 112   83 
516 35.5 135 3 71 108 97   221 
517 65 136 4.5 91 76 142   84 
518 45 134 3.5 56 114 90 36.1 24.6 76 
519 58.5 131 4.9 125 187 142 46 19 145 
520 43 131 3.2 50 180 152   72 
521  127 3.8 139 50 98 36.2 19.3 113 






No RIE ALT RIE PT High PT inn High PT man Dialysis Survival REF 8gr according to PT and Cr
1 10000 59.4  59.4  survived refpt>=25, refcr<=120 
2 17741 42   not required survived refpt>=25, refcr<=120 
3  38  56 not required Died refpt>=25, refCr>120, <=180 
4 5834 95.1   dialysis required Died refpt>=25, refCr>120, <=180 
5 18000 107  107 dialysis required Died refpt>=25, refcr<=120 
6 10739 50.1  66.99 not required survived  
7 2546 97  195 dialysis required Died  
8 3662 205  205 not required Died refpt>=25, refcr>=300 
9 8329 52.2  78.5 not required survived refpt<25, refcr<=120 
10 12506 42 51.3 90 dialysis required survived refpt>=25, refcr>180, <300 
11 8173 17.3  21.4 not required survived refpt<25, refcr<=120 
12 6586 85  110 not required survived refpt>=25, refcr<=120 
13 3994 40.6   dialysis required Died  
14 7480 68  115 not required survived refpt>=25, refcr<=120 
15 1027 59.3  59.3 not required survived refpt>=25, refCr>120, <=180 
16 6805 32.3  32.3 not required survived refpt<25, refcr>120, <=180 
17 13670 116   dialysis required survived refpt>=25, refcr>=300 
18 14750 40.3  40.3 not required survived  
19 12910 70 72 144 dialysis required Died refpt>=25, refCr>120, <=180 
20    15 not required Died  
21 1576 20   dialysis required Died refpt>=25, refCr>120, <=180 
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22 3644 162   dialysis required survived refpt>=25, refCr>120, <=180 
23 10595 120  200 dialysis required Died refpt>=25, refcr>180, <300 
24 9009  40  not required survived refpt>=25, refcr<=120 
25 11210 29.4   dialysis required Died refpt>=25, refcr>=300 
26 8434 72.1  93 not required survived refpt<25, refcr<=120 
27 7810 25.5  25.5 not required survived refpt>=25, refcr<=120 
28 748 26  37 not required survived refpt>=25, refcr<=120 
29 9776 49  49 not required survived refpt<25, refcr<=120 
30 10988 24.3  50 not required survived refpt>=25, refcr>=300 
31 17000 63.3  63.3 not required survived refpt>=25, refCr>120, <=180 
32 2381 29  31 not required survived refpt>=25, refcr<=120 
33 5492 75.6  99.5 not required survived refpt<25, refcr<=120 
34 3774 30.9  35 dialysis required Died . 
35 16400 65  65 dialysis required Died refpt<25, refcr<=120 
36 14276 57.3  57.3 not required survived refpt>=25, refcr<=120 
37 17920 31 87 130 not required survived refpt>=25, refcr<=120 
38 12906 44  80 not required survived refpt<25, refcr<=120 
39 5077 44   dialysis required survived refpt>=25, refcr>=300 
40 4320 32 52 63 dialysis required survived refpt>=25, refcr<=120 
41 6063 185   not required survived refpt>=25, refcr>180, <300 
42 2473 31.5   dialysis required Died refpt>=25, refcr>=300 
43 9713 26.5  59 not required survived refpt<25, refcr<=120 
44 13405 80.8  125 not required survived  
45 10994 20.2  82 not required survived refpt>=25, refcr<=120 
46 8300 27 27 49 not required survived  
47 8790 23   not required survived refpt<25, refcr<=120 
48 3270 50   dialysis required Died refpt>=25, refcr>=300 
49 3114 59 130  dialysis required Died refpt<25, refcr<=120 
50 2735 18   dialysis required Died refpt>=25, refcr>=300 
51 8628 205   dialysis required Died refpt<25, refcr<=120 
52 3916 61 61 130 dialysis required Died refpt>=25, refcr>180, <300 
53 9090 89.4 89.4  not required survived refpt>=25, refcr<=120 
54 2969 74  83 not required survived refpt>=25, refcr<=120 
55 9797 27.8 67  not required survived refpt<25, refcr<=120 
56 8964 31  50 not required survived refpt>=25, refCr>120, <=180 
57 9590 89  89 not required survived refpt>=25, refCr>120, <=180 
58 5902 16 32 22 not required survived refpt>=25, refcr<=120 
59 9276 46   not required survived refpt>=25, refCr>120, <=180 
60 6500 40.4  43.4 not required survived refpt<25, refcr<=120 
61 9756   49.4 not required survived refpt<25, refcr>120, <=180 
62 3740 36 56  not required survived refpt<25, refcr<=120 
63 10000 31.9   not required survived refpt>=25, refcr<=120 
64 11320 62   not required Died refpt<25, refcr>120, <=180 
65 1133   91 not required survived refpt<25, refcr<=120 
66 6192 120  120 dialysis required Died refpt>=25, refcr<=120 
67 8649 33  35 not required survived  
68     dialysis required Died  
69 6467 55.5  58.9 not required survived refpt>=25, refcr<=120 
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70 9016 36.1 36.1  not required survived . 
71 10000 85.8 89.3  not required survived refpt<25, refcr<=120 
72 2147 39.3  53.5 not required survived refpt>=25, refcr<=120 
73 6949 33  76.6 dialysis required Died refpt>=25, refcr>180, <300 
74 9494 24 45 71 not required survived refpt>=25, refcr<=120 
75 9945 50.2  50.2 not required survived refpt<25, refcr<=120 
76 9586 67  67 not required survived . 
77 10560 76 76 130 not required survived refpt<25, refcr<=120 
78 1091 58  79 dialysis required survived refpt>=25, refCr>120, <=180 
79 13560 15 30  not required survived refpt>=25, refcr<=120 
80 17255 54  54 not required survived refpt>=25, refcr<=120 
81 12240 98.5 142  dialysis required Died refpt>=25, refCr>120, <=180 
82 11140 49 49 87 not required survived refpt>=25, refcr<=120 
83 9596 45 45 70 not required survived refpt>=25, refcr<=120 
84 8292 36 36 68 not required survived refpt>=25, refcr<=120 
85 4080 45 90  not required survived refpt>=25, refcr<=120 
86 1182 37 85 71 not required survived refpt>=25, refcr<=120 
87 8499 36 39 61 not required survived refpt<25, refcr<=120 
88 18289 65.8 65.8  not required survived refpt>=25, refcr<=120 
89 9440 52  90 not required survived refpt<25, refcr<=120 
90 1767 39  58 not required survived refpt>=25, refcr<=120 
91 10490 66.3 86.3  not required survived refpt<25, refcr<=120 
92 5739 51 69 90 not required survived refpt>=25, refcr<=120 
93 1079 157  157 dialysis required Died refpt>=25, refcr<=120 
94 6749 37.3  37.3 not required survived refpt<25, refcr<=120 
95 9872 41.4 41.4  not required survived refpt<25, refcr<=120 
96 844 72  130 not required Died refpt<25, refcr>120, <=180 
97 3673 41 47  dialysis required Died refpt<25, refcr<=120 
98 4453 18   not required survived refpt<25, refcr<=120 
99 12010 33  43.9 not required survived refpt>=25, refCr>120, <=180 
100 6981 59.4  116 dialysis required survived refpt>=25, refcr<=120 
101 5303 84.9   dialysis required Died refpt>=25, refcr>180, <300 
102 16852 66.6 66.6  not required survived refpt<25, refcr>120, <=180 
103 5136 46 120  not required survived refpt<25, refcr<=120 
104 10000 120  120 dialysis required Died refpt>=25, refcr>180, <300 
105 10969 33   not required survived  
106 5091 56 56 153 dialysis required Died refpt>=25, refcr>=300 
107 7742 37 37  not required Died  
108 2325 35  48 not required survived  
109 10000 61.3  61.3 not required survived refpt>=25, refcr<=120 
110 6481 40 40 64 dialysis required survived  
111 311 25 55 120 not required survived  
112 2190 31 66  not required Died refpt>=25, refcr>180, <300 
113 11520 71 71 71 dialysis required Died refpt>=25, refcr<=120 
114     not required Died refpt>=25, refcr>=300 
115 2918 31 87 80 dialysis required Died refpt>=25, refcr<=120 
116 8782 29  29.8 not required survived refpt<25, refcr<=120 
117 25298 69  71.5 dialysis required survived refpt<25, refcr<=120 
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118 5520 54  67 dialysis required Died refpt>=25, refcr>180, <300 
119 760 33 103 180 dialysis required Died refpt<25, refcr>120, <=180 
120 16000 54.6  107 not required survived refpt<25, refcr<=120 
121 8359 48  48 not required survived refpt>=25, refcr<=120 
122 2236 44   not required survived refpt>=25, refcr>=300 
123 4447 49   dialysis required Died refpt>=25, refcr<=120 
124 4757 118  118 not required Died refpt>=25, refcr>=300 
125 14806 34 53  dialysis required survived refpt>=25, refcr>=300 
126 9400 60.6  60.6 not required survived refpt>=25, refcr<=120 
127 9891 77 200  dialysis required Died refpt>=25, refcr>180, <300 
128 11751 33 33 42.5 not required survived refpt>=25, refCr>120, <=180 
129 4795 41  41 dialysis required survived refpt>=25, refCr>120, <=180 
130 12800 73.8  100 not required survived refpt<25, refcr<=120 
131 6825 26 45  dialysis required Died  
132 12370 42.8  64 not required survived refpt>=25, refcr<=120 
133 9180 49  72 not required survived refpt>=25, refcr<=120 
134 10130 31  89.7 dialysis required Died refpt>=25, refcr<=120 
135 7059 38 103  dialysis required Died refpt>=25, refcr<=120 
136 3700 48.8  48.8 not required survived refpt>=25, refcr<=120 
137 301 27.8   not required Died refpt>=25, refcr<=120 
138  24 24 40 not required survived refpt<25, refcr<=120 
139 4166 30 31 71 not required survived  
140 13680 43 53 102 not required survived refpt>=25, refcr<=120 
141 10000 53 69  not required survived refpt>=25, refcr>180, <300 
142 1260 42 60 130 not required survived refpt<25, refcr<=120 
143 4177 37.6 72.9  not required Died refpt>=25, refcr>180, <300 
144 889 27  112 not required survived refpt<25, refcr<=120 
145 7933 35.7  74 not required survived refpt<25, refcr<=120 
146 6623 30   dialysis required Died refpt>=25, refcr>180, <300 
147 2938 63  117 dialysis required Died refpt>=25, refcr>180, <300 
148 8809 28   not required survived refpt>=25, refcr<=120 
149 4373 60.8  86.8 not required survived refpt>=25, refCr>120, <=180 
150 10000 97.3  120 not required survived refpt>=25, refcr<=120 
151 10000 59  77 not required survived refpt>=25, refCr>120, <=180 
152 8770 55.3  55.3 not required survived refpt>=25, refcr<=120 
153 6754 42 52  not required survived refpt<25, refcr<=120 
154 1318 29 48 53 not required Died refpt>=25, refcr<=120 
155 5856 49   dialysis required Died refpt>=25, refCr>120, <=180 
15 1362 42 77  not required Died refpt>=25, refcr>=300 
157   74  not required survived refpt<25, refcr<=120 
158 10130 32.3 32.3  not required survived refpt<25, refcr<=120 
159 4563 24   not required survived refpt>=25, refcr<=120 
160 8604 57.8   not required Died refpt>=25, refcr<=120 
161 10000 71.8 72  dialysis required survived refpt>=25, refcr<=120 
162 2966 39  39 not required survived refpt>=25, refcr<=120 
163 1628 29 57  not required survived  
164 2605 41   not required survived refpt>=25, refcr>=300 
165 10000 99   not required survived refpt>=25, refCr>120, <=180 
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166 10000 38.4  43.9 not required survived refpt>=25, refcr>180, <300 
167 7154 48  63 not required survived  
168 8060 51 72 99 not required survived refpt>=25, refcr<=120 
169 7430 32.8  176 not required survived refpt>=25, refcr<=120 
170 5315 93   not required survived refpt>=25, refcr>180, <300 
171 10140 35 35 66 not required survived refpt<25, refcr<=120 
172 8780 51  75.1 not required survived refpt>=25, refcr<=120 
173 4458 120  180 not required survived refpt<25, refcr<=120 
174 5447 39 67  not required survived refpt>=25, refcr<=120 
175 8330 240  240 dialysis required survived refpt>=25, refcr<=120 
176 12280 54   dialysis required Died refpt<25, refcr>180, <300 
177 10330 33.9  99 not required survived refpt>=25, refcr<=120 
178 7397 43   not required survived refpt<25, refcr<=120 
179 9056 85.4  89.6 not required survived refpt>=25, refcr<=120 
180 13631 57 74  not required survived refpt<25, refcr<=120 
181 3510 38.6  38.6 not required Died refpt>=25, refcr>180, <300 
182 7906 22.2  22.2 not required survived refpt>=25, refcr>=300 
183 3050 48  62.8 not required survived refpt>=25, refcr<=120 
184 5551 228 300 300 dialysis required Died refpt>=25, refcr>180, <300 
185 7051 23 64.7 74 dialysis required survived refpt>=25, refcr>=300 
186 10294 51 91  not required survived refpt>=25, refCr>120, <=180 
187 1668 180  180 dialysis required survived refpt<25, refcr<=120 
188 2898 79   dialysis required Died refpt>=25, refCr>120, <=180 
189 17190 42.3  42.3 not required survived refpt>=25, refcr<=120 
190 6543 20  20 not required survived refpt>=25, refcr<=120 
191 15400 64.4  71 not required survived refpt>=25, refcr>180, <300 
192 1549 51 200  dialysis required Died refpt>=25, refcr>=300 
193 10675 104   dialysis required survived refpt>=25, refcr<=120 
194 4300 120  180 not required Died refpt>=25, refcr<=120 
195 3583 68.7  141 not required survived refpt<25, refcr>120, <=180 
196  42   not required survived refpt<25, refcr<=120 
197 3820 53  80 not required survived refpt<25, refcr<=120 
198 7282 16 36  not required survived refpt>=25, refcr<=120 
199  150  150 not required Died refpt>=25, refcr<=120 
200 8085 150  150 dialysis required Died refpt<25, refcr<=120 
201 1497 106 106  dialysis required Died  
202 7301 31   not required survived refpt>=25, refcr<=120 
203 5630 50.6   dialysis required Died refpt>=25, refcr<=120 
204 3452 48.1  48.1 not required survived refpt>=25, refcr>=300 
205 3260 25 25 37 not required survived  
206 4319 70.5  70.5 not required survived refpt>=25, refcr<=120 
207 8022 34.3  50 not required survived refpt>=25, refcr>180, <300 
208 7661 107   dialysis required survived refpt<25, refcr<=120 
209 5491 31  1 dialysis required survived refpt>=25, refcr<=120 
210 12136 240  240 dialysis required survived refpt<25, refcr<=120 
211 5005 73.8  123 not required survived refpt<25, refcr<=120 
212 6558 25   not required survived refpt<25, refcr<=120 
213  25   dialysis required survived refpt<25, refcr<=120 
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214 1563 31 91 77 not required survived refpt<25, refcr>120, <=180 
215 17500 99   dialysis required survived refpt>=25, refCr>120, <=180 
216 10000 54 60  dialysis required survived refpt>=25, refcr<=120 
217 10890 78  81 not required survived refpt<25, refcr<=120 
218 2149 97.1  135 not required Died refpt>=25, refCr>120, <=180 
219 17400 25 29 55 not required survived refpt>=25, refcr<=120 
220 6998 91 130 210 dialysis required Died refpt>=25, refCr>120, <=180 
221 6547 52.3  52.3 not required survived refpt>=25, refCr>120, <=180 
222 4444 74.4   dialysis required Died refpt>=25, refcr>180, <300 
223 6383 51 51 107 dialysis required Died refpt>=25, refCr>120, <=180 
224 10455 33 33 54 not required survived  
225 11820 105 200  dialysis required Died refpt>=25, refCr>120, <=180 
226 8500 200  200 dialysis required Died refpt>=25, refcr>180, <300 
227 4583 41.5  55.4 not required survived refpt<25, refcr<=120 
228 4989 67   dialysis required survived refpt>=25, refCr>120, <=180 
229 7154 48  63 not required survived refpt<25, refcr<=120 
230 2219 41   dialysis required Died refpt>=25, refcr>=300 
231 5795 100  100 dialysis required Died refpt>=25, refcr<=120 
232 3456 40 50.5 57 not required survived refpt>=25, refcr<=120 
233 10000 40  120 dialysis required survived refpt>=25, refCr>120, <=180 
234 29790 68.4  68.4 not required survived refpt<25, refcr<=120 
235 5867 56   dialysis required survived refpt>=25, refCr>120, <=180 
236  52  52 not required survived refpt>=25, refcr<=120 
237 15200 120 120  not required survived  
238 10965 36  36 not required survived refpt>=25, refCr>120, <=180 
239 15645 32.8 33  not required survived refpt<25, refcr<=120 
240 1038 14.7  14.7 dialysis required survived refpt>=25, refcr>=300 
241 2956 56 116 140 not required Died refpt>=25, refCr>120, <=180 
242 4434 32 64 92 not required survived  
243 4360 64.1  99 not required survived refpt>=25, refcr>=300 
244 6159 64.6  64.6 not required survived refpt>=25, refcr<=120 
245 3931 46 81  not required survived refpt<25, refcr<=120 
246 10200 66 109 201 dialysis required survived refpt>=25, refcr<=120 
247 4992 118  118 dialysis required Died refpt>=25, refcr>180, <300 
248 7811 40 50 70 dialysis required survived refpt>=25, refCr>120, <=180 
249 14840 50   dialysis required survived  
250 12680 115  115 dialysis required survived refpt>=25, refcr>180, <300 
251 12910 34.6  34.6 not required survived refpt>=25, refcr<=120 
252 5823 45.1  48.4 not required survived refpt>=25, refCr>120, <=180 
253  42 42  not required Died refpt>=25, refcr>180, <300 
254 9788 49.3  76 not required survived refpt<25, refcr<=120 
255 4237 42   dialysis required Died refpt>=25, refCr>120, <=180 
256 15085 38  83 not required survived refpt<25, refcr<=120 
257 6340 34.6  34.6 dialysis required survived refpt>=25, refcr<=120 
258 6620 78  78 dialysis required survived refpt<25, refCr>=300 
259 8508 59.3 59.3  not required survived refpt<25, refcr<=120 
260 6680 65  66 not required survived refpt>=25, refcr<=120 
261 12592 26 26 0 not required survived refpt<25, refcr<=120 
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262 8229 88.2  88.2 not required survived refpt>=25, refcr<=120 
263 8800 24.9  43 not required survived refpt<25, refcr>180, <300 
264 10000 65.3  92 not required survived refpt>=25, refcr<=120 
265 10000 62.8  149 dialysis required Died refpt>=25, refCr>120, <=180 
266 8846 28 33 74 not required survived refpt<25, refcr<=120 
267 9784 62   dialysis required survived  
268 1170 24   dialysis required Died refpt>=25, refcr>180, <300 
269 5463 200  200 not required Died refpt>=25, refcr<=120 
270 9510 23.8  23.8 not required survived refpt>=25, refcr<=120 
271 838 57 63  dialysis required Died refpt>=25, refcr>180, <300 
272 3079 51 65 0 dialysis required Died refpt>=25, refcr<=120 
273 11600 38   dialysis required Died refpt>=25, refcr<=120 
274 418 40.5   not required Died refpt>=25, refcr>=300 
275 6807 62.5 124  not required survived refpt>=25, refcr<=120 
276 5439 135   dialysis required Died  
277 9788 125   dialysis required survived refpt<25, refcr<=120 
278 7009 30   dialysis required Died refpt>=25, refcr>180, <300 
279 2501 53.4  118 not required survived  
280 10000 71   dialysis required survived refpt>=25, refcr>180, <300 
281 910 34  34 not required survived refpt<25, refcr<=120 
282 14990 35.8 75  not required survived refpt>=25, refcr<=120 
283 5968 54.9 77  dialysis required survived refpt>=25, refcr>=300 
284 13775 48.3  48.3 dialysis required survived refpt>=25, refcr<=120 
285 3039 34   dialysis required Died refpt>=25, refcr>180, <300 
286 16200 42  51.3 dialysis required survived refpt<25, refcr<=120 
287 2105 59  84 not required Died refpt>=25, refcr>180, <300 
288 2123 27 27 28 not required survived refpt<25, refcr<=120 
289 6783 143  159 not required survived refpt>=25, refcr<=120 
290 11153 50 67 110 not required survived refpt>=25, refcr<=120 
291 1226 21 34 33 not required survived  
292 12170 58 58 110 dialysis required survived refpt<25, refcr<=120 
293 9472 30.8  45 not required survived refpt>=25, refcr>=300 
294 4625 74 74  not required Died refpt>=25, refCr>120, <=180 
295 10000 54.4   dialysis required Died refpt>=25, refcr<=120 
296 7941 26 27 63 dialysis required survived refpt<25, refcr>120, <=180 
297 10000 53.3 74.1  not required survived refpt>=25, refcr>180, <300 
298 5944 97.5  100 dialysis required Died refpt>=25, refCr>120, <=180 
299 13360 76.9  76.9 not required survived refpt>=25, refcr<=120 
300 9174 44.3  44.3 not required survived refpt<25, refcr<=120 
301     not required survived refpt>=25, refcr<=120 
302 10540 69  149 not required Died refpt>=25, refcr<=120 
303 11731 31 78  not required survived refpt<25, refcr>120, <=180 
304 8770 41 66  not required survived refpt>=25, refCr>120, <=180 
305    83 dialysis required Died refpt<25, refcr<=120 
306 9736 52  95 dialysis required Died  
307 7545 63  63 not required survived refpt>=25, refcr<=120 
308 10000 62.1  62.1 not required survived refpt>=25, refcr<=120 
309 11280 51  66 not required survived refpt<25, refcr<=120 
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310 7184 27 29 37 not required survived refpt<25, refcr>120, <=180 
311 11390 47  72.4 not required survived refpt>=25, refcr<=120 
312  56  56 dialysis required survived refpt>=25, refcr<=120 
313 13564 22.2  22.2 not required survived refpt>=25, refcr<=120 
314  25 25  not required survived refpt<25, refcr<=120 
315 5012 30  30 not required survived refpt>=25, refcr<=120 
316 15920 54  114 dialysis required survived refpt>=25, refCr>120, <=180 
317 11700 49  54 not required survived refpt<25, refcr<=120 
318 3306 36 48.6  not required survived refpt<25, refcr<=120 
319 12395 110  111 dialysis required Died refpt>=25, refcr<=120 
320 3034 41.5   dialysis required Died refpt>=25, refcr>=300 
321 3230 63  81 not required Died refpt>=25, refCr>120, <=180 
322 1446 40.1   dialysis required Died refpt>=25, refcr>=300 
323 6094 40  48 not required survived refpt>=25, refcr<=120 
324 6816 40  114 dialysis required survived  
325 5279 63   not required Died refpt>=25, refCr>120, <=180 
326 4503 32.7  32.7 not required survived  
327     . Died  
328 761 78  78 not required survived refpt>=25, refCr>120, <=180 
329 4964 58   dialysis required Died  
330     not required Died  
331 11935 58.3  58.3 not required survived refpt<25, refcr<=120 
332 7161 62.7  62.7 not required survived refpt<25, refcr<=120 
333 11500 35  73 dialysis required survived refpt>=25, refCr>120, <=180 
334 9407 67  100 not required survived  
335 7968 63 86.9 111 not required survived refpt>=25, refcr<=120 
336 8575 18 18  not required survived refpt<25, refcr<=120 
337 10910 37  59 not required survived refpt<25, refcr>180, <300 
338 6000 64.2 64.2  not required survived refpt>=25, refcr<=120 
339 7582 23  23 not required survived refpt<25, refcr<=120 
340 4725 102  102 dialysis required Died refpt>=25, refCr>120, <=180 
341 8231 36.3 50  not required survived refpt<25, refcr<=120 
342 15665 80  108 dialysis required Died  
343 5837 23   dialysis required survived refpt>=25, refCr>120, <=180 
344 1689 64 78.8  not required survived refpt>=25, refcr<=120 
345 5092 57 115  dialysis required Died  
346 8765 74 117 162 dialysis required Died refpt>=25, refCr>120, <=180 
347 13000 120   dialysis required survived refpt<25, refcr<=120 
348 10000 88.9  92 dialysis required Died refpt>=25, refcr>180, <300 
349 4051 44 44  dialysis required Died refpt>=25, refcr>180, <300 
350 1827 18 60.7 28 dialysis required Died refpt>=25, refcr>=300 
351  61  130 not required survived refpt>=25, refcr<=120 
352 6500 43   dialysis required survived refpt<25, refcr<=120 
353 10640 35 35 63 not required survived refpt>=25, refcr<=120 
354  59  59 dialysis required Died refpt>=25, refCr>120, <=180 
355 13080 92.8   dialysis required survived refpt>=25, refCr>120, <=180 
356 8611 51   not required survived refpt<25, refcr<=120 
357 2948 40 66 121 dialysis required Died refpt>=25, refcr>180, <300 
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358 1635 37  37 not required survived  
359 5449 81  81 not required Died refpt>=25, refcr<=120 
360 5292 25 25 5.7 not required survived refpt<25, refcr<=120 
361 7010 40  81 not required survived  
362 1062 66  80.3 not required survived refpt>=25, refcr<=120 
363 4770 48.7  80.1 dialysis required Died refpt>=25, refcr>=300 
364 3619 27 49  not required survived refpt<25, refcr<=120 
365 13380 111 111  dialysis required Died refpt>=25, refcr>=300 
366 4420 38.1 38.1  not required survived refpt>=25, refcr>180, <300 
367 8745 26 27  not required survived refpt<25, refcr<=120 
368 3686 112 135  dialysis required Died refpt>=25, refCr>120, <=180 
369 10450 28 34 48 not required survived refpt>=25, refcr>180, <300 
370 992 29.8   dialysis required Died refpt>=25, refCr>120, <=180 
371 2036 39 200 95 dialysis required Died refpt>=25, refcr>=300 
372 5980 46.3   not required survived refpt>=25, refcr>180, <300 
373 5573 15.9 19.8  not required survived refpt<25, refcr<=120 
374 7208 34.6  34.6 not required survived refpt>=25, refcr<=120 
375 12675 83.4  89.8 not required survived refpt<25, refcr<=120 
376 625 18 29 36 not required survived  
377  23  23 not required survived refpt>=25, refcr>=300 
378 492 21  33 not required survived refpt<25, refcr<=120 
379 5380 57  57.3 not required survived refpt<25, refcr<=120 
380 9197 39   dialysis required Died refpt>=25, refcr>=300 
381 13000 33  53 not required survived refpt<25, refcr<=120 
382 1940 55.3  56.2 dialysis required survived refpt<25, refcr>180, <300 
383 10000 43.8  43.8 not required survived refpt>=25, refcr<=120 
384 8286 48 200 200 dialysis required Died refpt>=25, refCr>120, <=180 
385 6163 120 120  dialysis required Died refpt<25, refcr>120, <=180 
386 12488 40 40 73 not required survived refpt>=25, refCr>120, <=180 
387 7562 67   not required survived refpt>=25, refcr<=120 
388 7927 35 78  dialysis required Died refpt>=25, refcr<=120 
389 10785 60 60  not required survived refpt>=25, refcr<=120 
390 12684 48 48.4 83 not required survived refpt>=25, refcr<=120 
391 9891 36   dialysis required survived  
392 10580 69.6  69.6 dialysis required survived refpt>=25, refCr>120, <=180 
393 13520 69 69 126 not required survived  
394 9000 63.7  63.7 not required survived refpt<25, refcr<=120 
395 11305 64  64 not required survived refpt>=25, refcr<=120 
396 5925 29  62 not required survived refpt<25, refcr<=120 
397 12465 101   dialysis required Died  
398 8298 36 91.2 72 not required survived refpt>=25, refcr<=120 
399 183 34.5 36.9  not required survived refpt>=25, refcr<=120 
400 4768 50 50  not required survived  
401 1146 33  41.7 not required survived refpt>=25, refCr>120, <=180 
402 8770 35  66 not required survived refpt>=25, refcr<=120 
403 7796 37 57 67 . survived refpt<25, refcr<=120 
404 3135 52 57 155 dialysis required Died refpt>=25, refcr>180, <300 
405 4538 110   dialysis required survived refpt>=25, refcr>=300 
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406 6730 15  15 not required survived refpt>=25, refcr<=120 
407 10000 42  66 not required survived refpt>=25, refcr<=120 
408 15600 55 130 104 dialysis required Died refpt>=25, refcr<=120 
409 2870 106  108 not required Died refpt>=25, refcr<=120 
410 13175 47  47 not required survived refpt<25, refcr<=120 
411 11783 20   dialysis required Died  
412 10000 27.9  56 not required survived refpt>=25, refcr<=120 
413 10000 56.6  65 not required survived refpt<25, refcr<=120 
414 10000 25  25 not required survived refpt>=25, refcr>=300 
415 122 28.8   not required Died  
416 11520 41 61  not required survived refpt<25, refcr<=120 
417 14358 74.5  87 not required survived refpt>=25, refcr>180, <300 
418 13715 46.8  46.8 dialysis required survived refpt>=25, refcr<=120 
419 3080 90.4  90.4 dialysis required survived refpt>=25, refcr<=120 
420 5444 28   dialysis required Died refpt>=25, refCr>120, <=180 
421 8454 54   dialysis required survived refpt<25, refcr>180, <300 
422 4372 13 23.5  not required survived refpt<25, refcr>180, <300 
423 5383 53  93 dialysis required survived refpt>=25, refcr<=120 
424 1526 9 12 16 not required survived refpt<25, refcr<=120 
425 1600 42  79 dialysis required survived refpt<25, refcr<=120 
526 11480 49 200 117 dialysis required survived refpt>=25, refcr<=120 
427 2143 31  120 dialysis required survived refpt>=25, refcr<=120 
428 8177 35.8  35.8 not required survived refpt>=25, refcr<=120 
429 10000 51 56.4  dialysis required survived refpt>=25, refcr<=120 
430 2949 55   dialysis required Died  
431 8675 73.2  73.2 dialysis required survived refpt>=25, refcr>180, <300 
432 14305 39 108  not required survived refpt>=25, refcr<=120 
433 14380 57.4  57.4 not required survived refpt>=25, refcr<=120 
434 13800 41 55 54 not required survived refpt>=25, refCr>120, <=180 
435 9617 33  33 not required survived refpt<25, refcr<=120 
436 11076 20 46.8 38 not required survived refpt>=25, refcr<=120 
437 2418 19  30.9 not required survived refpt>=25, refcr<=120 
438 6154 48 48  dialysis required Died refpt>=25, refcr>180, <300 
439 9840 42  81 not required survived  
440 2542 39  82 dialysis required Died refpt>=25, refcr<=120 
441 7508 46  92 not required survived refpt>=25, refcr<=120 
442 9625 57  61 dialysis required Died refpt>=25, refcr<=120 
443 8299 74.2 78.8  not required survived refpt<25, refcr<=120 
444 13350 67.2   not required survived refpt<25, refcr<=120 
445 14365 42  42 not required survived  
446 694 85 98 130 dialysis required survived refpt>=25, refCr>120, <=180 
447 4287 34   dialysis required Died refpt>=25, refcr>=300 
448 1463 200  200 not required Died refpt<25, refcr>120, <=180 
449 4113 35.3 50  not required survived refpt>=25, refcr<=120 
450 5422 45 45 65 not required survived refpt<25, refcr<=120 
451 1000 19 23 27 not required survived refpt<25, refcr<=120 
452 5357 47.5  54.5 not required survived  
453 11490 34.3  46 not required survived refpt<25, refcr<=120 
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454 10000 19  19 not required survived  
455 14440 56   dialysis required survived refpt>=25, refcr>180, <300 
456 6641 200   dialysis required Died refpt>=25, refcr>=300 
457 12700 53.3  53.3 not required survived refpt>=25, refcr<=120 
458 7611 17 17 26 not required survived refpt<25, refcr<=120 
459 10000 55 55  not required survived refpt>=25, refcr<=120 
460 3156 73   dialysis required Died  
461 10000 34  65 not required survived refpt>=25, refcr<=120 
462 45 18.5  19.5 not required survived refpt<25, refcr>120, <=180 
463 7565 33  113 not required Died refpt>=25, refcr<=120 
464 831 14.3   dialysis required Died refpt<25, refCr>=300 
465 5335 22 40 34 not required survived refpt>=25, refcr<=120 
466 10000 43  43 not required survived refpt>=25, refcr<=120 
467 5991 86  130 not required Died refpt>=25, refCr>120, <=180 
468 7430 73.3  73.3 not required survived refpt>=25, refcr<=120 
469 10000 65   not required survived refpt<25, refcr>120, <=180 
470 3014 55.2  200 dialysis required Died refpt>=25, refCr>120, <=180 
471 6236 240  240 dialysis required Died refpt<25, refcr<=120 
472 2569 58.8  106 dialysis required survived refpt<25, refcr<=120 
473 8112 42.6  200 dialysis required Died refpt>=25, refCr>120, <=180 
474 10000 21   not required survived refpt>=25, refCr>120, <=180 
475 1975 53 58 94 not required survived refpt>=25, refcr<=120 
476 10930 73  130 dialysis required survived refpt<25, refcr<=120 
477 4677 56.7  56 not required survived refpt>=25, refcr>=300 
478 2370 45.8  62 not required survived refpt<25, refcr<=120 
479 8224 67  95 not required survived refpt<25, refcr<=120 
480 7050 167   dialysis required Died refpt>=25, refcr<=120 
481 3443 22   not required survived refpt>=25, refCr>120, <=180 
482 7172 70  71 not required survived refpt>=25, refcr<=120 
483 3756 85.9   dialysis required Died  
484 18700 32 54 85 not required survived refpt<25, refcr<=120 
485 10000 69.6   dialysis required Died refpt>=25, refCr>120, <=180 
486 9756 26.2 26.2  not required survived refpt<25, refcr>120, <=180 
487 15200 53.5  53.5 not required survived refpt<25, refcr<=120 
488 4619 43  63 not required Died refpt>=25, refcr<=120 
489 8646 31  47 not required survived refpt<25, refcr<=120 
490 6254 28  41 . survived refpt>=25, refcr<=120 
491 15460 100  100 not required survived refpt<25, refcr<=120 
492 1909 25  50 not required survived refpt<25, refcr<=120 
493 18600 95.3  101 not required survived refpt>=25, refcr<=120 
494 10000 57.8  64 not required survived refpt>=25, refCr>120, <=180 
495 7138 155  190 dialysis required Died refpt>=25, refCr>120, <=180 
496 1333 19.8  72 not required survived refpt>=25, refcr>180, <300 
497  27  54 not required survived refpt>=25, refcr>180, <300 
498 1675 64 74  not required survived refpt>=25, refcr>180, <300 
499 4288 60.4  60.4 not required survived refpt>=25, refcr<=120 
500 4327 99 99 130 dialysis required Died refpt>=25, refcr>180, <300 
501 7674 73.8 159  dialysis required Died refpt>=25, refCr>120, <=180 
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502 1333 52.3   not required survived refpt<25, refcr>180, <300 
503 18269 130   dialysis required Died  
504 3777 16 38.3  not required survived refpt>=25, refcr<=120 
505 2979 17  28 not required survived refpt>=25, refcr<=120 
506 13493 23 32.8 44 not required survived refpt<25, refcr<=120 
507 2737 38 45  not required survived refpt>=25, refcr>=300 
508 5122 21.4  48.8 not required survived refpt>=25, refCr>120, <=180 
509 9011 51 51  not required survived refpt>=25, refcr>180, <300 
510 4190 38  114 not required Died refpt>=25, refcr<=120 
511 10000 29 29  not required survived  
512 10000 65.4  79 dialysis required survived refpt>=25, refCr>120, <=180 
513 7222 35 68 35 not required survived refpt>=25, refcr<=120 
514 10000 29 38.6  not required survived refpt<25, refcr<=120 
515 5399 19.9  73 not required survived refpt>=25, refcr<=120 
516 9960 34.8 59.1  dialysis required survived refpt>=25, refcr<=120 
517 6529 65  134 not required survived refpt<25, refcr>120, <=180 
518 4768 30 31  not required survived refpt<25, refcr<=120 
519 4532 78.6  79 not required survived refpt>=25, refcr<=120 
520 8718 35 45 50 not required survived refpt>=25, refcr<=120 
521 4949 35 50 100 not required survived  
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1 Cr<=120 72 >48h 84 >48h 
2 Cr<=120  Stag OD  stag OD 
3 Cr<=120 24 >12<=24   
4 Cr<=120 24 >12<=24 31 >24, <=48h 
5 Cr>120, <=180 36 >24<=48   
6 Cr<=120 11 <=12 64 >48h 
7 Cr>120, <=180  Stag OD  stag OD 
8 Cr>=300 96 >48h 101 >48h 
9 Cr<=120 10 <=12 36 >24, <=48h 
10 cr>180, <300 52 >48h 59 >48h 
11 cr>180, <300 6 <=12 88 >48h 
12 cr>180, <300 9 <=12 57 >48h 
13 Cr<=120 7 <=12 241 >48h 
14 Cr>=300 10 <=12 48 >24, <=48h 
15 Cr<=120 20 >12<=24   
16 Cr>120, <=180 24 >12<=24 70 >48h 
17 Cr>=300 52 >48h 52 >48h 
18 cr>180, <300  Stag OD  stag OD 
19 cr>180, <300  Stag OD  stag OD 
20      
21 cr>180, <300  Stag OD  stag OD 
22 cr>180, <300 36 >24<=48 40 >24, <=48h 
23 Cr>=300 33 >24<=48 48 >24, <=48h 
24 Cr<=120  Stag OD  stag OD 
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25 Cr>=300     
26 cr>180, <300 19 >12<=24 65 >48h 
27 Cr<=120 56 >48h 66 >48h 
28 Cr<=120 32 >24<=48 42 >24, <=48h 
29 cr>180, <300  Stag OD  stag OD 
30 Cr>=300     
31 Cr<=120 48 >24<=48 60 >48h 
32 Cr<=120 18 >12<=24 55 >48h 
33 Cr<=120 18 >12<=24 33 >24, <=48h 
34 Cr>=300  Stag OD  stag OD 
35 cr>180, <300  Stag OD  stag OD 
36 Cr<=120  Stag OD 79 >48h 
37 cr>180, <300 37 >24<=48 62 >48h 
38 Cr<=120 18 >12<=24 68 >48h 
39 Cr>=300 48 >24<=48 53 >48h 
40 Cr>=300 42 >24<=48 110 >48h 
41 cr>180, <300 96 >48h   
42 Cr>=300     
43 Cr>=300 9 <=12 71 >48h 
44 Cr<=120 12 <=12 75 >48h 
45 Cr<=120 24 >12<=24 53 >48h 
46 Cr<=120 5 <=12 53 >48h 
47 Cr<=120 36 >24<=48 78 >48h 
48 Cr>=300  Stag OD  stag OD 
49 Cr<=120  Stag OD  stag OD 
50 Cr>=300  Stag OD  stag OD 
51 Cr>120, <=180 4 <=12 48 >24, <=48h 
52 Cr>=300 6 <=12 40 >24, <=48h 
53 Cr<=120 26 >24<=48 55 >48h 
54 Cr<=120 20 >12<=24 51 >48h 
55 Cr<=120     
56 Cr<=120 48 >24<=48 72  
57 cr>180, <300  Stag OD 26 >24, <=48h 
58 Cr<=120 51 >48h 69 >48h 
59 Cr<=120 61 >48h 65 >48h 
60 Cr<=120 8 <=12   
61 Cr<=120 19 >12<=24   
62 Cr<=120 23 >12<=24   
63 cr>180, <300 23 >12<=24 77 >48h 
64 Cr<=120 16 >12<=24 38 >24, <=48h 
65 Cr<=120 9 <=12 20 >12, <=24h 
66 cr>180, <300 18 >12<=24 29 >24, <=48h 
67 Cr>120, <=180 1 <=12 52 >48h 
68   Stag OD  stag OD 
69 Cr>120, <=180 8 <=12 54 >48h 
70 Cr<=120 16 >12<=24 68 >48h 
71 Cr<=120  Stag OD  stag OD 
72 Cr<=120 17 >12<=24 25 >24, <=48h 
73 Cr>=300 28 >24<=48 54 >48h 
74 Cr<=120 45 >24<=48 64 >48h 
75 Cr<=120 15 >12<=24 60 >48h 
76 cr>180, <300 18 >12<=24 59 >48h 
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77 Cr<=120 11 <=12 46 >24, <=48h 
78 cr>180, <300 59 >48h 72  
79 Cr<=120 27 >24<=48 55 >48h 
80 Cr<=120     
81 Cr>120, <=180 42 >24<=48 75 >48h 
82 Cr<=120 19 >12<=24 70 >48h 
83 Cr<=120 36 >24<=48 47 >24, <=48h 
84 Cr<=120 26 >24<=48 50 >48h 
85 Cr<=120 18 >12<=24 40 >24, <=48h 
86 Cr<=120  Stag OD  stag OD 
87 Cr>120, <=180 22 >12<=24 46 >24, <=48h 
88 Cr<=120 22 >12<=24 88 >48h 
89 Cr>120, <=180 12 <=12 60 >48h 
90 Cr>180, <300 72 >48h 96 >48h 
91 Cr<=120 27 >24<=48 52 >48h 
92 Cr<=120  Stag OD  stag OD 
93 Cr>=300 71 >48h 75 >48h 
94 Cr<=120 18 >12<=24 45 >24, <=48h 
95 Cr>120, <=180 10 <=12 47 >24, <=48h 
96 Cr>120, <=180     
97 Cr>=300  Stag OD  stag OD 
98 Cr>120, <=180 16 >12<=24 70 >48h 
99 Cr>120, <=180 44 >24<=48 48 >24, <=48h 
100 Cr<=120  Stag OD  stag OD 
101 Cr>=300 48 >24<=48 54 >48h 
102 Cr>120, <=180 16 >12<=24 65 >48h 
103 Cr>120, <=180 12 <=12 74 >48h 
104 cr>180, <300     
105 Cr<=120  Stag OD  stag OD 
106 Cr>=300 72 >48h 80 >48h 
107 cr>180, <300 36 >24<=48 36 >24, <=48h 
108 Cr<=120  Stag OD  stag OD 
109 Cr<=120  Stag OD  stag OD 
110 Cr>=300  Stag OD  stag OD 
111 Cr<=120 17 >12<=24 36 >24, <=48h 
112 cr>180, <300     
113 Cr<=120 27 >24<=48 36 >24, <=48h 
114      
115 cr>180, <300 22 >12<=24 38 >24, <=48h 
116 Cr<=120     
117 Cr<=120 13 >12<=24 45 >24, <=48h 
118 cr>180, <300 44 >24<=48 66 >48h 
119 Cr>120, <=180 13 >12<=24 34 >24, <=48h 
120 Cr<=120 14 >12<=24 67 >48h 
121 Cr>120, <=180 44 >24<=48 61 >48h 
122 Cr>=300  Stag OD  stag OD 
123 Cr<=120 5 <=12 20 >12, <=24h 
124 Cr>=300  Stag OD  stag OD 
125 Cr>=300  Stag OD  stag OD 
126 Cr<=120 28 >24<=48 60 >48h 
127 Cr>120, <=180  Stag OD  stag OD 
128 Cr>120, <=180 45 >24<=48 50 >48h 
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129 Cr>120, <=180     
130 Cr<=120     
131 cr>180, <300  Stag OD  stag OD 
132 Cr>120, <=180 20 >12<=24 75 >48h 
133 Cr<=120 3 <=12 65 >48h 
134 cr>180, <300 36 >24<=48 60 >48h 
135 Cr>=300  Stag OD  stag OD 
136 Cr>120, <=180  Stag OD  stag OD 
137 Cr<=120     
138 Cr<=120 3 <=12 64 >48h 
139 Cr>120, <=180  Stag OD  stag OD 
140 Cr<=120 23 >12<=24 69 >48h 
141 cr>180, <300 47 >24<=48 50 >48h 
142 Cr<=120  Stag OD 36 >24, <=48h 
143 Cr>=300 26 >24<=48 50 >48h 
144 Cr<=120 24 >12<=24 30 >24, <=48h 
145 Cr<=120 16 >12<=24   
146 cr>180, <300     
147 Cr>=300  Stag OD 72 stag OD 
148 Cr<=120 41 >24<=48 64 >48h 
149 Cr>120, <=180  Stag OD 48 >24, <=48h 
150 Cr<=120 16 >12<=24 53 >48h 
151 cr>180, <300  Stag OD  stag OD 
152 Cr<=120 12 <=12 21 >12, <=24h 
153 Cr<=120 25 >24<=48 52 >48h 
154 Cr>120, <=180     
155 Cr>120, <=180 35 >24<=48 40 >24, <=48h 
15 Cr>=300     
157  1 <=12   
158 Cr<=120 17 >12<=24 50 >48h 
159 Cr<=120 7 <=12 40 >24, <=48h 
160 Cr>=300 17 >12<=24 65 >48h 
161 cr>180, <300 24 >12<=24 72  
162 Cr<=120 47 >24<=48 56 >48h 
163 Cr<=120  Stag OD  stag OD 
164 Cr>=300  Stag OD  stag OD 
165 Cr<=120 13 >12<=24 21 >12, <=24h 
166  30 >24<=48 82 >48h 
167 Cr<=120     
168 Cr>120, <=180 16 >12<=24 48 >24, <=48h 
169 Cr<=120 5 <=12   
170 cr>180, <300 68 >48h 68 >48h 
171 Cr<=120  Stag OD  stag OD 
172 Cr<=120 26 >24<=48 44 >24, <=48h 
173 Cr<=120  Stag OD  stag OD 
174 Cr>120, <=180  Stag OD  stag OD 
175 Cr>=300 20 >12<=24   
176 Cr>120, <=180 33 >24<=48 79 >48h 
177 Cr<=120 17 >12<=24   
178 Cr<=120  Stag OD  stag OD 
179 Cr>120, <=180 36 >24<=48 71 >48h 
180 Cr<=120 19 >12<=24 45 >24, <=48h 
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181 cr>180, <300     
182 Cr>=300 77 >48h 86 >48h 
183 Cr<=120 28 >24<=48 41 >24, <=48h 
184 cr>180, <300     
185 Cr>=300     
186 Cr>120, <=180 57 >48h 61 >48h 
187 cr>180, <300 8 <=12 51 >48h 
188 Cr>120, <=180  Stag OD  stag OD 
189 Cr<=120 60 >48h 70 >48h 
190 Cr<=120  Stag OD  stag OD 
191 cr>180, <300 36 >24<=48 48 >24, <=48h 
192 Cr>=300  Stag OD  stag OD 
193 Cr<=120 14 >12<=24 28 >24, <=48h 
194 cr>180, <300  Stag OD  stag OD 
195 Cr<=120 45 >24<=48 50 >48h 
196  20 >12<=24 64 >48h 
197 Cr<=120 22 >12<=24 44 >24, <=48h 
198 Cr<=120  Stag OD  stag OD 
199 cr>180, <300 18 >12<=24 39 >24, <=48h 
200 Cr>=300 26 >24<=48 36 >24, <=48h 
201 cr>180, <300  Stag OD  stag OD 
202 Cr<=120 31 >24<=48 37 >24, <=48h 
203 cr>180, <300 36 >24<=48 46 >24, <=48h 
204 Cr>=300 48 >24<=48 54 >48h 
205 Cr<=120   70 >48h 
206 Cr<=120 36 >24<=48 50 >48h 
207 cr>180, <300 7 <=12 71 >48h 
208 Cr<=120 14 >12<=24 48 >24, <=48h 
209 cr>180, <300 33 >24<=48 51 >48h 
210 cr>180, <300 8 <=12 48 >24, <=48h 
211 Cr<=120 24 >12<=24 54 >48h 
212 cr>180, <300     
213 Cr>120, <=180  Stag OD  stag OD 
214 Cr>120, <=180 22 >12<=24 25 >24, <=48h 
215 cr>180, <300 31 >24<=48 54 >48h 
216 Cr>120, <=180  Stag OD  stag OD 
217 cr>180, <300 19 >12<=24 49 >48h 
218 Cr>120, <=180 23 >12<=24 29 >24, <=48h 
219 Cr<=120 57 >48h 63 >48h 
220 Cr>120, <=180 45 >24<=48 52 >48h 
221 Cr<=120 52 >48h 60 >48h 
222 cr>180, <300  Stag OD  stag OD 
223 cr>180, <300 42 >24<=48 51 >48h 
224   Stag OD  stag OD 
225 cr>180, <300  Stag OD  stag OD 
226 cr>180, <300  Stag OD  stag OD 
227 Cr<=120     
228 Cr>120, <=180 41 >24<=48 58 >48h 
229 Cr<=120 15 >12<=24 91 >48h 
230 Cr>=300     
231 Cr>=300     
232 Cr>=300  Stag OD  stag OD 
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233 Cr<=120 32 >24<=48 39 >24, <=48h 
234 Cr<=120 8 <=12 80 >48h 
235 Cr>120, <=180 28 >24<=48 12 <=12h 
236 Cr<=120 47 >24<=48 55 >48h 
237 Cr>120, <=180  Stag OD  stag OD 
238 cr>180, <300     
239 Cr<=120 18 >12<=24 65 >48h 
240 Cr>=300 48 >24<=48 120 >48h 
241 Cr>120, <=180 25 >24<=48 31 >24, <=48h 
242 Cr<=120 21 >12<=24 27 >24, <=48h 
243 Cr>=300 50 >48h 66 >48h 
244 Cr<=120 91 >48h 101 >48h 
245 Cr<=120  Stag OD  stag OD 
246 Cr<=120 48 >24<=48   
247 cr>180, <300     
248 Cr>=300  Stag OD  stag OD 
249 Cr>120, <=180     
250 cr>180, <300 36 >24<=48 51 >48h 
251 Cr<=120 8 <=12 80 >48h 
252 Cr<=120 41 >24<=48 46 >24, <=48h 
253 cr>180, <300     
254 Cr>120, <=180 12 <=12 96 >48h 
255 cr>180, <300     
256 Cr>120, <=180 20 >12<=24   
257 Cr>=300 14 >12<=24 84 >48h 
258 Cr>=300 50 >48h 98 >48h 
259 Cr>120, <=180     
260 Cr<=120 14 >12<=24 62 >48h 
261 cr>180, <300 14 >12<=24 72  
262 Cr<=120     
263 cr>180, <300     
264 Cr<=120 12 <=12   
265 Cr>120, <=180     
266 Cr<=120 26 >24<=48 42 >24, <=48h 
267 cr>180, <300  Stag OD  stag OD 
268 cr>180, <300     
269 Cr<=120 24 >12<=24   
270 Cr<=120  Stag OD  stag OD 
271 Cr>=300  Stag OD  stag OD 
272 Cr>=300 120 >48h 126 >48h 
273 Cr<=120 15 >12<=24 23 >12, <=24h 
274 Cr>=300  Stag OD  stag OD 
275 Cr<=120     
276 cr>180, <300 24 >12<=24 56 >48h 
277 cr>180, <300 24 >12<=24   
278 Cr>=300  Stag OD  stag OD 
279 Cr<=120  Stag OD  stag OD 
280 Cr>=300  Stag OD  stag OD 
281 Cr<=120     
282 Cr<=120 6 <=12 72  
283 Cr>=300     
284 Cr<=120 5 <=12   
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285 cr>180, <300  Stag OD  stag OD 
286 Cr<=120   50 >48h 
287 cr>180, <300     
288 Cr<=120     
289 Cr<=120     
290 Cr<=120 46 >24<=48 58 >48h 
291 Cr<=120 7 <=12 30 >24, <=48h 
292 Cr>120, <=180  Stag OD  stag OD 
293 Cr>=300  Stag OD  stag OD 
294 cr>180, <300  Stag OD  stag OD 
295 Cr>120, <=180     
296 Cr>=300  Stag OD 7 <=12h 
297 cr>180, <300 60 >48h 67 >48h 
298 Cr>120, <=180 18 >12<=24 24 >12, <=24h 
299 Cr<=120 48 >24<=48 64 >48h 
300 Cr<=120 14 >12<=24 42 >24, <=48h 
301 Cr<=120     
302 Cr<=120 24 >12<=24 35 >24, <=48h 
303 cr>180, <300     
304 Cr>120, <=180   45 >24, <=48h 
305      
306 cr>180, <300 88 >48h 92 >48h 
307 Cr<=120 18 >12<=24 68 >48h 
308 Cr<=120 56 >48h 72  
309 cr>180, <300 48 >24<=48 86 >48h 
310 Cr>120, <=180  Stag OD  stag OD 
311 Cr<=120 5 <=12 68 >48h 
312 Cr>120, <=180 25 >24<=48 62 >48h 
313 Cr<=120 40 >24<=48 47 >24, <=48h 
314 Cr<=120 6 <=12 72  
315 Cr<=120 40 >24<=48 93 >48h 
316 cr>180, <300 26 >24<=48 36 >24, <=48h 
317 Cr>120, <=180 3 <=12 83 >48h 
318 Cr<=120 15 >12<=24 38 >24, <=48h 
319 Cr>120, <=180 48 >24<=48 80 >48h 
320 Cr>=300     
321 cr>180, <300 48 >24<=48 58 >48h 
322 Cr>=300  Stag OD 40 >24, <=48h 
323 Cr<=120  Stag OD  stag OD 
324 cr>180, <300     
325 Cr<=120 48 >24<=48 50 >48h 
326 Cr>120, <=180  Stag OD  stag OD 
327      
328 Cr<=120 48 >24<=48 60 >48h 
329 cr>180, <300     
330      
331 Cr<=120 29 >24<=48 66 >48h 
332 Cr<=120 12 <=12   
333 Cr>=300 24 >12<=24 50 >48h 
334 Cr<=120 40 >24<=48 48 >24, <=48h 
335 Cr<=120 51 >48h 57 >48h 
336 Cr<=120 10 <=12 63 >48h 
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337 Cr>=300 11 <=12 44 >24, <=48h 
338 Cr<=120 19 >12<=24 54 >48h 
339 Cr<=120 24 >12<=24 48 >24, <=48h 
340 Cr>120, <=180     
341 Cr<=120 20 >12<=24 52 >48h 
342 Cr<=120 12 <=12   
343 cr>180, <300 43 >24<=48 60 >48h 
344 Cr<=120  Stag OD  stag OD 
345 Cr<=120     
346 cr>180, <300 44 >24<=48 57 >48h 
347 Cr<=120 16 >12<=24 72  
348 cr>180, <300 52 >48h 59 >48h 
349 cr>180, <300     
350 Cr>=300  Stag OD  stag OD 
351 cr>180, <300 8 <=12   
352 Cr<=120 16 >12<=24 48 >24, <=48h 
353 Cr<=120  Stag OD  stag OD 
354  19 >12<=24 39 >24, <=48h 
355 Cr>120, <=180 36 >24<=48 64 >48h 
356 Cr<=120 18 >12<=24 50 >48h 
357 cr>180, <300 56 >48h 67 >48h 
358 Cr>120, <=180  Stag OD  stag OD 
359 Cr<=120 68 >48h 72  
360 Cr<=120 22 >12<=24 42 >24, <=48h 
361 Cr<=120  Stag OD  stag OD 
362 Cr<=120 55 >48h 62 >48h 
363 Cr>=300 72 >48h   
364 Cr<=120 19 >12<=24 37 >24, <=48h 
365 Cr>=300  Stag OD  stag OD 
366 cr>180, <300 57 >48h 68 >48h 
367 Cr<=120 11 <=12 38 >24, <=48h 
368 Cr>120, <=180  Stag OD  stag OD 
369 Cr>=300 45 >24<=48 54 >48h 
370 Cr>120, <=180  Stag OD  stag OD 
371 Cr>=300  Stag OD  stag OD 
372 Cr>120, <=180  Stag OD  stag OD 
373 Cr>=300  Stag OD  stag OD 
374 Cr>120, <=180  Stag OD  stag OD 
375 Cr<=120 7 <=12 60 >48h 
376 Cr<=120 15 >12<=24 21 >12, <=24h 
377 Cr>=300  Stag OD  stag OD 
378 Cr<=120 17 >12<=24 29 >24, <=48h 
379 cr>180, <300 16 >12<=24   
380 Cr>=300  Stag OD  stag OD 
381 Cr<=120 14 >12<=24 48 >24, <=48h 
382 Cr>=300  Stag OD  stag OD 
383 cr>180, <300 48 >24<=48   
384 cr>180, <300  Stag OD  stag OD 
385 cr>180, <300 16 >12<=24 69 >48h 
386 cr>180, <300 66 >48h 74 >48h 
387 Cr<=120 15 >12<=24 70 >48h 
388 cr>180, <300 29 >24<=48 41 >24, <=48h 
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389 Cr>120, <=180 15 >12<=24 60 >48h 
390 Cr<=120     
391 Cr>=300 130 >48h 130 >48h 
392 Cr>=300 55 >48h 72  
393 Cr<=120 12 <=12 67 >48h 
394 Cr<=120 1 <=12 78 >48h 
395 cr>180, <300 11 <=12 24 >12, <=24h 
396 Cr>120, <=180 22 >12<=24 52 >48h 
397 cr>180, <300 54 >48h 60 >48h 
398 Cr<=120  Stag OD  stag OD 
399 Cr<=120  Stag OD  stag OD 
400 Cr<=120  Stag OD  stag OD 
401 Cr>120, <=180 24 >12<=24 30 >24, <=48h 
402 Cr<=120     
403 Cr<=120 19 >12<=24 89 >48h 
404 cr>180, <300  Stag OD  stag OD 
405 Cr>=300     
406 Cr>=300 48 >24<=48 72  
407 Cr<=120 18 >12<=24   
408 Cr<=120 22 >12<=24 36 >24, <=48h 
409 Cr>120, <=180  Stag OD  stag OD 
410 Cr<=120 23 >12<=24 69 >48h 
411 Cr>=300 48 >24<=48   
412 Cr<=120 27 >24<=48 74 >48h 
413 Cr<=120 24 >12<=24 64 >48h 
414 Cr>=300  Stag OD  stag OD 
415 Cr>=300  Stag OD  stag OD 
416 Cr<=120 22 >12<=24 72  
417 Cr>120, <=180 72 >48h 86 >48h 
418 Cr>=300  Stag OD  stag OD 
419 cr>180, <300  Stag OD 50 >48h 
420 Cr<=120 27 >24<=48 42 >24, <=48h 
421 cr>180, <300 28 >24<=48 39 >24, <=48h 
422 Cr>=300  Stag OD  stag OD 
423 Cr<=120 30 >24<=48 46 >24, <=48h 
424 Cr<=120  Stag OD  stag OD 
425 Cr>120, <=180 12 <=12 44 >24, <=48h 
526 Cr<=120  Stag OD  stag OD 
427 Cr<=120 16 >12<=24 1 <=12h 
428 Cr<=120 86 >48h 86 >48h 
429 Cr>120, <=180 40 >24<=48 62 >48h 
430 cr>180, <300  Stag OD  stag OD 
431 Cr>=300     
432 Cr<=120 5 <=12 67 >48h 
433 Cr<=120 24 >12<=24   
434 Cr>120, <=180     
435 Cr<=120 6 Stag OD 56 >48h 
436 Cr<=120 46 >24<=48 48 >24, <=48h 
437 Cr>120, <=180  Stag OD 55 >48h 
438 cr>180, <300 30 >24<=48 36 >24, <=48h 
439 Cr<=120 34 >24<=48 72  
440 Cr>120, <=180 16 >12<=24 36 >24, <=48h 
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441 Cr<=120 20 >12<=24 51 >48h 
442 Cr>=300  Stag OD  stag OD 
443 Cr<=120  Stag OD  stag OD 
444 Cr<=120 12 <=12   
445 Cr<=120 18 >12<=24 66 >48h 
446 Cr>120, <=180     
447 Cr>=300  Stag OD  stag OD 
448 cr>180, <300     
449 Cr<=120  Stag OD 22 >12, <=24h 
450 Cr<=120  Stag OD  stag OD 
451 Cr<=120  Stag OD  stag OD 
452 Cr>=300  Stag OD  stag OD 
453 Cr<=120 15 >12<=24   
454 cr>180, <300 18 >12<=24 74 >48h 
455 cr>180, <300 26 >24<=48   
456 Cr>=300     
457 Cr<=120 48 >24<=48 72  
458 Cr<=120 48 >24<=48 48 >24, <=48h 
459 Cr<=120 28 >24<=48 57 >48h 
460 cr>180, <300  Stag OD  stag OD 
461 Cr<=120 36 >24<=48   
462 Cr<=120 6 <=12   
463 Cr<=120     
464 Cr>=300     
465 Cr<=120 36 >24<=48 72  
466 Cr<=120 10 <=12 45 >24, <=48h 
467 Cr>120, <=180 43 >24<=48   
468 Cr<=120 58 >48h   
469 Cr<=120  Stag OD  stag OD 
470 Cr>120, <=180 32 >24<=48 35 >24, <=48h 
471 Cr>120, <=180 26 >24<=48 37 >24, <=48h 
472 Cr<=120  Stag OD 35 >24, <=48h 
473 Cr<=120 17 >12<=24 24 >12, <=24h 
474 cr>180, <300 56 >48h 100 >48h 
475 Cr<=120  Stag OD  stag OD 
476 cr>180, <300 48 >24<=48   
477 Cr>=300 11 <=12 59 >48h 
478 Cr<=120 14 >12<=24   
479 Cr<=120 11 <=12 57 >48h 
480 cr>180, <300     
481 Cr<=120  Stag OD  stag OD 
482 Cr<=120 5 <=12 48 >24, <=48h 
483 cr>180, <300     
484 Cr<=120 21 >12<=24 46 >24, <=48h 
485 Cr>=300 24 >12<=24 55 >48h 
486 Cr<=120 22 >12<=24   
487 Cr<=120 16 >12<=24 42 >24, <=48h 
488 Cr<=120  Stag OD  stag OD 
489 Cr<=120 17 >12<=24 54 >48h 
490 Cr>120, <=180 16 >12<=24 46 >24, <=48h 
491 Cr>120, <=180 20 >12<=24 52 >48h 
492 Cr<=120 18 >12<=24 42 >24, <=48h 
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493 Cr<=120 62 >48h 68 >48h 
494 Cr<=120 31 >24<=48 54 >48h 
495 cr>180, <300 23 >12<=24   
496 Cr>120, <=180 7 <=12 72  
497 cr>180, <300  Stag OD  stag OD 
498 cr>180, <300  Stag OD 96 >48h 
499 Cr<=120  Stag OD  stag OD 
500 cr>180, <300 36 >24<=48 42 >24, <=48h 
501 Cr>120, <=180 33 >24<=48 41 >24, <=48h 
502 Cr>120, <=180 52 >48h 108 >48h 
503 Cr>=300  Stag OD  stag OD 
504 cr>180, <300  Stag OD  stag OD 
505 Cr<=120     
506 cr>180, <300  Stag OD  stag OD 
507 Cr>120, <=180  Stag OD  stag OD 
508 Cr<=120     
509 cr>180, <300 32 >24<=48 62 >48h 
510 Cr<=120 18 >12<=24 22 >12, <=24h 
511 Cr<=120  Stag OD  stag OD 
512 Cr>120, <=180 40 >24<=48 48 >24, <=48h 
513 Cr<=120  Stag OD  stag OD 
514 Cr<=120 21 >12<=24 47 >24, <=48h 
515 Cr<=120 12 <=12 48 >24, <=48h 
516 cr>180, <300 37 >24<=48 72  
517 Cr<=120     
518 Cr<=120 24 >12<=24 50 >48h 
519 Cr>120, <=180  Stag OD  stag OD 
520 Cr<=120   67 >48h 
521 Cr<=120 17 >12<=24 44 >24, <=48h 









Number Outcome ITU Stay RIE Stay SLTU Stay 
1 SURVIVED NO TP 0 3 3 
2 SURVIVED NO TP 0 6 6 
3 DIED NO TP 2 2 0 
4 DIED NO TP 5 6 1 
5 DIED NO TP 1 1 0 
6 SURVIVED NO TP 0 4 4 
7 DIED NO TP 3 5 2 
8 DIED NO TP 1 1 0 
9 SURVIVED NO TP 0 6 5 
10 SURVIVED NO TP 0 8 8 
11 SURVIVED NO TP 0 2 2 
12 SURVIVED NO TP 0 3 9 
13 DIED WITH TP 19 21 2 
14 SURVIVED NO TP 0 9 9 
15 SURVIVED NO TP 0 7 7 
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16 SURVIVED NO TP 0 5 5 
17 SURVIVED WITH TP 5 98 93 
18 SURVIVED NO TP 0 9 9 
19 DIED NO TP 4 5 2 
20 DIED NO TP 3 3 0 
21 DIED NO TP 24 24 0 
22 SURVIVED WITH TP 31 69 38 
23 DIED NO TP 2 3 1 
24 SURVIVED NO TP 0 5 5 
25 DIED NO TP 8 9 1 
26 SURVIVED NO TP 3 9 6 
27 SURVIVED NO TP 0 3 3 
28 SURVIVED NO TP 0 4 4 
29 SURVIVED NO TP 0 6 6 
30 SURVIVED NO TP 5 9 4 
31 SURVIVED NO TP 0 6 6 
32 SURVIVED NO TP 0 4 4 
33 SURVIVED NO TP 0 11 0 
34 DIED NO TP 11 11 0 
35 DIED NO TP 10 10 1 
36 SURVIVED NO TP 0 3 3 
37 SURVIVED NO TP 0 7 7 
38 SURVIVED NO TP 0 3 3 
39 SURVIVED NO TP 0 47 47 
40 SURVIVED NO TP 10 15 6 
41 SURVIVED WITH TP 1 112 111 
42 DIED NO TP 1 1 0 
43 SURVIVED NO TP 0 13 13 
44 SURVIVED NO TP 0 6 6 
45 SURVIVED NO TP 0 4 4 
46 SURVIVED NO TP 0 4 4 
47 SURVIVED NO TP 0 4 4 
48 DIED NO TP 6 6 0 
49 DIED NO TP 11 13 3 
50 DIED NO TP 5 7 0 
51 DIED NO TP 10 10 0 
52 DIED NO TP 2 2 0 
53 SURVIVED NO TP 0 5 5 
54 SURVIVED NO TP 0 7 7 
55 SURVIVED NO TP 0 3 3 
56 SURVIVED NO TP 0 7 7 
57 SURVIVED NO TP 0 9 9 
58 SURVIVED NO TP    
59 SURVIVED NO TP 10 11 2 
60 SURVIVED NO TP 0 6 6 
61 SURVIVED NO TP 2 7 5 
62 SURVIVED NO TP 0 4 4 
63 SURVIVED NO TP 0 18 16 
64 DIED WITH TP 8 12 7 
65 SURVIVED NO TP 0 5 5 
66 DIED WITH TP 3 36 33 
67 SURVIVED NO TP 0 6 6 
68 DIED NO TP  3 . 
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69 SURVIVED NO TP 0 4 4 
70 SURVIVED NO TP 0 4 4 
71 SURVIVED NO TP 0 3 3 
72 SURVIVED NO TP 0 4 4 
73 DIED NO TP 5 8 4 
74 SURVIVED NO TP 0 5 5 
75 SURVIVED NO TP 0 4 4 
76 SURVIVED NO TP 0 6 6 
77 SURVIVED NO TP 0 4 4 
78 SURVIVED NO TP 4 13 9 
79 SURVIVED NO TP 0 4 4 
80 SURVIVED NO TP 0 4 4 
81 DIED WITH TP 18 19 1 
82 SURVIVED NO TP 0 7 7 
83 SURVIVED NO TP 0 4 4 
84 SURVIVED NO TP 0 3 3 
85 SURVIVED NO TP 0 6 6 
86 SURVIVED NO TP 0 3 3 
87 SURVIVED NO TP 0 3 3 
88 SURVIVED NO TP 0 5 5 
89 SURVIVED NO TP 0 5 5 
90 SURVIVED NO TP 5 5 0 
91 SURVIVED NO TP 0 9 9 
92 SURVIVED NO TP 0 6 6 
93 DIED NO TP 3 4 1 
94 SURVIVED NO TP 0 5 5 
95 SURVIVED NO TP 0 14 14 
96 DIED NO TP 2 2 1 
97 DIED NO TP 9 10 2 
98 SURVIVED NO TP 5 9 6 
99 SURVIVED NO TP 0 10 10 
100 SURVIVED NO TP 5 19 14 
101 DIED NO TP 1 2 1 
102 SURVIVED NO TP 0 3 3 
103 SURVIVED NO TP 0 23 23 
104 DIED NO TP 7 7 0 
105 SURVIVED NO TP 0 4 4 
106 DIED NO TP 2 2 0 
107 DIED NO TP 0 2 2 
108 SURVIVED NO TP 0 3 3 
109 SURVIVED NO TP 0 5 5 
110 SURVIVED NO TP 2 11 13 
111 SURVIVED NO TP 2 10 11 
112 DIED NO TP 1 1 1 
113 DIED NO TP 5 6 2 
114 DIED NO TP 2 4 2 
115 DIED NO TP 5 7 3 
116 SURVIVED NO TP 0 3 3 
117 SURVIVED NO TP 0 7 7 
118 DIED NO TP 11 11 0 
119 DIED NO TP 15 18 4 
120 SURVIVED NO TP 0 3 3 
121 SURVIVED NO TP 0 9 9 
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122 SURVIVED NO TP 0 4 4 
123 DIED NO TP 6 7 1 
124 DIED NO TP 1 1 0 
125 SURVIVED NO TP 0 8 8 
126 SURVIVED NO TP 0 4 4 
127 DIED NO TP 3 4 2 
128 SURVIVED NO TP 0 4 4 
129 SURVIVED WITH TP 7 27 20 
130 SURVIVED NO TP 4 11 7 
131 DIED NO TP 3 3 1 
132 SURVIVED NO TP 0 5 5 
133 SURVIVED NO TP 0 6 4 
134 DIED NO TP 12 14 1 
135 DIED NO TP 2 2 0 
136 SURVIVED NO TP 0 13 13 
137 DIED NO TP 0 3 2 
138 SURVIVED NO TP 0 4 4 
139 SURVIVED NO TP 0 10 10 
140 SURVIVED NO TP 0 5 5 
141 SURVIVED NO TP 0 13 13 
142 SURVIVED NO TP 0 5 5 
143 DIED NO TP 0 3 2 
144 SURVIVED NO TP 0 8 8 
145 SURVIVED NO TP 0 5 5 
146 DIED NO TP 2 2 0 
147 DIED NO TP 2 2 0 
148 SURVIVED NO TP 0 6 6 
149 SURVIVED NO TP 4 13 7 
150 SURVIVED NO TP 0 14 14 
151 SURVIVED NO TP 0 6 6 
152 SURVIVED NO TP 0 3 3 
153 SURVIVED NO TP 0 6 6 
154 DIED NO TP 0 2 2 
155 DIED NO TP 5 6 2 
15 DIED NO TP 2 2 0 
157 SURVIVED NO TP 8 15 7 
158 SURVIVED NO TP 0 3 3 
159 SURVIVED NO TP 10 24 14 
160 DIED NO TP 4 5 1 
161 SURVIVED NO TP 9 19 10 
162 SURVIVED NO TP 0 6 6 
163 SURVIVED NO TP 6 11 4 
164 SURVIVED NO TP 3 5 3 
165 SURVIVED NO TP 7 10 3 
166 SURVIVED NO TP 1 8 7 
167 SURVIVED NO TP 0 4 4 
168 SURVIVED NO TP  8 . 
169 SURVIVED NO TP 8 14 6 
170 SURVIVED WITH TP 6 25 19 
171 SURVIVED NO TP 0 4 4 
172 SURVIVED NO TP 0 5 5 
173 SURVIVED NO TP 0 10 10 
174 SURVIVED NO TP 0 5 5 
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175 SURVIVED WITH TP 7 24 17 
176 DIED WITH TP 5 5 0 
177 SURVIVED NO TP 0 4 4 
178 SURVIVED NO TP 0 10 10 
179 SURVIVED NO TP 0 6 6 
180 SURVIVED NO TP 0 5 5 
181 DIED NO TP 4 4 0 
182 SURVIVED NO TP 0 5 5 
183 SURVIVED NO TP 0 8 8 
184 DIED NO TP 2 2 0 
185 SURVIVED NO TP 21 25 8 
186 SURVIVED NO TP 0 4 4 
187 SURVIVED WITH TP 7 33 26 
188 DIED NO TP 3 3 1 
189 SURVIVED NO TP 0 3 3 
190 SURVIVED NO TP 0 4 4 
191 SURVIVED NO TP 0 8 8 
192 DIED NO TP 4 5 2 
193 SURVIVED WITH TP 3 34 31 
194 DIED NO TP 2 2 0 
195 SURVIVED NO TP 9 21 12 
196 SURVIVED NO TP 0 3 3 
197 SURVIVED NO TP 0 5 5 
198 SURVIVED NO TP 0 5 5 
199 DIED NO TP 2 2 0 
200 DIED NO TP 1 2 1 
201 DIED NO TP 2 2 1 
202 SURVIVED NO TP 0 6 6 
203 DIED NO TP 2 3 1 
204 SURVIVED NO TP 0 5 5 
205 SURVIVED NO TP 0 3 3 
206 SURVIVED NO TP 0 4 4 
207 SURVIVED NO TP 0 3 3 
208 SURVIVED WITH TP 10 38 28 
209 SURVIVED WITH TP 7 26 20 
210 SURVIVED WITH TP 89 158 69 
211 SURVIVED NO TP 0 5 5 
212 SURVIVED NO TP 4 5 2 
213 SURVIVED NO TP 0 7 7 
214 SURVIVED NO TP 0 10 10 
215 SURVIVED WITH TP 5 20 15 
216 SURVIVED NO TP 0 8 8 
217 SURVIVED NO TP 0 8 8 
218 DIED NO TP 2 2 0 
219 SURVIVED NO TP 0 4 4 
220 DIED NO TP 2 2 0 
221 SURVIVED NO TP 0 6 6 
222 DIED NO TP 5 6 1 
223 DIED NO TP 3 4 2 
224 SURVIVED NO TP 0 3 3 
225 DIED NO TP 2 3 2 
226 DIED NO TP 1 1 0 
227 SURVIVED NO TP 0 6 6 
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228 SURVIVED WITH TP 6 37 31 
229 SURVIVED NO TP 0 4 4 
230 DIED NO TP 2 2 0 
231 DIED NO TP 2 4 0 
232 SURVIVED NO TP 13 23 12 
233 SURVIVED WITH TP 7 31 26 
234 SURVIVED NO TP 10 5 5 
235 SURVIVED WITH TP 5 18 14 
236 SURVIVED NO TP 0 4 4 
237 SURVIVED WITH TP 3 33 31 
238 SURVIVED NO TP 0 19 19 
239 SURVIVED NO TP 0 5 5 
240 SURVIVED NO TP 0 10 2 
241 DIED NO TP 0 4 4 
242 SURVIVED NO TP 0 4 4 
243 SURVIVED NO TP 0 6 6 
244 SURVIVED NO TP 0 3 3 
245 SURVIVED NO TP 0 5 5 
246 SURVIVED WITH TP 15 60 47 
247 DIED NO TP 2 2 0 
248 SURVIVED NO TP 2 13 12 
249 SURVIVED WITH TP 12 28 18 
250 SURVIVED WITH TP 33 67 34 
251 SURVIVED NO TP 0 3 3 
252 SURVIVED NO TP 0 7 7 
253 DIED NO TP 0 2 2 
254 SURVIVED NO TP 0 4 4 
255 DIED WITH TP 3 3 1 
256 SURVIVED NO TP 0 3 3 
257 SURVIVED NO TP 0 4 4 
258 SURVIVED NO TP 2 15 13 
259 SURVIVED NO TP 4 15 11 
260 SURVIVED NO TP 3 6 3 
261 SURVIVED NO TP 0 3 3 
262 SURVIVED NO TP 7 14 7 
263 SURVIVED NO TP 0 4 4 
264 SURVIVED NO TP 0 5 5 
265 DIED NO TP 3 3 0 
266 SURVIVED NO TP 0 7 7 
267 SURVIVED WITH TP 13 25 14 
268 DIED NO TP 5 5 1 
269 DIED NO TP 0 3 3 
270 SURVIVED NO TP 0 3 3 
271 DIED NO TP 15 16 1 
272 DIED NO TP 2 2 0 
273 DIED NO TP 12 13 2 
274 DIED NO TP 1 1 0 
275 SURVIVED NO TP 0 5 5 
276 DIED NO TP 1 1 1 
277 SURVIVED WITH TP 10 49 39 
278 DIED NO TP 2 2 0 
279 SURVIVED NO TP 1 9 8 
280 SURVIVED WITH TP 8 19 12 
 97
Number Outcome ITU Stay RIE Stay SLTU Stay 
281 SURVIVED NO TP 0 6 6 
282 SURVIVED NO TP 0 2 2 
283 SURVIVED NO TP 7 16 9 
284 SURVIVED NO TP 0 17 17 
285 DIED NO TP 2 2 0 
286 SURVIVED NO TP 6 10 4 
287 DIED NO TP 6 8 2 
288 SURVIVED NO TP 0 4 4 
289 SURVIVED NO TP 4 11 7 
290 SURVIVED NO TP 0 5 5 
291 SURVIVED NO TP 0 9 9 
292 SURVIVED NO TP 3 22 20 
293 SURVIVED NO TP 0 6 6 
294 DIED NO TP 1 1 0 
295 DIED NO TP 7 8 1 
296 SURVIVED NO TP 2 13 10 
297 SURVIVED NO TP 0 11 11 
298 DIED WITH TP 2 2 0 
299 SURVIVED NO TP 0 3 3 
300 SURVIVED NO TP 0 3 3 
301 SURVIVED NO TP 0 2 2 
302 DIED NO TP 2 3 1 
303 SURVIVED NO TP 0 7 7 
304 SURVIVED NO TP 0 6 6 
305 DIED NO TP 2 2 0 
306 DIED NO TP 16 19 7 
307 SURVIVED NO TP 0 3 3 
308 SURVIVED NO TP 0 3 3 
309 SURVIVED NO TP 0 6 6 
310 SURVIVED NO TP 0 5 5 
311 SURVIVED NO TP 0 10 6 
312 SURVIVED NO TP 0 15 2 
313 SURVIVED NO TP 0 4 4 
314 SURVIVED NO TP 0 3 3 
315 SURVIVED NO TP 0 4 4 
316 SURVIVED NO TP 3 13 11 
317 SURVIVED NO TP 0 5 5 
318 SURVIVED NO TP 0 6 6 
319 DIED NO TP 3 4 1 
320 DIED NO TP 20 22 2 
321 DIED NO TP 1 1 1 
322 DIED NO TP 0 3 3 
323 SURVIVED NO TP 3 9 6 
324 SURVIVED NO TP    
325 DIED NO TP 2 2 0 
326 SURVIVED NO TP 0 8 8 
327 DIED NO TP 10 10 1 
328 SURVIVED NO TP 6 11 5 
329 DIED NO TP 10 11 2 
330 DIED NO TP 2 2 0 
331 SURVIVED NO TP 0 2 2 
332 SURVIVED NO TP 0 6 6 
333 SURVIVED NO TP 0 5 5 
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334 SURVIVED NO TP 4 8 4 
335 SURVIVED NO TP 5 10 7 
336 SURVIVED NO TP 0 2 2 
337 SURVIVED NO TP 0 8 8 
338 SURVIVED NO TP 0 13 13 
339 SURVIVED NO TP 0 3 3 
340 DIED NO TP 1 2 1 
341 SURVIVED NO TP 0 4 4 
342 DIED NO TP 0 14 14 
343 SURVIVED NO TP 0 9 9 
344 SURVIVED NO TP 0 8 8 
345 DIED NO TP 2 3 1 
346 DIED NO TP 8 8 1 
347 SURVIVED WITH TP 5 28 22 
348 DIED NO TP 15 18 3 
349 DIED NO TP 2 2 0 
350 DIED NO TP 6 6 0 
351 SURVIVED NO TP 0 6 6 
352 SURVIVED NO TP 3 14 11 
353 SURVIVED NO TP 0 5 5 
354 DIED NO TP 1 1 0 
355 SURVIVED WITH TP 4 24 20 
356 SURVIVED NO TP 0 5 5 
357 DIED NO TP    
358 SURVIVED NO TP 3 7 4 
359 DIED NO TP 7 7 0 
360 SURVIVED NO TP 0 12 12 
361 SURVIVED NO TP 0 4 4 
362 SURVIVED NO TP 0 3 3 
363 DIED NO TP 3 3 0 
364 SURVIVED NO TP 2 9 9 
365 DIED NO TP 13 14 1 
366 SURVIVED NO TP 0 5 5 
367 SURVIVED NO TP 0 5 5 
368 DIED NO TP 4 4 0 
369 SURVIVED NO TP 0 6 5 
370 DIED NO TP 13 13 0 
371 DIED NO TP 3 5 3 
372 SURVIVED NO TP 0 3 3 
373 SURVIVED NO TP 0 7 7 
374 SURVIVED NO TP 0 5 5 
375 SURVIVED NO TP 5 18 13 
376 SURVIVED NO TP 0 5 5 
377 SURVIVED NO TP 0 6 6 
378 SURVIVED NO TP 0 3 3 
379 SURVIVED NO TP 0 8 8 
380 DIED WITH TP 7 7 0 
381 SURVIVED NO TP 0 3 3 
382 SURVIVED NO TP 0 11 11 
383 SURVIVED NO TP 0 4 4 
384 DIED NO TP 2 2 0 
385 DIED NO TP 4 4 0 
386 SURVIVED NO TP 0 5 5 
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387 SURVIVED NO TP 0 3 3 
388 DIED NO TP 2 2 0 
389 SURVIVED NO TP 0 4 4 
390 SURVIVED NO TP 0 4 4 
391 SURVIVED NO TP 13 21 12 
392 SURVIVED NO TP 13 18 5 
393 SURVIVED NO TP 0 5 5 
394 SURVIVED NO TP 0 4 4 
395 SURVIVED NO TP 0 10 8 
396 SURVIVED NO TP 0 6 6 
397 DIED NO TP 2 2 1 
398 SURVIVED NO TP 2 5 4 
399 SURVIVED NO TP 0 4 4 
400 SURVIVED NO TP 0 3 3 
401 SURVIVED NO TP 0 7 7 
402 SURVIVED NO TP 5 10 5 
403 SURVIVED NO TP  13 . 
404 DIED NO TP 2 2 0 
405 SURVIVED WITH TP 13 37 24 
406 SURVIVED NO TP 0 3 3 
407 SURVIVED NO TP 0 4 4 
408 DIED NO TP 9 9 1 
409 DIED NO TP 0 8 8 
410 SURVIVED NO TP 0 5 5 
411 DIED WITH TP  25 25 
412 SURVIVED NO TP 0 3 3 
413 SURVIVED NO TP 0 5 5 
414 SURVIVED NO TP 0 7 7 
415 DIED NO TP 2 2 0 
416 SURVIVED NO TP 0 3 3 
417 SURVIVED NO TP 0 4 4 
418 SURVIVED NO TP 0 7 7 
419 SURVIVED NO TP 12 24 11 
420 DIED NO TP 2 2 1 
421 SURVIVED WITH TP 7 23 17 
422 SURVIVED NO TP 0 6 6 
423 SURVIVED NO TP 7 18 11 
424 SURVIVED NO TP 0 8 8 
425 SURVIVED NO TP 0 7 7 
526 SURVIVED NO TP 14 25 12 
427 SURVIVED NO TP 0 10 10 
428 SURVIVED NO TP 0 3 3 
429 SURVIVED NO TP 11 24 13 
430 DIED NO TP 1 1 0 
431 SURVIVED NO TP 13 21 8 
432 SURVIVED NO TP 0 3 3 
433 SURVIVED NO TP 0 4 4 
434 SURVIVED NO TP 9 15 7 
435 SURVIVED NO TP 0 5 3 
436 SURVIVED NO TP 0 3 3 
437 SURVIVED NO TP 0 2 2 
438 DIED NO TP 9 10 2 
439 SURVIVED NO TP 0 4 4 
 100
Number Outcome ITU Stay RIE Stay SLTU Stay 
440 DIED NO TP 3 1 4 
441 SURVIVED NO TP 0 6 6 
442 DIED NO TP 8 9 1 
443 SURVIVED NO TP 17 26 9 
444 SURVIVED NO TP 0 3 3 
445 SURVIVED NO TP 0 4 4 
446 SURVIVED WITH TP 8 26 28 
447 DIED WITH TP    
448 DIED NO TP 2 2 0 
449 SURVIVED NO TP 0 7 7 
450 SURVIVED NO TP 0 11 11 
451 SURVIVED NO TP 0 3 3 
452 SURVIVED NO TP 0 9 9 
453 SURVIVED NO TP 0 3 3 
454 SURVIVED NO TP 0 5 5 
455 SURVIVED WITH TP 7 34 28 
456 DIED NO TP 10 10 0 
457 SURVIVED NO TP 0 3 3 
458 SURVIVED NO TP 0 3 3 
459 SURVIVED NO TP 0 6 6 
460 DIED NO TP 3 3 0 
461 SURVIVED NO TP 0 3 3 
462 SURVIVED NO TP 0 3 3 
463 DIED NO TP 9 10 2 
464 DIED NO TP 8 8 0 
465 SURVIVED NO TP 0 2 2 
466 SURVIVED NO TP 0 5 5 
467 DIED NO TP 2 2 0 
468 SURVIVED NO TP 0 6 6 
469 SURVIVED NO TP 0 5 5 
470 DIED NO TP 4 5 1 
471 DIED NO TP 2 2 1 
472 SURVIVED NO TP 0 12 12 
473 DIED NO TP 2 3 1 
474 SURVIVED NO TP 0 10 10 
475 SURVIVED NO TP 3 5 3 
476 SURVIVED NO TP 5 20 15 
477 SURVIVED NO TP 7 12 5 
478 SURVIVED NO TP 0 3 3 
479 SURVIVED NO TP 0 5 5 
480 DIED NO TP 3 3 0 
481 SURVIVED NO TP 6 37 32 
482 SURVIVED NO TP 0 6 6 
483 DIED NO TP 1 2 1 
484 SURVIVED NO TP 0 6 6 
485 DIED WITH TP 6 6 0 
486 SURVIVED NO TP 0 3 3 
487 SURVIVED NO TP 0 5 0 
488 DIED NO TP 7 7 0 
489 SURVIVED NO TP 0 3 3 
490 SURVIVED NO TP 0 12 10 
491 SURVIVED NO TP 0 10 10 
492 SURVIVED NO TP 0 3 0 
 101
Number Outcome ITU Stay RIE Stay SLTU Stay 
493 SURVIVED NO TP 9 16 7 
494 SURVIVED NO TP 0 4 4 
495 DIED NO TP 3 3 0 
496 SURVIVED NO TP 6 12 7 
497 SURVIVED NO TP 0 6 6 
498 SURVIVED NO TP 0 11 11 
499 SURVIVED NO TP 1 6 5 
500 DIED NO TP 2 2 1 
501 DIED NO TP 2 3 1 
502 SURVIVED NO TP 6 12 6 
503 DIED WITH TP 2 2 0 
504 SURVIVED NO TP 0 3 3 
505 SURVIVED NO TP 0 6 6 
506 SURVIVED NO TP 0 4 4 
507 SURVIVED NO TP 0 3 3 
508 SURVIVED NO TP 0 2 2 
509 SURVIVED NO TP 7 14 7 
510 DIED WITH TP 1 4 3 
511 SURVIVED NO TP 0 6 6 
512 SURVIVED NO TP 0 11 11 
513 SURVIVED NO TP 0 10 10 
514 SURVIVED NO TP 0 6 6 
515 SURVIVED NO TP 0 6 4 
516 SURVIVED NO TP 4 24 20 
517 SURVIVED NO TP 1 6 6 
518 SURVIVED NO TP 0 4 4 
519 SURVIVED NO TP 0 11 11 
520 SURVIVED NO TP 0 3 3 
521 SURVIVED NO TP 2 11 10 





Number: number of each patient. Code: code for each patient; DOB: date of birth; Ref: 
referring;  Cr: creatinine (µmol/l); Delay: time between ingestion and admission to referring 
hospital (h); Stag OD: staggered overdose; Asso ALC: associated alcohol; ALC intake: 
alcohol intake (unit/week); Na: plasma sodium (mmol/l); K: plasma potassium (mmol/l); Bic: 
plasma bicarbonate (mmol/l); Bil: bilirubin (µmol/l); ALP: alkaline phosphatase (U/l);  GGT: 
gamma glutamyl transpeptidase (U/l); H+: [H+] (mmol/l); ALT: alanine transaminase (U/l); PT: 
prothrombin time (Sec); APTT: partial prothrombin time; ITU stay: intensive care unit stay 
(day); ref 8gr: 8 groups according to PT and Cr in the referring hospital; TP: transplant; Blank 











Appendix 3.2:   Subjects who had degrees of renal dysfunction (referring Cr.120 umol/l), but not significant liver impairment (PT<25 sec) at 
first admission to referring hospital (n=26). Interval: time between ingestion and admission to referring hospital.  
 Number Code DOB Sex Age (y) Ref Cr (µmol/l) Ref PT (Sec) Ref ALT (IU/l) Delay  h 
1 JA060023 12-Sep-30 male 66.0 123 14 6805 24 
2 MB030076 03-Jan-71 female 23.0 130 19 9756 19 
3 RB090081 19-Apr-74 male 26.0 126 21.5 11320 16 
4 WC110124 19-Aug-39 female 63.0 170 18 844 Unknown 
5 WC080132 29-Oct-72 male 26.0 122 13 16852 16 
6 FD110154 30-Nov-58 male 41.0 132 21 760 13 
7 MH060269 12-Feb-80 female 17.0 131 18 3583 45 
8 SH130692 24-Aug-60 male 43.0 155 15 1563 22 
9 KM130694 14-Jan-83 male 21.0 155 14 7941 Staggered 
10 JM070397 03-Mar-70 male 28.0 136 23.5 11731 missing data 
11 JM120673 16-Oct-58 male 45.0 160 22 7184 Staggered 
12 RN090495 04-Dec-67 male 23.0 129 21 6163 16 
13 BS020575 04-Mar-72 male 21.0 132 15.6 1463 missing data 
14 DS040592 07-Sep-70 male 24.0 134 18 45 6 
15 AS080602 30-Mar-68 female 31.0 122 21.7 10000 missing data 
16 CT080623 24-Jan-65 female 34.0 124 22 9756 22 
17 RW090658 16-Oct-65 male 34.0 123 18 6529 missing data 
18 SG100237 04-Feb-82 male 29.0 217 22 12280 33 
19 EL030354 13-Jan-33 male 61.0 193 18 8800 missing data 
20 VM030440 01-Oct-45 male 49.0 284 23 10910 11 
21 EN030493 14-Sep-51 female 42.0 226 14.5 1940 Staggered 
22 AR090539 20-Sep-73 male 26.0 240 24.6 8454 28 
23 PR110542 27-Oct-73 male 28.0 254 23.5 4372 Staggered 
24 PW070642 18-Apr-53 male 44.0 252 24 1333 52 
25 WL040348 21-Sep-60 male 34.0 312 10 6620 50 
26 PS030595 07-Nov-49 female 45.0 1196 18 831 Unknown 
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Patient invitation letter 
 
 
Title of the study: Effects of Acetylcysteine in the management of paracetamol 
overdose 




Dear Sir/ Madam 
 
You are being asked to take part in a study in which we are examining how you respond to 
the treatment you may receive. You have taken an overdose of paracetamol and may need 
treatment with an antidote which is routinely used for this condition. We are studying the 
effects of the antidote in a group of patient. Before you decide whether to take part it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following carefully and ask if there is anything that is not clear, 
or if you would like more information. Please take time to decide whether or not you wish to 
take part and. If you do not wish to take part in this study it will not affect your treatment in 
any way. 
 
Thank you for your time. 
Yours faithfully, 
 
Dr Nasrin Pakravan 
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Patient information sheet  
 
 
Title of the study: Effects of Acetylcysteine in the management of paracetamol 
overdose 





You are being asked to take part in a study in which we are examining how your body 
responds to the treatment you may receive. You have taken an overdose of paracetamol and 
may need treatment with an antidote to protect you from the poisonous effects of the 
paracetamol.This antidote, NAC, N-acetylcysteine, protects your liver from very serious liver 
injury which occurs when paracetamol is taken in overdose. Unfortunately a small group of 
patients may suffer a range of side effects from treatment and we are trying to understand 
more about this so we can prevent it happening, or identify which patients are more likely to 
have a problem. These effects include in particular feeling sick, and flushed. As treatment is 
essential, if needed, this is an important practical problem for us, even though all these side 
effects can be treated successfully. 
 
You are being asked to take part in this study as you have taken an overdose of paracetamol 
and you may need NAC as treatment. We are hoping to study 50 patients.  
 
It is up to you to decide whether or not to take part. If you decided to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care you 
receive. 
 
If the drug level in your blood shows that you require NAC treatment and you agree to take 
part in this study, you will be asked to allow us to use the routine blood samples taken when 
you were admitted for this research, and to provide some extra blood samples (15 ml) just 
before, 15 min, 30 min, 1 hour and 2 hours after starting treatment with NAC. Taking extra 
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We are also asking your permission to use these clinical samples for research to measure 
some chemicals in your blood that may be involved in causing side effects.  
 
To investigate better how your body responds to NAC, we need to accurately record your 
blood pressure, pulse rate, respiratory rate and temperature every half an hour till 2 hours 
and then every hour till 4 hours after start of NAC treatment and then as routinely to the end 
of your treatment.  
 
To detect any change in your breathing, you will be asked to take a standard test involving a 
short sharp breath into a peak flow tube before and 1, 2, 4 hours after starting NAC and then 
every 4 hours to the end of your treatment which takes 20 hours. 
 
Blood samples will be taken either by one of the nursing staff or myself. All the results will be 
kept anonymous, and your personal details will not be disclosed to a third party. If you agree 
we will inform your GP of your participation in the study. 
 
This study has been reviewed by the Lothian Local Research Ethics Committee. If you have 
any further questions feel free to ask or contact the telephone number above. 
 
Thank you for reading this information sheet.  
 
 
Dr Nasrin Pakravan 




















Appendix 5.3: Patient Consent Form 
 
 
Ref NO: 06/S1101/10 
Version 2 
Date: 20/03/2006 




Patient Consent Form 
 
Effects of Acetylcysteine in the management of paracetamol overdose 
Researcher: Dr. Nasrin Pakravan 
 
                                                                                             Please initial box 
 
1- I confirm that I have read and understand the patient information sheet dated 
16.03.2006 (Version 2) for the above study, and have had the opportunity to ask 
questions.  
2- I understand that this study will normally involve me providing  additional blood 
samples, to routine samples being taken during my time in the hospital. An 
additional cannula will be inserted in my arm for taking blood samples. My blood 
pressure, pulse rate, respiratory rate and temperature will be recorded more 
frequently than clinical routine. I also understand that a standard test of breathing 
involving me making a short breath into a peak flow tube will be measured for this 
study. 
3- I understand that the results of the above samples will be used for research.  
 
4- I understand that sections of any of my notes may be looked at by responsible 
individuals from the Scottish Poison Information Bureau and the Toxicology unit at 
the Royal Infirmary of Edinburgh or from regulator authorities where is relevant to my 
taking part in research.  I give permission for these individuals to have access to my 
records. 
 
5- I realise that my participation is voluntary and that I can withdraw my consent at any 
time without giving any reason, without my medical care or legal rights being 
affected. 
 
6- I understand that my general practitioner (GP) will be informed from my participation 
in this study. 
 
7- I agree that to take part in the above study. 
 
       _______________________              ____________               ____________ 
Name of Patient                                      Date                                Signature 
__________________________            _____________             _____________ 
Name of person taking consent              Date                                Signature 
(If different from researcher) 
___________________________          ______________           _____________ 









Appendix 5.4: Data Collection Sheet 
 
NAC Reaction Study 
Study Ref No: 06/S1101/10 
Version 1 
Patient ID NO        
        
 Subject Data Collection Sheet 
 
Date: 




Gender:                                    Male                       Female                                Age:  
Patient’s weight (Kg)                                               Patient’s height (M)             
Paracetamol overdose            YES                         NO                  
Name of drugs taken 
Alcohol consumption:             before drug ingestion (h)                with drug                 after (h)     
Alleged amount of paracetamol (g):                            
Date of ingestion:                          Time of ingestion                                Staggered 
Date of admission                          Time of admission     
PMH such as liver disease, heart disease, Diabetes, allergic disease, HIV, …. 
Drug Hx:       Allergic Hx:          Hay Fever     Asthma               Allergy to animal                                         
Drug allergy    Family history of allergy           YES                   NO             Unknown      
History of NAC treatment                                 YES                   NO             Unknown      
History of previous reaction to NAC                 YES                   NO             Unknown                                 
Alcohol consumption            NO                       YES:                             Unit per week                          
 High risk drug:                     NO                        YES    
Phenobarbitone                    Phenytoin               Carbamazepine            Primidone               
Rifampicin                      St John Wort                        Other 
Paracetamol level                hours after ingestion                                     Location on R line:    
 Under high risk line             Over high risk                                               over normal 
treatment line 
NAC treatment                Reaction to NAC                                       YES                        NO 
 
 






Appendix 5.5: Observation Sheet 
 
NAC Reaction Study 
Study Ref No: 06/S1101/10 
Version 1 
Patient ID NO: 
 
 
                                              Observation Sheet 
 
 
First bag of NAC                          
Date:                                               Time started:                                  Time finished 
 
 
Second bag of NAC                   
 Date:                                             Time started:                                   Time finished 
 
 
Third bag of NAC                       





















    Comment 
0 
 
       
30 min 
 
       
1h        
2h        
3h        
4h        
8h        
12h        
16h        
20h        
 
Appendix 5.6: Adverse Reactions Sheet 
NAC Reaction Study 
Study Ref No: 06/S1101/10                                                     
Version 1                                                                                     Adverse Reactions Sheet 
Type of reaction Time of initiation Time of Termination Treatment required                Other 
 
Rash     
Pruritus     
Flushing     
Coughing     
Wheezing     
Dyspnoea     
Nausea     
Vomiting     
Chest Pain     
Abdominal Cramp     
Diarrhoea     
Fever (T ≥38)     
Hypotension 
(SBP<90 mmHg) 
    
Hypertension 
(BP>140 /90 mmHg 
    
Tachycardia 
 (PR>120 ) 
    
Bronchospasm     
Abdominal Cramp     
Diarrhoea     
Angioedema     
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Appendix 5.7: Blood Sampling Sheet 
 
 
NAC Reaction Study 
Study Ref No: 06/S1101/10                                                     
Version 1                                                              
 Patient ID NO: 
 
 




Sample / time point 
0 
(baseline) 15 min 30 min 1h 2h   4h  20h Comment 
tPA 3 ml     3 ml 3 ml 3 ml     
Histamine 3 ml 3 ml 3 ml 3 ml 3 ml       
NAC 3 ml   3 ml  3 ml 3 ml 3 ml   
Tryptase 3 ml   3 ml 3 ml 3 ml       
II,V,VII,VIII,IX,X 3 ml   3 ml 3 ml 3 ml 3 ml 3 ml   
vWf, IL6 3 ml   3 ml 3 ml 3 ml 3 ml 3 ml   





















Appendix 5.8: Plasma histamine (ng/ml) at baseline and time points after IV NAV infusion commencement and time of initiation and/or peak 






Time between INAC 
infusion initiation and  
start/peak of adverse 
reactions His 0  0min His 1 15min His 2 30min  His 3 60min His 4 120min 
5 start at 40min 0.98 0 0.73 15 0.22 30 0.57 60 0.5 120 
6 start at 45min 0.44 0 NS NS NS NS 0.69 60 0.32 120 
7 start at 80min 0.76 0 0.19 18 0.3 43 0.19 73 0.32 133 
9 start at 30min 0.26 0 0.24 17 0.24 33 0.41 68 0.25 128 
13 no reaction 0.82 0 0.53 20 0.73 40 0.72 70 0.84 120 
17 start at 20-40min 1.2 0 0.5 15 0.76 30 0.47 60 0.36 120 
18 start at 15 and 130min 1.41 0 0.71 15 0.7 30 0.7 70 1.83 190 
19 start at 55 0.17 0 0.75 15 0.38 30 0.97 60 0.4 125 










  22 start  at 15 0.35 0 0.31 15 0.35 35 0.37 65 0.28 140 
1 peak at 60 min 0.48 0 2.28 13 2.44 30 0.92 60 0.75 120 
2 start  at 30-40 0.36 0 0.25 15 0.86 30 0.24 60 0.25 120 
12 start at 30-40 0.48 0 0.93 16 0.81 37 2.82 58 1.85 123 





  21 start at 17 min 0.86 0 0.68 20 0.5 35 1.38 65 0.57 125 
8 peak at 22 min 0.37 0 0.32 15 1.53 30 0.6 75 0.47 140 
10 peak at 35 min 0.27 0 0.27 20 1.33 35 0.27 60 0.26 120 
14 peak at 85min 0.5 0 0.29 15 1.76 35 1.13 70 0.81 135 
3 peak at 55min 0.62 0 0.24 15 0.11 30 2.16 70 0.78 120 
4 peak at 30min 0.79 0 0.58 15 0.68 30 1.34 60 0.39 120 







  16 peak at 27min 0.49 0 0.93 17 0.53 35 1.48 65 0.33 125 
 
Appendix 5.9: Plasma NAC concentration (µg/100µl) at baseline and time points 
(baseline, 1h, 2h and 4h) after IV NAC infusion commencement  in each subject . NS: 
no sample. (1: minimal ADRs, 2: moderate ADRs, 3: severe ADRs) (intensive study). 
  
Subject no Severity NAC baseline NAC 30min NAC 2h NAC 4h NAC 20h 
1 2 0 9 4.75 4.25 NS 
2 2 0.53 1.2 3.18 NS 2.3 
3 3 0 12 4.5 2.75 1.7 
4 3 0.3 NS 1 NS NS 
5 1 0.53 9.5 3.75 3.75 1.65 
6 1 0 7.5 6.75 1 3.22 
7 1 0 10.25 6.75 3.5 1.75 
8 3 0 7.25 3.27 2.3 1.5 
9 1 0 4.55 3.62 3.12 0 
10 3 0 5.03 3.22 NS NS 
11 3 0 9.5 3.7 3.47 2.4 
12 2 0 11.5 4.75 4.17 2.5 
13 1 0 9.25 4.25 2.7 1.6 
14 3 0 13 3.77 NS NS 
15 2 0 15 6.25 4.1 0.7 
16 3 0.53 10.75 4.7 3.52 0 
17 1 0 11.77 6.43 3.72 1.57 
18 1 0 6 3 0.75 0.78 
19 1 0 8.5 4.75 5.02 1.28 
20 1 0 12.5 5.02 3.27 2.23 
21 2 0 8.03 3.8 2 0 




Appendix 5.10: Plasma histamine concentration at baseline and different time points 
after IV NAC infusion in each subject in the group with minimal ADRs, N=10, His: 
Plasma histamine (ng/ml), T: time (min) ((Intensive study). NS: no sample (intensive 
study). 
 
Subject No His 0 T 0 His 1 T1 min His 2 T2 min His 3 T3 h His 4 T4 h 
5 0.98 0 0.73 15 0.22 30 0.57 60 0.5 120 
6 0.44 0 NS  NS  0.69 60 0.32 120 
7 0.76 0 0.19 18 0.3 43 0.19 73 0.32 133 
9 0.26 0 0.24 17 0.24 33 0.41 68 0.25 128 
13 0.82 0 0.53 20 0.73 40 0.72 70 0.84 120 
17 1.2 0 0.5 15 0.76 30 0.47 60 0.36 120 
18 1.41 0 0.71 15 0.7 30 0.7 70 1.83 190 
19 0.17 0 0.75 15 0.38 30 0.97 60 0.4 125 
20 0.52 0 0.39 20 0.68 35 0.55 70 0.82 120 






Appendix 5.11: Plasma histamine concentration at baseline and different time points 
after IV NAC infusion in each subject in the group with moderate ADRs. N=5, His: 





Appendix 5.12: plasma histamine concentration at baseline and different time points 
after IV NAC infusion in subjects with severe ADRs, N=7, His=plasma histamine 






Subject  No His 0  T 0  His 1 T15min His 2 T30min His 3 T1h  His 4 T2h 
1 0.48 0 2.28 13 2.44 30 0.92 60 0.75 120 
2 0.36 0 0.25 15 0.86 30 0.24 60 0.25 120 
12 0.48 0 0.93 16 0.81 37 2.82 58 1.85 123 
15 0.49 0 0.35 18 0.64 30 0.99 65 0.51 125 
21 0.86 0 0.68 20 0.5 35 1.38 65 0.57 125 
Subject  No His 0  T 0  His 1 T1 His 2 T2 His 3 T3  His 4 T4 
8 0.37 0 0.32 15 1.53 30 0.6 75 0.47 140 
10 0.27 0 0.27 20 1.33 35 0.27 60 0.26 120 
14 0.50 0 0.29 15 1.76 35 1.13 70 0.81 135 
3 0.62 0 0.24 15 0.11 30 2.16 70 0.78 120 
4 0.79 0 0.58 15 0.68 30 1.34 60 0.39 120 
11 0.42 0 0.53 15 1.09 35 1.82 70 0.9 130 
16 0.49 0 0.93 17 0.53 35 1.48 65 0.33 125 
 114
Appendix 5.13: histamine validation experiment: plasma histamine (ng/ml) in 8 healthy 
volunteers (4 male and 4 female). Samples were collected and cooled at once, but 
spun at different time points (5 min, 15 min, 30 min and 60 min) after collection. His: 
histamine; T: spinning time (minute after blood collection) (intensive study). 
 
Subject no T5min His5min T15min His15m T30min His30min T60m T60min 
1 5 0.48 15 0.491 30 0.333 60 0.374 
2 5 0.503 15 0.992 30 0.693 75 1.293 
3 5 0.829 15 0.644 30 0.764 60 0.483 
4 5 0.562 15 0.686 30 0.831 60 0.803 
5 5 1.006 15 0.548 30 0.374 60 0.618 
6 5 0.488 15 0.744 30 0.583 60 0.479 
7 5 0.483 15 0.386 30 0.344 60 0.419 




Appendix 5.14: plasma tryptase  concentration (µg/l) at baseline and time points 
(baseline, 1h, 2h and 4h) after IV NAC infusion commencement in each subject. NS: no 
sample. (1: minimal ADRs, 2: moderate ADRs, 3: severe ADRs) (intensive study). 
 
Subject no Severity Tryp 0 µg/l T0 min Tryp 30m T30min Tryp1h T 1h  Tryp 2h T 2h  
1 2 6.49 0 6.51 30 8.4 60 11.5 120 
2 2 1 0 1 40 1 60 1 120 
3 3 9.62 0 7.15 30 8.23 55 9.33 120 
4 3 4.74 0 3.51 30 3.57 60 4.18 120 
5 1 4.68 0 3.36 30 2.81 60 3.58 120 
6 1 5.15 0 NS  1.53 85 3.76 145 
7 1 2.65 0 1.62 40 1.99 72 2.06 132 
8 3 1 0 1 40 1 75 1.67 135 
9 1 1 0 1 33 1 68 1 128 
10 3 3.69 0 NS 35 4.11 60 6.29 120 
11 3 4.15 0 7.41 45 6.92 75 5.89 135 
12 2 12.9 0 10.6 35 7.11 65 12.5 123 
13 1 4.16 0 1.99 40 4.57 70 2.91 130 
14 3 1.67 0 1 35 1 70 1.36 135 
15 2 1.92 0 1.56 35 3.28 65 4.23 125 
16 3 2.47 0 1.37 35 1.2 65 3.28 125 
17 1 3.59 0 2.21 30 1.14 60 1.62 120 
18 1 1 0 1 30 1 70 1 130 
19 1 6.28 0 5.58 30 5.65 60 5.31 125 
20 1 5.41 0 4.13 30  60 5.14 120 
21 2 NS 0 NS 30 NS 60 NS 120 











Appendix 5.15: plasma CRP concentration (mg/l) at baseline and time points 
(baseline, 1h, 2h and 4h) after IV NAC infusion commencement  in each subject. NS: 
no sample. (1: minimal ADRs, 2: moderate ADRs, 3: severe ADRs) (Intensive study). 
 
 
Subject no Severity CRP baseline CRP 1h CRP 2h CRP 4h 
1 2 10 10 10  
2 2 1 1 1 1 
3 3 8 2 8 2 
4 3 2 7 2 NS 
5 1 1 1 1 1 
6 1 1 1 1 1 
7 1 1 1 1 1 
8 3 1 1 1 1 
9 1 1 1 1 2 
10 3 50 NS NS NS 
11 3 4 4 4 4 
12 2 1 1 1 1 
13 1 31 27 33 39 
14 3 6 6 6 NS 
15 2 4 4 4 4 
16 3 1 1 1 1 
17 1 1 2 2 2 
18 1 NS 1 1 1 
19 1 1 1 1 1 
20 1 2 NS 2 1 
21 2 1 1 1 7 

















Appendix 5.16: plasma IL6 (pg/ml) concentration at baseline and time points  
(baseline, 30 min, 1h, 2h, 4h and 20h) after IV NAC infusion commencement in each 




Subject no Severity IL6 baseline IL6 30min IL6 1h IL6 2h IL6 4h IL6 20hh 
1 2 5.9 2 0.7 3.6 1.3 NS 
2 2 5.2 4.9 3.1 3.5 1.6 NS 
3 3 4 3.2 4.8 14.3 13.5 NS 
4 3 1.1 NS 1.4 3.3 NS NS 
5 1 1.1 NS 1.1 1.9 2.8 1.2 
6 1 2.1 2 2.9 2 5.9 8.3 
7 1 0.5 1.3 0.4 0.5 1.8 1.7 
8 3 4 3.2 4.8 14.3 13.5 NS 
9 1 3 2.2 2 2.2 2.5 1.9 
10 3 2.8 NS NS 5.5 NS NS 
11 3 0.4 0.7 1.2 2.8 1.8 NS 
12 2 4.3 0.9 1.8 3.3 5 NS 
13 1 31.2 29.6 33 31.4 34.6 28.4 
14 3 2.4 2.2 1.8 2.3 NS NS 
15 2 16.3 22.6 9.9 21.1 21.9 NS 
16 3 4.6 4 4.4 5.2 4.9 NS 
17 1 19.4 10.9 18.8 14.3 9.5 NS 
18 1 4 4.3 8.5 19.2 20.5 9.3 
19 1 0.3 0.5 0.7 1.3 6.8 1 
20 1 1.2 0.7 1.1 1.2 1.06 4.4 
21 2 4.9 3.4 3 4 10.6 6.1 


























Appendix 5.17: plasma tPA activity (u/ml) concentration at baseline and time points 
(baseline, 1h, 2h and 4h) after IV NAC infusion commencement in each subject . NS: 
no sample. (1: minimal ADRs, 2: moderate ADRs, 3: severe ADRs) (Intensive study). 
 
 
Subject no Severity tPA act baseline tPA act 1h tPA act 2h tPA act 4h 
1 2 0.1 0.3 0.1 0.2 
2 2 0.1 0.1 0.1 0.1 
3 3 0.1 0.1 0.1 0.1 
4 3 0.5 0.8 0.5 NS 
5 1 0.2 0.1 0.1 0.3 
6 1 0.1 0.1 0.3 0.3 
7 1 0.4 0.6 0.4 0.3 
8 3 0.7 2 0.8 0.2 
9 1 0.1 0.1 0.1 0.1 
10 3 NS NS NS NS 
11 3 0.6 1.7 0.9 0.9 
12 2 0.6 0.2 0.5 3.1 
13 1 0.1 0.1 0.1 0.1 
14 3 0.8 1.7 0.9 NS 
15 2 0.9 2.2 1.1 0.9 
16 3 0.3 1.4 0.6 0.5 
17 1 0.9 0.1 0.1 0.1 
18 1 0.1 0.1 0.1 0.1 
19 1 0.43 1.09 0.1 0.1 
20 1 0.3 0.4 0.1 0.3 
21 2 0.1 0.1 0.1 0.1 



























Appendix 5.18: plasma tPA antigen (ng/ml) concentration at baseline and time points 
(baseline, 1h, 2h and 4h) after IV NAC infusion commencement in each subject.NS: no 
sample. (1: minimal ADRs, 2: moderate ADRs, 3: severe ADRs) (Intensive study). 
 
 
Subject no Severity tPA Ag baseline tPA Ag 1h tPA Ag 2h tPA Ag 4h 
1 2 14.5 13.1 12 10 
2 2 3.2 8.8 14.8 14.2 
3 3 99.6 88.9 94.9 97.5 
4 3 8.4 6.8 6.8 NS 
5 1 12.9 14.9 13.2 14.8 
6 1 12.9 16.5 20.6 14.4 
7 1 1.8 2.7 2.5 3.5 
8 3 9.9 11.8 13.4 6 
9 1 16.7 15.4 13.9 8.6 
10 3 NS NS NS NS 
11 3 6 6.2 9.7 7.9 
12 2 6.3 3.6 9.2 15.9 
13 1 29.9 20.6 46.1 35.7 
14 3 3.2 4.8 3.8 NS 
15 2 8.7 14.8 12.8 6.8 
16 3 6.1 11.5 6.1 6 
17 1 16.6 16.6 35.3 31.2 
18 1 17.5 15.6 19.2 23.8 
19 1 8.6 10.9 14.9 33.8 
20 1 54.1 48.9 19.9 53.9 
21 2 29.8 40.6 29.4 18.9 
























Appendix 5.19: plasma vWf (ng/ml) concentration at baseline and time points 
(baseline, 30min,1h, 2h, 4h and 20h) after IV NAC infusion commencement in each 




Subject no Severity vWf base line vWf 30min vWf 1h vWf 2h vWf 4h vWf 20h 
1 2 1.09 2.83 0.68 0.97 0.94 NS 
2 2 1.92 1.82 1.49 1.67 0.56 1.5 
3 3 1 0.86 0.99 1.06 1.06 1.06 
4 3 1.06 0.99 0.72 1.07 NS NS 
5 1 0.88 0.69 0.75 0.83 0.76 1.23 
6 1 0.89 NS 1.84 1.91 1.03 2.3 
7 1 0.97 0.52 1.04 0.88 1.13 1.14 
8 3 1 0.86 0.99 1.06 1.06 1.66 
9 1 1.7 1.69 1.93 1.98 1.56 NS 
10 3 1.51 NS NS 1.79 NS NS 
11 3 0.78 0.75 1.01 1.06 1.21 0.95 
12 2 2.21 2.12 2.06 2.17 2.19 2.04 
13 1 2.16 2.98 3.25 0.94 2.72 0.9 
14 3 1.2 1.2 1.12 1.04  NS 
15 2 1.57 2.58 NS 1.32 1.13 1.46 
16 3 0.86 0.88 0.69 0.78 0.82 NS 
17 1 1.57 1.85 2.44 2.01 1.85 1.59 
18 1 0.8 0.72 1.74 1.17 1.37 1.58 
19 1 1.79 1.4 1.51 1.3 1.53 1.27 
20 1 1.92 2.07 1.62 1.83 2.08 NS 
21 2 3.23 3.13 3.02 2.19 2.38 2.02 























Appendix 5.20: plasma clotting factor II concentration (iu/l) at baseline and time points 
(baseline, 30 min, 1h, 2h, 4h and 20h) after IV NAC infusion commencement in each 




Subject no Severity FacII baseline FacII 30min FacII1h FacII2h FacII4h FacII20h 
1 2 0.95 0.717 0.878 1.01 0.936 NS 
2 2 0.571 0.411 0.491 0.496 0.529 0.512 
3 3 1.051 0.884 0.903 0.903 0.878 0.796 
4 3 0.512 0.445 0.501 0.792 NS NS 
5 1 0.765 0.665 0.665 0.717 0.626 0.736 
6 1 1.21 NS 1.051 1.01 0.89 1.35 
7 1 0.807 0.853 0.83 0.571 0.726 0.972 
8 3 0.745 0.649 0.558 0.726 0.717 0.786 
9 1 0.736 0.665 0.507 0.476 0.491 0.476 
10 3 0.991 NS NS 0.878 NS NS 
11 3 1.238 1.139 1.187 1.212 1.265 1.094 
12 2 0.847 0.755 NS 0.676 0.83 0.903 
13 1 0.612 0.449 0.425 0.471 0.441 0.584 
14 3 0.755 0.673 0.641 0.755 NS NS 
15 2 0.919 0.775 NS 0.818 0.83 0.89 
16 3 0.736 0.517 0.491 0.584 NS NS 
17 1 0.851 0.691 0.701 0.719 0.691 0.803 
18 1 0.717 0.591 0.641 0.605 0.649 0.393 
19 1 1.03 0.853 0.736 0.919 0.936 0.954 
20 1 0.936 0.807 NS 0.83 0.796 0.936 
21 2 0.781 0.617 0.701 0.647 0.803 0.781 






















Appendix 5.21: plasma clotting factor V concentration (iu/l)  at baseline and time 
points (baseline, 30 min, 1h, 2h, 4h and 20h) after IV NAC infusion commencement in 




Subject no Severity Fac V baseline Fac V 30min Fac V 1h Fac V 2h Fac V 4h Fac V 20h 
1 2 1.088 1 1.133 1.133 1.133 NS 
2 2 0.238 0.238 0.256 0.256 0.244 0.262 
3 3 0.716 0.716 0.74 0.829 0.719 0.694 
4 3 0.768 0.651 0.74 0.697 NS NS 
5 1 0.526 0.526 0.657 0.694 0.575 0.827 
6 1 0.827 NS 1.18 0.694 1.004 1.526 
7 1 0.482 0.631 0.631 0.43 0.575 0.827 
8 3 0.716 0.716 0.694 0.928 0.827 1.133 
9 1 0.455 0.575 0.575 0.542 0.612 0.74 
10 3 1.46 NS NS 1.595 NS NS 
11 3 0.928 1.045 1.18 1.18 1.18 1.045 
12 2 0.74 0.524 NS 0.797 0.928 0.994 
13 1 0.651 0.651 0.542 0.716 0.694 1.088 
14 3 0.455 0.51 0.355 0.542 NS NS 
15 2 0.542 0.716 NS 0.768 0.74 0.827 
16 3 0.575 0.496 0.455 0.631 NS NS 
17 1 0.524 0.586 0.638 0.697 0.638 0.803 
18 1 0.355 0.298 0.346 0.312 0.337 0.14 
19 1 1.004 1.045 1.133 1.045 1.133 1.088 
20 1 1.045 1.045 NS 1.18 1.18 1.231 
21 2 0.771 1.039 0.994 1.039 1.086 1.039 























Appendix 5.22: plasma clotting factor VII concentration (iu/l) at baseline and time 
points (baseline, 30 min, 1h, 2h, 4h and 20h) after IV NAC infusion commencement in 
each subject. NS: no sample. (1: minimal ADRs, 2: moderate ADRs, 3: severe ADRs) 
(intensive study). 
 
Subject no Severity Fac VII base Fac VII 30min Fac VII 1h Fac VII 2h Fac VII 4h Fac VII 20h 
1 2 1.126 0.838 0.838 0.733 0.733 NS 
2 2 0.419 0.272 0.286 0.259 0.217 0.217 
3 3 0.392 0.268 0.263 0.239 0.231 0.226 
4 3 0.79 0.621 0.65 0.6 NS NS 
5 1 0.698 0.508 0.444 0.534 0.409 0.52 
6 1 1.126 NS 0.921 1.17 0.577 0.865 
7 1 0.733 0.665 0.621 0.334 0.471 0.65 
8 3 1.636 1.167 1.167 1.209 0.984 1.052 
9 1 0.577 0.508 0.46 0.392 0.419 0.409 
10 3 0.838 NS NS 0.665 NS NS 
11 3 0.79 0.621 0.621 0.607 0.577 0.562 
12 2 1.088 0.838 NS 0.812 0.77 0.784 
13 1 0.635 0.439 0.392 0.392 0.313 0.562 
14 3 0.483 0.37 0.336 0.336 NS NS 
15 2 0.838 0.65 NS 0.577 0.592 0.65 
16 3 0.409 0.324 0.235 0.297 NS NS 
17 1 0.934 0.646 0.646 0.6 0.527 0.765 
18 1 0.239 0.134 0.131 0.105 0.101 0.069 
19 1 1.126 0.865 0.865 0.812 0.733 0.812 
20 1 1.167 0.921 NS 0.865 0.79 0.838 
21 2 0.754 0.489 0.501 0.466 0.434 0.527 

























Appendix 5.23: plasma clotting factor VIII concentration (iu/l) at baseline and time 
points (baseline, 30 min, 1h, 2h, 4h and 20h) after IV NAC infusion commencement in 




Subject no Severity Fac VIII baseline Fac VIII30min Fac VIII1 h Fac VIII2h Fac VIII4h Fac VIII20h 
1 2 0.791 0.752 0.64 0.657 0.733 NS 
2 2 2.44 3.039 3.039 3.039 2.316 1.53 
3 3 0.855 0.909 1.407 1.318 1.343 1.819 
4 3 0.886 0.758 0.886 0.662 NS NS 
5 1 0.567 0.577 0.504 0.741 0.607 0.82 
6 1 2.852 NS 3.011 3.964 2.403 2.193 
7 1 1.094 1.665 1.004 0.725 0.897 1.391 
8 3 0.95 1.158 0.728 1.057 1.223 1.294 
9 1 1.294 1.33 1.395 1.282 1.381 1.235 
10 3 1.158 NS NS 1.934 NS NS 
11 3 0.577 0.768 0.851 0.931 0.89 1.241 
12 2 1.437 1.222 NS 1.156 1.536 1.165 
13 1 1.486 1.202 1.498 1.63 1.767 1.754 
14 3 0.952 0.857 0.917 0.989 NS NS 
15 2 0.897 0.845 NS 0.938 0.945 1.202 
16 3 1.559 0.521 0.464 0.68 NS NS 
17 1 1.282 0.938 1.212 1.212 0.982 1.146 
18 1 1.641 1.414 1.658 1.461 1.702 1.425 
19 1 1.193 1.346 1.848 1.379 1.617 1.313 
20 1 1.949 2.405 NS 2.137 1.934 1.335 
21 2 2.171 3.326 2.759 2.24 2.025 1.549 






















Appendix 5.24: plasma clotting factor IX concentration (iu/l) at baseline and time 
points (baseline, 30 min, 1h, 2h, 4h and 20h) after IV NAC infusion commencement in 









30min Fac IX 1h 
Fac IX 
2h Fac IX 4h 
Fac IX 
20h 
1 2 0.783 0.75 0.757 0.776 0.81 NS 
2 2 0.812 0.453 0.447 0.426 0.426 0.389 
3 3 1.113 0.914 0.99 0.922 0.922 0.906 
4 3 1.044 0.845 0.964 0.763 NS NS 
5 1 0.486 0.367 0.537 0.636 0.565 0.738 
6 1 1.548 NS 1.328 2.115 1.063 1.594 
7 1 0.619 0.666 0.591 0.418 0.535 0.894 
8 3 0.955 0.824 0.81 0.89 0.875 1.063 
9 1 0.738 0.684 0.698 0.641 0.69 0.906 
10 3 1.063 NS NS 1.063 NS NS 
11 3 1.194 1.047 1.218 1.31 1.296 1.194 
12 2 1.17 1.016 NS 0.903 1.006 1.036 
13 1 0.682 0.575 0.56 0.619 0.494 0.745 
14 3 1.112 0.877 0.718 0.939 NS NS 
15 2 0.948 0.796 NS 0.804 0.894 1.079 
16 3 0.672 0.398 0.376 0.481 NS NS 
17 1 1.194 0.86 0.844 0.903 0.844 1.158 
18 1 0.961 0.781 0.812 0.672 0.731 0.379 
19 1 0.93 0.835 0.903 0.835 0.885 1.006 
20 1 1.6 1.38 NS 1.409 1.31 1.583 
21 2 1.27 1.047 1.101 1.016 1.146 1.101 























Appendix 5.25: plasma clotting factor X (iu/l) concentration at baseline and different 
time (baseline, 30 min, 1h, 2h, 4h and 20h) points after IV NAC infusion in each subject 
with different severity. NS: no sample. (1: minimal ADRs, 2: moderate ADRs, 3: severe 















1 2 0.617 0.537 0.584 0.566 0.56 NS 
2 2 0.759 0.69 0.735 0.677 0.686 0.506 
3 3 0.998 0.854 0.984 0.872 0.784 0.731 
4 3 0.636 0.58 0.621 0.699 NS NS 
5 1 0.673 0.584 0.774 0.745 0.613 0.673 
6 1 1.092 NS 0.938 1.632 0.656 0.805 
7 1 0.577 0.717 0.58 0.417 0.515 0.64 
8 3 1.07 0.793 0.763 0.858 0.793 0.911 
9 1 0.671 0.604 0.555 0.555 0.614 0.625 
10 3 1.07 NS NS 0.635 NS NS 
11 3 1.21 0.974 0.997 1.021 1.021 0.841 
12 2 1.045 0.875 NS 0.825 0.841 0.858 
13 1 0.458 0.322 0.278 0.392 0.262 0.33 
14 3 0.696 0.528 0.511 0.537 NS NS 
15 2 1.045 0.749 NS 0.709 0.735 0.793 
16 3 0.693 0.426 0.414 0.528 NS NS 
17 1 0.952 0.709 0.696 0.709 0.683 0.778 
18 1 0.841 0.636 0.647 0.583 0.564 0.271 
19 1 1.021 0.809 0.841 0.841 0.809 0.778 
20 1 1.273 0.974 NS 0.93 0.893 1.021 
21 2 0.911 0.696 0.722 0.709 0.763 0.722 























Appendix 5.26: plasma clotting factor XI concentration (iu/l) at baseline and time 
points (baseline, 30 min, 1h, 2h, 4h and 20h) after IV NAC infusion commencement in 




Subject no Severity FacXI baseline FacXI 30min FacXI 1h FacXI 2h FacXI 4h FacXI 20h 
1 2 0.617 0.537 0.584 0.566 0.56 NS 
2 2 0.759 0.69 0.735 0.677 0.686 0.506 
3 3 0.998 0.854 0.984 0.872 0.784 0.731 
4 3 0.686 0.58 0.621 0.699 NS NS 
5 1 0.673 0.584 0.774 0.745 0.613 0.673 
6 1 1.092 NS 0.938 1.632 0.656 0.805 
7 1 0.577 0.717 0.58 0.417 0.515 0.64 
8 3 0.681 0.745 0.621 0.694 0.632 0.699 
9 1 0.621 0.665 0.694 0.628 0.648 0.55 
10 3 0.53 NS NS 0.635 NS NS 
11 3 0.832 0.849 0.86 0.866 0.816 0.796 
12 2 0.932 0.769 NS 0.849 0.838 0.895 
13 1 0.243 0.24 0.238 0.272 0.243 0.235 
14 3 0.726 0.669 0.673 0.694 NS NS 
15 2 0.849 0.779 NS 0.774 0.805 0.821 
16 3 0.621 0.5 0.448 0.546 NS NS 
17 1 0.753 0.68 0.684 0.706 0.673 0.706 
18 1 0.784 0.677 0.714 0.624 0.632 0.445 
19 1 0.595 0.644 0.617 0.617 0.577 0.566 
20 1 0.901 0.81 NS 0.816 0.779 0.779 
21 2 0.953 1.04 0.998 0.974 0.9 0.725 
22 1 0.537 0.462 0.453 NS 0.401 NS 
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